accession,prop_value
NCT00006045:I.1001,"Histologically proven acute myelogenous leukemia (AML) that may have been primary AML, secondary AML, or preceded by hematologic disorder"
NCT00006045:I.1002,"All FAB subtypes except M3 Must meet one of the following three criteria: 
- First relapse within 1 year after documentation of a previous complete remission (CR) achieved by chemotherapy- Refractory to prior chemotherapy comprised of a minimum of 1 induction course, including cytarabine at a minimum of 500 mg/m2 (e.g., 100 mg/m2/day for 5 days) plus an anthracycline 
- No high dose cytarabine (no cumulative dose greater than 3 g/m2)"
NCT00006045:I.1003,"First relapse from a previous CR with subsequent autologous bone marrow transplantation (BMT), only if all of the following criteria are met:- First BMT At least 100 days but less than 1 year posttransplantation- At least 25% cellularity of the bone marrow- Previous BMT included full hematopoietic recovery, defined by all of the following:-- Hemoglobin at least 10 g/dL (without transfusion)-- Platelet count at least 100,000/mm3 (without transfusion)-- Absolute neutrophil count at least 1,500/mm3"
NCT00006045:I.1004,"No transplantation candidates"
NCT00006045:I.1005,"Bone marrow blasts (leukemic cells) greater than 10%No chronic myelogenous leukemia in blast crisis"
NCT00006045:I.1006,"No active CNS leukemia"
NCT00006045:I.2001,"Age: 18 and over"
NCT00006045:I.2002,"Karnofsky 50-100%"
NCT00006045:I.2003,"Bilirubin less than 2.0 mg/dL (unless related to Gilbert's disease or due to leukemic infiltration)"
NCT00006045:I.2004,"SGOT or SGPT no greater than 4 times upper limit of normal (unless related to AML)C1522609"
NCT00006045:I.2005,"Creatinine less than 2.0 mg/dL (unless related to AML)"
NCT00006045:I.2006,"Left ventricular function normalNo unstable cardiac arrhythmias, unstable angina pectoris, or myocardial infarction within the past 6 monthsNo New York Heart Association class III or IV heart diseaseNo electrocardiogram evidence of active ischemia"
NCT00006045:I.2007,"Not pregnant or nursingNegative pregnancy testFertile patients must use effective contraception during and for 1 month after studynegation"
NCT00006045:I.2008,"HIV negative"
NCT00006045:I.2009,"No other active malignancy requiring therapyNo active serious infection that is uncontrolled by antimicrobial therapyMedically stableNo significant organ dysfunction"
NCT00006045:I.3001,"At least 30 days since prior experimental biologic therapy (e.g., interleukin-2)No concurrent biologic therapy, including bone marrow transplantation"
NCT00006045:I.3002,"For first relapse AML with recent or prior chemotherapy: Prior hydroxyurea given as a short course (up to 48 hours) allowed, if needed, to reduce the peripheral leukocyte countHydroxyurea must be discontinued prior to studyFor refractory AML with recent or prior chemotherapy: Greater than 2 weeks since prior chemotherapy except hydroxyurea given as aboveNo other concurrent chemotherapy"
NCT00006045:I.3003,"No concurrent radiotherapy"
NCT00006045:I.3004,"No other concurrent experimental therapy 
Concurrent therapy for other preexisting diseases allowed"
NCT00048295:I.1001,"Age at least 12 years"
NCT00048295:I.1002,"Weight at least 36 kg"
NCT00048295:I.1003,"CDAI score of 220 - 400"
NCT00048295:I.1004,"Documentation of Crohns disease activity by endoscopy, biopsy or imaging in the last 2 years"
NCT00048295:I.1005,"No TNF-alpha inhibitor treatment for three months prior to first study drug infusion"
NCT00048295:I.2001,"Known severe, fixed, symptomatic stenosis of the small or large intestine with significant dilation"
NCT00048295:I.2002,"Extensive external fistulization (>3 external fistulae which are expressible with gentle compression); colostomy or ileostomy"
NCT00048295:I.2003,"Active infection, including infectious colitis, or infection with HIV, Hepatitis B or Hepatitis C"
NCT00048295:I.2004,"Malignancy within 3 years or poorly controlled medical illness"
NCT00048295:I.2005,"Requires intravenous heparin therapy or with a history of a bleeding problem"
NCT00050999:I.1001,"18 Years and older"
NCT00050999:I.1002,"Histopathologically confirmed recurrent or persistent CTCL as determined by reference pathology lab"
NCT00050999:I.1003,"Patient must have had 1 to 3 prior CTCL therapies. Repeated use of the same agent is considered to be 1 therapy unless it is part of a different combination regimen. Only 1 prior combination cytotoxic regimen is permitted. Topical or systemic steroids are not considered a therapy"
NCT00050999:I.1004,"Interleukin-2 receptor (IL-2R) expression on at least 20% of tumor cells as determined by immunohistochemistry"
NCT00050999:I.1005,"Stage IA - III disease and unlikely to progress during the first month on study. Life expectancy of at least 12 months. Measurable or evaluable disease. Lymph node involvement no greater than LN2. No CTCL involvement of bone marrow."
NCT00050999:I.1006,"No active CNS disease, kidney or liver disease, significant pulmonary disease, or cardiac disease. No systemic infections"
NCT00050999:I.1007,"Willingness to be randomized to a placebo treatment only arm"
NCT00050999:I.1008,"ECOG performance status 0 or 1"
NCT00050999:I.2001,"Patients must not have previously received treatment with DAB389IL-2 or DAB486IL 2 (previous candidate compound evaluated in a clinical setting)."
S.0000:I.0000,"Medical diagnosis of CTCL, and positivity for the CD4 receptor"
S.0000:I.0001,"Late stage CTCL"
S.0000:I.0002,"Have received at least one prior anti-cancer therapy with inadequate effect"
S.0000:I.0003,"WHO performance status 0,1 or 2"
S.0000:I.0004,"Age 18 or older"
S.0000:I.0005,"Certain rare types of CTCL"
S.0000:I.0006,"Previous treatment with other anti-CD4 medications"
S.0000:I.0007,"More than two previous treatments with systemic chemotherapy"
S.0000:I.0008,"Certain anti-psoriasis or anti-cancer therapies within the last 4 weeks before entering this trial"
S.0000:I.0009,"Some types of steroid treatments less than two weeks before entering the trial"
S.0000:I.0010,"Prolonged exposure to sunlight or UV light during the trial"
S.0000:I.0011,"Other cancer diseases, except certain skin cancers or cervix cancer"
S.0000:I.0012,"Chronic infectious disease requiring medication"
S.0000:I.0013,"Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, lung, heart, hormonal, nerve or blood diseases"
S.0000:I.0014,"Certain laboratory values which are too high or too low"
S.0000:I.0015,"HIV positivity"
S.0000:I.0016,"Pregnant or breast-feeding women"
S.0000:I.0017,"Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial"
S.0000:I.0018,"If you are participating in another trial with a different new drug 4 weeks before you enter this trial"
NCT00071084:I.1001,"Medical diagnosis of CTCL, and positivity for the CD4 receptor. - Late stage CTCL"
NCT00071084:I.1002,"Have received at least one prior anti-cancer therapy with inadequate effect"
NCT00071084:I.1003,"WHO performance status 0,1 or 2 - Male or female, age 18 or older. - Signed informed consent."
NCT00071084:I.2001,"Certain rare types of CTCL."
NCT00071084:I.2002,"Previous treatment with other anti-CD4 medications. - More than two previous treatments with systemic chemotherapy. - Certain anti-psoriasis or anti-cancer therapies within the last 4 weeks before entering this trial. - Some types of steroid treatments less than two weeks before entering the trial"
NCT00071084:I.2003,"Prolonged exposure to sunlight or UV light during the trial. - Other cancer diseases, except certain skin cancers or cervix cancer. - Chronic infectious disease requiring medication. - Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, lung, heart, hormonal, nerve or blood diseases. - Certain laboratory values which are too high or too low. - HIV positivity"
NCT00071084:I.2004,"Pregnant or breast-feeding women. - Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial"
NCT00071084:I.2005,"If you are participating in another trial with a different new drug 4 weeks before you enter this trial"
NCT00071084:I.3001,Diagnosis
NCT00071084:I.3002,"Lymphoma, T-Cell, Cutaneous"
NCT00071084:I.3003,"Diagnostic Neoplasm Staging"
NCT00071084:I.3004,"Therapeutic procedure"
NCT00071084:I.3005,"WHO performance status finding"
NCT00071084:I.3006,Age
NCT00071084:I.3007,Medication
NCT00071084:I.3008,Chemotherapy
NCT00071084:I.3009,"Exposure to sunlight"
NCT00071084:I.3010,Infection
NCT00071084:I.3011,"HIV negative"
NCT00071084:I.3012,pregnant
NCT00071084:I.3013,"Breast feeding"
NCT00071084:I.3014,Contraception
NCT00071084:I.3015,Enrollment
NCT00151099:I.1001,"18 Years to 40 Years"
NCT00151099:I.1002,Female
NCT00151099:I.1003,"Patients with surgery for dysgnathia"
NCT00151099:I.2001,"Diabetes mellitus"
NCT00151112:I.1001,"18 Years and older"
NCT00151112:I.1002,"Single shot axillary block"
NCT00151112:I.2001,"Lateral position not possible"
NCT00151112:I.3001,Age
NCT00151112:I.3002,"Anesthesia procedures"
NCT00153062:I.1001,"50 Years and older"
NCT00153062:I.1002,"Male or female subjects 55 year or older who have suffered an ischemic stroke within the past 90 days and who meet all other inclusion criteria. Include also patients of ages 50 - 54 years and/or 90 to 120 days after the qualifying stroke provided the patient has at least two of the following additional risk factors: Diabetes mellitus,Hypertension (systolic blood pressure (BP)>=140 millimeters of Mercury (mmHg) or diastolic BP>=90mmHg), Smoker at time of qualifying stroke,Obesity (Body mass index (BMI)>30, BMI=weight in kilograms (kg)/[height in meters (m)]2), Previous vascular disease (stroke, MI, or peripheral arterial disease prior to qualifying stroke), End-organ-damage (retinopathy, left ventricular hypertrophy (LVH), or microalbuminuria),Hyperlipidemia"
NCT00153062:I.2001,"hemorrhagic stroke (must be ruled out by imaging)"
NCT00153062:I.2002,"unable to give informed consent"
NCT00153062:I.2003,"known brain tumor, severe renal or hepatic insufficiency, current active peptic ulcer disease, severe coronary artery disease including unstable angina pectoris or an MI within the previous 3 months,or history of a hemostatic disorder or systemic bleeding"
NCT00153062:I.2004,"hyperkalemia, uncorrected volume or sodium depletion"
NCT00153062:I.2005,"pre-stroke history of dementia, modified Rankin score greater than 4"
NCT00153062:I.2006,"qualifying stroke induced by surgical or cardiovascular procedure"
NCT00153062:I.2007,"uncontrolled hypertension at entry above 180/110 mmHg (goal blood pressures are lower)"
NCT00153062:I.2008,"Systolic blood pressure (SBP) 120 mmHg or less for hospitalized patients. Currently taking an Angiotensin II receptor blocker (ARB) and not able or willing to switch to alternative. Required or planned continuing treatment with antithrombotics or anticoagulants including heparin or warfarin or non-study platelet inhibitors"
NCT00153062:I.2009,"syndrome of asthma, rhinitis and nasal polyps"
NCT00153062:I.2010,"scheduled for major surgery, carotid endarterectomy, or carotid angioplasty (4 weeks post surgery is allowed)"
NCT00153062:I.2011,"unlikely to be released from hospital following the qualifying stroke or presence of a severe disability likely to lead to being bedridden or demented or a non-vascular disease or condition which makes it unlikely that the patient will survive to the end of the trial"
NCT00153062:I.2012,"history of thrombocytopenia or neutropenia"
NCT00153062:I.3001,Age
NCT00153062:I.3002,"Ischemic stroke"
NCT00153062:I.3003,"Diabetes mellitus"
NCT00153062:I.3004,"Hypertensive disease"
NCT00153062:I.3005,"Smoking Status"
NCT00153062:I.3006,Obesity
NCT00153062:I.3007,"Body mass index"
NCT00153062:I.3008,Diagnosis
NCT00153062:I.3009,Stroke
NCT00153062:I.3010,"Acute myocardial infarction"
NCT00153062:I.3011,"Peripheral Arterial Diseases"
NCT00153062:I.3012,Retinopathy
NCT00153062:I.3013,"Left Ventricular Hypertrophy"
NCT00153062:I.3014,Microalbuminuria
NCT00153062:I.3015,Hyperlipidemia
NCT00153062:I.3016,"Brain hemorrhage"
NCT00153062:I.3017,"Brain Neoplasms"
NCT00153062:I.3018,"Renal Insufficiency"
NCT00153062:I.3019,"Hepatic Insufficiency"
NCT00153062:I.3020,"Peptic Ulcer"
NCT00153062:I.3021,"Coronary artery disease (CAD)"
NCT00153062:I.3022,"Bleeding tendency"
NCT00153062:I.3023,hyperkalemia
NCT00153062:I.3024,Dementia
NCT00153062:I.3025,"Rankin score"
NCT00153062:I.3026,"Complication of surgical and medical care, unspecified"
NCT00153062:I.3027,"Systolic Blood Pressure"
NCT00153062:I.3028,Medication
NCT00153062:I.3029,"Angiotensin II receptor antagonist"
NCT00153062:I.3030,"Anticoagulant treatment"
NCT00153062:I.3031,"Antithrombic Drugs"
NCT00153062:I.3032,Heparin
NCT00153062:I.3033,Warfarin
NCT00153062:I.3034,"Therapeutic procedure"
NCT00153062:I.3035,Asthma
NCT00153062:I.3036,"Life expectancy"
NCT00153062:I.3037,"Platelet count - finding"
NCT00153062:I.3038,"White Blood Cells"
NCT00153062:I.3039,Neutropenia
NCT00153062:I.3040,Thrombocytopenia
NCT00156338:I.1001,"18 Years to 90 Years"
NCT00156338:I.1002,"epidural anesthesia"
NCT00156338:I.1003,"ASA I-III"
NCT00156338:I.2001,"metastasized cancer"
NCT00156338:I.2002,pregnancy
NCT00157157:I.1001,"The subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level<= 2% of normal, as documented at screening"
NCT00157157:I.1002,"The subject is<6 years of age"
NCT00157157:I.1003,"The subject's legally authorized representative has provided written informed consent"
NCT00157157:I.2001,"The subject has a history of exposure to factor VIII other than rAHF PFM or more than 3 infusions of commercially available rAHF PFM (i.e., ADVATE) within 28 days prior to screening, as determined by the subject's medical history. Any infusion of factor VIII replacement products prior to the 28-day period excludes the subject from participation"
NCT00157157:I.2002,"The subject has received more than 3 infusions of rAHF PFM (commercially available and/or study product) between screening and prior to the initial recovery infusion"
NCT00157157:I.2003,"The subject has a detectable inhibitor to factor VIII, as measured in the screening sample by the Nijmegen assay in the central laboratory"
NCT00157157:I.2004,"The subject has a history of inhibitor to factor VIII at any time prior to screening"
NCT00157157:I.2005,"The subject has a known hypersensitivity to rAHF PFM"
NCT00157157:I.2006,"The subject has any 1 of the following laboratory abnormalities at the time of screening:
1) Platelet count<100,000/mm^3
2) Hemoglobin concentration<10 g/dL (100 g/L)
3) Serum creatinine>1.5 times the upper limit of normal (ULN) for age
4) Total bilirubin>2 times the ULN for age"
NCT00157157:I.2007,"The subject has an inherited or acquired hemostatic defect other than hemophilia A (e.g., qualitative platelet defect or von Willebrand's disease)"
NCT00157157:I.2008,"The subject is known to be seropositive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV), as determined by the subject's medical history"
NCT00157157:I.2009,"At the time of enrollment, the subject has a clinically significant chronic disease other than hemophilia A"
NCT00157157:I.2010,"The subject is currently participating in another investigational drug study, or has participated in any clinical study involving an investigational drug within 120 days of the screening visit"
NCT00157157:I.2011,"The subject (or the subject's legally authorized representative) is identified by the investigator as being unable or unwilling to cooperate with study procedures"
NCT00157157:I.2012,"The subject has received any blood product, including packed red blood cells (RBC), platelets, plasma, or cryoprecipitate"
NCT00157157:I.3001,Diagnosis
NCT00157157:I.3002,"Hemophilia A"
NCT00157157:I.3003,"Factor VIII Measurement"
NCT00157157:I.3004,Age
NCT00157157:I.3005,"Informed Consent"
NCT00157157:I.3006,Medication
NCT00157157:I.3007,"Factor VIII"
NCT00157157:I.3008,"Factor VIII inhibitor screening test"
NCT00157157:I.3009,Hypersensitivity
NCT00157157:I.3010,"Platelet count - finding"
NCT00157157:I.3011,Hemoglobin
NCT00157157:I.3012,Creatinine
NCT00157157:I.3013,Bilirubin
NCT00157157:I.3014,"Coagulation Factor Deficiency"
NCT00157157:I.3015,"HIV negative"
NCT00157157:I.3016,"Hepatitis B, C"
NCT00157157:I.3017,Enrollment
NCT00157157:I.3018,Compliance
NCT00157157:I.3019,"Blood product"
NCT00160524:I.1001,"18 Years and older"
NCT00160524:I.1002,"previously completed studies CDP870-031 or CDP870-032"
NCT00160706:I.1001,"18 Years and older"
NCT00160706:I.1002,"Previously withdrawn from study CDP870-031 or CDP870-032 due to an exacerbation of Crohn's disease"
NCT00160706:I.2001,Age
NCT00160706:I.2002,Enrollment
NCT00160706:I.2003,Diagnosis
NCT00160706:I.2004,"Crohn's Disease"
NCT00165828:I.1001,"Adult aged between 18 years and 74 years"
NCT00165828:I.1002,"Focal epileptic seizures with or without secondary generalization"
NCT00165828:I.1003,"Present treatment with one or two antiepileptic drugs (constant dosage during 8 weeks baseline phase prior to initiation of treatment with zonisamide). Stimulation of the vagus nerve is permitted and will not be counted as antiepileptic drug."
NCT00165828:I.1004,"For women of childbearing potential (postmenopausal for more than 1 year): possible pregnancy during the study can be excluded (by hysterectomy, sterilization or simultaneous application of two recognized methods of contraception (no oral contraceptives only)"
NCT00165828:I.1005,"For male patients with partners of childbearing potential: a safe method of contraception is practiced during their study participation"
NCT00165828:I.1006,"Written consent to participate in the study"
NCT00165828:I.2001,"At least 6 focal or clonicotonic seizures documented completely in a seizure diary or the patient chart during the 8 prospective or retrospective weeks baseline phase."
NCT00165828:I.3001,"Epileptic state during the past year"
NCT00165828:I.3002,"Non-epileptic fits"
NCT00165828:I.3003,"Generalized epilepsy"
NCT00165828:I.3004,"More than 4 weeks of seizure freedom during baseline phase"
NCT00165828:I.3005,"Concomitant progressive CNS disease including progressive myoclonus epilepsy"
NCT00165828:I.3006,"Concomitant treatment with vigabatrine and / or topiramate"
NCT00165828:I.3007,"Hepatic and/or renal insufficiency (creatine>2mg% or GPT>2 times ULN)"
NCT00165828:I.3008,"Body weight<= 40 kg"
NCT00165828:I.3009,"(History of) kidney stones; erythrocyturia, family history (in parents, children, brothers and sisters or grandparents) of kidney stones"
NCT00165828:I.3010,"(History of) drug and/or alcohol dependence"
NCT00165828:I.3011,"Active psychosis"
NCT00165828:I.3012,"Suicide attempt during the past 3 years"
NCT00165828:I.3013,"Pre-treatment with zonisamide"
NCT00165828:I.3014,"Known hypersensitivity to sulfonamides"
NCT00165828:I.3015,"Concomitant treatment with neuroleptic drugs"
NCT00165828:I.3016,"pregnant or breast feeding woman"
NCT00165828:I.3017,"participation in another therapy study within 3 months prior to or during this study"
NCT00165828:I.3018,"blood donation planned during or within 4 weeks after the participation in this study"
NCT00165828:I.3019,"elective surgery planned during the participation in this study"
NCT00165828:I.3020,"patient is not willing or not capable to meet the study demands"
NCT00165828:I.3021,"patient does not agree to the forwarding of his/her pseudonymous data"
NCT00165828:I.3022,"patient without legal competence"
NCT00165828:I.4001,"More than 4 consecutive weeks of freedom from seizure during baseline phase"
NCT00168051:I.1001,"18 Years to 64 Years"
NCT00168051:I.1002,Male
NCT00168051:I.1003,"Severe hemophilia A"
NCT00168051:I.1004,"Previously treated patients with at least 150 exposure days to any Factor VIII product"
NCT00168051:I.2001,"Hypersensitivity to any recombinant Factor VIII product"
NCT00168051:I.2002,"History of or current Factor VIII inhibitor"
NCT00168051:I.2003,"Bleeding episode or other reason requiring Factor VIII treatment within 3 days of study"
NCT00175903:I.1001,"16 Years and older"
NCT00175903:I.1002,"Diagnosis of epilepsy (all types of seizures) was made during the past year"
NCT00175903:I.1003,"Subjects must have had at least two unprovoked seizures in the past 2 years with at least one during the last 6 months"
NCT00175903:I.1004,"Female subjects without childbearing potential are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method."
NCT00175903:I.2001,"Subjects previously allocated to a trial treatment (CBZ, VPA and LEV) used in this trial"
NCT00175903:I.2002,"Participation in another clinical trial with an investigational drug or device within 12 weeks of the selection visit (V1), or at any time during this trial"
NCT00175903:I.2003,"Pregnant or lactating women"
NCT00175903:I.2004,"Presence of known pseudoseizures within the last year"
NCT00175903:I.2005,"Uncountable seizures (clusters) or history of convulsive status epilepticus"
NCT00175903:I.2006,"Any disorder or condition that may interfere with the absorption, distribution, metabolisation or excretion of drugs"
NCT00175903:I.2007,"History of suicide attempt, current suicidal ideation, or other serious psychiatric disorders requiring or having required hospitalization or medication within the previous five years"
NCT00175903:I.2008,"Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors"
NCT00175903:I.2009,"Presence of a terminal illness or any medical condition that might interfere with the subject's trial participation"
NCT00175903:I.3001,Age
NCT00175903:I.3002,Diagnosis
NCT00175903:I.3003,Epilepsia
NCT00175903:I.3004,Convulsion
NCT00175903:I.3005,pregnant
NCT00175903:I.3006,"Breast feeding, Nursing"
NCT00175903:I.3007,Contraception
NCT00175903:I.3008,Enrollment
NCT00175903:I.3009,"Pseudoseizure (Hysterical fits, factitious seizures)"
NCT00175903:I.3010,"Epileptic state"
NCT00175903:I.3011,Malabsorption
NCT00175903:I.3012,"Renal Insufficiency"
NCT00175903:I.3013,"Hepatic Insufficiency"
NCT00175903:I.3014,"Attempted Suicide"
NCT00175903:I.3015,"Psychosis (Psychotic disorder)"
NCT00175903:I.3016,"Brain Neoplasms"
NCT00175903:I.3017,"CNS disorder, Central Nervous System Disease"
NCT00175903:I.3018,"Degenerative Neurologic Disease"
NCT00175903:I.3019,"end stage disease"
NCT00185211:I.1001,"18 Years to 48 Years"
NCT00185211:I.1002,"Patients who have reached scheduled end of study in BENEFIT, either by developing CDMS or by completing 24 months"
NCT00185211:I.2001,"No participation in the initial BENEFIT study"
NCT00185211:I.3001,Age
NCT00185211:I.3002,Enrollment
NCT00185211:I.3003,"Study End Date"
NCT00185250:I.1001,"18 Years to 75 Years"
NCT00185250:I.1002,"Unexplained heart with evidence of Adeno-, Entero- and/or Parvoviruses which must be identified directly in the heart tissue"
NCT00185250:I.1003,"Being in a chronic (at least 6 month after the onset of clinical symptoms) and stable phase of the disease"
NCT00185250:I.1004,"Impaired cardiac function"
NCT00185250:I.2001,"Severe (decompensated) or acute heart failure"
NCT00185250:I.2002,"Any other disease which could better explain the patient's clinical symptoms"
NCT00185250:I.2003,"Any other severe and/or malignant disease"
NCT00185250:I.2004,"Suffering from convulsions, depression or suicidal ideas judged by a physician"
NCT00185250:I.2005,"Serious viral or bacterial infections during the last weeks"
NCT00185250:I.2006,"Pregnancy or lactation"
NCT00185250:I.3001,Age
NCT00185250:I.3002,Diagnosis
NCT00185250:I.3003,"Cardiac disorder"
NCT00185250:I.3004,"Heart failure"
NCT00185250:I.3005,Cardiomyopathy
NCT00185250:I.3006,"Viral cardiomyopathy"
NCT00185250:I.3007,Adenovirus
NCT00185250:I.3008,Enterovirus
NCT00185250:I.3009,Parvovirus
NCT00185250:I.3010,"Chronic disease"
NCT00185250:I.3011,"Cardiac rate"
NCT00185250:I.3012,"Cardiac ejection fraction"
NCT00185250:I.3013,"Cardiac Arrhythmia"
NCT00185250:I.3014,"Malignant Neoplasms"
NCT00185250:I.3015,disorder
NCT00185250:I.3017,Convulsion
NCT00185250:I.3018,Depression
NCT00185250:I.3019,Infection
NCT00185250:I.3020,"Severe (Qualitative Concept)"
NCT00185250:I.3021,pregnant
NCT00185250:I.3022,"Breast feeding, Nursing"
NCT00185393:I.1001,"18 Years and older"
NCT00185393:I.1002,"Non Hodgkin Lymphoma stage III or IV at timepoint of diagnosis"
NCT00185393:I.1003,"Patients who have achieved a remission after first line chemotherapy"
NCT00185393:I.1004,"No less than 6 weeks and no more than 12 weeks since last dose of chemotherapy"
NCT00185393:I.1005,"written informed consent"
NCT00185393:I.2001,"Any other anticancer treatment for NHL except the preceding first line chemotherapy"
NCT00185393:I.2002,"Prior radiation therapy"
NCT00185393:I.2003,"Patients who have not recovered from the toxic effects of the first line chemotherapy"
NCT00185393:I.2004,"Any other cancer or history of cancer less than 10 years ago"
NCT00185393:I.2005,"Patients with known HIV positivity"
NCT00185393:I.2006,"patients with pleural effusion or ascites"
NCT00185393:I.2007,"female patients who are pregnant or breast feeding (women of childbearing potential must have a negative serum pregnancy test at study entry)"
NCT00185393:I.2008,"Adults not employing an effective method of birth control during study treatment and 12 months thereafter"
NCT00185393:I.2009,"Patients unable or unwilling to comply with protocol"
NCT00185393:I.3001,Age
NCT00185393:I.3002,Diagnosis
NCT00185393:I.3003,"Lymphoma, Non-Hodgkin (Non-Hodgkins lymphoma)"
NCT00185393:I.3004,"Diagnostic Neoplasm Staging"
NCT00185393:I.3005,"Disease remission"
NCT00185393:I.3006,Medication
NCT00185393:I.3007,Chemotherapy
NCT00185393:I.3008,"Informed Consent"
NCT00185393:I.3009,"First-Line Treatment (primary treatment)"
NCT00185393:I.3010,Radiotherapy
NCT00185393:I.3011,"Recovery - healing process"
NCT00185393:I.3012,"Malignant Neoplasms"
NCT00185393:I.3013,"HIV negative"
NCT00185393:I.3014,"Pleural effusion disorder"
NCT00185393:I.3015,Ascites
NCT00185393:I.3016,pregnant
NCT00185393:I.3017,"Breast feeding, Nursing"
NCT00185393:I.3018,"Serum pregnancy test (B-HCG)"
NCT00185393:I.3019,Contraception
NCT00185393:I.3020,Compliance
NCT00190047:I.1001,"18 Years to 85 Years"
NCT00190047:I.1002,"Patients with ischemic stroke, (that is, stroke that results from a blockage of blood flow to part of the brain), which is accompanied by language dysfunction (e.g. inability to understand speech), visual field defect or inattention to one side of the body or the space around the patient"
NCT00190047:I.1003,"Patients in whom the study treatment can start no less than 1 and not more than 9 hours after the stroke's onset"
NCT00190047:I.1004,"Patients with moderate-severe degree of neurological deficit in the 9 hours after stroke onset (defined as NIHSS score of 7 to 20)"
NCT00190047:I.1005,"Patients that can understand the requirements of the study and are willing to provide written informed consent (If the subject is incapacitated, informed consent will be sought from a legally acceptable representative.)"
NCT00190047:I.2001,"Patients with a brain (intracerebral or subarachnoid) hemorrhage per screening computed tomography scan"
NCT00190047:I.2002,"candidates for thrombolytic therapy for the current stroke"
NCT00190047:I.2003,"patients having a mental impairment that renders them incapable to understand the study's requirements"
NCT00190047:I.2004,"patients with other diseases that in the investigator's opinion may lead, independently of the current stroke, to further deterioration in the subject's neurological status during the trial period, or may confuse the evaluation of the present stroke"
NCT00190047:I.2005,"Patients likely to undergo a procedure involving cardiopulmonary bypass during the study period"
NCT00190047:I.2006,"Patients with medical conditions that may not enable them to complete the study (e.g life-threatening diseases,)"
NCT00190047:I.2007,"Patients whose condition improves already during the screening period"
NCT00190047:I.2008,"Patients who already have functional limitations before the present study (retrospective Modified Rankin Scale score of>3)"
NCT00190047:I.2009,"Patients who suffered a stroke within the past 90 days that seems to have been in the same brain region as the current acute stroke"
NCT00190047:I.2010,"Patients with severe hypertension (systolic BP>210 mm Hg or diastolic BP>120 mm Hg) or hypotension (systolic BP<90 mm Hg),"
NCT00190047:I.2011,"Patients with significant history of renal or liver disease(s) (serum creatinine of>2.0 mg/dL, alanine aminotransferase, aspartate aminotransferase, or gamma-glutamyl transferase values of>threefold the upper normal limit)"
NCT00190047:I.2012,"Patients with a platelet count of<100,000/mm3"
NCT00190047:I.2013,"Female patients of childbearing potential who are not using adequate and effective birth control measures or who are pregnant or lactating (the screening evaluation of female subjects of childbearing potential will include a serum pregnancy test.)"
NCT00190047:I.2014,"Patients who are users of addictive agents, or alcoholics"
NCT00190047:I.2015,"Patients who have received an investigational drug within the 90 days before the present stroke or such that are past recipients of DP-b99"
NCT00190047:I.3001,Age
NCT00190047:I.3002,Diagnosis
NCT00190047:I.3003,"Ischemic stroke"
NCT00190047:I.3004,"Disorder of language"
NCT00190047:I.3005,"Visual field defect"
NCT00190047:I.3006,Hemi-inattention
NCT00190047:I.3007,Onset
NCT00190047:I.3008,NIH-SS
NCT00190047:I.3009,"Neurologic deficit"
NCT00190047:I.3010,"Informed Consent"
NCT00190047:I.3011,Compliance
NCT00190047:I.3012,"Brain hemorrhage"
NCT00190047:I.3013,"Therapeutic procedure"
NCT00190047:I.3014,Medication
NCT00190047:I.3015,"Mental impairment disorders"
NCT00190047:I.3016,"Cardiopulmonary bypass operation"
NCT00190047:I.3017,"Life expectancy"
NCT00190047:I.3018,"Rankin score"
NCT00190047:I.3019,"Hypertensive disease"
NCT00190047:I.3020,Hypotension
NCT00190047:I.3021,Creatinine
NCT00190047:I.3022,"GPT (Serum)"
NCT00190047:I.3023,"GOT (Serum)"
NCT00190047:I.3024,"Gamma Glutamyl Transpeptidase Measurement"
NCT00190047:I.3025,"Platelet count - finding"
NCT00190047:I.3026,pregnant
NCT00190047:I.3027,"Breast feeding, Nursing"
NCT00190047:I.3028,Contraception
NCT00190047:I.3029,"Alcohol abuse"
NCT00190047:I.3030,"Drug abuse"
NCT00190047:I.3031,Enrollment
NCT00195507:I.1001,"18 Years and older"
NCT00195507:I.1002,"Stable, active plaque psoriasis"
NCT00195507:I.1003,"Failure to respond to the following systemic therapies: Methotrexate, Cyclosporine, PUVA or Fumarate"
NCT00195507:I.2001,"Evidence of skin conditions other than psoriasis that would interfere with evaluations of the effect of the study"
NCT00195507:I.2002,"Systemic psoriasis therapy within 28 days prior"
NCT00195507:I.3001,Age
NCT00195507:I.3002,Diagnosis
NCT00195507:I.3003,Psoriasis
NCT00195507:I.3004,"Nummular psoriasis (Plaque psoriasis, Discoid psoriasis)"
NCT00195507:I.3005,Medication
NCT00195507:I.3006,Methotrexate
NCT00195507:I.3007,Ciclosporin
NCT00195507:I.3008,PUVA
NCT00195507:I.3009,Fumarate
NCT00195507:I.3010,"Dermatosis (Skin disorder, Dermatological disease)"
NCT00195507:I.3011,"Systemic Therapy"
NCT00204321:I.1001,"18 Years to 75 Years"
NCT00204321:I.1002,"renal transplantation stable function"
NCT00204321:I.2001,"acute rejection"
NCT00204321:I.3001,Age
NCT00204321:I.3002,"Therapeutic procedure"
NCT00204321:I.3003,Diagnosis
NCT00204321:I.3004,"Renal transplant"
NCT00204321:I.3005,"Functional status of graft"
NCT00204321:I.3006,"Acute rejection of renal transplant"
NCT00204334:I.1001,"18 Years to 75 Years"
NCT00204334:I.1002,"kidney transplant recipient stable kidney function"
NCT00204334:I.1003,"Hb between 10mg/ml and 10.5mg/ml"
NCT00204334:I.2001,"acute rejection"
NCT00204334:I.2002,"Hb above 12.0mg/dl"
NCT00204334:I.3001,Age
NCT00204334:I.3002,"Renal transplant"
NCT00204334:I.3003,"kidney function"
NCT00204334:I.3004,Stability
NCT00204334:I.3005,Hemoglobin
NCT00204334:I.3006,"Acute rejection of renal transplant"
NCT00206167:I.1001,"40 Years and older"
NCT00206167:I.1002,both
NCT00206167:I.1003,"A clinical diagnosis of COPD with symptoms for more than 2 years"
NCT00206167:I.1004,"Smoking history of 10 or more pack years"
NCT00206167:I.1005,"COPD exacerbation within 1-12 months before first visit"
NCT00206167:I.2001,"A history of asthma"
NCT00206167:I.2002,"Patients taking oral steroids"
NCT00206167:I.2003,"Any significant disease or disorder that may jeopardize the safety of the patient"
NCT00214578:I.1001,"Age 18 Years to 65 Years"
NCT00214578:I.1002,"In- or outpatients with schizophrenia, 18-65 years old, requiring a change in treatment due to insufficient efficacy or tolerability and giving signed informed consent."
NCT00214578:I.2001,"Known diabetes mellitus, high HbA1c, fasting plasma glucose and/or high 2h glucose-OGTT"
NCT00214578:I.2002,"Previous use of atypicals (3 months) or other medications that might influence glucose metabolism"
NCT00214578:I.2003,"Contraindications or non-responsiveness for any of the treatments or other safety issues"
NCT00214578:I.2004,"Expected non-compliance to treatment and/or study procedures"
NCT00214578:I.3001,Age
NCT00214578:I.3002,Diagnosis
NCT00214578:I.3003,"Schizophrenic disorders"
NCT00214578:I.3004,"Treatment changed"
NCT00214578:I.3005,Effectiveness
NCT00214578:I.3006,"Informed Consent"
NCT00214578:I.3007,"Diabetes mellitus"
NCT00214578:I.3008,"Hemoglobin A1c (HbA1c)"
NCT00214578:I.3009,"Oral Glucose Tolerance Test (OGTT)"
NCT00214578:I.3010,"Plasma fasting glucose level"
NCT00214578:I.3011,Medication
NCT00214578:I.3012,"Treatment noncompliance"
NCT00220779:I.1001,"18 Years to 55 Years"
NCT00220779:I.1003,"Symptoms consistent with Multiple Sclerosis up to 5 years"
NCT00220779:I.1004,"Diagnosis of multiple sclerosis according to McDonald criteria."
NCT00220779:I.1005,"Diagnosis of relapsing-remitting (RR) multiple sclerosis (MS) (Defined as periods of worsening of neurological function with full recovery or with sequelae and residual deficit upon recovery, periods between disease relapses characterized by lack of disease progression)"
NCT00220779:I.1006,"Kurtzke Extended Disability Status Scale (EDSS)<5.0"
NCT00220779:I.1007,"Females or males, females of childbearing potential must use adequate contraception"
NCT00220779:I.1008,"Clinically stable for at least 30 days prior to entry"
NCT00220779:I.1009,"At least 9 hyperintense T2 lesions on MRI or 1 Gd-enhancing lesion according to McDonald/Barkhof dissemination-in-space criteria at entry"
NCT00220779:I.1010,"Written informed consent obtained prior to the initiation of any study related procedures"
NCT00220779:I.2001,"Females who are pregnant, breast feeding, or if, of childbearing potential, unwilling to practice adequate contraception throughout the study"
NCT00220779:I.2002,"Prior therapy with azathioprine or any immunosuppressant agents within 6 months prior to study entry"
NCT00220779:I.2003,"Prior steroid, methylprednisolone or adrenocorticotropic hormone (ACTH) therapy within 30 days prior to study entry"
NCT00220779:I.2004,"Therapy with interferons (Betaseron(R), Avonex(R), Rebif(R)), glatiramer acetate (Copaxone(R)) or IGIV within 3 months prior to study entry or during the study"
NCT00220779:I.2005,"Use of an investigational compound within 6 months prior to study entry"
NCT00220779:I.2006,"Cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease (CCS III or IV), or malignant hypertension"
NCT00220779:I.2007,"History of renal insufficiency or serum creatinine levels greater than 2.5 mg/dL (221 umol/L)"
NCT00220779:I.2008,"Known selective IgA deficiency or known antibodies to IgA"
NCT00220779:I.2009,"Conditions whose symptoms and effects could alter protein catabolism and/or IgG utilization (e.g., protein-losing enteropathies, nephrotic syndrome)"
NCT00220779:I.3001,age
NCT00220779:I.3003,diagnosis
NCT00220779:I.3004,Medication
NCT00220779:I.3005,"Multiple Sclerosis"
NCT00220779:I.3006,Symptoms
NCT00220779:I.3007,"Multiple Sclerosis, Relapsing-Remitting"
NCT00220779:I.3008,"Stable Disease"
NCT00220779:I.3009,Contraception
NCT00220779:I.3010,"Hyperintense lesions in the basal ganglia on MRI"
NCT00220779:I.3011,"Informed Consent"
NCT00220779:I.3012,pregnant
NCT00220779:I.3013,"Mother currently breast-feeding"
NCT00220779:I.3014,"Immunomodulatory or immunosuppressive therapy"
NCT00220779:I.3015,"Therapeutic Corticosteroid"
NCT00220779:I.3016,steroids
NCT00220779:I.3017,Interferons
NCT00220779:I.3018,"Immunoglobulins, Intravenous"
NCT00220779:I.3019,"glatiramer acetate"
NCT00220779:I.3020,"Cardiac disorder"
NCT00220779:I.3021,"Renal Insufficiency"
NCT00220779:I.3022,"Immunoglobulin A deficiency"
NCT00220779:I.3023,"regulation of protein catabolic process"
NCT00221000:I.1001,"18 Years and older"
NCT00221000:I.1002,"Patients must have a history of RA per the ACR criteria for the classification of RA"
NCT00221000:I.1003,"Patients must have moderately to severely active RA"
NCT00221000:I.1004,"Patients who are not on oral corticosteroids OR Patients who have been on a stable dose of oral corticosteroids at a prednisone equivalent dosage greater than or equal to 15 mg/day for at least 4 weeks prior to screening."
NCT00221000:I.1005,"Patients must have a platelet count greater than or equal to 100,000/cmm."
NCT00221000:I.1006,"Female patients must be one of the following: postmenopausal, surgically incapable of bearing children, practicing an acceptable method of birth control (acceptable methods may include hormonal contraceptives, intrauterine device, and spermicide and barrier). Abstinence or partner/spouse sterility may also qualify at the Investigator's discretion. If a female patient is of childbearing potential, she must have a negative urine pregnancy test at screening."
NCT00221000:I.1007,"Patients must be able and willing to comply with all study procedures"
NCT00221000:I.1008,"Patients must be willing to sign an ICF"
NCT00221000:I.1009,"Patients must have a body weight greater than or equal to 40 kg (88 lb)."
NCT00221000:I.2001,"Patients who have a form of arthritis or arthropathy, other than RA, or any current inflammatory condition that might confound the assessments (e.g., other connective tissue diseases or Lyme disease)."
NCT00221000:I.2002,"Patients who have been enrolled in any investigational therapy study for the treatment of RA within 4 weeks prior to the start of the Treatment Period, or patients who are scheduled to receive investigational therapies or a plasma based apheresis procedure (e.g., a protein A column) for the treatment of RA during the course of the study."
NCT00221000:I.2003,"Patients unable to tolerate the extracorporeal volume shifts associated with ECP treatment due to the presence of any of the following conditions: uncompensated congestive heart failure, pulmonary edema, severe chronic obstructive pulmonary disease, severe asthma, renal failure, or hepatic failure."
NCT00221000:I.2004,"Patients with a poor tolerability of venipuncture or a lack of adequate venous access for required treatments and blood sampling."
NCT00221000:I.2005,"Patients who have a known hypersensitivity or allergy to psoralen (methoxsalen)"
NCT00221000:I.2006,"Patients who have a known hypersensitivity or allergy to both heparin and citrate products"
NCT00221000:I.2007,"Patients who are taking any of the following permitted DMARDs and biological agents and have not been on a stable dose for the specific indicated periods of time prior to screening: MTX for at least 8 weeks; leflunomide for at least 8 weeks; infliximab for at least 14 weeks; etanercept for at least 12 weeks; adalimumab for at least 12 weeks"
NCT00221000:I.2008,"Patients who are taking any of the following permitted medications and have not been on a stable dose for at least 4 weeks prior to screening: NSAIDs; anakinra; hydroxychloroquine; chloroquine; sulfasalazine; D-penicillamine; gold salts; azathioprine; oral corticosteroids (greater than or equal to 15 mg/day, prednisone equivalent dose)."
NCT00221000:I.2009,"Patients whom the Investigator believes cannot be maintained on stable doses of permitted concomitant RA medications throughout the Treatment Period"
NCT00221000:I.2010,"Patients who are taking any of the following prohibited medications: cyclophosphamide; chlorambucil; intramuscular (IM) or intravenous (IV) corticosteroid injection(s), within 4 weeks of screening; intra-articular corticosteroid injection(s)>60 mg prednisone equivalent total dose, within 4 weeks of screening"
NCT00221000:I.2011,"Patients who have any known malignant disease (other than basal cell carcinoma) currently or within the last 5 years"
NCT00221000:I.2012,"Patients who have a pre-existing blood dyscrasia such as bone marrow hypoplasia, leukopenia, thrombocytopenia, significant anemia, or a coagulation disorder"
NCT00221000:I.2013,"Patients with a persistent or severe infection within 12 weeks of screening."
NCT00221000:I.2014,"Patients with a history of drug or alcohol abuse within 12 weeks of screening."
NCT00221000:I.2015,"Patients with impaired hepatic function at screening as shown by abnormal liver function tests (LFT; i.e., aspartate transaminase [AST] or alanine transaminase [ALT]levels>2 x the upper limit of normal [ULN])"
NCT00221000:I.2016,"Women who are pregnant or lactating"
NCT00221000:I.3001,Age
NCT00221000:I.3002,Diagnosis
NCT00221000:I.3003,"Rheumatoid Arthritis"
NCT00221000:I.3004,Moderately
NCT00221000:I.3006,"C-Reactive Protein Measurement"
NCT00221000:I.3007,Medication
NCT00221000:I.3008,Methotrexate
NCT00221000:I.3009,"Therapeutic Corticosteroid"
NCT00221000:I.3010,"Platelet count - finding"
NCT00221000:I.3011,Contraception
NCT00221000:I.3012,Compliance
NCT00221000:I.3013,"Informed Consent"
NCT00221000:I.3014,Weight
NCT00221000:I.3015,Arthritis
NCT00221000:I.3016,Inflammation
NCT00221000:I.3017,Enrollment
NCT00221000:I.3018,"Chronic congestive heart failure"
NCT00221000:I.3019,"Lung diseases"
NCT00221000:I.3020,"Renal Insufficiency"
NCT00221000:I.3021,"Hepatic Insufficiency"
NCT00221000:I.3022,Hypersensitivity
NCT00221000:I.3023,"Nonsteroidal Antiinflammatory Drug"
NCT00221000:I.3024,"Malignant Neoplasms"
NCT00221000:I.3025,"White Blood Cell Count procedure (WBC)"
NCT00221000:I.3026,Hemoglobin
NCT00221000:I.3027,"Blood Coagulation Disorders"
NCT00221000:I.3028,Infection
NCT00221000:I.3029,"Alcohol abuse"
NCT00221000:I.3030,"Drug abuse"
NCT00221000:I.3031,"GOT (Serum)"
NCT00221000:I.3032,"GPT (Serum)"
NCT00221000:I.3033,pregnant
NCT00221000:I.3034,"Breast feeding, Nursing"
NCT00225186:I.1001,"18 to 45 years"
NCT00225186:I.1002,"Female patients with endometriosis-associated pelvic pain"
NCT00225186:I.2001,"Pregnant or lactating women"
NCT00225186:I.2002,"History or suspicion of hormone dependent tumor"
NCT00225186:I.2003,"Therapy resistant endometriosis or need for primary surgical treatment"
NCT00225186:I.2004,"Any other conditions which forbid the participation"
NCT00225186:I.3001,Age
NCT00225186:I.3002,Diagnosis
NCT00225186:I.3003,Gender
NCT00225186:I.3004,"Endometriosis, site unspecified"
NCT00225186:I.3005,Pain
NCT00225186:I.3006,pregnant
NCT00225186:I.3007,"Breast feeding, Nursing"
NCT00225186:I.3008,"Malignant Neoplasms"
NCT00226408:I.1001,"18 Years to 70 Years"
NCT00226408:I.1002,"Histological documented cutaneous malignant melanoma Stage IIIa, IIIb, IIIc (AJCC 2002)"
NCT00226408:I.1003,"R0 resection dating back no longer than 56 days"
NCT00226408:I.1004,"Performance status (ECOG 0-1)"
NCT00226408:I.1005,"Bone marrow funktion: White cell count>3000 cells/ul, platletts>100000 cells/ul, hemoglobin>10 g/dl"
NCT00226408:I.1006,"Liver and kidney funktion: Serum creatinin<1.5 times upper limit of normal, AST and ALT<2.5 times upper limit of normal, Serum bilirubin<2 times upper limit of normal"
NCT00226408:I.1007,"Written inform consent"
NCT00226408:I.2001,"Confirmed distant metastasis"
NCT00226408:I.2002,"Choroid or mucosal melanoma"
NCT00226408:I.2003,"Pregnant or lactating women and women of childbearing potential not using a reliable form of contraception"
NCT00226408:I.2004,"Active autoimmun disease"
NCT00226408:I.2005,"patients with history of neuropsychiatric disease requiring hospitalization"
NCT00226408:I.2006,"Severe medical condition such us: Florid hepatitis, Severe acute infection, Myocardial infarction within the past year, symptomatic angina pectoris, Grade III to IV congestive heart failure, serious pulmonary disease, HIV-positive patients with an AIDS - defining condition"
NCT00226408:I.2007,"treatment in another clinical drug trial within the last 30 days"
NCT00226408:I.2008,"A history of hypersensitivity to interferon alfa"
NCT00226408:I.2009,"History of maignant disease during the past 5 years (except for curatively treated skin carcinoma or in situ carcinoma)"
NCT00226408:I.2010,"Prior high dose interferon alfa therapy.Prior adjuvant low dose or intermediate-dose interferon alfa therapy is allowed"
NCT00226408:I.3001,Age
NCT00226408:I.3002,Diagnosis
NCT00226408:I.3003,"Malignant melanoma"
NCT00226408:I.3004,"Diagnostic Neoplasm Staging"
NCT00226408:I.3005,"Therapeutic procedure"
NCT00226408:I.3006,"ECOG performance status finding"
NCT00226408:I.3007,"White Blood Cell Count procedure (WBC)"
NCT00226408:I.3008,"Platelet count - finding"
NCT00226408:I.3009,Hemoglobin
NCT00226408:I.3010,Creatinine
NCT00226408:I.3011,"GOT (Serum)"
NCT00226408:I.3012,"GPT (Serum)"
NCT00226408:I.3013,Bilirubin
NCT00226408:I.3014,"Informed Consent"
NCT00226408:I.3015,Metastasis
NCT00226408:I.3016,pregnant
NCT00226408:I.3017,"Breast feeding, Nursing"
NCT00226408:I.3018,Contraception
NCT00226408:I.3019,"Autoimmune Disease"
NCT00226408:I.3020,"Psychosis (Psychotic disorder)"
NCT00226408:I.3021,Hepatitis
NCT00226408:I.3022,"Systemic infection"
NCT00226408:I.3023,"Heart infarction"
NCT00226408:I.3024,"Chronic congestive heart failure"
NCT00226408:I.3025,"Lung diseases"
NCT00226408:I.3026,"Acquired Immunodeficiency Syndrome"
NCT00226408:I.3027,Enrollment
NCT00226408:I.3028,Hypersensitivity
NCT00226408:I.3029,"Malignant Neoplasms"
NCT00226408:I.3030,Medication
NCT00233662:I.1001,"16 Years and older"
NCT00233662:I.1002,"Written informed consent"
NCT00233662:I.1003,"Diagnosed with chronic plaque psoriasis and require systemic therapy"
NCT00233662:I.1004,"CD4+ lymphocyte counts at or above the lower limit of normal for Covance Central Laboratory Services, Inc., unless on a stable dose of prednisone (counts must be at or above 300 cells/mm3)."
NCT00233662:I.2001,"Unstable erthrodermic or pustular psoriasis"
NCT00233662:I.2002,"Diagnosis of guttate psoriasis"
NCT00233662:I.2003,"Serious local infection or systemic infection within 3 months prior to first dose of alefacept"
NCT00233662:I.2004,"Positive for HIV antibody"
NCT00233662:I.2005,"Known invasive malignancy within 5 years of enrollment. Patients with a history of treated squamous cell and/or basal cell carcinomas limited to the skin are not excluded"
NCT00233662:I.2006,"Evidence of active tuberculosis, Current treatment for active tuberculosis or tuberculosis prophylaxis"
NCT00233662:I.2007,"Female patients unwilling to practice effective contraception as defined by the investigator"
NCT00233662:I.2008,"Female patients who are pregnant or breast-feeding"
NCT00233662:I.2009,"Current enrollment in any other investigational drug study"
NCT00233662:I.2010,"Previous participation in this study or previous alefacept studies"
NCT00233662:I.3001,Age
NCT00233662:I.3002,"Informed Consent"
NCT00233662:I.3003,Diagnosis
NCT00233662:I.3004,Psoriasis
NCT00233662:I.3005,"Systemic Therapy"
NCT00233662:I.3006,"Absolute CD4 count procedure"
NCT00233662:I.3007,"exfoliative psoriasis"
NCT00233662:I.3008,"Psoriasis guttata"
NCT00233662:I.3009,"pustular psoriasis"
NCT00233662:I.3010,Infection
NCT00233662:I.3011,"Human immunodeficiency virus infection"
NCT00233662:I.3012,"Malignant Neoplasms"
NCT00233662:I.3013,Medication
NCT00233662:I.3014,TBC
NCT00233662:I.3015,Contraception
NCT00233662:I.3016,pregnant
NCT00233662:I.3017,"Breast feeding, Nursing"
NCT00233662:I.3018,Enrollment
NCT00235144:I.1001,"18 years and older"
NCT00235144:I.1002,"Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR patients with documented silent ischemia"
NCT00235144:I.1003,"Treatment of a single de novo native coronary artery lesion in a major coronary artery in patients with single or multi-vessel disease; patients with multiple lesions can be included only if the other lesions do not require treatment"
NCT00235144:I.1004,"Target vessel diameter at the lesion site is>=2.50mm and<=3.0mm in diameter (visual estimate)"
NCT00235144:I.1005,"Target lesion is>=15mm and<=32mm in length (visual estimate)"
NCT00235144:I.1006,"Target lesion stenosis is>50% and<100% (visual estimate)"
NCT00235144:I.2001,"Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK>2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment"
NCT00235144:I.2002,"Has unstable angina classified as Braunwald III B or C and A I-II-III, or is having a peri infarction"
NCT00235144:I.2003,"Unprotected left main coronary disease with>=50% stenosis"
NCT00235144:I.2004,"Significant (>50%) stenoses proximal or distal to the target lesion that might require revascularization or impede runoff"
NCT00235144:I.2005,"Have an ostial target lesion"
NCT00235144:I.2006,"Angiographic evidence of thrombus within target lesion"
NCT00235144:I.2007,"Heavily calcified lesion and/or calcified lesion which cannot be successfully predilated"
NCT00235144:I.2008,"Documented left ventricular ejection fraction<=25%"
NCT00235144:I.3001,Age
NCT00235144:I.3002,Diagnosis
NCT00235144:I.3003,"Ischemic chest pain"
NCT00235144:I.3004,"Canadian Cardiovascular Society classification of angina"
NCT00235144:I.3005,"Single vessel disease"
NCT00235144:I.3006,"Double vessel disease"
NCT00235144:I.3007,"Triple vessel disease"
NCT00235144:I.3008,"Coronary artery disease (CAD)"
NCT00235144:I.3009,"Vessel lumen diameter"
NCT00235144:I.3010,"Stenotic lesion length"
NCT00235144:I.3011,Stenosis
NCT00235144:I.3012,"Acute myocardial infarction"
NCT00235144:I.3013,CK
NCT00235144:I.3014,CK-MB
NCT00235144:I.3015,"OPERATIONS / PROCEDURES"
NCT00235144:I.3016,"Coronary arteriography"
NCT00235144:I.3017,Thrombus
NCT00235144:I.3018,Calcification
NCT00235144:I.3019,"Cardiac ejection fraction"
NCT00240474:I.1001,"aged at least 60 years old"
NCT00240474:I.1002,"mean SBP>140 mmHg and mean DBP<=95 mmHg"
NCT00240474:I.1003,"24-hour mean ambulatory SBP>125 mmHg"
NCT00240474:I.1004,"hypertensive patients not on current antihypertensive therapy or able to stop their current treatment for a period of up to eighteen weeks"
NCT00240474:I.1005,"willing and able to provide written informed consent"
NCT00240474:I.2001,"women of child-bearing potential who are NOT practicing acceptable means of birth control"
NCT00240474:I.2002,"known or suspected secondary hypertension"
NCT00240474:I.2003,"mean SBP>=200 mmHg"
NCT00240474:I.2004,"hepatic and/or renal dysfunction as defined by the following laboratory parameters:               Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney. Clinically relevant hypokalemia or hyperkalemia.  Uncorrected volume or sodium depletion."
NCT00240474:I.2005,"Primary aldosteronism, unspecified"
NCT00240474:I.2006,"Hereditary fructose intolerance syndrome"
NCT00240474:I.2007,"Biliary Obstruction"
NCT00240474:I.2008,"patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists"
NCT00240474:I.2009,"history of drug or alcohol dependency within the previous six months"
NCT00240474:I.2010,"chronic administration of any medication known to affect blood pressure, other than the trial medication"
NCT00240474:I.2011,"concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form."
NCT00240474:I.2012,"symptomatic congestive heart failure (New York Heart Academy (NYHA) functional class CHF II-IV)"
NCT00240474:I.2013,"unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery<3 months prior to informed consent"
NCT00240474:I.2014,"stroke<6 months prior to informed consent"
NCT00240474:I.2015,"sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant arrhythmias as determined by the investigator"
NCT00240474:I.2016,"hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve"
NCT00240474:I.2017,"insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for the previous three months"
NCT00240474:I.2018,"night-shift workers who routinely sleep during the daytime and whose working hours include midnight to 4:00 AM"
NCT00240474:I.2019,"known allergic hypersensitivity to any component of the formulations under investigation"
NCT00240474:I.2020,"concomitant therapy with lithium, cholestyramine or colestipol resins. non-compliance with study medication (defined as<80% or>120%) during the run-in period"
NCT00240474:I.2021,"current treatment with any antihypertensive agent"
NCT00240474:I.2022,"any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan, amlodipine or hydrochlorothiazide"
NCT00241514:I.1001,"Age 18 Years and older"
NCT00241514:I.1002,"Signed informed consent."
NCT00241514:I.1003,"Completed the SH-NEN-0001 study with relief of upper GI symptom. Relief is defined as""last 7 days with a diary assessment of None or Minimal, but allowing up to 2 days to be rated as Mild during the 7-day period""."
NCT00241514:I.1004,"A clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily NSAID treatment for at least 6 months. Daily NSAID treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include COX-2 selective NSAIDs, multiple NSAIDs, and high-dose NSAIDs."
NCT00241514:I.1005,"Daily NSAID treatment dose and type: (Must have been stable for at least 9 weeks prior to inclusion and. Are expected to remain stable for the duration of the study. and. Must be administered orally. If more than one type of NSAID treatment is used, at least one type must be administered orally)."
NCT00241514:I.1006,"Hp negative on Histology performed at baseline endoscopy in the study SHNEN- 0001."
NCT00241514:I.2001,"Discontinuation from study SH-NEN-0001"
NCT00241514:I.2002,"Pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation."
NCT00241514:I.2003,"Pain, discomfort or burning in the upper abdomen not associated with the use of NSAIDs, including COX-2 selective NSAIDs."
NCT00241514:I.2004,"Pregnancy or lactation. Women of childbearing potential must maintain effective contraception during the study period as judged by the investigator."
NCT00241514:I.2005,"Need for continuous concomitant therapy with: (Anticoagulants, Corticosteroids at doses higher than explained under inclusion criterion)"
NCT00241540:I.1001,"18 years of age, or older"
NCT00241540:I.1002,"Capable of completing the diary card"
NCT00241540:I.1003,"Ability to complete the HRQL questionnaires"
NCT00241540:I.1004,"A clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily NSAID treatment for at least 7 months."
NCT00241540:I.1005,"Daily NSAID treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include COX-2 selective NSAIDs, multiple NSAIDs, and high-dose aspirin (>325 mg/day)."
NCT00241540:I.1006,"Daily NSAID treatment dose and type: (Must have been stable for at least 4 weeks prior to baseline endoscopy and. Are expected to remain stable for the duration of the study. and. Must be administered orally for the duration of the study. If more than one type of NSAID treatment is used, at least one type must be given orally)."
NCT00241540:I.2001,"Current, or history of, gastric or duodenal ulcer"
NCT00241540:I.2002,"Current, or history of, esophageal, gastric or duodenal surgery."
NCT00241540:I.2003,"History of GERD, not associated with NSAID use."
NCT00241540:I.2004,"Pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation."
NCT00241540:I.2005,"Pain, discomfort or burning in the upper abdomen not associated with the use of NSAIDs, including COX-2 selective NSAIDs, as judged by the investigator."
NCT00241540:I.2006,"Endoscopic Barrett's esophagus(>3 cm) or significant dysplastic changes in the esophagus"
NCT00242775:I.1001,"Age 12 Years and older"
NCT00242775:I.1002,"Diagnosed with asthma since at least 6 months prior to first visit"
NCT00242775:I.1003,"Prescribed daily use of glucocorticosteroids for at least 3 months prior to first visit"
NCT00242775:I.1004,"At least one asthma exacerbation>1 but<12  months prior to first visit"
NCT00242775:I.2001,"Respiratory infection affecting asthma within 30 days before first visit"
NCT00242775:I.2002,"Use of oral, rectal, or parenteral glucocorticosteroids for within 30 days before first visit"
NCT00242775:I.2003,"Any significant disease or disorder that may jeopardize the safety of the patient"
NCT00242801:I.1001,"Age 18 Years and older"
NCT00242801:I.1002,"Life expectancy of at least 8 weeks.                Histologically or cytologically confirmed non-small cell bronchogenic carcinoma: adenocarcinoma (including bronchoalveolar), squamous cell carcinoma, large cell carcinoma or mixed (adenocarcinoma and squamous) or undifferentiated carcinoma.                           Not suitable for chemotherapy.               WHO Performance status<=3."
NCT00242801:I.2001,"Newly diagnosed CNS mets"
NCT00242801:I.2002,"<1 week since completion of prior radiotherapy or persistence of any radiotherapy related toxicity"
NCT00242801:I.2003,"ALT/AST>5 x upper limit of normal"
NCT00242801:I.2004,"ANC<1.0 x 109/L or platelets<100 x 109/L"
NCT00244465:I.1001,"Patients who received Xyrem on prescription"
NCT00244465:I.2001,"No limitations"
NCT00245765:I.1001,"men and women>18 years"
NCT00245765:I.1002,"Chronic plaque psoriasis stable for at least 3 months and moderate to severe for at least 6 months"
NCT00245765:I.1003,"PASI ? 12 and BSA ? 10%"
NCT00245765:I.1004,"Candidates for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy"
NCT00245765:I.2001,"Erythrodermic, guttate, palmar or plantar, generalized pustular form of psoriasis"
NCT00245765:I.2002,"A history of chronic infection, recent serious or life-threatening infection (within six months, including herpes zoster), or any current sign or symptom that may indicate an infection (e.g. fever, cough)"
NCT00245765:I.2003,"Leukocyte Count, White Blood Cell Count procedure (WBC)"
NCT00245765:I.2004,"Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis)"
NCT00245765:I.2005,"Lupus Erythematosus, Systemic"
NCT00245765:I.2006,"Non respect of adequate wash out periods for treatments that might have an impact on the disease"
NCT00245765:I.2007,"Any associated disease that could be impacted by the study treatment intake"
NCT00245765:I.2008,"Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study"
NCT00246974:I.1001,"Age 18 Years and older"
NCT00246974:I.1002,"Histologically or cytologically-confirmed transitional cell carcinoma of the urothelium"
NCT00246974:I.1003,"Locally advanced or metastatic disease"
NCT00246974:I.1004,"At least one measurable lesion as defined by RECIST"
NCT00246974:I.1005,Chemotherapy-naiv
NCT00246974:I.2001,"Previous chemotherapy or other systemic antitumour therapy"
NCT00246974:I.2002,"Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma, cervical cancer in situ or locally limited prostate cancer"
NCT00247390:I.1001,"Age 18 years and older"
NCT00247390:I.1002,"Females of childbearing potential who are sexually active must agree to use adequate contraception"
NCT00247390:I.1003,"Females of childbearing potential can neither be pregnant nor lactating from Screening throughout the duration of the study"
NCT00247390:I.1004,"Body mass index between 18 and 34, inclusive"
NCT00247390:I.1005,"Based on sleep history, has had chronic insomnia for at least 3 months"
NCT00247390:I.1006,"Based on sleep history, reports a subjective sleep latency greater than or equal to 45 min"
NCT00247390:I.1007,"Based on sleep history, reports a subjective total sleep time less than or equal to 6.5 hours"
NCT00247390:I.1008,"Based on sleep history, habitual bedtime is between 10:00 PM and 1:00 AM"
NCT00247390:I.1009,"Mean latency to persistent sleep of greater than 20 minutes on two consecutive screening nights with neither night less than 15 minutes"
NCT00247390:I.1010,"A mean of 60 minutes of wake time during the 480 minutes in bed across two nights with no night less than 45 minutes"
NCT00247390:I.1011,"Based on sleep history, normally uses pharmacological assistance to sleep 0 to 4 times per week in the last 3 months"
NCT00247390:I.2001,"Known hypersensitivity to ramelteon or related compounds, including melatonin, and melatonin related compounds"
NCT00247390:I.2002,"Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first dose of single-blind study medication, whichever is longer"
NCT00247390:I.2003,"Sleep schedule changes required by employment (eg, shift worker) within three months prior to the administration of single-blind study medication"
NCT00247390:I.2004,"Flown across greater than three time zones within 7 days prior to or during screening"
NCT00247390:I.2005,"Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of single-blind study medication"
NCT00247390:I.2006,"Has ever had a history of seizures, sleep apnea, restless leg syndrome, periodic leg movement syndrome, chronic obstructive pulmonary disease or fibromyalgia"
NCT00247390:I.2007,"History of psychiatric disorder within the past 6 months"
NCT00247390:I.2008,"History of alcohol abuse within the past 12 months, as defined in Diagnostic&Statistical Manual of Mental Disorders, 4th Edition Revised, or regularly consumes more than 14 alcoholic drinks per week, or consumed any alcoholic drinks within 24 hours of any polysomnogram visits"
NCT00247390:I.2009,"History of drug abuse within the past 12 months, as defined in Diagnostic&Statistical Manual of Mental Disorders, 4th Edition Revised"
NCT00247390:I.2010,"Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, neurological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of single-blind study medication"
NCT00247390:I.2011,"Apnea hypopnea index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night"
NCT00247390:I.2012,"Periodic Leg Movement Syndrome with arousal index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night"
NCT00247390:I.2013,"Positive urine drug screen at Screening Visit 1 or any of the polysomnogram assessment visits"
NCT00247390:I.2014,"Positive breathalyzer test on any of the polysomnogram assessment visits"
NCT00247390:I.2015,"Uses tobacco products (including nicotine gum and patch) or any other products that may interfere with the sleep wake cycle during nightly awakenings"
NCT00247390:I.2016,"Used any central nervous system medication or other drugs or supplements known to affect sleep/wake function within 1 week (or 5 half lives of the drug, whichever is longer) prior to the administration of single-blind study medication. These medications must not have been used to treat psychiatric disorders."
NCT00247390:I.2017,"Intends to continue taking any disallowed medication or any prescription medication or over the counter medication that is known to affect the sleep/wake function or otherwise interfere with evaluation of the study medication. The subject must report all prescription and over the counter medications taken in the three weeks prior to screening"
NCT00247390:I.2018,"Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:"
NCT00247390:I.2019,Anxiolytics
NCT00247390:I.2020,Sedatives
NCT00247390:I.2021,Hypnotics
NCT00247390:I.2022,"CNS active drugs (including herbal)"
NCT00247390:I.2023,Antidepressants
NCT00247390:I.2024,"Narcotic analgesics"
NCT00247390:I.2025,Anticonvulsants
NCT00247390:I.2026,"Beta blockers"
NCT00247390:I.2027,"Sedating H1 antihistamines"
NCT00247390:I.2028,"St. John's Wort"
NCT00247390:I.2029,"Systemic steroids"
NCT00247390:I.2030,Kava-kava
NCT00247390:I.2031,"Respiratory stimulants"
NCT00247390:I.2032,Ginkgo-biloba
NCT00247390:I.2033,Decongestants
NCT00247390:I.2034,"Over-the-counter and prescription stimulants"
NCT00247390:I.2035,Antipsychotics
NCT00247390:I.2036,"Over-the-counter and prescription diet aids"
NCT00247390:I.2037,"Muscle Relaxants"
NCT00247390:I.2038,"Melatonin and all other drugs or supplements known to affect sleep/wake function"
NCT00247390:I.2039,"Any additional condition(s) that in the Investigator's opinion would affect sleep/wake function, prohibit the subject from completing  the study, indicate that continuation in the study would not be in the best interests of the subject"
NCT00247390:I.2040,"History of hepatitis B or hepatitis C"
NCT00247390:I.3001,Age
NCT00247390:I.3002,Diagnosis
NCT00247390:I.3003,Contraception
NCT00247390:I.3004,"Breast feeding, Nursing"
NCT00247390:I.3005,pregnant
NCT00247390:I.3006,"Body mass index"
NCT00247390:I.3007,"Chronic Insomnia"
NCT00247390:I.3008,"Reduced sleep latency"
NCT00247390:I.3009,Bedtime
NCT00247390:I.3010,"Allergic reaction to substance"
NCT00247390:I.3011,"Ramelteon (substance)"
NCT00247390:I.3012,"Melatonin (substance)"
NCT00247390:I.3013,"Blind study"
NCT00247390:I.3014,Medication
NCT00247390:I.3015,"Time zone"
NCT00247390:I.3016,Screening
NCT00247390:I.3017,"Weight loss advised"
NCT00247390:I.3018,Convulsion
NCT00247390:I.3019,"SAS - Sleep apnea syndrome"
NCT00247390:I.3020,"Restless legs syndrome"
NCT00247390:I.3021,"Periodic leg movements of sleep"
NCT00247390:I.3022,"Chronic Obstructive Pulmonary Disease"
NCT00247390:I.3023,Fibromyalgia
NCT00247390:I.3024,"Psychiatric disorder"
NCT00247390:I.3025,"Alcohol abuse"
NCT00247390:I.3026,"Drug abuse"
NCT00247390:I.3027,"Liver diseases"
NCT00247390:I.3028,"Kidney Diseases"
NCT00247390:I.3029,"Endocrine system diseases"
NCT00247390:I.3030,"Disease affecting entire cardiovascular system"
NCT00247390:I.3031,"Disorder of gastrointestinal tract"
NCT00247390:I.3032,"Lung diseases"
NCT00247390:I.3033,"Diseases of blood and bloodforming organs"
NCT00247390:I.3034,"Neurological disorder"
NCT00247390:I.3035,"MD - metabolic disorders"
NCT00247390:I.3036,"Periodic limb movement disorder (PLMD)"
NCT00247390:I.3037,"Urine drug screen positive"
NCT00247390:I.3038,Polysomnogram
NCT00247390:I.3039,"Breathalyzer test"
NCT00247390:I.3040,positive
NCT00247390:I.3041,"Use of tobacco products at least daily"
NCT00247390:I.3042,"Nicotine chewing gum"
NCT00247390:I.3043,"Nicotine m/r transdermal patch"
NCT00247390:I.3044,"Organic disorder of sleep wake cycle"
NCT00247390:I.3045,"Central nervous system agents"
NCT00247390:I.3046,"Single-blind study"
NCT00247390:I.3047,"Misuse of over-the-counter medications"
NCT00247390:I.3048,"Herbal drugs"
NCT00247390:I.3049,"Anxiolytic Agents"
NCT00247390:I.3050,"Sedative (substance)"
NCT00247390:I.3051,"Hypnotic agent"
NCT00247390:I.3052,"Antidepressive Agents"
NCT00247390:I.3053,"Narcotic analgesic product"
NCT00247390:I.3054,"Anticonvulsant (substance)"
NCT00247390:I.3055,"Adrenergic beta-Antagonists"
NCT00247390:I.3056,"H1 antihistamine (substance)"
NCT00247390:I.3057,"St. John's Wort"
NCT00247390:I.3058,"Long term (current) use of systemic steroids"
NCT00247390:I.3059,"Kava kava"
NCT00247390:I.3060,"Respiratory stimulant (substance)"
NCT00247390:I.3061,"Ginkgo biloba extract"
NCT00247390:I.3062,"Decongestant preparation"
NCT00247390:I.3063,"Stimulant (substance)"
NCT00247390:I.3064,"Prescription (procedure)"
NCT00247390:I.3065,"Antipsychotic agent (substance)"
NCT00247390:I.3066,"Diet Aid"
NCT00247390:I.3067,"Muscle relaxants"
NCT00247390:I.3068,"Type B viral hepatitis"
NCT00247390:I.3069,"Viral hepatitis C"
NCT00251901:I.1001,"Age 18 Years to 70 Years"
NCT00251901:I.1002,"Pain or discomfort in the chest without any identifiable cause and severe enough for the patient to seek primary medical or similar care"
NCT00251901:I.1003,"History of pain or discomfort in the chest for at least the last two weeks prior to enrollment"
NCT00251901:I.2001,"Signs, symptoms or relevant investigations suggestion present symptomatic coronary heart disease"
NCT00251901:I.2002,"Patients whose pain or discomfort in the chest warrants urgent cardiac investigation"
NCT00251901:I.3001,Age
NCT00251901:I.3002,Diagnosis
NCT00251901:I.3003,"Chest Pain"
NCT00251901:I.3004,"Past medical history"
NCT00251901:I.3005,"Medical care, unspecified"
NCT00251901:I.3006,Enrollment
NCT00251901:I.3007,"Coronary artery disease (CAD)"
NCT00251901:I.3008,Investigation
NCT00251901:I.3009,Cardiac
NCT00251966:I.1001,"Age>= 60 years"
NCT00251966:I.1002,"A clinical diagnosis of a condition (cardiovascular and/or cerebrovascular protection or other reasons) that requires daily intake of low-dose ASA, 75-325 mg, and is expected to continue for the duration of the study (daily is defined as at least 5 days per week)"
NCT00251966:I.1003,"No gastric and/or duodenal ulcer at the baseline endoscopy"
NCT00251966:I.1004,"H. pylori negative by serology test at screening"
NCT00251966:I.2001,"Upper GI symptoms"
NCT00251966:I.2002,"Erosive oesophagitis"
NCT00251966:I.2003,Malignancy
NCT00251966:I.3001,Age
NCT00251966:I.3002,Diagnosis
NCT00251966:I.3003,"Acetylsalicylic Acid (ASA)"
NCT00251966:I.3004,"Gastric ulcer"
NCT00251966:I.3005,"Duodenal Ulcer"
NCT00251966:I.3006,"Endoscopy (procedure)"
NCT00251966:I.3007,"Helicobacter pylori"
NCT00251966:I.3008,Negative
NCT00251966:I.3009,"Serologic test (procedure)"
NCT00251966:I.3010,Screening
NCT00251966:I.3011,"Upper Gastrointestinal Series"
NCT00251966:I.3012,"Erosive oesophagitis"
NCT00251966:I.3013,"Malignant Neoplasms"
NCT00252863:I.1001,"Age 18 Years and older"
NCT00252863:I.1002,"Patients with asthma, either well-controlled on a regular therapy with a combination of long-acting beta-agonists and inhaled corticosteroids or symptomatic on therapy with inhaled corticosteroids alone"
NCT00252863:I.2001,"Any other significant lung disease other than asthma"
NCT00252863:I.2002,"Any disease that might put patients at risk if they participate in the study"
NCT00252863:I.3001,Age
NCT00252863:I.3002,Diagnosis
NCT00252863:I.3003,Asthma
NCT00252863:I.3004,treatment
NCT00252863:I.3005,"Beta-adrenoceptor agonist"
NCT00252863:I.3006,"Therapeutic Corticosteroid"
NCT00252863:I.3007,"Lung diseases"
NCT00252863:I.3008,"disease risk"
NCT00255281:I.1001,"Age 18 Years to 80 Years"
NCT00255281:I.1002,"Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity"
NCT00255281:I.2001,"Clinically significant sinus and/or AV node dysfunction. Serum or plasma potassium<3.8 mmol/L or>5.0 mmol/L. QTc(Bazett)>450 ms. Any QRS duration>150 ms"
NCT00255281:I.3001,Age
NCT00255281:I.3002,Diagnosis
NCT00255281:I.3003,Cardioversion
NCT00255281:I.3004,"Atrial fibrillation"
NCT00255281:I.3005,"Use of anticoagulation"
NCT00255281:I.3006,"Echocardiography, Transesophageal"
NCT00255281:I.3007,Thrombus
NCT00255281:I.3008,"Coronary sinus rhythm disorder"
NCT00255281:I.3009,"Atrioventricular nodal disease"
NCT00255281:I.3010,"Serum potassium abnormal"
NCT00255281:I.3011,"Plasma potassium abnormal"
NCT00261352:I.1001,"Men or women who are>=18 years of age"
NCT00261352:I.1002,"Provision of a written informed consent"
NCT00261352:I.1003,"Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control"
NCT00261352:I.1004,"Diagnosed with type 2 diabetes"
NCT00261352:I.1005,"Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents"
NCT00261352:I.2001,"Type 1 diabetes"
NCT00261352:I.2002,"New York Heart Association heart failure Class III or IV"
NCT00261352:I.2003,"Treatment with chronic insulin"
NCT00261352:I.2004,"History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)"
NCT00261352:I.2005,"History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)"
NCT00261352:I.2006,"Creatinine levels above the normal range"
NCT00261352:I.2007,"Received any investigational product in other clinical studies within 12 weeks"
NCT00261352:I.2008,"Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study"
NCT00261352:I.3001,Age
NCT00261352:I.3002,Diagnosis
NCT00261352:I.3003,"Informed Consent"
NCT00261352:I.3004,"Postmenopausal period"
NCT00261352:I.3005,Hysterectomy
NCT00261352:I.3006,Contraception
NCT00261352:I.3007,"Diabetes Mellitus, Non-Insulin-Dependent"
NCT00261352:I.3008,Diet
NCT00261352:I.3009,"Anti-diabetic Agent"
NCT00261352:I.3010,"Diabetes Mellitus, Insulin-Dependent"
NCT00261352:I.3011,"Heart failure"
NCT00261352:I.3012,"New York Heart Association Class III"
NCT00261352:I.3013,"New York Heart Association Class IV"
NCT00261352:I.3014,"Therapeutic Insulin"
NCT00261352:I.3015,Insulin
NCT00261352:I.3016,chronic
NCT00261352:I.3017,Hypersensitivity
NCT00261352:I.3018,"intolerance to substance"
NCT00261352:I.3019,peroxisome
NCT00261352:I.3020,"Fenofibrate (substance)"
NCT00261352:I.3021,"Metformin (substance)"
NCT00261352:I.3022,"Pioglitazone hydrochloride"
NCT00261352:I.3023,"Rosiglitazone maleate"
NCT00261352:I.3024,"Hydroxymethylglutaryl-CoA Reductase Inhibitors"
NCT00261352:I.3025,Myopathy
NCT00261352:I.3026,"Abnormalities, Drug-Induced"
NCT00261352:I.3027,"Creatine Kinase"
NCT00261352:I.3028,"Elevated liver enzyme levels"
NCT00261352:I.3029,Neutropenia
NCT00261352:I.3030,"Creatinine abnormal NOS"
NCT00261352:I.3031,"Clinical study"
NCT00261352:I.3032,"Physical examination procedure"
NCT00261352:I.3033,"Laboratory test"
NCT00261352:I.3034,Electrocardiogram
NCT00261352:I.3035,"patient safety"
NCT00264056:I.1001,"age between 18 and 70"
NCT00264056:I.1002,"histologically proven malignant melanoma with advanced inoperable soft tissue metastases"
NCT00264056:I.1003,"progressive disease upon systemic first-line chemotherapy"
NCT00264056:I.1004,"2 or more bidimensionally measurable soft tissue lesions"
NCT00264056:I.1005,"WHO performance status (ECOG) of 2 or more"
NCT00264056:I.1006,"life expectancy of 8 weeks and more"
NCT00264056:I.1007,"prior informed consent"
NCT00264056:I.2001,"participation in other therapy studies"
NCT00264056:I.2002,"pregnancy or breast feeding"
NCT00264056:I.2003,"concomitant clinically significant infection"
NCT00264056:I.2004,"cardiac pacemaker or other medical implants, or implants within the hyperthermia treated region (including a safe distance of 5 cm)"
NCT00264056:I.2005,"lack of physiological heat sensitivity within the hyperthermia treated region (including a safe distance of 5 cm)"
NCT00264056:I.3001,Age
NCT00264056:I.3002,Diagnosis
NCT00264056:I.3003,"Malignant melanoma"
NCT00264056:I.3004,"Secondary malignant neoplasm of soft tissues"
NCT00264056:I.3005,"Progressive Disease"
NCT00264056:I.3006,"Systemic Chemotherapy"
NCT00264056:I.3007,"Soft tissue lesion"
NCT00264056:I.3008,"ECOG performance status finding"
NCT00264056:I.3009,"ECOG performance status - grade 2"
NCT00264056:I.3010,"Life expectancy"
NCT00264056:I.3012,"Informed Consent"
NCT00264056:I.3013,Pregnancy
NCT00264056:I.3014,"Breast feeding, Nursing"
NCT00264056:I.3015,Infection
NCT00264056:I.3016,"Artificial cardiac pacemaker"
NCT00264056:I.3017,"Biomedical implant"
NCT00264056:I.3018,"Hyperthermia Treatment"
NCT00264056:I.3019,"Intolerant of heat"
NCT00272948:I.1001,"Age<18 years"
NCT00272948:I.1002,"myeloablative conditioning and autologous or allogeneic stem cell transplantation with at least one of the following risk factors for VOD: Pre-existing liver disease, Second myeloablative HSCT, History of treatment with gemtuzumab ozogamicin (MYLOTARGO, GO, CMA-676, Wyeth), Allogeneic HSCT for leukemia beyond the second relapse, Osteopetrosis (OP), Conditioning with busulfan and melphalan, Macrophage activating syndromes (MAS, like hemophagocytic lymphohistiocytosis, Griscelli, Chediak-Higashi), Adrenoleukodystrophy (ALD)"
NCT00272948:I.2001,"Pregnant patients"
NCT00272948:I.2002,"Patients who are transplanted but do not fulfill any of the above mentioned criteria"
NCT00272948:I.3001,Age
NCT00272948:I.3002,Diagnosis
NCT00272948:I.3003,"Stem cell transplantation"
NCT00272948:I.3004,"Autologous Hematopoietic Stem Cell Transplantation"
NCT00272948:I.3005,"Allogeneic Hematopoietic Stem Cell Transplantation, HSCT"
NCT00272948:I.3006,"Venoocclusive disease"
NCT00272948:I.3007,"Liver diseases"
NCT00272948:I.3008,"Gemtuzumab ozogamicin, CMA-676"
NCT00272948:I.3009,leukemia
NCT00272948:I.3010,"Recurrent Disease"
NCT00272948:I.3011,"Albers-Schonberg disease"
NCT00272948:I.3012,Myleran
NCT00272948:I.3013,Melphalan
NCT00272948:I.3014,"Macrophage-Activating Factors"
NCT00272948:I.3015,"Hemophagocytic Lymphohistiocytosis"
NCT00272948:I.3016,"Chediak-Higashi Syndrome"
NCT00272948:I.3017,Adrenoleukodystrophy
NCT00272948:I.3018,pregnant
NCT00272948:I.3019,"Transplant procedure"
NCT00273338:I.1001,"Age>= 18 years"
NCT00273338:I.1002,"Histopathologically or cytologically proven adenocarcinoma of the prostate"
NCT00273338:I.1003,"Documented metastatic prostate adenocarcinoma"
NCT00273338:I.1004,"Documented progression while on androgen ablation therapy detected by rising prostate specific antigen (PSA) and/or imaging"
NCT00273338:I.1005,"Eastern Cooperative Oncology Group (ECOG) performance status<= 2"
NCT00273338:I.1006,"Adequate hematologic, renal and hepatic function"
NCT00273338:I.1007,"Life expectancy>= 3 months"
NCT00273338:I.2001,"Prior chemotherapy, except estramustine"
NCT00273338:I.2002,"Prior chemotherapy with docetaxel"
NCT00273338:I.2003,"Prior isotope therapy (e.g., strontium-89, samarium-153, etc.)"
NCT00273338:I.2004,"One or more contraindications to the use of corticosteroids"
NCT00273338:I.2005,"History of cancer-related hypercalcemia"
NCT00273338:I.3001,Age
NCT00273338:I.3002,Diagnosis
NCT00273338:I.3003,"Prostate Adenocarcinoma"
NCT00273338:I.3004,"Metastatic prostate cancer"
NCT00273338:I.3005,"Course of illness"
NCT00273338:I.3006,"androgen ablation therapy"
NCT00273338:I.3007,"Prostate-Specific Antigen"
NCT00273338:I.3008,"Diagnostic Imaging"
NCT00273338:I.3009,"ECOG performance status - grade 0"
NCT00273338:I.3010,"ECOG performance status - grade 1"
NCT00273338:I.3011,"ECOG performance status - grade 2"
NCT00273338:I.3012,"Hematologic function"
NCT00273338:I.3013,"kidney function"
NCT00273338:I.3014,"Hepatic function"
NCT00273338:I.3016,Chemotherapy
NCT00273338:I.3017,"Estramustine (substance)"
NCT00273338:I.3018,Taxotere
NCT00273338:I.3019,"radioisotope therapy"
NCT00273338:I.3020,"Strontium 89 therapy"
NCT00273338:I.3021,"Samarium 153"
NCT00273338:I.3022,"Contraindication to medical treatment"
NCT00273338:I.3023,"Therapeutic Corticosteroid"
NCT00273338:I.3024,Hypercalcemia
NCT00274573:I.1001,"Male or female patients 40 years of age or older"
NCT00274573:I.1002,"All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria: Patients must have relatively stable, mild to severe airway obstruction with an FEV1 =<70% of predicted normal and an FEV1/FVC<70 %. Predicted normal values will be taken from the print-outs of the spirometers. Spirometers have to calibrated according to ECCS."
NCT00274573:I.1003,"Patients must be current or ex-smokers with a smoking history of 10 or more than 10 pack-years. Pack Years = Number of cigarettes/day : 20 x years of smoking (Patients who have never smoked cigarettes must not be included)"
NCT00274573:I.1004,"Patients must be able to perform all study related tests, acceptable pulmonary function tests, including Peak Expiratory Flow Rate (PEFR) measurements, and must be able to maintain diary cards during the study period as required in the protocol"
NCT00274573:I.1005,"Patients must be able to inhale medication from the HandiHaler"
NCT00274573:I.1006,"All patients must sign an Informed Consent Form prior to participation in the trial i.e. prior to pre-study washout of their usual pulmonary medications"
NCT00274573:I.2001,"Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study."
NCT00274573:I.2002,"Patients with a recent history (i.e., one year or less) of myocardial infarction."
NCT00274573:I.2003,"Patients with any cardiac arrhythmia requiring drug therapy or who have been hospitalised for heart failure within the past three years."
NCT00274573:I.2004,"Patients who regularly use daytime oxygen therapy for more than 1 hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy."
NCT00274573:I.2005,"Patients with known active tuberculosis."
NCT00274573:I.2006,"Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma are allowed."
NCT00274573:I.2007,"Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis."
NCT00274573:I.2008,"Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion 1."
NCT00274573:I.2009,"Patients with any respiratory infection in the past six weeks prior to the Screening Visit (Visit 1) or during the run-in period."
NCT00274573:I.2010,"Patients who are currently in a pulmonary rehabilitation programme or who have completed a pulmonary rehabilitation programme in the six week prior to the Screening Visit (Visit 1)."
NCT00274573:I.2011,"Patients with known hypersensitivity to anticholinergic drugs, lactose or any other components of the inhalation capsule delivery system."
NCT00274573:I.2012,"Patients with known symptomatic prostate hypertrophy or bladder neck obstruction."
NCT00274573:I.2013,"Patients with known narrow-angle glaucoma."
NCT00274573:I.2014,"Patients using oral corticosteroid medication at unstable doses (i.e., less than four weeks on a stable dose before Visit 1) or at doses in excess of the equivalent of 10 mg of prednisolone per day or 20 mg every other day."
NCT00274573:I.2015,"Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e. oral contraceptives, intrauterine devices, diaphragm or subdermal implants)."
NCT00274573:I.2016,"Patients with a history of asthma, allergic rhinitis or atopy."
NCT00274573:I.2017,"Patients with a history of and/or active significant alcohol or drug abuse."
NCT00274573:I.2018,"Patients who have taken an investigational drug within one month prior to Screening Visit (Visit 1). A log of all subjects screened, and reasons for exclusion for those not randomised will be maintained."
NCT00274573:I.3001,Age
NCT00274573:I.3002,disorder
NCT00274573:I.3004,"Chronic Obstructive Pulmonary Disease"
NCT00274573:I.3005,Spirometry
NCT00274573:I.3006,"Respiratory obstruction"
NCT00274573:I.3007,"Forced expired volume in one second/vital capacity ratio"
NCT00274573:I.3008,"European Coal and Steel Community"
NCT00274573:I.3010,"Pack years (assessment scale)"
NCT00274573:I.3011,Test
NCT00274573:I.3012,"Lung function tests"
NCT00274573:I.3013,"Peak expiratory flow rate measurement"
NCT00274573:I.3014,"Peak expiratory flow rate monitoring using diary"
NCT00274573:I.3015,"Home Medications"
NCT00274573:I.3016,"Informed Consent"
NCT00274573:I.3017,"Subject Participation Status in Clinical Study"
NCT00274573:I.3018,"disease risk"
NCT00274573:I.3019,"Heart infarction"
NCT00274573:I.3020,"Cardiac Arrhythmia"
NCT00274573:I.3021,"Drug Therapy"
NCT00274573:I.3022,"Heart failure"
NCT00274573:I.3023,"Warburg Therapy"
NCT00274573:I.3024,"Active tuberculosis"
NCT00274573:I.3025,"Malignant Neoplasms"
NCT00274573:I.3026,"Basal cell carcinoma"
NCT00274573:I.3027,"Lung structure"
NCT00274573:I.3028,Obstruction
NCT00274573:I.3029,Mucoviscidosis
NCT00274573:I.3030,Bronchiectasis
NCT00274573:I.3031,"Opening of chest"
NCT00274573:I.3032,"Pulmonary resection"
NCT00274573:I.3033,"Respiratory Tract Infections"
NCT00274573:I.3034,Screening
NCT00274573:I.3035,"Pulmonary rehabilitation programme completed"
NCT00274573:I.3036,"Anticholinergic allergy"
NCT00274573:I.3037,"Lactose malabsorption"
NCT00274573:I.3038,"Inhaled drug administration"
NCT00274573:I.3039,"adenofibromatous hypertrophy of prostate"
NCT00274573:I.3040,"Bladder neck obstruction"
NCT00274573:I.3041,"Chronic narrow angle glaucoma"
NCT00274573:I.3042,"Therapeutic Corticosteroid"
NCT00274573:I.3043,"prednisolone (substance)"
NCT00274573:I.3044,pregnant
NCT00274573:I.3045,"Breast feeding, Nursing"
NCT00274573:I.3046,"Contraception, Birth control"
NCT00274573:I.3047,"Oral contraceptive preparation"
NCT00274573:I.3048,"Intrauterine contraceptive device"
NCT00274573:I.3049,"Subdermal implantation of progesterone"
NCT00274573:I.3050,"Implant, device"
NCT00274573:I.3051,"Subcutaneous route"
NCT00274573:I.3052,"Vaginal contraceptive diaphragm (device)"
NCT00274573:I.3053,Asthma
NCT00274573:I.3054,"Allergic rhinitis due to allergen"
NCT00274573:I.3055,"Atopic Allergy"
NCT00274573:I.3056,"Alcohol abuse"
NCT00274573:I.3057,"Drug abuse"
NCT00274573:I.3058,"Investigational New Drug"
NCT00274573:I.3059,Screening
NCT00274573:I.3060,"patient encounter"
NCT00274573:I.3061,"Random Allocation"
NCT00275379:I.1001,"Age 18 Years and older"
NCT00275379:I.1002,"Subjects seeking medical treatment for symptoms consistent with IC that have been ongoing for>9 months or seeking medical treatment for a previous documented diagnosis of IC"
NCT00275379:I.1003,"Subjects who are not surgically sterile or postmenopausal (amenorrheic>12 months) must agree and commit to the use of a medically acceptable, highly-effective (i.e. double-barrier or IUD), non-hormonal form of birth control during the study and for 30 days after the last dose of test"
NCT00275379:I.2001,"Use of herbal supplements (except for a daily multivitamin/mineral supplement not containing herbal components)"
NCT00275379:I.2002,"History of cancer (other than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer) with less than 5 years documentation of a disease-free state"
NCT00275379:I.2003,"Vaginitis or vaginal infection within 1 month before randomization"
NCT00275379:I.3001,Age
NCT00275379:I.3002,Diagnosis
NCT00275379:I.3003,"medical treatment approach"
NCT00275379:I.3004,"Interstitial Cystitis"
NCT00275379:I.3005,"Contraceptive method: female sterilization"
NCT00275379:I.3006,Postmenopause
NCT00275379:I.3007,"Absence of menstruation"
NCT00275379:I.3008,"Informed Consent"
NCT00275379:I.3009,"Contraception, Birth control"
NCT00275379:I.3010,"Barrier contraception method"
NCT00275379:I.3011,"Intrauterine contraceptive device"
NCT00275379:I.3012,"Herbal supplement"
NCT00275379:I.3013,"Malignant Neoplasms"
NCT00275379:I.3014,"Basal cell carcinoma"
NCT00275379:I.3015,"Squamous cell carcinoma"
NCT00275379:I.3016,"Carcinoma of cervix"
NCT00275379:I.3017,"Inflammation of vagina"
NCT00275379:I.3018,"Vaginal infection"
NCT00275379:I.3019,"Random Allocation"
NCT00289978:I.1001,"Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis"
NCT00289978:I.1002,"Patients with a relapsing-remitting disease course"
NCT00289978:I.1003,"Patients with EDSS score of 0-5.5"
NCT00289978:I.2001,"Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc."
NCT00289978:I.2002,"Pregnant or nursing women"
NCT00289978:I.3001,Age
NCT00289978:I.3002,disorder
NCT00289978:I.3004,"Multiple Sclerosis"
NCT00289978:I.3005,"Multiple Sclerosis, Relapsing-Remitting"
NCT00289978:I.3006,EDSS
NCT00289978:I.3007,"Chronic disease of immune system"
NCT00289978:I.3008,"Malignant Neoplasms"
NCT00289978:I.3009,"Lung diseases"
NCT00289978:I.3010,Acuteness
NCT00289978:I.3011,"Heart failure"
NCT00289978:I.3012,pregnant
NCT00289978:I.3013,"Breast feeding, Nursing"
NCT00291746:I.1001,"Age 18 Years to 79 Years"
NCT00291746:I.1002,"Subjects who seek medical advice at 
their family doctor (primary carephysician) for symptoms thought by 
the primary care physician to arisefrom the upper GI tract"
NCT00291746:I.1003,"The symptoms thought to pertain to 
the upper GI tract must have beenpresent for at least 4 weeks prior to 
Visit 1 and to have occurred at leasttwice a week during that period"
NCT00291746:I.1004,"The symptoms thought to pertain to 
the upper GI tract must have been ofat least mild severity for a minimum 
of 3 days during the week prior toVisit 1"
NCT00291746:I.2001,"Upper GI endoscopy performed within 
a year prior to Visit 1"
NCT00291746:I.2002,"Previous anti-reflux surgery, surgery for peptic ulcer or any form of upper gastrointestinal resective surgery"
NCT00291746:I.2003,"Contra-indication to the BravoTM procedure such as subjects with a history of bleeding diathesis, strictures anywhere along the GI-tract, esophageal varices, obstructions, or subjects equipped with a pacemaker, an implantable cardiac defibrillator or an implantable neurostimulator (NB: subjects with severe esophagitis (grade D) confirmed by endoscopy at Visit 2 can continue the study without performing the BravoTM procedure)"
NCT00291746:I.3001,Age
NCT00291746:I.3002,Diagnosis
NCT00291746:I.3003,"Encounter for medical advice NOS"
NCT00291746:I.3004,"General practitioner (GP)"
NCT00291746:I.3005,"Upper Gastrointestinal System"
NCT00291746:I.3006,"patient encounter"
NCT00291746:I.3007,"Severity (qualifier value)"
NCT00291746:I.3008,"Endoscopy (procedure)"
NCT00291746:I.3009,"Period (temporal concept)"
NCT00291746:I.3010,"Anti-reflux surgery"
NCT00291746:I.3011,"Peptic Ulcer"
NCT00291746:I.3012,"operative procedures"
NCT00291746:I.3013,Resection
NCT00291746:I.3014,"Medical Contraindication"
NCT00291746:I.3015,"Esophagus acid reflux test with intraluminal pH electrode"
NCT00291746:I.3016,"Bleeding tendency"
NCT00291746:I.3017,"Fibrous stenosis"
NCT00291746:I.3018,"Oesophageal Varices"
NCT00291746:I.3019,"Obstruction of esophagus"
NCT00291746:I.3020,"Artificial cardiac pacemaker"
NCT00291746:I.3021,"cardiac defibrillator"
NCT00291746:I.3022,Neurostimulator
NCT00291746:I.3023,"Esophagitis grade IV"
NCT00293943:I.1001,"Age 50 - 85 years"
NCT00293943:I.1002,"Idiopathic paroxysmal symptomatic atrial fibrillation refractory to antiarrhythmic therapy"
NCT00293943:I.1003,"Patient willing to participate in randomized trial and an invasive follow-up at month 3 (-6)"
NCT00293943:I.1004,"Structural normal heart"
NCT00293943:I.1005,"Patient willing and able to participate in 12 months follow-up period"
NCT00293943:I.1006,"ECG documentation of atrial fibrillation (ECG, Holter, event recorders, etc) for at least one AF event in the prior year (related to symptomatic or asymptomatic episodes) with an average number of one episode per month"
NCT00293943:I.1007,"Written informed consent of the patient"
NCT00293943:I.2001,"Patients who have had previous pulmonary vein ablation procedures. Patients with atrial fibrillation secondary to a reversible cause"
NCT00293943:I.2002,"Known presence of intracardiac or other thrombi"
NCT00293943:I.2003,"Evidence of obstructive lung disease requiring bronchodilator therapy"
NCT00293943:I.2004,"Pregnant females or those of child bearing potential who have not had a negative pregnancy test within 48 hours before treatment."
NCT00293943:I.2005,"Other medical illness (i.e. cancer, congestive heart failure) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with limited life-expectancy (i.e., less than one year)"
NCT00293943:I.2006,"History of bleeding diathesis or suspected pro-coagulant state contraindication to anticoagulation therapy"
NCT00293943:I.2007,"Hyperthyroidism or hypothyroidism manifested clinically and in laboratory tests (TSH, T3, T4)"
NCT00293943:I.2008,"Participation in a clinical trial within the last 30 days. Simultaneous participation in a registry (e.g. project AB1 of the AFNET) is permitted."
NCT00293943:I.2009,"Drug addiction or chronic alcohol abuse"
NCT00293943:I.2010,"Legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical trial"
NCT00293943:I.2011,"Evidence of an uncooperative attitude"
NCT00293943:I.3001,Age
NCT00293943:I.3002,disorder
NCT00293943:I.3003,"Paroxysmal atrial fibrillation"
NCT00293943:I.3004,"Antiarrhythmic drug"
NCT00293943:I.3005,"Subject Participation Status in Clinical Study"
NCT00293943:I.3006,"Randomized Clinical Trial"
NCT00293943:I.3007,Follow-up
NCT00293943:I.3008,"Invasive (qualifier value)"
NCT00293943:I.3009,"Heart structure"
NCT00293943:I.3010,Electrocardiogram
NCT00293943:I.3011,Documentation
NCT00293943:I.3012,"Atrial fibrillation"
NCT00293943:I.3013,"Holter Electrocardiography"
NCT00293943:I.3014,"EVENT RECORDER, CARDIAC (IMPLANTABLE)"
NCT00293943:I.3015,"Episode (qualifier value)"
NCT00293943:I.3016,"Informed Consent"
NCT00293943:I.3017,"Pulmonary venous structure"
NCT00293943:I.3018,"Ablation Therapy"
NCT00293943:I.3019,"Intracardiac thrombus"
NCT00293943:I.3020,Thrombus
NCT00293943:I.3021,"Lung Diseases, Obstructive"
NCT00293943:I.3022,"Inhaled bronchodilator therapy"
NCT00293943:I.3023,"Negative Pregnancy Test"
NCT00293943:I.3024,"Pregnancy detection examination"
NCT00293943:I.3025,"Malignant Neoplasms"
NCT00293943:I.3026,"Congestive heart failure"
NCT00293943:I.3027,"Life expectancy"
NCT00293943:I.3028,"Bleeding tendency"
NCT00293943:I.3029,"Medical Contraindication"
NCT00293943:I.3030,"Anticoagulation Therapy"
NCT00293943:I.3031,Hyperthyroidism
NCT00293943:I.3032,Hypothyroidism
NCT00293943:I.3033,Registry
NCT00293943:I.3034,"Drug addiction"
NCT00293943:I.3035,"Alcoholic Intoxication, Chronic"
NCT00293943:I.3036,"Persistent or Significant Disability or Incapacity"
NCT00293943:I.3037,"Disturbance of understanding"
NCT00293943:I.3038,"Uncooperative behavior"
NCT00296309:I.1001,"Age 60 Years and older"
NCT00296309:I.1002,"Patients with end stage kidney disease who are suitable candidates for primary renal transplantation or retransplantation are eligible for the study. Patients receiving a kidney transplant, from a cadaveric or living donor (not HLA identical) with compatible ABO blood type can be included."
NCT00296309:I.2001,"Patient has an immunological high risk"
NCT00296309:I.2002,"Cold ischemia time greater than 30 hours"
NCT00296309:I.2003,"Patient has significant liver disease"
NCT00296309:I.2004,"Patient is allergic or intolerant to study medication"
NCT00296309:I.2005,"Patient or donor is known to be HIV positive."
NCT00296309:I.2006,"Patient with malignancy or history of malignancy"
NCT00296309:I.2007,"Patient has significant, uncontrolled concomitant infections"
NCT00296309:I.3001,Age
NCT00296309:I.3002,disorder
NCT00296309:I.3003,"Renal Disease, End-Stage"
NCT00296309:I.3004,"Renal transplant"
NCT00296309:I.3005,retransplantation
NCT00296309:I.3006,"Structure of transplanted kidney"
NCT00296309:I.3007,"Live donor"
NCT00296309:I.3008,"Donor person"
NCT00296309:I.3009,"Human leukocyte antigen"
NCT00296309:I.3010,"ABO blood group antigen system"
NCT00296309:I.3011,"Immunological Risk Factors"
NCT00296309:I.3012,"Cold Ischemic Time"
NCT00296309:I.3013,"Liver diseases"
NCT00296309:I.3014,"Drug intolerance"
NCT00296309:I.3015,"HIV Seropositivity"
NCT00296309:I.3016,"Malignant Neoplasms"
NCT00296309:I.3017,Infection
NCT00296361:I.1001,"Age 18 Years to 60 Years"
NCT00296361:I.1002,"Patients having end stage kidney disease who will undergo primary renal transplantation or retransplantation are eligible for the study. Patients receiving a kidney transplant, from a cadaveric or living donor (not HLA identical) with compatible AB0 blood type can be included."
NCT00296361:I.2001,"Patient has a high immunological risk"
NCT00296361:I.2002,"Cold ischemia time greater than 30 hours"
NCT00296361:I.2003,"Patient has significant liver disease"
NCT00296361:I.2004,"Patient has severe hyper-cholesterolaemia"
NCT00296361:I.2005,"Patient is allergic or intolerant to study medication"
NCT00296361:I.2006,"Patient requires ongoing dosing with corticosteroids."
NCT00296361:I.2007,"Patient or donor is known to be HIV positive"
NCT00296361:I.2008,"Patient with malignancy or history of malignancy"
NCT00296361:I.3001,Age
NCT00296361:I.3002,Diagnosis
NCT00296361:I.3003,"Renal Disease, End-Stage"
NCT00296361:I.3004,"Renal transplant"
NCT00296361:I.3005,retransplantation
NCT00296361:I.3006,"Structure of transplanted kidney"
NCT00296361:I.3007,"Live donor"
NCT00296361:I.3008,"Donor person"
NCT00296361:I.3009,"Human leukocyte antigen"
NCT00296361:I.3010,"ABO blood group antigen system"
NCT00296361:I.3011,"Immunological Risk Factors"
NCT00296361:I.3012,"Cold Ischemic Time"
NCT00296361:I.3013,"Liver diseases"
NCT00296361:I.3014,Hypercholesterolaemia
NCT00296361:I.3016,"Drug intolerance"
NCT00296361:I.3017,"Therapeutic Corticosteroid"
NCT00296361:I.3018,"continuous, ongoing"
NCT00296361:I.3019,"HIV Seropositivity"
NCT00296361:I.3020,"Malignant Neoplasms"
NCT00299923:I.1001,"Age 18 Years and older"
NCT00299923:I.1002,"Relapsers to previous combination therapy with (PEG-)IFN alfa-/Ribavirin and a negative HCV-RNA test result at the end of this regular treatment course and positive HCV-RNA test result during the follow-up period."
NCT00299923:I.1003,"Termination of (PEG-)IFN alfa-/ribavirin therapy at least 3 months prior to enrolment"
NCT00299923:I.1004,"Chronic HCV infection genotype 1 or 3"
NCT00299923:I.1005,"Serum HCV-RNA quantifiable at>100 IU/mL by COBAS AmpliPrep or another quantitative HCV-RNA PCR test (reported in IU)"
NCT00299923:I.1006,"Compensated liver disease (Child-Pugh A)"
NCT00299923:I.1007,"Exclusion of HCC in patients with cirrhosis or transition to cirrhosis. In patients with AFP>50 ng/mL an established assay for exclusion of HCC has to be done"
NCT00299923:I.1008,"Negative urine or blood pregnancy test"
NCT00299923:I.1009,"All fertile males and females must use two reliable forms of effective contraception (combined) during treatment with study drugs and 6 months post treatment"
NCT00299923:I.2001,"Hypersensitiveness to Interferon, PEG-IFN alfa-2a, Ribavirin and Amantadine or other ingredient of the drugs"
NCT00299923:I.2002,"Ongoing pregnancy or breast feeding"
NCT00299923:I.2003,"Male partners of women who are pregnant or with women without effective contraception"
NCT00299923:I.2004,"Signs or symptoms of hepatocellular carcinoma"
NCT00299923:I.2005,"Chronic HCV infection genotype 2, 4, 5 or 6"
NCT00299923:I.2006,"Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment<6 months prior to the first dose of study drug and during study period. Exception: patients who have had a limited (<7 days) course of acyclovir or valacyclovir for herpetic lesions<1 month prior to the first administration of test drug are not excluded."
NCT00299923:I.2007,"Any investigational drug<6 weeks prior to the first dose of study drug"
NCT00299923:I.2008,"Positive test for anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HIV"
NCT00299923:I.2009,"History or other evidence of a medical condition associated with chronic liver disease other than HCV"
NCT00299923:I.2010,"History or other evidence of decompensated liver disease or a Child-Pugh score>6."
NCT00299923:I.2011,"Hb<12 g/dL (<120 g/L) in women or<13 g/dL (<130 g/L) in men at screening"
NCT00299923:I.2012,"Any patient with an increased baseline risk for anemia or for whom anemia would be medically problematic"
NCT00299923:I.2013,"Neutrophil count<1,500 cells/mm3 and/or platelet count<90,000 cells/mm3"
NCT00299923:I.2014,"Serum creatinin concentration>1.5 mg/dl"
NCT00299923:I.2015,"History of severe psychiatric disease, especially depression."
NCT00299923:I.2016,"History of a severe seizure disorder that can not be stabilized by medication"
NCT00299923:I.2017,"History of immunologically mediated disease"
NCT00299923:I.2018,"Chronic pulmonary disease associated with functional limitation"
NCT00299923:I.2019,"History of severe cardiac disease"
NCT00299923:I.2020,"History of major organ transplantation except corneatransplantation"
NCT00299923:I.2021,"Evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study"
NCT00299923:I.2022,"Thyroid dysfunction not adequately controlled"
NCT00299923:I.2023,"Evidence of severe retinopathy or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension"
NCT00299923:I.2024,"Evidence of active drug abuse within one year of study entry except of a prescribed stable opioid substitution"
NCT00299923:I.2025,"Take of Memantine during study period"
NCT00299923:I.2026,"Cardiomyopathy and myocarditis"
NCT00299923:I.2027,"AV-Block II and III"
NCT00299923:I.2028,"Pre-existing bradycardia<55 counts/min"
NCT00299923:I.2029,"Known QT-interval (QTc after Bazett>420 ms) or recognized U-waves or congenital QT-syndrome"
NCT00299923:I.2030,"History of severe ventricular arrhythmia incl. Torsade de pointes"
NCT00299923:I.2031,"Simultaneous therapy with Budipin or other medicine that extend the QT-interval like (e.g.antiarrhythmic drugs class IA and class III, antipsychotic drugs, tri- and tetracyclic antidepressants, antihistaminics, macrolide, gyrase inhibitors, Azol-antimykotics)"
NCT00299923:I.2032,"Patients with obstructive glaucoma"
NCT00299923:I.2033,"Patients with excitableness and confusion"
NCT00299923:I.2034,"Patients with delirium and exogenic psychosis in the anamnesis"
NCT00299923:I.2035,Prostataadenome
NCT00299923:I.2036,"Diuretic medication of the type combination Triamterene/ Hydrochlorothiazide"
NCT00299923:I.2037,"Inability or unwillingness to provide informed consent or abide by the requirements of the study"
NCT00299923:I.3001,Age
NCT00299923:I.3002,Diagnosis
NCT00299923:I.3003,"Recurrent Disease"
NCT00299923:I.3004,"Combination therapy"
NCT00299923:I.3005,"Polyethylene Glycols"
NCT00299923:I.3006,"Interferon Alpha"
NCT00299923:I.3007,"Ribavirin (substance)"
NCT00299923:I.3008,"Hepatitis C virus RNA (substance)"
NCT00299923:I.3009,Test
NCT00299923:I.3010,Negative
NCT00299923:I.3011,Treatment
NCT00299923:I.3012,positive
NCT00299923:I.3013,Follow-up
NCT00299923:I.3014,"Period (temporal concept)"
NCT00299923:I.3015,"Enrolment, Registration"
NCT00299923:I.3016,"Hepatitis C virus"
NCT00299923:I.3017,chronic
NCT00299923:I.3018,Infection
NCT00299923:I.3019,Genotype
NCT00299923:I.3020,"Serum (substance)"
NCT00299923:I.3021,"International Units (qualifier value)"
NCT00299923:I.3022,"Polymerase Chain Reaction"
NCT00299923:I.3023,"Quantitative (qualifier value)"
NCT00299923:I.3024,"Liver diseases"
NCT00299923:I.3026,"Child-Pugh Score"
NCT00299923:I.3027,"Hepatocellular Carcinoma"
NCT00299923:I.3028,"Liver Cirrhosis"
NCT00299923:I.3029,"Alpha-1-fetoprotein Measurement"
NCT00299923:I.3030,"Assay technique"
NCT00299923:I.3031,"Urine pregnancy test negative"
NCT00299923:I.3032,"Negative Pregnancy Test"
NCT00299923:I.3033,blood
NCT00299923:I.3034,Fertile
NCT00299923:I.3035,"Male gender"
NCT00299923:I.3036,"Female Gender"
NCT00299923:I.3037,"Contraception, Birth control"
NCT00299923:I.3038,"Allergic reaction to substance"
NCT00299923:I.3039,"Interferon (substance)"
NCT00299923:I.3040,"Peginterferon alpha-2a (substance)"
NCT00299923:I.3041,"Amantadine (substance)"
NCT00299923:I.3042,Medication
NCT00299923:I.3043,"Pregnancy, Gestation"
NCT00299923:I.3044,pregnant
NCT00299923:I.3045,"Breast feeding, Nursing"
NCT00299923:I.3046,signs
NCT00299923:I.3047,Symptoms
NCT00299923:I.3048,"Systemic Therapy"
NCT00299923:I.3049,"Antiviral treatment"
NCT00299923:I.3050,"Immunotherapy, antineoplastic"
NCT00299923:I.3051,"Immunomodulatory or immunosuppressive therapy"
NCT00299923:I.3052,"Acyclovir (substance)"
NCT00299923:I.3053,"Valacyclovir (substance)"
NCT00299923:I.3054,"eczema herpeticum"
NCT00299923:I.3055,"Investigational New Drug"
NCT00299923:I.3056,"Hepatitis A Virus"
NCT00299923:I.3057,"Immunoglobulin M"
NCT00299923:I.3058,"Hepatitis B Surface Antigens"
NCT00299923:I.3059,"Hepatitis B core IgM level"
NCT00299923:I.3060,"Human immunodeficiency virus"
NCT00299923:I.3061,"End Stage Liver Disease"
NCT00299923:I.3062,Hemoglobin
NCT00299923:I.3063,"Male population group"
NCT00299923:I.3064,"Human, Female"
NCT00299923:I.3065,"disease risk"
NCT00299923:I.3066,Anaemia
NCT00299923:I.3067,Baseline
NCT00299923:I.3068,"Neutrophil count (procedure)"
NCT00299923:I.3069,"Platelet count - finding"
NCT00299923:I.3070,"Serum Creatinine Measurement"
NCT00299923:I.3071,Concentration
NCT00299923:I.3072,"Psychiatric disorder"
NCT00299923:I.3074,Depression
NCT00299923:I.3075,Epilepsia
NCT00299923:I.3076,"Stabilization (procedure)"
NCT00299923:I.3077,Immunotherapy
NCT00299923:I.3078,"Lung diseases"
NCT00299923:I.3079,"Limitation (attribute)"
NCT00299923:I.3080,"Functional Status, Level of function"
NCT00299923:I.3081,"Cardiac disease"
NCT00299923:I.3082,"Organ Transplantation"
NCT00299923:I.3083,"Major (qualifier value)"
NCT00299923:I.3084,"Corneal transplant (procedure)"
NCT00299923:I.3085,disorder
NCT00299923:I.3086,"Malignant Neoplasms"
NCT00299923:I.3087,"Thyroid dysfunction"
NCT00299923:I.3088,Retinopathy
NCT00299923:I.3089,"Ophthalmological disorder"
NCT00299923:I.3090,"Diabetes mellitus"
NCT00299923:I.3091,"Hypertensive disease, High Blood Pressure"
NCT00299923:I.3092,"Drug abuse"
NCT00299923:I.3093,"Active (qualifier value)"
NCT00299923:I.3094,"Prescription (procedure)"
NCT00299923:I.3095,"Opioid Substitution"
NCT00299923:I.3096,Stability
NCT00299923:I.3097,"Memantine (substance)"
NCT00299923:I.3098,"Take- dosing instruction imperative (qualifier value)"
NCT00299923:I.3099,Cardiomyopathy
NCT00299923:I.3100,Myocarditis
NCT00299923:I.3101,"Atrioventricular Block"
NCT00299923:I.3102,"Decreased heart rate"
NCT00299923:I.3103,"QTC interval"
NCT00299923:I.3104,"Finding of ECG QT interval (finding)"
NCT00299923:I.3105,"U wave feature (observable entity)"
NCT00299923:I.3106,Syndrome
NCT00299923:I.3107,congenital
NCT00299923:I.3108,"Ventricular arrhythmia"
NCT00299923:I.3109,"Ventricular tachycardia, polymorphic with Q-T prolongation"
NCT00299923:I.3110,"Simultaneous (qualifier value)"
NCT00299923:I.3111,"1-(1,1-Dimethylethyl)-4,4-diphenylpiperidine"
NCT00299923:I.3112,"Antiarrhythmic drug"
NCT00299923:I.3113,"Antipsychotic agent (substance)"
NCT00299923:I.3114,"Tricyclic Antidepressive Agents"
NCT00299923:I.3115,"Tetracyclic antidepressant (substance)"
NCT00299923:I.3116,antihistaminics
NCT00299923:I.3117,"Macrolide (substance)"
NCT00299923:I.3118,"DNA Gyrase Inhibitors [MoA]"
NCT00299923:I.3119,"Azole antifungal (substance)"
NCT00299923:I.3120,Glaucoma
NCT00299923:I.3121,"Angle Closure Glaucoma"
NCT00299923:I.3122,Excitable
NCT00299923:I.3123,"Confusional state (disorder)"
NCT00299923:I.3124,"Delirium (disorder)"
NCT00299923:I.3125,"Psychosis (Psychotic disorder)"
NCT00299923:I.3126,exogen
NCT00299923:I.3127,"Immunologic Memory"
NCT00299923:I.3128,"Hyperplasia of prostate"
NCT00299923:I.3129,"Diuretic (substance)"
NCT00299923:I.3130,"Triamterene (substance)"
NCT00299923:I.3131,"Hydrochlorothiazide (substance)"
NCT00299923:I.3132,"Informed Consent"
NCT00299923:I.3133,Requirement
NCT00299923:I.3134,"Clinical Trials"
NCT00303589:I.1001,"Age adult patients,>=18 years of age"
NCT00303589:I.1002,"skin or skin structure infection requiring hospitalization"
NCT00303589:I.1003,"clinical diagnosis of a skin or skin structure infection caused by bacteria known or suspected to be susceptible to the randomized study treatment"
NCT00303589:I.1004,"material from site of infection is clinically purulent or seropurulent"
NCT00303589:I.2001,"presenting with sustained shock (SBP<90mm Hg for>2 hours, despite adequate fluid resuscitation)"
NCT00303589:I.2002,"known or suspected concomitant bacterial infection requiring antibiotic treatment"
NCT00303589:I.2003,"skin infection or chronic non-healing ulcer of>2 weeks duration"
NCT00303589:I.2004,"patients in whom surgery is the primary treatment"
NCT00303589:I.3001,Age
NCT00303589:I.3002,Diagnosis
NCT00303589:I.3003,"Adult disease"
NCT00303589:I.3004,"Skin Infection"
NCT00303589:I.3005,"Inpatient care (regime/therapy)"
NCT00303589:I.3006,"Clinical Diagnosis (contextual qualifier)"
NCT00303589:I.3007,Integument
NCT00303589:I.3008,Bacterium
NCT00303589:I.3009,"Randomized Clinical Trial"
NCT00303589:I.3010,Purulent
NCT00303589:I.3011,"SKIN LESION, SEROPURULENT"
NCT00303589:I.3012,"Circulatory collapse"
NCT00303589:I.3013,"Sustained (qualifier value)"
NCT00303589:I.3014,"Systolic Blood Pressure"
NCT00303589:I.3015,"Resuscitation procedure"
NCT00303589:I.3016,"Body Fluid or Substance"
NCT00303589:I.3017,"Bacterial infectious disease"
NCT00303589:I.3018,Concomitant
NCT00303589:I.3019,"Antibiotic Therapy (procedure)"
NCT00303589:I.3020,"non-healing ulcer of skin"
NCT00303589:I.3021,chronic
NCT00303589:I.3022,"operative procedures"
NCT00303589:I.3023,"First-Line Therapy"
NCT00306215:I.1001,"Age 18 Years and older"
NCT00306215:I.1002,"moderate to severe Crohn's Disease"
NCT00306215:I.1003,"CDAI 250-450"
NCT00306215:I.1004,CRP>7.5
NCT00306215:I.1005,"signed written informed consent"
NCT00306215:I.2001,">100 cm of small bowel resected"
NCT00306215:I.2002,"ileostomy, colostomy or rectal pouch"
NCT00306215:I.2003,"diagnosis of ulcerative colitis or indeterminate colitis"
NCT00306215:I.2004,"evidence of short bowel syndrome requiring enteral or parenteral supplementation or total parenteral nutrition"
NCT00306215:I.2005,"hepatitis B, C or HIV infection"
NCT00306215:I.2006,"history of infection requiring IV antibiotics"
NCT00306215:I.2007,"serious or GI infection in the previous 12 weeks"
NCT00306215:I.3001,Age
NCT00306215:I.3002,Diagnosis
NCT00306215:I.3003,"Crohn's Disease"
NCT00306215:I.3004,"Crohn's disease activity index"
NCT00306215:I.3005,"C-Reactive Protein Measurement"
NCT00306215:I.3006,"Informed Consent"
NCT00306215:I.3007,"Small intestine excision"
NCT00306215:I.3008,"Creation of ileostomy"
NCT00306215:I.3009,"Colostomy Procedure"
NCT00306215:I.3010,"Rectal pouch"
NCT00306215:I.3011,"Ulcerative calcitis"
NCT00306215:I.3012,"Colitis of Indeterminate Type"
NCT00306215:I.3013,"Evidence of"
NCT00306215:I.3014,"Short Bowel Syndrome"
NCT00306215:I.3015,"Enteral (qualifier value)"
NCT00306215:I.3016,"Nutritional Supplementation"
NCT00306215:I.3017,"Parenteral Therapeutic Nutritional Supplementation"
NCT00306215:I.3018,"Parenteral Nutrition, Total"
NCT00306215:I.3019,"Type B viral hepatitis"
NCT00306215:I.3020,"Viral hepatitis C"
NCT00306215:I.3021,"Human immunodeficiency virus infection"
NCT00306215:I.3022,Infection
NCT00306215:I.3023,"Antibiotic Drugs"
NCT00306215:I.3024,Intravenous
NCT00306215:I.3025,"Serious (qualifier value)"
NCT00306215:I.3026,"Gastrointestinal Infection"
NCT00309621:I.1001,"Age 18 Years to 75 Years"
NCT00309621:I.1002,"Chronic hand dermatitis, rated as severe by physicians global assessment, present for at least 6 months, that has not responded to the avoidance of allergens and irritants and the use of topical steroids"
NCT00309621:I.2001,"female of childbearing potential, unless participating in a pregnancy prevention program"
NCT00309621:I.2002,psoriasis
NCT00309621:I.2003,"active major psychiatric condition"
NCT00309621:I.3001,Age
NCT00309621:I.3002,Diagnosis
NCT00309621:I.3003,"Chronic hand dermatitis"
NCT00309621:I.3005,"Physician (occupation)"
NCT00309621:I.3006,Assessment
NCT00309621:I.3007,"Allergen (substance)"
NCT00309621:I.3008,"Irritant (substance)"
NCT00309621:I.3009,Steroids
NCT00309621:I.3010,"Topical Route of Drug Administration"
NCT00309621:I.3011,"female, female gender"
NCT00309621:I.3012,fertil
NCT00309621:I.3013,"Pregnancy, Gestation"
NCT00309621:I.3014,"prevention program"
NCT00309621:I.3015,Psoriasis
NCT00309621:I.3016,"Psychiatric disorder"
NCT00309621:I.3017,"Active (qualifier value)"
NCT00309621:I.3018,"Major (qualifier value)"
NCT00312845:I.1001,"Man or woman and age 18 years or older"
NCT00312845:I.1002,"Diagnosis of follicular B-NHL of the following subtypes (World Health Organization [WHO] classification 1997): follicular lymphoma (FL) (Grades 1 and 2)."
NCT00312845:I.1003,"Documented relapse or progression following prior antineoplastic treatment. New lesions or objective evidence of progression of existing lesions must document relapse or progression following the previous therapy."
NCT00312845:I.1004,"If any prior regimen included rituximab, the subject must have responded (complete response [CR], unconfirmed complete response [CRu], partial response [PR]), and the time to progression (TTP) from the first dose of rituximab must have been 6 months or more."
NCT00312845:I.1005,"At least 1 measurable tumor mass (greater than 1.5 cm in the longest dimension and greater than 1.0 cm in the short axis) that has not been previously irradiated, or has grown since previous irradiation"
NCT00312845:I.1006,"In the opinion of the investigator the decision to initiate treatment is justified to manage the subject's lymphoma"
NCT00312845:I.1007,"No active central nervous system lymphoma"
NCT00312845:I.1008,"Eastern Cooperative Oncology Group [ECOG] status ? 2"
NCT00312845:I.1009,"Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and have a negative serum beta-human chorionic gonadotropin (?-hCG) pregnancy test at screening."
NCT00312845:I.1010,"Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study."
NCT00312845:I.1011,"In countries where health authorities have approved the pharmacogenomic testing, subjects or their legally acceptable representatives must have signed a separate informed consent that they agree to participate in the genetic part and protein testing part of the study; participation in the genetic and protein testing component is mandatory for pharmacogenomics testing, but optional for serum protein testing and future testing."
NCT00312845:I.2001,"Diagnosed or treated for a malignancy other than NHL within 1 year of randomization, or who were previously diagnosed with a malignancy other than NHL and have any radiographic or biochemical marker evidence of malignancy. Subjects with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy are not excluded."
NCT00312845:I.2002,"Clinical evidence of a transformation from indolent NHL to a more aggressive form of NHL."
NCT00312845:I.2003,"Prior treatment with VELCADE; Antineoplastic (including unconjugated therapeutic antibodies), experimental, or radiation therapy within 3 weeks before randomization;      Nitrosoureas within 6 weeks before randomization; Radioimmunoconjugates or toxin immunoconjugates within 10 weeks before randomization;                      Stem cell transplant within 6 months before randomization;                    Major surgery within 2 weeks before randomization."
NCT00312845:I.2004,"Residual toxic effects of previous therapy or surgery of Grade 3 or worse"
NCT00312845:I.2005,"Peripheral neuropathy or neuropathic pain of Grade 2 or worse"
NCT00312845:I.2006,"Have received an experimental drug or used an experimental medical device within 21 days before the planned start of treatment."
NCT00312845:I.2007,"History of allergic reaction attributable to compounds containing boron or mannitol"
NCT00312845:I.2008,"Known anaphylaxis or immunoglobulin E (IgE)-mediated hypersensitivity to murine proteins or to any component of rituximab including polysorbate 80 and sodium citrate dihydrate"
NCT00312845:I.2009,"Concurrent treatment with another investigational agent"
NCT00312845:I.2010,"Female subject who is pregnant or breast-feeding"
NCT00312845:I.3001,Age
NCT00312845:I.3002,Diagnosis
NCT00312845:I.3003,"Male population group"
NCT00312845:I.3004,"Human, Female"
NCT00312845:I.3005,"Lymphoma, Non-Hodgkin (Non-Hodgkins lymphoma)"
NCT00312845:I.3006,"Follicular low grade B-cell lymphoma, Follicular non-Hodgkin lymphoma"
NCT00312845:I.3007,"Follicular lymphoma grade I, unspecified site"
NCT00312845:I.3008,"Follicular lymphoma grade II, unspecified site"
NCT00312845:I.3009,"World Health Organization (WHO) classification of impairments, disabilities and handicap scale"
NCT00312845:I.3010,"Recurrent Disease"
NCT00312845:I.3011,"Documented (qualifier value)"
NCT00312845:I.3012,"Disease Progression, Course of illness"
NCT00312845:I.3013,"Antineoplastic Drug/Agent Therapy"
NCT00312845:I.3014,Treatment
NCT00312845:I.3015,"Previous (qualifier value)"
NCT00312845:I.3016,"Abnormal tissue appearance"
NCT00312845:I.3017,"Evidence of"
NCT00312845:I.3018,"Treatment Regimen"
NCT00312845:I.3019,Rituximab
NCT00312845:I.3020,"Complete Response (CR)"
NCT00312845:I.3021,"partial response (partial remission)"
NCT00312845:I.3022,"Time to Progression"
NCT00312845:I.3023,"Mass of body structure,                       Mass (morphologic abnormality), Tumor Mass"
NCT00312845:I.3024,"Therapeutic radiology procedure"
NCT00312845:I.3025,"Malignant lymphoma"
NCT00312845:I.3026,"Central Nervous System Lymphoma"
NCT00312845:I.3027,"Active (qualifier value)"
NCT00312845:I.3028,"ECOG performance status finding"
NCT00312845:I.3029,"female, female gender"
NCT00312845:I.3030,"Postmenopausal period"
NCT00312845:I.3031,"Operative Surgical Procedures"
NCT00312845:I.3032,"Sterile (qualifier value)"
NCT00312845:I.3033,"Non - drinker"
NCT00312845:I.3034,"Contraception, Birth control"
NCT00312845:I.3035,"Oral contraceptive preparation"
NCT00312845:I.3036,"Prescription (procedure)"
NCT00312845:I.3037,"Contraceptive agent (substance)"
NCT00312845:I.3038,"Injection procedure"
NCT00312845:I.3039,"Intrauterine contraceptive device"
NCT00312845:I.3040,"Barrier contraception method"
NCT00312845:I.3041,"Double (qualifier value)"
NCT00312845:I.3042,"Contraceptive Patch"
NCT00312845:I.3043,"Male sterilization (procedure)"
NCT00312845:I.3044,Entry
NCT00312845:I.3045,"Clinical Trials"
NCT00312845:I.3046,"Serum pregnancy test (B-HCG)"
NCT00312845:I.3047,"Negative Pregnancy Test"
NCT00312845:I.3048,Screening
NCT00312845:I.3049,"Informed Consent"
NCT00312845:I.3050,"Pharmacogenomic Test"
NCT00312845:I.3051,"Procurement of patient informed consent, investigational study"
NCT00312845:I.3052,"Subject Participation Status in Clinical Study"
NCT00312845:I.3053,"Genetic screening method"
NCT00312845:I.3054,"Serum/plasma protein test"
NCT00312845:I.3055,Testing
NCT00312845:I.3056,Future
NCT00312845:I.3057,"Mandatory Testing"
NCT00312845:I.3058,Optional
NCT00312845:I.3059,"Malignant Neoplasms"
NCT00312845:I.3060,"Random Allocation"
NCT00312845:I.3061,"Biochemical Markers"
NCT00312845:I.3062,Biomarker
NCT00312845:I.3063,"Radiographic (qualifier value)"
NCT00312845:I.3064,"Basal cell carcinoma"
NCT00312845:I.3065,"Squamous cell carcinoma"
NCT00312845:I.3066,"In situ cancer"
NCT00312845:I.3067,"Clinical (qualifier value)"
NCT00312845:I.3068,"Cell Transformation"
NCT00312845:I.3069,"Indolent Non-Hodgkin Lymphoma"
NCT00312845:I.3070,"Aggressive Non-Hodgkin Lymphoma"
NCT00312845:I.3071,Velcade
NCT00312845:I.3072,"Immunotherapy, antineoplastic"
NCT00312845:I.3073,"Antibody (substance)"
NCT00312845:I.3074,"Unconjugated (qualifier value)"
NCT00312845:I.3075,"Antibody Therapy"
NCT00312845:I.3076,"Therapies, Investigational"
NCT00312845:I.3077,"radiation therapy"
NCT00312845:I.3078,"Nitrosourea Compound"
NCT00312845:I.3079,Radioimmunoconjugate
NCT00312845:I.3080,Immunoconjugates
NCT00312845:I.3081,"Toxin (substance)"
NCT00312845:I.3082,"stem cell transplantation"
NCT00312845:I.3083,"operative procedures"
NCT00312845:I.3084,"Major (qualifier value)"
NCT00312845:I.3085,"Residual (qualifier value)"
NCT00312845:I.3086,Toxic
NCT00312845:I.3087,"poisonous effects"
NCT00312845:I.3088,"Previous (qualifier value)"
NCT00312845:I.3089,"Grade 3"
NCT00312845:I.3090,"Disorders of the peripheral nervous system"
NCT00312845:I.3091,"Neuropathic Pain"
NCT00312845:I.3092,"Grade 2"
NCT00312845:I.3093,"Investigational New Drug"
NCT00312845:I.3094,"Investigational Medical Device"
NCT00312845:I.3095,"Allergic disorder"
NCT00312845:I.3096,"Boron (substance)"
NCT00312845:I.3097,"Mannitol (substance)"
NCT00312845:I.3098,"Anaphylactic shock"
NCT00312845:I.3099,"IgE-mediated hypersensitivity disorder"
NCT00312845:I.3100,Murine
NCT00312845:I.3101,"Protein (substance)"
NCT00312845:I.3102,"Polyoxethylenesorbitan oleate"
NCT00312845:I.3103,"sodium citrate dihydrate"
NCT00312845:I.3104,"Combined Modality Therapy"
NCT00312845:I.3105,"Investigational New Drug, Experimental Drug"
NCT00312845:I.3106,pregnant
NCT00312845:I.3107,"Breast feeding, Nursing"
NCT00321464:I.1001,"Age 18 Years and older"
NCT00321464:I.1002,"Adults with histologically or cytologically confirmed breast adenocarcinoma"
NCT00321464:I.1003,"radiographic evidence of at least one bone mets"
NCT00321464:I.1004,"ECOG performance status finding"
NCT00321464:I.1005,"adequate organ function"
NCT00321464:I.2001,"Current or prior IV bisphosphonate administration"
NCT00321464:I.2002,"current or prior oral bisphosphonates for bone mets"
NCT00321464:I.2003,"life expectancy<6 months"
NCT00321620:I.1001,"Age 18 Years and older"
NCT00321620:I.1002,"Men>/= 18 years of age with histologically confirmed prostate cancer"
NCT00321620:I.1003,"Radiographic evidence of at least one bone metastasis"
NCT00321620:I.1004,"Failure of at least one hormonal therapy as evidenced by a rising PSA"
NCT00321620:I.1005,"Serum testosterone level of<50 ng/dL"
NCT00321620:I.1006,"ECOG performance 0,1 or 2"
NCT00321620:I.1007,"Adequate organ function"
NCT00321620:I.2001,"Current or prior IV bisphosphonate administration"
NCT00321620:I.2002,"Current or prior oral bisphosphonates for bone mets"
NCT00321620:I.2003,"life expectancy<6 months"
NCT00322621:I.1001,"Age 18 Years and older"
NCT00322621:I.1002,"Have pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes with the pain beginning in the feet and present for at least 6 months."
NCT00322621:I.1003,"May not be pregnant and agree to utilize medically acceptable and reliable means of birth control during participation in the study."
NCT00322621:I.1004,"Score of 4 or greater on the Brief Pain Inventory on the 24-hour average pain item."
NCT00322621:I.2001,"History of substance abuse or dependence within the past year, excluding nicotine and caffeine."
NCT00322621:I.2002,"Serious or unstable cardiovascular, hepatic (acute liver injury such as hepatitis or severe cirrhosis),kidney, respiratory, or blood disorder, seizure disorder, problems with peripheral vascular disease, or other medical conditions or psychiatric conditions that would hinder your participation or be likely to lead to hospitalization during the course of the study."
NCT00322621:I.2003,"Taking monoamine oxidase inhibitor (MAOI) within 14 days of starting the study or the potential need to take during or within 5 days after discontinuation from the study."
NCT00322621:I.2004,Fluoxetine
NCT00322621:I.2005,"Unstable blood sugar control and uncontrolled or poorly controlled hypertension."
NCT00326027:I.1001,"Age 18 Years and older"
NCT00326027:I.1002,"Written informed consent"
NCT00326027:I.1003,"Inpatients (hospitalization during the entire study period is mandatory)"
NCT00326027:I.1004,"Symptomatic (heartburn, acid regurgitation or dysphagia for at least 1 day since admission to the hospital) non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD, LA Grade A-D)"
NCT00326027:I.2001,"Known Zollinger-Ellison syndrome or other gastric hypersecretory condition"
NCT00326027:I.2002,"Previous acid-lowering surgery or other surgery of the esophagus and/or upper gastrointestinal tract (exception: polypectomy and cholecystectomy)"
NCT00326027:I.2003,"On initial endoscopy, presence of obstructive esophageal strictures, Schatzki's ring, esophageal diverticula, esophageal varices, achalasia or Barrett's esophagus with known high-grade dysplasia or longer than 3 cm"
NCT00326027:I.2004,"Acute peptic ulcer and/or ulcer complications"
NCT00326027:I.2005,"Pyloric stenosis (disorder)"
NCT00326027:I.2006,"Known inflammatory bowel diseases"
NCT00327379:I.1001,"Age 18 Years and older"
NCT00327379:I.1002,"Subjects requiring elective spinal fusion surgery involving 3 to 7 vertebral levels with instrumentation. One vertebral level is defined as encompassing two vertebral bodies and one inter-vertebral disc space, so that a contiguous spinal fusion involving 3 vertebral levels would include 4 vertebral bodies and 3 inter-vertebral disc spaces."
NCT00327379:I.2001,"Subjects with previous exposure to aprotinin in the last 6 months. If the subject has undergone cardiac surgery in the last 6 months, all attempts should be made to ascertain if aprotinin was administered during cardiac surgery. If no records are available, or if the subject received aprotinin, the subject should be excluded."
NCT00327379:I.2002,"Subjects with a known or suspected allergy to aprotinin."
NCT00327379:I.2003,"Subjects with sepsis or a known bone infection."
NCT00327379:I.2004,"Personal history of malignant neoplasm of bone"
NCT00327379:I.2005,"Subjects with a creatinine clearance<30mL/min as calculated by the Cockcroft-Gault formula."
NCT00327379:I.2006,"Subjects with a history of bleeding diathesis or known coagulation factor deficiency."
NCT00327379:I.2007,"Subjects with failure of a major organ system or any active significant medical illness that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study."
NCT00327379:I.2008,"Subjects who refuse to receive allogenic blood products for religious or other reasons."
NCT00327379:I.2009,"Subjects whose preoperative red blood cell volume is so low that a blood transfusion would be likely to be given perioperatively (preoperative hematocrit or hemoglobin values<24% or<8 g/dl, respectively)."
NCT00327379:I.2010,"Subjects who have participated in an investigational drug study within the past 30 days."
NCT00327379:I.2011,"Subjects with a history of deep vein thrombosis or pulmonary embolism."
NCT00327379:I.2012,"Subjects who are pregnant or breast feeding."
NCT00327379:I.2013,"Women of childbearing potential in whom the possibility of pregnancy cannot be excluded by a negative serum pregnancy test at screening."
NCT00327379:I.2014,"Women of childbearing potential who are not using a reliable method of contraception."
NCT00327379:I.2015,"Antifibrinolytic Agents"
NCT00327379:I.2016,"Subjects on chronic anticoagulant treatment with Vit K antagonists that cannot be temporarily discontinued for the surgical procedure (as per local practices)."
NCT00329303:I.1001,"Age up to 18 Years"
NCT00329303:I.1002,"Subject having responded to treatment in study C87040 and having relapsed during the follow-up period."
NCT00329303:I.2001,"Erythrodermic, guttate, palmar or plantar, generalized pustular form of psoriasis"
NCT00329303:I.2002,"A history of chronic infection, recent serious or life-threatening infection (within six months, including herpes zoster), or any current sign or symptom that may indicate an infection (e.g. fever, cough)"
NCT00329303:I.2003,"White Blood Cell Count procedure (WBC)"
NCT00329303:I.2004,"Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis)"
NCT00329303:I.2005,"Lupus Erythematosus, Systemic"
NCT00329303:I.2006,"Non respect of adequate wash out periods for treatments that might have an impact on the disease"
NCT00329303:I.2007,"Any associated disease that could be impacted by the study treatment intake"
NCT00329303:I.2008,"Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study"
NCT00331890:I.1001,"Patient,>18 years old"
NCT00331890:I.1002,"Patients must be treated within 24 hours of their initial stroke symptoms onset."
NCT00331890:I.1003,"Patients with a measurable focal neurological deficit lasting for a minimum of 60 minutes."
NCT00331890:I.1004,"Patients must have a CT scan and/or conventional MRI compatible with the clinical diagnosis of acute ischemic stroke prior to being randomized."
NCT00331890:I.1005,"Patients must have an acute ischemic stroke referable to the middle cerebral artery territory"
NCT00331890:I.1006,"At inclusion, NIHSS score>7, with at least 2 of these points from sections 5&6 (motor)"
NCT00331890:I.1007,"Immediately (i.e. minutes) pre-stroke, MRS<2"
NCT00331890:I.1008,"Women of childbearing potential must have a negative pregnancy test prior to enrolment"
NCT00331890:I.1009,"Signed informed consent"
NCT00331890:I.2001,"Patients in coma: patients having a score of>=2 in the items regarding the level of consciousness in the NIHSS (1a)"
NCT00331890:I.2002,"CT or conventional MRI evidence of brain tumor, cerebral edema with a clinically significant mass midline shift with compression of the ventricles, brainstem or cerebellar infarction, subarachnoid and/or intracerebral and/or intraventricular hemorrhage"
NCT00331890:I.2003,"History of ventricular dysrhythmias, acute myocardial infarction within 72 hours prior to enrolment, unstable angina, decompensated congestive heart failure or any other acute, severe, uncontrollable or sustained cardiovascular condition that, in the Investigator's opinion, may interfere with effective participation in the study"
NCT00331890:I.2004,"Previous disorders that may confound the interpretation of the neurological scales"
NCT00331890:I.2005,"Drug addiction-related disorders"
NCT00331890:I.2006,"Pre existing dementia, when dementia implies a disability, measured as an score of>=2 in the previous MRS"
NCT00331890:I.2007,"Pre existing medical condition that, in the Investigator's opinion, may interfere with the patient's suitability and participation in the study"
NCT00331890:I.2008,"Patients participating in another clinical trial or receiving a non-approved drug (clinical investigational drug)<30 days prior to screening"
NCT00331890:I.2009,"Patients under current treatment with citicoline"
NCT00332709:I.1001,"Age 18 Years and older"
NCT00332709:I.1002,"Compliant postmenopausal women with primary operable breast cancer after 4 to 6 years of therapy with tamoxifen (end of tamoxifen therapy within last 6 months)"
NCT00332709:I.1003,"ECOG performance status finding"
NCT00332709:I.1004,"Patients without severe osteoporosis at study entry"
NCT00332709:I.1005,"No evidence of relapse at the time of randomization"
NCT00332709:I.1006,"Adequate function of bone marrow, kidney, and liver"
NCT00332709:I.2001,"Estrogen- and progesterone-receptor status negative or unknown"
NCT00332709:I.2002,"Completion of adjuvant tamoxifen therapy more than 6 months prior to study start"
NCT00332709:I.2003,"Inflammatory Breast Carcinoma, Mastitis carcinomatosa"
NCT00332709:I.2004,"Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures"
NCT00332709:I.2005,"Recent (within 6 weeks) or planned dental or jaw surgery"
NCT00332709:I.2006,"History of diseases with influence on bone metabolism such as Paget's disease and primary overactive parathyroid"
NCT00332709:I.2007,"Prior or concomitant therapies: chemotherapy within the last 12 months, intravenous or oral bisphosphonates, systemic corticosteroids, anabolic steroids or growth hormones, Tibolone, parathyroid hormone, systemic sodium fluoride or any drugs known to affect the skeleton (such as calcitonin, mithramycin, or gallium nitrate)"
NCT00332709:I.2008,"Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancers or in situ cancer of the cervix. Patients with previous other cancer(s) must have been disease-free for at least 5 years."
NCT00332709:I.2009,"Patients currently receiving oral bisphosphonates must discontinue these at least 3 weeks prior to study start."
NCT00332852:I.1001,"Age 18 Years and older, female"
NCT00332852:I.1002,"Compliant postmenopausal women with primary operable breast cancer after complete surgery and suitable for endocrine treatment"
NCT00332852:I.1003,"Nodal status negative or positive"
NCT00332852:I.1004,"Good Health status<=2 (Eastern Cooperative Oncology Group)"
NCT00332852:I.1005,"Estrogen- and/or progesterone-receptor positive"
NCT00332852:I.1006,"Adequate marrow, kidney and liver function"
NCT00332852:I.2001,"Metastatic or inflammatory breast cancer"
NCT00332852:I.2002,"Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancer or in situ cancer of the cervix. Patients with other previous cancers must have been disease-free for at least 5 years and Patients with uncontrolled, non-malignant systemic cardiovascular, kidney, and liver diseases."
NCT00332852:I.2003,"Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures."
NCT00332852:I.2004,"Recent (within 6 weeks) or planned dental or jaw surgery"
NCT00332852:I.2005,"Patients with primary overactive parathyroid"
NCT00332852:I.2006,"Patients with a known hypersensitivity to zoledronic acid or other bisphosphonates."
NCT00333411:I.1001,"18 Years to 75 Years"
NCT00333411:I.1002,"Patients with stable moderate to severe plaque-type psoriasis involving>10% body surface area, with minimum disease severity PASI>10 and with static PGA of at least moderate (score of at least 3) at screening visit"
NCT00333411:I.1003,"Psoriasis disease duration of at least 6 months prior to screening"
NCT00333411:I.1004,"Patients must be candidates for systemic psoriasis treatment or phototherapy"
NCT00333411:I.1005,"Patient must give informed consent and sign an approved consent form prior to any study procedures, including wash out of prohibited medications (Patients participating in the PK sub-study will sign an additional consent form. Refusal to participate in the sub-study will not exclude from participation in the main trial)"
NCT00333411:I.2001,"Patients with primary guttatae, erythrodermic, or pustular psoriasis"
NCT00333411:I.2002,"Patients who have previously discontinued efalizumab treatment due to lack of efficacy"
NCT00333411:I.2003,"Patients using treatments that could interfere with the primary endpoint of the study (cf. protocol section 4.2.2.1)"
NCT00333411:I.2004,"Patients on treatment with warfarin, paracetamol (acetaminophen), some NSAIDs, some antidepressants, medications known to induce or inhibit CYP3A4, or any other concomitant medication where potential drug-drug interactions with BIRT 2584 XX could either result in decreased efficacy or an unacceptable benefit-risk assessment, and where replacement of that concomitant medication with a safe equivalent drug is not possible (cf. protocol section 4.2.2.2 and the Investigator Site File)."
NCT00333411:I.2005,"Patients with active liver disease or history of any significant liver disease"
NCT00333411:I.2006,"Any clinically significant illness or unstable disease which according to investigator judgement may either put the patient at risk because of participation in the study or may influence the results of the study or the patients ability to participate"
NCT00333411:I.2007,"Patient with serum creatinine and/or white blood cell count>1.5 x ULN at screening (Repeat laboratory is allowed once between screening and randomisation prior to excluding the patient)"
NCT00333411:I.2008,"Patients with ALT, AST and/or total bilirubin>1.5xULN at screening (Repeat laboratory is allowed once between screening and randomisation prior to excluding the patient)"
NCT00333411:I.2009,"Abnormal values of other laboratory parameters at screening that would define a clinically significant disease as described above (Repeat laboratory is allowed once between screening and randomisation prior to excluding the patient)"
NCT00333411:I.2010,"Positive testing at screening, or history of HIV or hepatitis B or hepatitis C, or any serious infection (requiring hospitalisation or parenteral antibiotic therapy) in the past 3 months prior to screening"
NCT00333411:I.2011,"History of malignancy in the past 5 years or suspicion of active malignant disease except treated cutaneous squamous cell or basal cell carcinoma"
NCT00333411:I.2012,"Patients with the following findings at the screening visit that could interfere with cardiac repolarisation:
marked baseline prolongation of QT/QTc interval as measured on ECG (e.g. QTc interval>450ms),
history of additional risk factors for Torsade de pointe (e.g. heart failure, - hypokalemia, family history of long QT syndrome),use of concomitant medications that prolong the QT/QTc interval"
NCT00333411:I.2013,"History of drug or alcohol abuse within the past two years"
NCT00333411:I.2014,"Pre-menopausal (last menstruation 1 year prior to screening) sexually active woman who:
is pregnant or nursing,is of child bearing potential and not practicing acceptable methods of birth control, or does not plan to continue practising an acceptable method throughout the study (acceptable methods of birth control include surgical sterilisation, intrauterine devices, double barrier, male partner sterilisation, but not hormonal contraceptives) [A negative serum pregnancy test at screening (Visit 1) and a negative urine test prior to randomisation (Visit 2) are required]"
NCT00333411:I.2015,"Patient not willing to avoid excess sun exposure during the trial duration"
NCT00333411:I.2016,"Patients who have taken an investigational drug, within the last 4 weeks or 5 half lives (which ever is greater) prior to randomisation [Patients who have been treated with any investigational antibody or fusion protein within the past 12 weeks before randomisation are excluded]"
NCT00333411:I.2017,"Known allergy to BIRT 2584 XX or to the excipients used for tablet formulation"
NCT00333411:I.2018,"Body mass index>34 kg/m2 at screening"
NCT00333411:I.3001,Age
NCT00333411:I.3002,Psoriasis
NCT00333411:I.3003,"Systemic Therapy"
NCT00333411:I.3004,Phototherapy
NCT00333411:I.3005,"Informed Consent"
NCT00333411:I.3006,"Psoriasis guttata"
NCT00333411:I.3007,"exfoliative psoriasis"
NCT00333411:I.3008,"pustular psoriasis"
NCT00333411:I.3009,Medication
NCT00333411:I.3010,"Liver diseases"
NCT00333411:I.3011,Creatinine
NCT00333411:I.3012,"White Blood Cell Count procedure (WBC)"
NCT00333411:I.3013,"GPT (Serum)"
NCT00333411:I.3014,"GOT (Serum)"
NCT00333411:I.3015,Bilirubin
NCT00333411:I.3016,"Human immunodeficiency virus infection"
NCT00333411:I.3017,Hepatitis
NCT00333411:I.3018,"Systemic infection"
NCT00333411:I.3019,"Malignant Neoplasms"
NCT00333411:I.3020,Electrocardiogram
NCT00333411:I.3021,"Drug abuse"
NCT00333411:I.3022,"Alcohol abuse"
NCT00333411:I.3023,pregnant
NCT00333411:I.3024,"Breast feeding, Nursing"
NCT00333411:I.3025,Contraception
NCT00333411:I.3026,"Serum pregnancy test (B-HCG)"
NCT00333411:I.3027,"Sun Exposure"
NCT00333411:I.3028,Enrollment
NCT00333411:I.3029,Hypersensitivity
NCT00333411:I.3030,"Body mass index"
NCT00334295:I.1001,"18 Years and older"
NCT00334295:I.1002,"Female Gender"
NCT00334295:I.1003,"Histologically confirmed, recurrent or metastatic endometrial carcinoma"
NCT00334295:I.1004,Postmenopausal
NCT00334295:I.1005,"Hormonreceptor positive tumor"
NCT00334295:I.2001,"Pre-treatment with Fulvestrant"
NCT00334295:I.2002,"Previous endocrine therapy of the endometrial carcinoma"
NCT00334295:I.2003,"Previous malignancy less than 3 years ago other than in situ carcinoma of the cervix, basal cell carcinoma or squamous carcinoma of the skin"
NCT00343161:I.1001,"18 Years to 55 Years"
NCT00343161:I.1003,"Signed informed consent"
NCT00343161:I.1004,"Patients who seek medical advice in primary care for symptoms thought to be GERD-related"
NCT00343161:I.2001,"Clinical GERD diagnosis/treatment within last 3 month"
NCT00343161:I.2002,"History of severe esophagitis (i.e. LA grade C or D)"
NCT00343161:I.2003,"Previous anti-reflux surgery"
NCT00343161:I.2004,"History of drug abuse"
NCT00343161:I.2005,"Female patients who are pregnant or lactating or at risk of pregnancy"
NCT00343161:I.3001,age
NCT00343161:I.3003,diagnosis
NCT00343161:I.3004,Medication
NCT00343161:I.3005,"Gastroesophageal reflux disease"
NCT00343161:I.3006,"Informed Consent"
NCT00343161:I.3007,Esophagitis
NCT00343161:I.3008,"Anti-reflux surgery"
NCT00343161:I.3009,pregnant
NCT00343161:I.3010,treatment
NCT00343161:I.3011,"Drug abuse"
NCT00343161:I.3012,"Breast feeding, Nursing"
NCT00349076:I.1001,"age at least 18 Years"
NCT00349076:I.1002,"Histologically proven, advanced primary carcinoma of the rectum (tumor ? 12cm from the anal verge, with clinically staged T3/4 or any node-positive disease"
NCT00349076:I.1003,"No prior therapy except a diverting stoma"
NCT00349076:I.1004,"ECOG performance status finding<= 2"
NCT00349076:I.1005,"Adequate bone marrow function: Leukocytes>3,5 x 10^9/L Absolute neutrophil count>1,5 x 10^9/L Platelet count>100 x 10^9/L Hemoglobin>10 g/dl"
NCT00349076:I.1006,"Adequate hepatic function: Total bilirubin<2,0 mg/dl ALAT, ASAT, alkaline phosphatase, gamma-GT<3 x ULN 7. Serum creatinine<1,5 mg/dl, creatinine-clearance>50 ml/min"
NCT00349076:I.1007,"Written informed consent before randomization"
NCT00349076:I.2001,"Pregnant or breast feeding women"
NCT00349076:I.2002,"Fertile patients without adequate contraception during therapy"
NCT00349076:I.2003,"Past or ongoing drug abuse or alcoholic excess"
NCT00349076:I.2004,"Prior Chemotherapy"
NCT00349076:I.2005,"Prior radiotherapy to the pelvis"
NCT00349076:I.2006,"Prior (within 4 weeks) or concurrent treatment with any other investigational agent"
NCT00349076:I.2007,"Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule"
NCT00349076:I.2008,"History of severe somatic or psychological diseases: - instable cardiac disease not well controlled with medication, myocardial infarction within the last 6 months:* Central nervous system disorders or psychiatric disability including dementia or epileptic disease. * active uncontrolled intercurrent infections or sepsis"
NCT00349076:I.2009,"Peripheral neuropathy>2 (NCI CTC AE grading)"
NCT00349076:I.2010,"Previous or concurrent malignancies, with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix. The inclusion of patients with other adequately treated tumors within the last 5 years has to be discussed with the principal investigator"
NCT00349076:I.2011,"Chronic diarrhea (>NCI CTC AE-Grad 1)"
NCT00349076:I.2012,"Known allergy to substances containing platinum compounds"
NCT00349076:I.2013,"Concurrent use of the antiviral agent sorivudine or chemically related analogues"
NCT00349076:I.2014,"Known deficiency of dehydropyrimidindehydrogenase (DPD)"
NCT00351910:I.1001,"18 Years to 65 Years"
NCT00351910:I.1002,"A documented diagnosis of major depressive disorder"
NCT00351910:I.2001,"Patients with a DSM IV Axis I disorder other than MDD within 6 months of enrolment"
NCT00351910:I.2002,"Patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the patient's current psychiatric status"
NCT00351910:I.2003,"Patients whose current episode of depression exceeds 12 months or is less than 4 weeks prior to enrolment"
NCT00354627:I.1001,"age at least 18 Years"
NCT00354627:I.1002,"Patient is at least 3-class experienced (3 classes of licensed oral antiretrovirals: nucleoside/tide reverse transcriptase inhibitors [N[t]RTI], protease inhibitors [PI], non-nucleoside reverse transcriptase inhibitors [NNRTI])"
NCT00354627:I.1003,"Patients with primary NNRTI resistance can be included if they are experienced with at least 2 classes of ARVs (PIs, N[t]RTIs) and meet all the other inclusion criteria"
NCT00354627:I.1004,"Patient has previously received 2 different PI-based regimens"
NCT00354627:I.1005,"Patient is unable to use currently approved NNRTIs due to resistance (primary or acquired) and/or intolerance"
NCT00354627:I.1006,"Patient, if currently receiving an ARV regimen, is not achieving adequate virologic suppression on his/her current regimen."
NCT00354627:I.2001,"Prior or current participation in DUET trials (TMC125-C206 or TMC125-C216)."
NCT00354627:I.2002,"Use of disallowed concomitant therapy, including disallowed antiretrovirals (ARV)"
NCT00354627:I.2003,"Use of investigational ARVs (with exceptions)"
NCT00354627:I.2004,"Any active clinically significant disease (e.g., cardiac dysfunction, pancreatitis, acute viral infection) or findings during screening of medical history or physical examination that is not either resolved or stabilized for at least 30 days before the Screening Phase"
NCT00354627:I.2005,"Pregnant or breast-feeding female"
NCT00354627:I.2006,"Female patient of childbearing potential not using effective non-hormonal birth control methods"
NCT00354627:I.2007,"Patients with specific laboratory abnormalities"
NCT00354627:I.2008,"Patients with clinical or laboratory evidence of significantly decreased hepatic function or decompensation."
NCT00355849:I.1001,"age>=18 Years"
NCT00355849:I.1002,"Diabetes Mellitus, Non-Insulin-Dependent"
NCT00355849:I.1003,"one or more oral antihyperglycemic medications"
NCT00355849:I.1004,"once-daily insulin glargine"
NCT00355849:I.1005,"HbA1c greater than or equal to 7.5 and less than or equal to 10.5%"
NCT00355849:I.1006,Non-smoker
NCT00355849:I.2001,"taking a TZD dose greater than what is indicated"
NCT00355849:I.2002,"more than two episodes of severe hypoglycemia during the 6 months prior"
NCT00355849:I.2003,"Have had a lower respiratory infection in the 3 months prior"
NCT00355849:I.2004,"systemic Steroid Therapy"
NCT00355849:I.2005,"clinical signs or symptoms of liver disease, acute or chronic hepatitis"
NCT00355849:I.2006,"history of renal transplantation"
NCT00355849:I.2007,"active or untreated malignancy"
NCT00355849:I.2008,"Require more than 150 U/day of insulin glargine"
NCT00356109:I.1001,"age>=18 Years"
NCT00356109:I.1002,"Type 1 diabetes for at least 24 months"
NCT00356109:I.1003,"Have an HbA1c less than or equal to 11%"
NCT00356109:I.1004,"Patients who are on an insulin regimen involving 2 or 3 preprandial injections per day for at least 2 months"
NCT00356109:I.1005,Non-smoker
NCT00356109:I.2001,"Require a daily total insulin dosage greater than 150 U at screening"
NCT00356109:I.2002,"Patients who have a current or past history of asthma, chronic obstructive pulmonary disease, other clinically relevant pulmonary disease"
NCT00356109:I.2003,"systemic Steroid Therapy"
NCT00356109:I.2004,"Clinical signs or symptoms of liver disease, acute or chronic hepatitis"
NCT00356109:I.2005,"History of lung transplantation and/or lung cancer"
NCT00356109:I.2006,"Diagnosed with pneumonia in the 3 months prior to screening"
NCT00356109:I.2007,"History of renal transplantation"
NCT00356109:I.2008,"Active or untreated malignancy"
NCT00357227:I.1001,"age 50 Years to 85 Years"
NCT00357227:I.1002,"Clinical diagnosis of permanent, paroxysmal or episodic atrial fibrillation in the past or at present"
NCT00357227:I.2001,"Cardiac pacemaker"
NCT00357227:I.2002,"Metal implants"
NCT00357227:I.2003,"History of acute stroke"
NCT00357227:I.2004,"Diagnosis of vascular or degenerative dementia"
NCT00357227:I.2005,"History of brain tumors"
NCT00357227:I.2006,"History of severe brain injury"
NCT00357227:I.2007,"History of psychiatric disorders"
NCT00357227:I.2008,"Pregnancy, Gestation"
NCT00359762:I.1001,"age 18 Years to 85 Years"
NCT00359762:I.1002,"Diagnosed with type 2 diabetes mellitus."
NCT00359762:I.1003,"Treated with diet and exercise and a stable, maximally tolerated dose of metformin for at least 3 months prior to screening."
NCT00359762:I.1004,"HbA1c>=6.5% and<=9.0%."
NCT00359762:I.1005,"Body Mass Index (BMI)>=25 kg/m2 and<40 kg/m2."
NCT00359762:I.2001,"Participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to screening."
NCT00359762:I.2002,"Characteristics contraindicating metformin or glimepiride use."
NCT00359762:I.2003,"Receiving drugs that directly affect gastrointestinal motility."
NCT00359762:I.2004,"Receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy."
NCT00359762:I.2005,"Have used any prescription drug to promote weight loss within 3 months prior to screening."
NCT00359762:I.2006,
NCT00372229:I.1001,"age>= 18 Years"
NCT00372229:I.1002,"primary or secondary renal allograft within preceding 14 days"
NCT00372229:I.1003,"IgG seropositive for CMV"
NCT00372229:I.1004,"receiving immunosuppressive therapy"
NCT00372229:I.2001,"active CMV infection"
NCT00372229:I.2002,"current/history of malignancy"
NCT00372229:I.2003,"acute steroid resistant rejection episode since transplantation."
NCT00373373:I.1001,"age>= 61 Years"
NCT00373373:I.1002,"Patients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML)"
NCT00373373:I.1003,"Bone marrow aspirate or biopsy must contain>= 20% blasts of all nucleated cells, with the exception of AML FAB M6, where>= 30% of non-erythroid cells must be leukemic blasts"
NCT00373373:I.1004,"Age>= 61 years"
NCT00373373:I.1005,"Informed consent, personally signed and dated to participate in the study"
NCT00373373:I.1006,"Male patients enrolled in this trial must use adequate barrier birth control measures during the course of the Sorafenib treatment and for at least 3 months after the last administration of Sorafenib"
NCT00373373:I.2001,"Central nervous system manifestation of AML"
NCT00373373:I.2002,"Cardiac Disease: Heart failure NYHA III or IV.  Active coronary artery disease (MI more than 6 months prior to study entry is permitted).  Serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)"
NCT00373373:I.2003,"Chronically impaired renal function (creatinin clearance<30 ml/min)"
NCT00373373:I.2004,"Chronic pulmonary disease with relevant hypoxia"
NCT00373373:I.2005,"Inadequate liver function (ALT and AST>= 2.5 x ULN)"
NCT00373373:I.2006,"Total bilirubin>= 1.5 x ULN"
NCT00373373:I.2007,"Resting blood pressure (BP) consistently higher than systolic 160 mmHg and/or diastolic 95 mmHg"
NCT00373373:I.2008,"Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardise compliance with the protocol"
NCT00373373:I.2009,"Uncontrolled active infection"
NCT00373373:I.2010,"Concurrent malignancies other than AML"
NCT00373373:I.2011,"Previous treatment of AML except hydroxyurea and up to 2 days<= 100 mg/m2/d cytarabine"
NCT00373373:I.2012,"Known HIV and/or hepatitis C infection"
NCT00373373:I.2013,"Evidence or history of CNS disease, including primary or metastatic brain tumors, seizure disorders"
NCT00373373:I.2014,"Thrombotic or embolic events such as cerebrovascular accident or pulmonary embolism within 1 year of study entry"
NCT00373373:I.2015,"Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy"
NCT00373373:I.2016,"History of organ allograft"
NCT00373373:I.2017,"Concomitant treatment with kinase inhibitors, angiogenesis inhibitors and Myelotarg"
NCT00373373:I.2018,"Patients with major surgery, open biopsy or significant traumatic injury within 4 weeks of start or first dose"
NCT00373373:I.2019,"Serious, non-healing wound, ulcer or bone fracture"
NCT00373373:I.2020,"Allergy to study medication or excipients in study medication"
NCT00373373:I.2021,"Investigational drug therapy outside of this trial during or within 4 weeks of study entry"
NCT00373373:I.2022,"Patients who are not eligible for standard chemotherapy"
NCT00376337:I.1001,"age>=18 Years"
NCT00376337:I.1002,"Adult patients with HSCT, acute leukaemia or myelodysplastic syndrome, with proven (probable only in case of pulmonary aspergillosis) invasive aspergillosis and refractory or intolerant to amphotericin B or voriconazole products"
NCT00376337:I.2001,"Patients with allergic bronchopulmonary aspergillosis, chronic pulmonary aspergillosis, aspergilloma, sinus aspergillosis or external otitis"
NCT00376337:I.2002,"patient with previous salvage therapy for the current episode of fungal infection"
NCT00384046:I.1001,"age 40 Years to 70 Years"
NCT00384046:I.1002,"Women will be screened for study participation according to the following inclusion criteria at Week -4. Eligible women must be a woman one year post menopausal, 40-70 years old in general good health on transdermal HRT and in a stable monogamous sexual relationship with low sexual desire causing distress."
NCT00384046:I.2001,"Women will be screened for study participation according to the following exclusion criteria at Week -4 or as specified. Eligible women must not have any medical, physical, psychological, or pharmacological condition that could confound safety or efficacy."
NCT00385372:I.1001,"age 7 Years to 80 Years"
NCT00385372:I.1002,"signed informed consent"
NCT00385372:I.1003,"chronic urticaria (duration: at least 6 weeks)"
NCT00385372:I.1004,"patients who suffered from urticaria and/or angio oedema at least once a week for a duration of at least 4 weeks)"
NCT00385372:I.1005,"Males and females, age between 7 and 80 years"
NCT00385372:I.1006,"inpatients and outpatients"
NCT00385372:I.1007,"oral antihistamines and glucocorticosteroids are allowed as concomitant medication (if needed)"
NCT00385372:I.2001,"pregnant or breastfeeding woman"
NCT00385372:I.2002,"patients suffering from diabetes mellitus"
NCT00385372:I.2003,"patients with cachexia"
NCT00385372:I.2004,"known food allergies of food which will be administrated within the elimination diet (e.g. milk, cereals)"
NCT00385372:I.2005,"isolated urticaria with known aetiology (e.g. physical urticaria, aquagene urticaria, urticaria factitia, cholinergic urticaria), Urticaria pigmentosa mastocytoses)"
NCT00385372:I.2006,"patients, seemed to be uncompliant under suspicion of the investigator"
NCT00391287:I.1001,"age at least 18 Years"
NCT00391287:I.1002,"Patients with established CRF as an indication for the treatment of anemia"
NCT00391287:I.1003,"Patients who are receiving or are about to receive (within 1 month) a marketed erythropoietin product by the s.c. route of administration"
NCT00391287:I.1004,"Patients who are likely to continue to receive s.c. erythropoietin product(s) for at least 1 year"
NCT00391287:I.2001,"Patients with a history of pure red cell aplasia or aplastic anemia"
NCT00391287:I.2002,"Patients who are experiencing unexplained loss or lack of effect to a recombinant erythropoietin product ongoing at the time of enrollment"
NCT00391287:I.2003,"Patients who have had prior recombinant erythropoietin treatment whose anemia had never responded (primary lack of efficacy)"
NCT00391287:I.2004,"Patients with a history of EPO antibodies prior to enrollment"
NCT00391287:I.2005,"Subjects who are currently receiving immunosuppressive medication (e.g., cyclosporine, tacrolimus, sirolimus, mycophenolic mofetil, azathioprine, or monoclonal antibodies) or corticosteroids at a dose corresponding to>15 mg/day prednisolone"
NCT00391287:I.2006,"Subjects whose first s.c. exposure to any erythropoietin product was>1 year prior to enrollment"
NCT00391872:I.1001,"age at least 18 Years"
NCT00391872:I.1002,"Male or female 18 years or older who has been hospitalised for chest pain and potential ACS"
NCT00391872:I.1003,"Females of child-bearing potential must have a negative pregnancy test at enrollment and be willing to use 2 methods of reliable contraception"
NCT00391872:I.2001,"Persons with moderate or severe liver disease"
NCT00391872:I.2002,"Persons who have already been treated with an invasive (angioplasty) procedure for the current episode of ACS"
NCT00391872:I.2003,"Persons who are being treated with blood clotting agents that cannot be stopped"
NCT00393692:I.1001,"Age at least 50 Years"
NCT00393692:I.1002,"Must be considered reliable, willing and able to give informed consent."
NCT00393692:I.1004,"Must have age-related macular degeneration in at least one eye"
NCT00393692:I.1005,"Clear media to allow imaging"
NCT00393692:I.2001,"any history of retinal surgery, including laser treatment, photodynamic therapy, radiation or intravitreal injections"
NCT00393692:I.2002,"history of retinal vascular occlusions"
NCT00393692:I.2003,"any concurrent intraocular condition that, in the opinion of the investigator, could exclude the patient from the medical or ethical point of view"
NCT00395070:I.1001,"age at least 18 Years"
NCT00395070:I.1002,"Confirmed Stage 3 or Stage 4 melanoma that may have had previous treatment via surgery, radiation or biologic drugs (typically Interferon Alpha or Interleukin-2)"
NCT00395070:I.1003,"At least 1 melanoma tumor that is 1cm x 1cm or greater in size (about the size of a dime) and can be injected"
NCT00395070:I.1004,"Normal blood chemistries and blood cell counts"
NCT00395070:I.1005,"At least 18 years old and able and willing to provide informed consent to participate"
NCT00395070:I.2001,"Previous chemotherapy treatment for melanoma"
NCT00395070:I.2002,"Melanoma lesions in the brain or liver (however, lesions in the lungs are allowed)"
NCT00395070:I.2003,"If surgical removal of all lesions would be possible and could be curative"
NCT00395070:I.2004,"Any melanoma tumors>10cm x 10cm in size"
NCT00395070:I.2005,"Known condition resulting in a suppressed immune system"
NCT00395070:I.2006,"Female subjects who are pregnant"
NCT00402727:I.1001,"age at least 18 Years"
NCT00402727:I.1002,"Written informed consent"
NCT00402727:I.1003,"Men or women of 18 years and above with a diagnosis of bacterial skin and skin structure infection that requires"
NCT00402727:I.1004,"Inpatient care (regime/therapy)"
NCT00402727:I.1005,"Initial parenteral therapy for at least 48 hours and"
NCT00402727:I.1006,"Meets at least one of the following criteria:"
NCT00402727:I.1007,"Involvement of deep soft tissue (e.g. fascial, muscle layers)"
NCT00402727:I.1008,"Requirement for a significant surgical intervention including surgical  drainage, drainage procedure guided by imaging and/or debridement"
NCT00402727:I.1009,"Association with a significant underlying disease that may complicate  response to treatment. An underlying disease is considered significant if  it includes any of the following conditions that are present at the time of  presentation: cancer (except basal- or squamous-cell cancer of the skin),  cardiac (i.e., congestive heart disease), diabetes mellitus, hepatic (i.e.,  cirrhosis or another form of chronic liver disease), immunologic, renal  disease, respiratory, transplantation or vascular disease"
NCT00402727:I.1010,"Duration of infection<21 days"
NCT00402727:I.1011,"Diagnosis of one of the following skin and skin structure infections that requires hospitalization and initial parenteral antibiotic therapy for at least 48 hours:"
NCT00402727:I.1012,"Major abscess(es) associated with extensive cellulitis, which requires  antibiotic therapy in addition to surgical incision and drainage"
NCT00402727:I.1013,"Diabetic foot infection of mild to severe intensity (perfusion, extent/size,  depth/tissue loss, infection and sensation (PEDIS) grade 2-4) in the presence or  absence of osteomyelitis. Subjects with osteomyelitis may only be enrolled if  the infected bone is completely removed by surgery and if residual infection  requiring antibiotics is still present following surgery"
NCT00402727:I.1014,"Wound infection including: post surgical (surgical incision), post-traumatic,  human bite/clenched fist and animal bite wound and wound associated with  injection drug abuse:"
NCT00402727:I.1015,"Infections must have occurred within 30 days of a surgical procedure,  trauma, animal bite, or human bite, and involve the skin and skin  structures at the site of the incision, trauma, or bite"
NCT00402727:I.1016,"In addition, post-surgical/trauma wound infections must meet the following  criteria:"
NCT00402727:I.1017,"Involvement of deep soft tissues (e.g. fascial and muscle layers) of  the incision/trauma"
NCT00402727:I.1018,"At least one of the following criteria:"
NCT00402727:I.1019,"Purulent drainage from the deep incision/trauma"
NCT00402727:I.1020,"Identification of an infecting organism from an aseptically   obtained culture of fluid or tissue from incision/trauma"
NCT00402727:I.1021,"At least one of the following signs and symptoms:"
NCT00402727:I.1022,"Localized pain or tenderness"
NCT00402727:I.1023,"Fever (see below) AND the incision (in case of post-surgical   wound infections) is deliberately opened by a surgeon, unless the   culture is negative"
NCT00402727:I.1024,"Abscess or other evidence of infection involving the deep   incision/trauma, found on direct examination, during   reoperation/operation (in case of trauma), or by histologic or   radiologic examination"
NCT00402727:I.1025,"Diagnosis of a deep incisional/post-trauma Skin Structure Infections  (SSI) by a surgeon or attending physician"
NCT00402727:I.1026,"Bite wounds/clenched fist infections and wounds associated with  injection drug abuse must meet the criteria defining a Complicated  Skin and Skin Structure Infections (cSSSI)"
NCT00402727:I.1027,"Infected ischemic ulcers with at least one of the following conditions:"
NCT00402727:I.1028,"Peripheral Vascular Diseases"
NCT00402727:I.1029,"Conditions pre-disposing to pressure sores such as paraplegia, peripheral  neuropathy"
NCT00402727:I.1030,"Presence of at least 3 of the following signs or symptoms:"
NCT00402727:I.1031,"Purulent drainage or discharge"
NCT00402727:I.1032,"Erythema extending>1 cm from the wound edge"
NCT00402727:I.1033,Fluctuance
NCT00402727:I.1034,"Pain or tenderness to palpation"
NCT00402727:I.1035,"Swelling or induration"
NCT00402727:I.1036,"Fever, defined as body temperature"
NCT00402727:I.1037,">37.5°C (axillary)"
NCT00402727:I.1038,">38°C (orally)"
NCT00402727:I.1039,">38.5°C (tympanically) or"
NCT00402727:I.1040,">39°C (rectally)"
NCT00402727:I.1041,Or
NCT00402727:I.1042,"Elevated total peripheral white blood cell (WBC) count>12,000/mm3 or"
NCT00402727:I.1043,">15 % immature neutrophils (bands) regardless of total peripheral   WBC count"
NCT00402727:I.1044,"C-Reactive Protein Measurement"
NCT00402727:I.1045,"Specimen obtained for culture from infected area by needle aspiration of obviously purulent material or by tissue biopsy or by curettage of the surface of ulcer within 48 hours prior to the initiation of study drug therapy"
NCT00402727:I.1046,"Duration of treatment of the skin/skin structure infection is anticipated to be at least 7 days."
NCT00402727:I.1047,"Surgical drainage or debridement of infected wounds or abscesses, if necessary, have to have been completed<= 48 hours after the initiation of study drug therapy"
NCT00402727:I.2001,"Women, who are pregnant or lactating, or in whom pregnancy can not be excluded (Note: a urine pregnancy test has to be performed for all women of childbearing potential before randomization to the study drug)"
NCT00402727:I.2002,"The following skin and skin structure infections:"
NCT00402727:I.2003,"Necrotizing fasciitis including Fourniers gangrene, ecthyma gangrenosum,  streptococcal necrotizing fasciitis and clostridial necrotizing fasciitis"
NCT00402727:I.2004,"Burn wound infections"
NCT00402727:I.2005,"Secondary infections of a chronic skin disease (e.g. atopic dermatitis)"
NCT00402727:I.2006,"Infection of prosthetic materials (e.g. subcutaneous tissue infection related to  a central venous catheter or permanent cardiac pacemaker battery pack). Subjects  with removal of a prosthetic device involved in an infection should not be  included"
NCT00402727:I.2007,"Infections where a surgical procedure alone is definitive therapy"
NCT00402727:I.2008,"Subjects with uncomplicated skin and skin structure infections including  folliculitis and furunculosis, carbunculosis, simple abscesses and superficial  cellulitis"
NCT00402727:I.2009,"Known hypersensitivity to quinolones and/or any type of beta-lactam antibiotic drugs or any of the excipients"
NCT00402727:I.2010,"Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin-clavulanic acid"
NCT00402727:I.2011,"Severe, life threatening disease with a life expectancy of<2 months"
NCT00402727:I.2012,"Immunosuppression including:"
NCT00402727:I.2013,"Known neutropenia (neutrophil count<1000/µL)"
NCT00402727:I.2014,"Known lymphopenia with absolute CD4+ T cell count<200/mm3"
NCT00402727:I.2015,"Acquired immunodeficiency syndrome (AIDS)-defining event and/or concomitant  therapy with Highly Active Antiretroviral Therapy (HAART)"
NCT00402727:I.2016,"Chronic treatment (>/= 2 weeks) with known immunosuppressant therapy (including  treatment with>15 mg/day of systemic prednisone or equivalent)"
NCT00402727:I.2017,"Any other congenital or acquired immune defect or immunosuppression"
NCT00402727:I.2018,"Known severe hepatic insufficiency (Child Pugh C) or transaminases increase>5 fold upper limit of normal (ULN)"
NCT00402727:I.2019,"Known renal impairment with a baseline measured or calculated serum creatinine clearance<40 mL/min"
NCT00402727:I.2020,"Known prolongation of the QT interval or concomitant use of drugs reported to increase the QT interval (e.g. Class IA or Class III antiarrhythmics [eg., quinidine, procainamide, amiodarone, sotalol], neuroleptics [e.g. haloperidol], tricyclic antidepressive agents, certain antimicrobials [e.g. pentamidine, halofantrine], certain antihistaminics[e.g. terfenadine], and other [cisapride, vincamine IV, depridil, diphemanil])"
NCT00402727:I.2021,"Uncorrected hypokalemia"
NCT00402727:I.2022,"Clinically relevant bradycardia"
NCT00402727:I.2023,"Clinically relevant heart failure with reduced left ventricular ejection fraction (i.e., below 40%)"
NCT00402727:I.2024,"Previous history of symptomatic arrhythmias"
NCT00402727:I.2025,"Previous history of tendon disease/disorder with quinolones"
NCT00402727:I.2026,"Known or suspected concomitant bacterial infection requiring additional systemic antibacterial treatment, e.g. underlying septic arthritis"
NCT00402727:I.2027,"Requiring therapy with probenecid"
NCT00402727:I.2028,"Treatment with a systemic or topical antibacterial agent for>24 hours in the previous 7 days preceding study entry unless the subject showed no response or had worsening of clinical signs and symptoms despite 3 or more days of prior therapy and a culture obtained at the time of subject enrollment showed persistence of a pathogen which is susceptible to the study drugs. The prior antimicrobial therapy must not have been a fluoroquinolone or a beta lactam/beta lactamase combination"
NCT00402727:I.2029,"Infection known to be due to a Methicillin-Resistant Staphylococcus Aureus (MRSA), Methicillin-Resistant Staphylococcus Epidermidis (MRSE) or Vancomycin Resistant Enterococcus (VRE) as the single isolated pathogen"
NCT00402727:I.2030,"Previous enrolment in this study"
NCT00402727:I.2031,"Participation in any clinical investigational drug study within 4 weeks of screening"
NCT00402727:I.2032,"Previous history of seizure disorders"
NCT00403832:I.1001,"non infectious uveitis"
NCT00403832:I.1002,"no active inflammation"
NCT00403832:I.1003,"significant visual disturbance related to lens opacification"
NCT00403832:I.1004,"Age at least 18 years"
NCT00403832:I.2001,"vitreous opacification"
NCT00403832:I.2002,"ocular hypertension/glaucoma"
NCT00403832:I.3001,Diagnosis
NCT00403832:I.3002,Cataract
NCT00403832:I.3003,Uveitis
NCT00403832:I.3004,Inflammation
NCT00403832:I.3005,"Visual disturbance"
NCT00403832:I.3006,Age
NCT00403832:I.3007,"Vitreous opacities"
NCT00403832:I.3008,Glaucoma
NCT00404092:I.1001,"age at least 18 Years"
NCT00404092:I.1002,"Immunocompromised due to hematologic malignancies, bone marrow failure syndromes, hematopoietic stem cell transplantation, solid organ transplantation, other conditions resulting in severe neutropenia, HIV infection, prolonged corticosteroid therapy, treatment with other immunosuppressive medications, or other immunocompromising conditions that place patients at risk for invasive fungal infections."
NCT00404092:I.1003,"Evidence of proven or probable invasive aspergillosis, by modified EORTC criteria"
NCT00404092:I.2001,"Concomitant other systemic antifungal agents are not permitted on study."
NCT00404092:I.2002,"Chronic invasive fungal infection, defined as signs/symptoms of invasive fungal infection present for>4 weeks preceding entry into study"
NCT00404092:I.2003,"Prior systemic therapy of>= 4 days with any polyene anti-fungal agent within 14 days of study enrollment"
NCT00404092:I.2004,"Prior systemic therapy of>= 4 days with non-polyenes for the current, documented IFI."
NCT00404482:I.1001,"age up to 16 Years"
NCT00404482:I.1002,Uveitis
NCT00404482:I.1003,JIA
NCT00404885:I.1001,"age at least 13 Years"
NCT00404885:I.1002,"Documented history of non-infectious anterior, anterior and intermediate- or panuveitis"
NCT00404885:I.1003,"Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated."
NCT00404885:I.1004,"Grade of>= 2+ for anterior chamber cells at time of enrollment"
NCT00404885:I.1005,"Considered by the investigator to require corticosteroid-sparing therapy."
NCT00404885:I.1006,"Subjects not planning to undergo elective ocular surgery during the study"
NCT00404885:I.2001,"Uveitis of infectious etiology"
NCT00404885:I.2002,"Presence of an ocular toxoplasmosis scar"
NCT00404885:I.2003,"An immune suppression regimen that includes an alkylating agent within the previous 90 days"
NCT00405743:I.1001,"Age at least 18 Years"
NCT00405743:I.1002,"ARM A and B: Phase I CP-4055 single agent"
NCT00405743:I.1003,"Patients must have relapsed/refractory leukemias for which no standard therapies are anticipated to result in a durable response or have failed potentially curative therapy, or have refused or are considered unsuitable for standard therapy"
NCT00405743:I.1004,"ARM C: CP-4055 in combination with idarubicin"
NCT00405743:I.1005,"Patients with relapsed/refractory AML for which no standard therapies are anticipated to result in a durable response or who have failed potentially curative therapy, or who refuse or are considered unsuitable for standard therapy"
NCT00405743:I.1006,"ARM A, B, C: CP-4055 as single agent and/or in combination with idarubicin"
NCT00405743:I.1007,"ECOG performance status finding<= 2"
NCT00405743:I.1008,"Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this study. Nursing patients are excluded."
NCT00405743:I.1009,"Male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last CP-4055 dose"
NCT00405743:I.1010,"Patients must be capable of understanding and complying with parameters as outlined in the protocol, and able and willing to sign a written informed consent form"
NCT00405743:I.1011,"In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents, or at least 5 half-lives for noncytotoxic agents."
NCT00405743:I.1012,"Patients must have the following clinical laboratory values:"
NCT00405743:I.1013,"Serum creatinine<= 1.5 x the institutional upper limit of normal (ULN)"
NCT00405743:I.1014,"Total bilirubin<= 1.5 x the ULN unless considered due to Gilbert's syndrome"
NCT00405743:I.1015,"Alanine aminotransferase (ALT) (SGPT), or aspartate aminotransferase (AST) (SGOT)<= 2.5 x the ULN unless considered due to organ leukemic involvement"
NCT00405743:I.1016,"Patients with a confirmed diagnosis of AML who have received cytotoxic chemotherapy"
NCT00405743:I.2001,"A history of allergic reactions or sensitivity attributed to compounds of similar chemical or biologic composition to CP-4055, i.e., ara-C and/or egg"
NCT00405743:I.2002,"Known positive status for human immunodeficiency virus (HIV) or hepatitis B or C"
NCT00405743:I.2003,"Pregnant and nursing patients are excluded"
NCT00405743:I.2004,"Uncontrolled intercurrent illness"
NCT00405743:I.2005,"Active heart disease"
NCT00405743:I.2006,"Patients receiving any other standard or investigational cytotoxic treatment for their hematologic malignancy other than a maximum of 5 g of hydroxyurea to a maximum of 5 days in cycle 1 of therapy"
NCT00405743:I.2007,"Any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities"
NCT00405743:I.2008,"Performed Exclusion Criterion"
NCT00405743:I.2009,"Patients with hypersensitivity to idarubicin or any other component of the product, and/or other anthracyclines or anthracenediones"
NCT00408187:I.1001,"age at least 18 Years"
NCT00408187:I.1002,"Aged>= 18 years of age inclusive at time of screening."
NCT00408187:I.1003,"Diagnosed with plaque psoriasis>= 6 months prior to screening."
NCT00408187:I.1004,"Diagnosis of stable, plaque psoriasis, i.e. psoriasis must not be spontaneously improving or worsening in the 4 weeks prior to the screening visit."
NCT00408187:I.1005,"Psoriasis failing at least one systemic treatment regimen or where other systemic therapies are contraindicated or where tolerability is an issue."
NCT00408187:I.1006,"Plaque psoriasis involving>= 10% of the body surface area and a SPGA score>= 3 at screening and prior to randomization at the day 0 visit."
NCT00408187:I.1007,"Not pregnant or nursing."
NCT00408187:I.1008,"Sexually active women of childbearing potential or<1 year post-menopausal and sexually active men who are not surgically sterile must use a reliable form of birth control during study treatment and for at least 3 months after the last dose of study drug. Surgically sterile females are not considered to be of childbearing potential. Reliable forms of birth control include oral or depot contraceptives, and double-barrier methods."
NCT00408187:I.1009,"Written informed consent prior to washout and screening procedures."
NCT00408187:I.1010,"Able to keep study appointments and cooperate with all study requirements, in the opinion of the Investigator."
NCT00408187:I.2001,"Has generalized erythrodermic, guttate, or pustular psoriasis."
NCT00408187:I.2002,"Have other dermatoses that would interfere with the evaluation of psoriasis, at the discretion of the Investigator."
NCT00408187:I.2003,"A current malignancy or history of malignancy within 5 years or a history of lymphoma at any time. Subjects can be enrolled with a history of squamous or basal cell carcinoma that has been surgically excised or removed with curettage and electrodesiccation."
NCT00408187:I.2004,"Has a current, uncontrolled bacterial, viral, or fungal infection that requires intravenous antibiotics or antifungals or has had such infections within 60 days prior to screening."
NCT00408187:I.2005,"Personal history of tuberculosis"
NCT00408187:I.2006,"Serologic evidence or known latent HIV, HBV or HCV virus."
NCT00408187:I.2007,"Uncontrolled hypertension of systolic blood pressure>= 160 mmHg or diastolic blood pressure>= 90 mmHg."
NCT00408187:I.2008,"MDRD GFR<60 mL/min."
NCT00408187:I.2009,"Variation between the screening and Visit 1 SCr>= 30%."
NCT00408187:I.2010,"ALT, AST, GGT>= 2x upper limit of normal (ULN)."
NCT00408187:I.2011,"White Blood Cell Count procedure (WBC)"
NCT00408187:I.2012,"Requires the following prohibited medications or treatments during the washout or treatment period: drugs potentiating the nephrotoxicity of voclosporin, drugs interfering with its pharmacokinetics, drugs considered to contribute to psoriasis flare. Or, systemic and topical psoriasis medication that may interfere with assessment of study drug efficacy."
NCT00408187:I.2013,"Has used any investigational drug or device within 30 days or 10 half lives (whichever is longer) prior to the screening visit."
NCT00408187:I.2014,"Current participation in another clinical trial of any drug or biological agent."
NCT00408187:I.2015,"Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3 months of randomization. Biological agents include any virus, live vaccine, therapeutic serum, toxin, antitoxin, monoclonal antibodies or analogous product applicable to the prevention, treatment, or cure of diseases or injuries of man."
NCT00408187:I.2016,"Previous exposure to voclosporin."
NCT00408187:I.2017,"A history of clinically defined allergy to ciclosporin, constituents of Neoral or any of the constituents of the ISA247 formulation."
NCT00408187:I.2018,"A history of alcoholism or drug addiction."
NCT00408187:I.2019,"Body weight (observable entity)"
NCT00408187:I.2020,"A history of disease, including mental/emotional disorder that would interfere with the subject's participation in the study, in the evaluation of his/her response or that might cause the administration of voclosporin to pose a significant risk to the subject, in the opinion of the Investigator."
NCT00408473:I.1001,"age 18 Years to 65 Years"
NCT00408473:I.1002,"History of first symptomatic&documented episode of AF"
NCT00408473:I.1003,"LVEF>40% and not on AAD and in sinus rhythm at time of recruitment"
NCT00408473:I.2001,"History of more than 1 symptomatic documented AF episode, persistent or permanent AF."
NCT00408473:I.2002,"History of ablation for previous AF"
NCT00408473:I.2003,"Reversible cause for AF (e.g.thyroid, alcohol, pulmonary embolism, surgery"
NCT00408473:I.2004,"Severe symptoms during AF episode (e.g.syncope, chest pain)"
NCT00408473:I.2005,"All types of treated arrhythmias other than AF"
NCT00408473:I.2006,"History of myocardial infarction (MI), coronary artery disease (CAD), heart failure (I, II, III and IV of New York Heart Association -NYHA- classification) or valvular diseases"
NCT00408473:I.2007,"LVEF - Left ventricular ejection fraction"
NCT00408473:I.2008,"Bradycardia<40 beats/min and all ECG abnormalities: PR>240ms or QRS>120 ms or QTc>440 ms"
NCT00408473:I.2009,"Brugada Syndrome (disorder)"
NCT00408473:I.2010,"Conduction disturbances: complete bundle branch block (LBBB) or (RBBB), bifascicular block"
NCT00408473:I.2011,"2nd or 3rd degree atrioventricular (AV) block"
NCT00408473:I.2012,"Coronary sinus rhythm disorder"
NCT00408473:I.2013,"Severe hypertension with:Systolic blood pressure>= 180 mmHg, and / or Diastolic blood pressure>= 100 mmHg"
NCT00408473:I.2014,"Left ventricular hypertrophy (LVH) with septal thickness>14 mm on Echocardiogram"
NCT00408473:I.2015,"(Artificial) Cardiac pacemaker"
NCT00408473:I.2016,"Heart surgery within the last 6 months, or non-stable postoperative condition"
NCT00408473:I.2017,"Renal failure: serum creatinine>= 150 µmol/l or creatinine clearance<= 50 ml/min (Cockroft and Gault formula"
NCT00408473:I.2018,"Uncorrected electrolytic abnormalities"
NCT00408473:I.2019,"Have used recently in the last 3 months prior to the inclusion any of the following treatments: Oral amiodarone, Treatments that lengthen QT interval (e.g.Sultopride, Drugs causing torsades de pointe (e.g.mizolastine, pentamidine, sparfloxacin, moxifloxacin, Bupropion"
NCT00408473:I.2020,"Anti-hypertensive drugs other than permitted in the study: ACE-I, ARB (sartans) and DHP from Calcium channel blockers (CCB"
NCT00408746:I.1001,"age up to 5 Years"
NCT00408746:I.1002,"Premature Birth"
NCT00408746:I.1003,"infants of the tertiary care level University Hospital of Münster"
NCT00408746:I.1004,"delivery between May 1999 and December 2008"
NCT00408746:I.1005,"caucasian origin"
NCT00408746:I.1006,"written informed consent by both parents"
NCT00408746:I.2001,"history of orotracheal intubation / orogastric tube feeding"
NCT00408746:I.2002,Hydrocephalus
NCT00408746:I.2003,"palatal cleft, congenital syndrome, head / neck malformation"
NCT00408746:I.2004,"congenital metabolic disease beyond osteopenia of prematurity"
NCT00409175:I.1001,"age 18 Years to 75 Years"
NCT00409175:I.1002,"Amyloid documented by biopsy."
NCT00409175:I.1003,"Documented V30M TTR mutation."
NCT00409175:I.1004,"Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status ?50."
NCT00409175:I.1005,"If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control. If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the duration of the study. For both females and males, birth control must be used for at least 3 months after the last dose of study medication."
NCT00409175:I.1006,"Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements."
NCT00409175:I.2001,"Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)."
NCT00409175:I.2002,"AL amyloidosis, Idiopathic amyloidosis"
NCT00409175:I.2003,"If female, patient is pregnant or breast feeding."
NCT00409175:I.2004,"Prior liver transplantation."
NCT00409175:I.2005,"No recordable sensory threshold for vibration perception in both feet, as measured by CASE IV."
NCT00409175:I.2006,"Positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV)."
NCT00409175:I.2007,"Renal insufficiency or liver function test abnormalities."
NCT00409175:I.2008,"New York Heart Association (NYHA) Functional Classification ?III."
NCT00409175:I.2009,"Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic inflammatory diseases)."
NCT00409175:I.2010,"Co-morbidity anticipated to limit survival to<18 months."
NCT00409175:I.2011,"Patient received an investigational drug/device and/or participated in another clinical investigational study within 60 days before Baseline."
NCT00409799:I.1001,"age at least 18 Years"
NCT00409799:I.1002,"Radiological evidence of a tibial plateau fracture requiring grafting"
NCT00409799:I.1003,"Females of child-bearing potential must be willing to undergo a pregnancy test (urine) prior to treatment start (at screening)."
NCT00409799:I.2001,"Concomitant ipsilateral fractures of the limb other than the fracture of the tibial plateau."
NCT00409799:I.2002,"Active or past history of malignant tumor."
NCT00409799:I.2003,"Evidence of systemic or localized infection at time of surgery."
NCT00409799:I.2004,"Pregnant or lactating females."
NCT00419705:I.1001,"age 40 Years to 90 Years"
NCT00419705:I.1002,"Diagnosis of Acute Ischemic Stroke within 24 hours"
NCT00419705:I.1003,"Clinical diagnosis of Acute Ischemic Stroke after exclusion of hemorrhage by a CT scan or susceptibility weighted MRI sequences"
NCT00419705:I.1004,"NIH stroke scale ?7 - ?22"
NCT00419705:I.2001,">24hours from symptom onset to time of treatment"
NCT00419705:I.2002,"Evidence of intracranial, subdural, or subarachnoid hemorrhage"
NCT00419705:I.2003,"Clinical presentation of intracranial hemorrhage"
NCT00419705:I.2004,"Pre stroke ?3 mRS"
NCT00419705:I.2005,"The presence of a brainstem or cerebellar stroke"
NCT00419705:I.2006,"Transient Ischaemic Attack (TIA), transient cerebral ischemia"
NCT00419705:I.2007,"Seizure at stroke onset"
NCT00419705:I.2008,"Blood sugar level"
NCT00419705:I.2009,"Sustained systolic BP>220mmHG<80mmHG or diastolic>140mmHG<50mmHG"
NCT00419705:I.2010,"Bacterial embolus"
NCT00419705:I.2011,"CNS tumor (except asymptomatic meningioma)"
NCT00419705:I.2012,"Dermatologic condition of the scalp (e.g. Psoriasis)"
NCT00419705:I.2013,"Thrombolytic therapy"
NCT00419705:I.2014,"Head implant (e.g. Clipped aneurysm, Hakim valve)"
NCT00420212:I.1001,"Age 18 Years to 55 Years"
NCT00420212:I.1002,"Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:"
NCT00420212:I.1003,"Aged 18 to 55 years old, inclusive, at the time of informed consent."
NCT00420212:I.1004,"Must have a confirmed diagnosis of RRMS according to McDonald criteria #1-4."
NCT00420212:I.1005,"Must have a baseline EDSS<= 5.0, inclusive."
NCT00420212:I.1006,"Must have relapsing-remitting disease course."
NCT00420212:I.2001,"Unless otherwise specified, candidates will be excluded from study entry if any of the following exclusion criteria exist at randomization:"
NCT00420212:I.2002,"Other chronic disease of the immune system, malignancies, acute urologic, pulmonary, gastrointestinal disease."
NCT00420212:I.2003,"Pregnant or nursing women."
NCT00420472:I.1001,"age at least 18 Years"
NCT00420472:I.1002,"Adult (person)"
NCT00420472:I.1003,"first or second kidney transplant"
NCT00420472:I.1004,"EC-MPS therapy for>=6 months, with a stable dose for>=2 months"
NCT00420472:I.1005,"lower than recommended dose of EC-MPS (<1440g/day) due to gastrointestinal complaints."
NCT00420472:I.2001,"patients who have participated in this study before"
NCT00420472:I.2002,"patients currently participating in another clinical trial, or who participated in one during the last 30 days."
NCT00427024:I.1001,"age at least 18 Years"
NCT00427024:I.1002,"individuals transplanted with a donor kidney"
NCT00427024:I.1003,"Acute graft rejection"
NCT00427024:I.2001,"Pregnancy, Gestation"
NCT00427024:I.2002,"Malignant Neoplasms"
NCT00427024:I.2003,"Human immunodeficiency virus infection"
NCT00442065:I.1001,"age at least 19 Years"
NCT00442065:I.1002,"Diagnosis of abdominal aortic aneurysm 50 mm or larger in diameter, 40 mm or larger in diameter if symptomatic (i.e. pain, embolisation), or documented AAA growth of more than 5 mm within the previous 6 months, and/or including extension into common iliac artery(ies), or any saccular aneurysm."
NCT00442065:I.1003,"Infrarenal neck with a minimum length of 15 mm and a neck angulation between 60° and 90°, as assessed in 3 dimensions."
NCT00442065:I.1004,"The iliac artery diameter must be of appropriate diameter (1 mm smaller than the device diameter), with an appropriate distal landing length. The tortuosity of the common or external iliac arteries or femoral arteries must be low to medium (refer to operations manual)."
NCT00442065:I.1005,"Patient provides written informed consent."
NCT00442065:I.1006,"Patients>18 years who are suitable for endovascular repair."
NCT00442065:I.1007,"Patient fit for endovascular surgery, with a diameter at the access sites of 7mm or larger bilaterally."
NCT00442065:I.1008,"Patient has a life expectancy longer than the duration of the study."
NCT00442065:I.2001,"Ruptured Aneurysm"
NCT00442065:I.2002,"Patient has insufficient length of proximal aneurysm neck (<15mm from aneurysm to lowest renal artery and<20 mm from the aneurysm to the SMA)."
NCT00442065:I.2003,"Aneurysm extends above renal arteries."
NCT00442065:I.2004,"Proximal neck of aneurysm has significant loose thrombus associated with it, or significant circumferential calcifications."
NCT00442065:I.2005,"Pregnant or nursing patients."
NCT00442065:I.2006,"Patient unfit for bail-out surgery and appropriate anaesthesia."
NCT00442065:I.2007,"Patient with an acute or chronic aortic dissection or mycotic aneurysm (defined by localised asymmetric aneurysm sac)."
NCT00442065:I.2008,"Patient has current non-localised infection."
NCT00442065:I.2009,"Patient has known allergy to graft materials, Nitinol, or contrast media."
NCT00442065:I.2010,"Patient's where imaging is problematic. An example is an obese patient."
NCT00442065:I.2011,"Patient has co-morbidities that deny vascular access, including small / tortuous access vessels."
NCT00445081:I.1002,"Age>= 18 and<55"
NCT00445081:I.1003,"Body weight (observable entity)"
NCT00445081:I.1004,"confirmed diagnosis of AE (UK working party criteria)"
NCT00445081:I.1005,"objective SCORAD>40"
NCT00445081:I.1006,DLQI>10
NCT00445081:I.1007,"resistancy against topical treatment options including steroids and calcineurin-inhibitors"
NCT00445081:I.2001,"participation to another clinical trial within the last 4 weeks before baseline"
NCT00445081:I.2002,"pregnant or breastfeeding"
NCT00445081:I.2003,"women of childbearing potential without adequate contraception"
NCT00445081:I.2004,"allergy against prednisolone or Ciclosporine A"
NCT00445081:I.2005,"acute bacterial or viral infection"
NCT00445081:I.2006,"History of neoplastic disease"
NCT00445081:I.2007,"Diabetes mellitus"
NCT00445081:I.2008,"Hypertensive disease, High Blood Pressure"
NCT00445081:I.2009,Glaucoma
NCT00445081:I.2010,"Peptic Ulcer"
NCT00445081:I.2011,"Severe osteoporosis"
NCT00445081:I.2012,"Personal history of tuberculosis"
NCT00445081:I.2013,"Ulcerative colitis (UC), Colitis ulcerative"
NCT00445081:I.2014,Diverticulitis
NCT00445081:I.2015,"concurrent treatment with chloroquin, Mefloquin, Statins, Warafin"
NCT00445081:I.2016,"Creatinine clearance (CrCl)  measurement"
NCT00445081:I.2017,"UV treatment within 8 weeks before inclusion"
NCT00445081:I.2018,"ongoing systemic immunosuppressive treatment"
NCT00445081:I.2019,"planned vaccination within 8 weeks before study entry, during study and 2 weeks after end of study"
NCT00445081:I.2020,POLIOMYELITIS
NCT00445081:I.2021,"Lymphadenitis after BCG vaccination"
NCT00445081:I.2022,Hyperuricemia
NCT00445081:I.2023,"Chronic liver disease"
NCT00445081:I.2024,"Xeroderma pigmentosum, Cockaye-Syndrome, Bloom Syndrome"
NCT00445081:I.2025,"Psychiatric co-morbidity"
NCT00445081:I.2026,"drug or alcohol abuse"
NCT00447772:I.1001,"age at least 18 Years"
NCT00447772:I.1002,"De novo patients with cervical dystonia"
NCT00447772:I.1003,"Outpatient, Out-Patient"
NCT00447772:I.1004,"Written informed consent to participate in the study"
NCT00447772:I.2001,"Pre-treatment of cervical dystonia with botulinum toxin"
NCT00447772:I.2002,"Pre-treatment with botulinum toxin for any indication other than cervical dystonia within the past 12 months"
NCT00447772:I.2003,"Pure retro- or antecollis"
NCT00447772:I.2004,"Neurological or other diseases which may affect head and neck motor function or neuromuscular transmission, e.g. polyneuropathy with pareses, myasthenia, myopathy, motor neurone diseases, Bekhterev's disease"
NCT00450684:I.1001,"congenital heart defect"
NCT00450684:I.1002,"morphologic heart failure of the right or left system ventricle with an ejection fraction of absolute<= 40%"
NCT00450684:I.1003,"NYHA II - IV"
NCT00450684:I.1004,"optimal drug therapy for heart failure according to the ESC guidelines"
NCT00450684:I.1005,"QRS-interval>= 120 ms (according to at least two ECG)"
NCT00450684:I.1006,"chronic stimulation of the subpulmonary ventricle by a 1- or 2-ventricle pacemaker, which also meets the above mentioned criteria"
NCT00450684:I.1007,"morphologically right ventricle in system position and significant insufficiency of the systemic AV valve, which also meets the above mentioned criteria"
NCT00450684:I.1008,"electromechanic dyssynchrony as defined in study protocol"
NCT00450684:I.2001,"PTCA, cardiomyoplasty, myocardium infarction, instable angina pectoris or cerebral insult within 6 weeks before the planned cardiac resynchronization therapy"
NCT00450684:I.2002,"pulmonary hypertension/Eisenmenger syndrome"
NCT00450684:I.2003,"univentricular heart without Fontan procedure"
NCT00450684:I.2004,"life expectancy less than 1 year due to a non-cardiac disease"
NCT00450684:I.2005,"expected poor compliance of the patient, e.g. Trisomic 21 or other mental retardation"
NCT00450684:I.2006,"ergospirometry cannot be performed"
NCT00450684:I.2007,"Pregnancy, Gestation"
NCT00450684:I.2008,"participation in a clinical trial within the last 4 weeks or current participation in a clinical trial (except studies of the Competence Network for Congenital Heart Defects)"
NCT00450684:I.2009,"diseases or functional disorders that exclude participation according to physician's convenience"
NCT00450684:I.2010,"Uncooperative behavior"
NCT00450684:I.2011,"known or continuous drug or alcohol abuse"
NCT00456092:I.1001,"age at least 18 Years"
NCT00456092:I.1002,"diagnosis of psoriatic arthritis (Moll and Wright criteria) including symmetrical or asymmetrical peripheral joint involvement for at least 6 months"
NCT00456092:I.1003,"active psoriatic arthritis defined as at least 3 tender and at least 3 swollen joints"
NCT00456092:I.1004,"Rheumatoid factor negative"
NCT00456092:I.1005,"if on MTX, must be on for at least 24 weeks and on stable dose at least 56 days before screening"
NCT00456092:I.1006,"if on oral steroids, must be on stable dose of prednisone<=10mg/day or equivalent for 28 days"
NCT00456092:I.1007,"if on NSAID, must be on a stable dose at least 14 days prior to screening"
NCT00456092:I.1008,"Lab criteria: Hb>9g/dL, HCT>27%, WBC>3000/uL and<20000/uL, neut>1500/uL, platelets>100,000/uL, creatinine<1.5mg/dL, total bilirubin<2.0mg/dL, AST and ALT<1.5 ULN"
NCT00456092:I.1009,"FCBP must have negative pregnancy tests and be on two forms of contraception throughout the study"
NCT00456092:I.1010,"Males must use barrier contraception with FCBP partner"
NCT00456092:I.2001,"clinically significant diseases"
NCT00456092:I.2002,"any condition placing subject at risk"
NCT00456092:I.2003,"pregnant or lactating females"
NCT00456092:I.2004,"history of TB infection within 3 years"
NCT00456092:I.2005,"history of incompletely treated latent TB"
NCT00456092:I.2006,"clinically significant abnormality on CXR at screening"
NCT00456092:I.2007,"current erythrodermic, guttate or pustular psoriasis"
NCT00456092:I.2008,"history of infected joint prosthesis within 5 years"
NCT00456092:I.2009,"systemic therapy including sulphasalazine, leflunomide, chloroquine, hydroxychloroquine, gold, parenteral steroids, penicillamine, cyclosporine, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus, azathioprine and fumaric acid esters within 28 days of randomization"
NCT00456092:I.2010,"topical therapy for treatment of psoriasis within 14 days of randomization (except mild or moderate steroids and non medicated emollients)"
NCT00456092:I.2011,"phototherapy within 28 days randomization"
NCT00456092:I.2012,"etanercept within 56 days randomization"
NCT00456092:I.2013,"Adalimumab, efalizumab, or infliximab within 84 days randomization"
NCT00456092:I.2014,"alefacept within 24 weeks randomization"
NCT00456092:I.2015,"use of any intra-articular steroids within 28 days randomization"
NCT00456092:I.2016,"use of any investigational medication within 28 days randomization or 5 half-lives whichever is longer"
NCT00456092:I.2017,"clinically significant abnormality on ECG at screening"
NCT00456092:I.2018,"high risk factors for HIV or hepatitis B or C"
NCT00456092:I.2019,"history of malignancy within 5 years (except basal cell skin carcinomas and/or fewer than 3 treated squamous cell skin carcinomas"
NCT00456092:I.2020,"evidence of skin conditions at screening that would interfere with evaluations of psoriasis"
NCT00459667:I.1001,"age 18 Years to 55 Years"
NCT00459667:I.1002,"Completion of the BEYOND study 306440 as scheduled"
NCT00459667:I.1003,"Relapsing multiple sclerosis"
NCT00459667:I.1004,"Medical assessment by the investigator that there is no objection to the patient's participation in this trial considering the medical experience from study 306440. Special attention should be given to laboratory abnormalities and clinically relevant liver, renal and bone-marrow dysfunction."
NCT00459667:I.1005,"Females of child-bearing potential:"
NCT00459667:I.1006,"Agreement to practice adequate contraception methods and"
NCT00459667:I.1007,"Negative Pregnancy Test"
NCT00459667:I.1008,"No lactation"
NCT00459667:I.1009,"Written informed consent"
NCT00459667:I.2001,"Serious or acute heart diseases"
NCT00459667:I.2002,"History of severe depression or suicide attempt"
NCT00459667:I.2003,"Epilepsy not adequately controlled by treatment"
NCT00459667:I.2004,"Known allergy to IFNs, to human albumin or to mannitol"
NCT00459667:I.2005,"Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study"
NCT00464204:I.1001,"age 18 Years to N/A"
NCT00464204:I.1002,"Severe sepsis"
NCT00464204:I.1003,"Requirement for fluid resuscitation"
NCT00464204:I.2001,"Serum Creatinine, Serum Creatinine Measurement"
NCT00464204:I.2002,"Kidney Failure, Chronic"
NCT00464204:I.2003,Anuria
NCT00464204:I.2004,"Requirement for renal support"
NCT00478777:I.1001,"age at least 18"
NCT00478777:I.1002,"Must understand and voluntarily sign an informed consent form."
NCT00478777:I.1003,"Must be>=18 years of age at the time of signing the informed consent form."
NCT00478777:I.1004,"Must be able to adhere to the study visit schedule and other protocol requirements."
NCT00478777:I.1005,"Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles of anti-myeloma treatment or that has relapsed with progressive disease after treatment."
NCT00478777:I.1006,"Subjects may have been previously treated with thalidomide and/or radiation therapy. In addition, radiation therapy initiated prior to or at baseline (Day 1) may be given concurrently with study therapy, provided that all other eligibility criteria are satisfied."
NCT00478777:I.1007,"Subjects must discontinue all anti-myeloma drug or non-drug therapy prior to the first dose of study drug with the exception of radiation therapy initiated prior to or at baseline (Day 1)."
NCT00478777:I.1008,"Measurable levels of myeloma paraprotein in serum (>0.5 g/dL) or urine (>0.2 g excreted in a 24-hour collection sample)."
NCT00478777:I.1009,"ECOG performance status<= 2"
NCT00478777:I.1010,"Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study:                                         1) for at least 28 days before starting study drug 2) while participating in the study                               and 3) for at least 28 days after discontinuation from the study."
NCT00478777:I.2001,"The presence of any of the following will exclude a subject from study enrollment:"
NCT00478777:I.2002,"Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form."
NCT00478777:I.2003,"Pregnant or lactating females."
NCT00478777:I.2004,"Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study."
NCT00478777:I.2005,"Any of the following laboratory abnormalities:"
NCT00478777:I.2006,"Absolute Neutrophil Count"
NCT00478777:I.2007,"Platelet count<75,000/mm^3 (75 x 109/L) for subjects in whom<50% of the bone  marrow nucleated cells are plasma cells."
NCT00478777:I.2008,"Platelet count<30,000/mm^3 (30x10^9/L) for subjects in whom>=50% of bone marrow  nucleated cells are plasma cells."
NCT00478777:I.2009,"Serum Creatinine Measurement"
NCT00478777:I.2010,"Serum SGOT/AST or SGPT/ALT>3.0 x upper limit of normal (ULN)"
NCT00478777:I.2011,"Serum Total Bilirubin Measurement"
NCT00478777:I.2012,"Prior history of malignancies other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for>=1 year."
NCT00478777:I.2013,"Prior history of stroke and/or thromboembolic event"
NCT00478777:I.2014,"Known hypersensitivity to thalidomide or dexamethasone."
NCT00478777:I.2015,"Prior history of uncontrollable side effects to dexamethasone therapy."
NCT00478777:I.2016,"The development of a desquamating rash while taking thalidomide."
NCT00478777:I.2017,"Neuropathy>= Grade 2."
NCT00479557:I.1001,"age 50 Years to 85 Years"
NCT00479557:I.1002,"Diagnosis of probable Alzheimer's Disease with Mini-Mental State Examination (MMSE) score of 16-26 (except Germany: 21-26)"
NCT00479557:I.1003,"Brain MRI consistent with Alzheimer Disease"
NCT00479557:I.1004,"Concurrent use of Cholinesterase inhibitor or memantine allowed if stable"
NCT00479557:I.1005,"Other inclusion criteria apply"
NCT00479557:I.2001,"Significant Neurological Disease other than Alzheimer's disease"
NCT00479557:I.2002,"Major psychiatric disorder"
NCT00479557:I.2003,"Contraindication to undergo brain MRI"
NCT00479557:I.2004,"Clinically significant systemic illness"
NCT00479557:I.2005,"Other exclusion criteria apply"
NCT00486759:I.1001,"age at least 18"
NCT00486759:I.1002,"CD20-positive diffuse large B-cell lymphoma"
NCT00486759:I.1003,"low-intermediate, high-intermediate or high risk disease and/or bulky tumor (.7.5 cm)"
NCT00486759:I.1004,"ECOG performance status finding<=2"
NCT00486759:I.2001,"prior treatment for diffuse large B-cell lymphoma"
NCT00486759:I.2002,"types of non-Hodgkin's lymphoma other than DLBCL"
NCT00486759:I.2003,"CNS Lymphoma"
NCT00501059:I.1001,"age at least 55"
NCT00501059:I.1002,"Males aged 55 years and above with 2 to 4 risk factors. Male Risk Factors:"
NCT00501059:I.1003,"Elevated cholesterol (Tchol>200 mg/dL or LDL>130 mg/dL, as measured at  screening) irrespective of current treatment"
NCT00501059:I.1004,"Current smoking: defined as any cigarette smoking in the past 12 months"
NCT00501059:I.1005,"Low HDL cholesterol (HDL<40 mg/dL, as measured at screening)"
NCT00501059:I.1006,"Elevated blood pressure (SBP>140 mmHg, as measured at screening)"
NCT00501059:I.1007,"Currently on any medication to treat high blood pressure"
NCT00501059:I.1008,"Positive family history of early CHD (a first-degree relative [father, mother,  brother, sister, son, daughter] suffered a heart attack [myocardial infarction]before the age of 60 years)"
NCT00501059:I.1009,"Females aged 60 and above with 3 or more risk factors. Female Risk Factors:"
NCT00501059:I.1010,"Elevated cholesterol (Tchol>240 mg/dL or LDL>160 mg/dL, as measured at  screening) irrespective of current treatment"
NCT00501059:I.1011,"Current smoking: defined as any cigarette smoking in the past 12 months"
NCT00501059:I.1012,"Low HDL cholesterol (HDL<40 mg/dL, as measured at screening)"
NCT00501059:I.1013,"Elevated blood pressure (SBP>140 mmHg, as measured at screening)"
NCT00501059:I.1014,"Currently on any medication to treat high blood pressure"
NCT00501059:I.1015,"Positive family history of early CHD (a first-degree relative [father, mother,  brother, sister, son, daughter] suffered a heart attack [myocardial infarction]before the age of 60 years)"
NCT00501059:I.1016,"An understanding and willingness to comply with trial procedures and has given written informed consent to participate in the trial"
NCT00501059:I.2001,"History of a documented vascular event, such as MI, stroke, coronary artery angioplasty or stenting, coronary artery bypass graft, relevant arrhythmias, or congestive heart failure or vascular intervention"
NCT00501059:I.2002,"Patients who are at higher than moderate risk on the basis of their diabetes status, other factors known to the investigator, or the currently used national risk score"
NCT00501059:I.2003,"Known contraindications to the study drug, e.g. hypersensitivity to acetylsalicylic acid"
NCT00501059:I.2004,"Recent (in the past year) history of gastrointestinal or genitourinary bleeding or other bleeding disorders"
NCT00501059:I.2005,"Active diagnosed and documented reflux esophagitis"
NCT00501059:I.2006,"Patients presenting with any medical condition, or psychiatric or substance abuse disorder, that, in the opinion of the investigator, is likely to affect the patient's ability to complete the study or precludes the patient's participation in the study"
NCT00501059:I.2007,"Lactating women or women of childbearing potential"
NCT00501059:I.2008,"Severe liver disease or damage based on the clinical judgment of the investigator"
NCT00501059:I.2009,"Severe renal disease or damage based on the clinical judgement of the investigator"
NCT00501059:I.2010,"A definite indication for acetylsalicylic acid therapy, other antiplatelet drug, or anticoagulant in the opinion of the physician"
NCT00501059:I.2011,"A history of asthma induced by administration of salicylates or substances with a similar action, notably NSAIDS"
NCT00501059:I.2012,"Chronic, frequent (>5 days/month) use of NSAIDs (including aspirin, or aspirin containing products), COX-2 inhibitors or metamizole"
NCT00501059:I.2013,"Current participation in any other trials involving investigational products within 30 days prior to the Screening Visit"
NCT00501059:I.2014,"anticoagulants, use, long term"
NCT00501059:I.2015,"Sitting systolic blood pressure"
NCT00502840:I.1001,"age 18 Years to 75 Years"
NCT00502840:I.1002,"adult patients with rheumatoid arthritis who participated in ML19070, and have completed the week 24 visit"
NCT00502840:I.1003,"eligible for re-treatment (DAS28>2.6 after week 24, swollen joint count>=4, tender joint count>=4)."
NCT00502840:I.2001,"patients who have withdrawn from treatment in ML19070 pre-week 16"
NCT00502840:I.2002,"patients with a previous response in DAS28<0.6 to MabThera after week 16"
NCT00502840:I.2003,"concurrent treatment with any DMARD except for methotrexate, any TNF alpha inhibitor, or other biologic or investigational agent."
NCT00505388:I.1001,"Age at least 18  years"
NCT00505388:I.1002,"Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this programme"
NCT00505388:I.1003,"signed and dated informed consent(ICF)"
NCT00505388:I.1004,"for patients under-age, signed and dated ICF form from both the patient and the patient's parent/legal guardian is required"
NCT00505388:I.2001,"Involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)"
NCT00505570:I.1001,"age 18 Years to 65 Years"
NCT00505570:I.1002,"Subjects who have migraine headaches with aura diagnosed by a doctor"
NCT00505570:I.1003,"Subjects who have not responded to or cannot take common migraine preventive medications"
NCT00505570:I.2001,"Subjects with a clinical history of stroke"
NCT00505570:I.2002,"Subjects who cannot take aspirin and clopidogrel (Plavix)"
NCT00505570:I.2003,"Subjects who are pregnant or desire to become pregnant within the next year"
NCT00506688:I.1001,"age at least 8"
NCT00506688:I.1002,"Male or female patient, 8 years (pediatric 8 - 17 years inclusive, adult 18 years)"
NCT00506688:I.1003,"Confirmed diagnosis of CF (positive sweat chloride, 60 mEq/liter by pilocarpine iontophoresis and/or a genotype with two identifiable mutations consistent with CF accompanied by one or more clinical features with the CF phenotype)"
NCT00506688:I.1004,"Patient is able to perform acceptable spirometric maneuvers according to ATS standards"
NCT00506688:I.1005,"FEV1>40% predicted and<90% predicted"
NCT00506688:I.1006,"The patient is clinically stable fulfilling the following: No evidence of acute upper or lower respiratory tract infection within 4 weeks of screening. No pulmonary exacerbation requiring an use of i.v./oral/inhaled antibiotics, or oral corticosteroids within 4 weeks of screening. FEV1 at Visit 2 is within a range of +10% and -10% of FEV1 from the Visit 1. (If FEV1 at V2 is not within that range, V2 may be re-scheduled once within 7 days)"
NCT00506688:I.1007,"Concomitant or chronic medication is planned to be continued unchanged for the entire study duration"
NCT00506688:I.1008,"The patient or the patient's legally acceptable representative is able to give informed consent in accordance with ICH and GCP guidelines and local legislation"
NCT00506688:I.1009,"Patient is able to comply with the study visit schedule and willing and able to complete the assessments specified in the protocol."
NCT00506688:I.2001,"History of allergy/hypersensitivity (including medication allergy) that is deemed relevant to the trial by the investigator. Relevance in this context refers to any increased risk of hypersensitivity reaction to trial medication. (Specific concerns currently identified with respect to the use of inhaled glutathione in allergic patients per se are not existing)"
NCT00506688:I.2002,"Concomitant inhaled thiol-containing medications (e.g., inhaled N-acetylcysteine). Such medication had to be finished at least 2 weeks before the screening visit. Oral N-acetylcysteine may be continued."
NCT00506688:I.2003,"New oral or inhaled thiol-containing medications (e.g., inhaled or oral N-acetylcysteine) throughout the study period."
NCT00506688:I.2004,"Patient with a known relevant substance abuse, including alcohol or drug abuse."
NCT00506688:I.2005,"Pregnant or lactating woman or female patient of child bearing potential who is sexually active and not using a medically approved form of contraception such as oral or injectable contraceptives, intrauterine devices, double-barrier method, contraceptive patch, male partner sterilization or condoms."
NCT00506688:I.2006,"Patient with a documented persistent colonization with B. cepacia (defined as>1 positive culture within the past year)."
NCT00506688:I.2007,"Start of a new concomitant or chronic medication for CF within 4 weeks of screening."
NCT00506688:I.2008,"Existing cycling medication regimen without completion of at least 3 cycles prior to the screening visit or the drug cycles of other therapies are not in accordance with the 4-week time-schedule for the single visits of this study"
NCT00506688:I.2009,"Clinically relevant diseases or medical conditions other than CF or CF-related conditions that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data. This includes, but is not limited to, significant hematological, hepatic,renal, cardiovascular, and neurological diseases (diabetic patients may participate if their disease is under good control prior to screening)."
NCT00506688:I.2010,"Participation in another study with an investigational drug within one month or 6 halflives(whichever is greater) preceding the screening visit."
NCT00506688:I.2011,"The patient is an employee of the investigator or the institution with direct involvement in the trial or other trials under the direction of the investigator or their members."
NCT00507832:I.1001,"age 18 Years to 70 Years"
NCT00507832:I.1002,"Diagnosis: Prurigo nodularis"
NCT00507832:I.1003,"Pruritus intensity>VAS 3 (Visual analoge scale 0 to 10)"
NCT00507832:I.1004,"Nodules on arms and legs (target areas: arms)"
NCT00507832:I.1005,"No effective current external or internal antipruritic medication"
NCT00507832:I.1006,"Signed informed consent"
NCT00507832:I.2001,"prurigo nodularis with massive excoriations and/or local infections"
NCT00507832:I.2002,"atopic dermatitis, predisposition for atopic dermatitis"
NCT00507832:I.2003,"Itch intensity<VAS 4 (visual analoge scale 0 to 10)"
NCT00507832:I.2004,"Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG test. Pregnancy should be ruled out before stating the study by a b-subunit HCG test."
NCT00507832:I.2005,"Females of childbearing potential and not practicing a medically approved, highly effective (low failure rate) method of contraception during and up to at least 4 weeks after the end of treatment.'Medically approved'contraception may include implants, injectables, combined oral contraceptives, some IUDs (e.g. intrauterine device), sexual abstinence or if the woman has a vasectomized partner."
NCT00507832:I.2006,"active psychosomatic and psychiatric diseases"
NCT00507832:I.2007,"History of active malignancy of any organ system"
NCT00507832:I.2008,"actual diseases which need therapy and may induce pruritus (e.g. deficiency of iron, zinc)"
NCT00507832:I.2009,"Systemic immunosuppression"
NCT00507832:I.2010,"Topical use of tacrolimus, pimecrolimus, steroids or capsaicin within 2 weeks prior to study entry"
NCT00507832:I.2011,"current and past (within 2 weeks prior to study entry) systemic use of antihistamines, steroids, cyclosporin A and other immunosuppressants, paroxetin, fluvoxamine (selective serotonin reuptake-inhibitors, study possible in case of medication since 6 months due to depression without having any Antipruritic effect) naltrexone and UV-therapy."
NCT00507832:I.2012,"wound healing disturbances, disposition for keloids, current medication which leads to increased bleeding during procedure e.g. acetylsalicylic acid (ASS), marcumar (no suction blister possible)"
NCT00507832:I.2013,"History of hypersensitivity to pimecrolimus 1% cream or hydrocortisone 1% cream"
NCT00507832:I.2014,"Participation in other clinical studies within the last 4 weeks"
NCT00508664:I.1001,"age 18 Years to 75 Years"
NCT00508664:I.1002,"Histologically confirmed, primary only with laryngectomy respectable squamous-cell carcinoma of the larynx or hypopharynx"
NCT00508664:I.1003,"T3-T4a carcinoma of the glottis"
NCT00508664:I.1004,"T2-T4a carcinoma of the supraglottic, only controllable by laryngectomy and if applicable by root of tongue segmental resection"
NCT00508664:I.1005,"T2-T4a carcinoma of the hypopharynx only controllable by laryngectomy (for example T2, post cricoidal) and hypopharynx segmental resection"
NCT00508664:I.1006,"N-status: cervical metastases (N<=3) have to be rehabilitate by surgical procedures"
NCT00508664:I.1007,"Blood count: Leukocytes>3500/mm\3, Neutrophils>1500/ mm\3, Thrombocytes>8000/ mm\3"
NCT00508664:I.1008,"Clinical Chemistry Finding"
NCT00508664:I.1009,"adequate renal function, defined by serum creatinine and urea not>25% upper NL, creatinine-clearance>60 ml/min/1,72 m\2"
NCT00508664:I.1010,"adequate hepatic function with SGOT, SGPT not>50% and bilirubin not>upper NL"
NCT00508664:I.1011,"Electrolytes normal"
NCT00508664:I.1012,"anesthetic risk normal or low-grade elevated"
NCT00508664:I.1013,"age 18-75 years"
NCT00508664:I.1014,"written informed consent"
NCT00508664:I.1015,"effective contraception after individual advice for men and women if there is a  possibility of reproductive potential (effective contraception are: oral  contraception with estrogen and gestagen (no minipill), vaginal ring,  contraception patch, estrogen free ovulation suppressors, hormone spiral with  progesterone, injection for three month with depot gestagen, hormone releasing  implantation (luteal hormone containing rod), abstinence or sterilization  (vasectomy) of the male)"
NCT00508664:I.2001,"primary cancer treatable by operational larynx-conserving procedures"
NCT00508664:I.2002,"distant metastases (M1-Status)"
NCT00508664:I.2003,"total tumor volume exceeding 80 ml or larynx skeleton punctuated with infiltration of surrounding soft tissues respectively the esophageal aditus (exclusive cartilage infiltration represents no exclusion criteria)"
NCT00508664:I.2004,"tumor-specific prior chemo- or radiotherapy"
NCT00508664:I.2005,"metachronous or synchronous malignant tumor (exception basalioma) [in case of a controlled tumor of different localization with a non-treated interval over 5 years to the present therapy the patient can be included after consultation with the coordinating investigator]"
NCT00508664:I.2006,"Life expectancy"
NCT00508664:I.2007,"Karnofsky performance status<70%"
NCT00508664:I.2008,"serious cardiopulmonary concomitant disease (cardiac insufficiency grade III and IV according NYHA status, myocardial infarction, angina pectoris, respiratory global insufficiency)"
NCT00508664:I.2009,"Chronic diseases with permanent-therapy (uncontrolled diabetes, active rheumatoid arthritis)"
NCT00508664:I.2010,"recurrent pneumonia, COPD GOLD stage<2, chronic inflammation of intestine or any other concomitant diseases, which disallow study participation in the opinion of the responsible physician"
NCT00508664:I.2011,"Other circumstances (contra-indications), which disallow treatment with Docetaxel, Cisplatin, 5-FU, Cetuximab or radiotherapy"
NCT00508664:I.2012,"Expected absent patient compliance"
NCT00508664:I.2013,"Periodic follow-up not possible (for example address outside germany)"
NCT00508664:I.2014,"Pregnant or breast-feeding woman"
NCT00508664:I.2015,"Absent or constricted legal capacity"
NCT00508664:I.2016,"Participation to another clinical trial with any investigational study within 30 days prior to study screening"
NCT00509184:I.1001,"age 18 Years to 75 Years"
NCT00509184:I.1002,"verified follicular lymphoma grade 1 or 2"
NCT00509184:I.1003,"only nodal involvement (incl. Waldeyer) clinical stage I or II"
NCT00509184:I.1004,"Tumor volume<= 7 cm"
NCT00509184:I.1005,"adequate bone marrow reserves"
NCT00509184:I.2001,"ECOG performance status finding>2"
NCT00509184:I.2002,"Follicular lymphoma grade III, unspecified"
NCT00509184:I.2003,"Bulky Disease (>7cm)"
NCT00509184:I.2004,"involvement of the spleen"
NCT00509184:I.2005,"neoplasia in PMH (except: basalioma, spinalioma)"
NCT00509184:I.2006,"Immunodeficiency syndromes, viral hepatitis, connective tissue disease"
NCT00509184:I.2007,"severe psychiatric disease"
NCT00509184:I.2008,"pregnancy or breast feeding"
NCT00509184:I.2009,"known allergies against foreign proteins"
NCT00510406:I.1001,"age at least 45 Years"
NCT00510406:I.1002,"male patients with LUTS associated with BPH diagnosed>3 months"
NCT00510406:I.1003,"International prostate symptom score>13"
NCT00510406:I.1004,"voiding and storage symptoms"
NCT00510406:I.1005,"Maximal urinary flow rate"
NCT00510406:I.2001,"post void residual volume>200 mL"
NCT00510406:I.2002,"symptomatic urinary tract infection"
NCT00518895:I.1001,"age at least 18 Years"
NCT00518895:I.1002,"Histologically confirmed diagnosis of melanoma"
NCT00518895:I.1003,"Progressive disease that is not surgically resectable, or metastatic Stage IV"
NCT00518895:I.1004,"Low-normal LDH, defined as<= 0.8 times the upper limit of normal"
NCT00518895:I.1005,"No prior chemotherapy"
NCT00518895:I.1006,"Measurable Disease"
NCT00518895:I.1007,"ECOG performance status finding<= 1"
NCT00518895:I.1008,"At least 4 weeks and recovery from effects of major prior surgery or other therapy, including immunotherapy, radiation therapy, or cytokine, biologic or vaccine therapy"
NCT00518895:I.1009,"Prior immunotherapy allowed"
NCT00518895:I.1010,"Adequate organ function"
NCT00518895:I.2001,"Prior cytotoxic chemotherapy, including regional perfusion, or prior Genasense treatment"
NCT00518895:I.2002,"Primary ocular or mucosal melanoma"
NCT00518895:I.2003,"Metastatic Malignant Neoplasm to the Bone"
NCT00518895:I.2004,"History or presence of brain metastasis or leptomeningeal disease"
NCT00518895:I.2005,"Significant medical disease other than cancer"
NCT00518895:I.2006,"Organ allograft"
NCT00522834:I.1001,"age at least 18 Years"
NCT00522834:I.1002,"Histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin"
NCT00522834:I.1003,"ECOG performance status finding<=2"
NCT00522834:I.1004,"Measurable disease according to modified RECIST"
NCT00522834:I.1005,"Life expectancy>12 weeks"
NCT00522834:I.1006,"LDH<= 2.0 x ULN"
NCT00522834:I.1007,"Clinical lab values within protocol parameters."
NCT00522834:I.1008,"At least 18 years old and able and willing to provide informed consent to participate"
NCT00522834:I.2001,"Previous cytotoxic chemotherapy treatment for melanoma"
NCT00522834:I.2002,"Received more than one regimen of immunotherapy, kinase inhibitor, biologic therapy, vaccine or investigational non-chemotherapeutic treatment for melanoma."
NCT00522834:I.2003,"Presence of brain metastases"
NCT00522834:I.2004,"Presence or history (<= 5 years) of a second malignancy other than nonmelanoma skin cancer or cervical carcinoma in situ"
NCT00522834:I.2005,"Female subjects who are pregnant or nursing"
NCT00525512:I.1001,"age at least 40 Years"
NCT00525512:I.1002,"All patients must sign an informed consent"
NCT00525512:I.1003,"Diagnosis of COPD with specific spirometric criteria (determined at study visits)"
NCT00525512:I.1004,"Age>= 40 years"
NCT00525512:I.1005,"Medical Research Council Dyspnea Scale>= 2"
NCT00525512:I.1006,"Current or ex-smoker with a>= 10 pack-year smoking history"
NCT00525512:I.1007,"Ability to exercise on treadmill"
NCT00525512:I.2001,"Significant diseases other than COPD such as history of life-threatening pulmonary obstruction, thoracotomy with pulmonary resection, interstitial lung disease, CF, pulmonary thromboembolic disease, clinically evident bronchiectasis, active tuberculosis, or known moderate to severe renal impairment"
NCT00525512:I.2002,"Clinical history of asthma"
NCT00525512:I.2003,"Use of supplemental oxygen therapy"
NCT00525512:I.2004,"Respiratory tract infection or COPD exacerbation in the 6 weeks prior to Visit 1 or during the washout period prior to Visit 3 (may randomize 6 weeks after recovery)"
NCT00525512:I.2005,"Recent history (<= 12 months) of myocardial infarction"
NCT00525512:I.2006,"Unstable or life-threatening cardiac arrhythmia"
NCT00525512:I.2007,"Malignancy treated with radiation therapy or chemotherapy in the last 5 years"
NCT00525512:I.2008,"Pregnant or nursing women"
NCT00525512:I.2009,"Known hypersensitivity to anticholinergic drugs or any component of the study medications"
NCT00525512:I.2010,"Participation in pulmonary or cardiac rehab program within 13 weeks of Visit 1"
NCT00525512:I.2011,"Estimated life expectancy<2 years"
NCT00525512:I.2012,"Symptomatic prostatic hyperplasia or bladder neck obstruction"
NCT00525512:I.2013,"Known narrow-angle glaucoma"
NCT00525512:I.2014,"Any condition that is contraindicated for exercise"
NCT00525512:I.2015,"Orthopaedic, muscular, neurological or cardiac disease that would interfere with regular participation in aerobic exercise or with exercise testing"
NCT00525512:I.2016,"Body mass index<18 kg/m2 or>35 kg/m2 list truncated for space"
NCT00528567:I.1001,"age at least 18 Years"
NCT00528567:I.1002,Adulthood
NCT00528567:I.1003,"operable primary invasive breast cancer"
NCT00528567:I.1004,"completed definitive loco-regional surgery"
NCT00528567:I.1005,"primary tumor centrally confirmed as triple negative."
NCT00528567:I.2001,"locally advanced breast cancers"
NCT00528567:I.2002,"previous breast cancer history"
NCT00528567:I.2003,"clinically significant cardiovascular disease."
NCT00531206:I.1001,"age at least 18 Years"
NCT00531206:I.1002,"Highly pre-treated male and female adult patients with virus resistant to multiple protease inhibitors. Aptivus (tipranavir), co-administered with low dose Norvir (ritonavir), is indicated for combination antiretroviral treatment of HIV-1 infection in highly pre-treated adult patients with virus resistant to multiple protease inhibitors."
NCT00531206:I.2001,"Age<18 years"
NCT00531206:I.2002,"pregnant female patients"
NCT00531206:I.2003,"Hypersensitivity to the active substance or to any of the excipients."
NCT00531206:I.2004,"Patients with moderate or severe (Child-Pugh B or C) hepatic impairment."
NCT00531206:I.2005,"Rifampicin should not be used with Aptivus (tipranavir) because co-administration may cause large decreases in tipranavir concentrations which may in turn significantly decrease the tipranavir therapeutic effect."
NCT00531206:I.2006,"Herbal preparations containing St John's wort must not be used while taking Aptivus (tipranavir) due to the risk of decreased plasma concentrations and reduced clinical effects of tipranavir."
NCT00531206:I.2007,"Co-administration of Aptivus (tipranavir) with low dose Norvir (ritonavir), with active substances that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. These active substances include antiarrhythmics (amiodarone, bepridil, quinidine), antihistamines (astemizole, terfenadine), ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (cisapride), neuroleptics (pimozide, sertindole), sedatives/hypnotics (triazolam) and HMG-CoA reductase inhibitors (simvastatin and lovastatin). In addition, co-administration of Aptivus (tipranavir) with low dose Norvir (ritonavir), with drugs that are highly dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide and propafenone, is contraindicated."
NCT00534287:I.1001,"age at least 18 Years"
NCT00534287:I.1002,"Severe sepsis or septic shock according to ACCP/SCCM criteria"
NCT00534287:I.1003,"Onset of severe sepsis or septic shock<24 h"
NCT00534287:I.1004,"Informed Consent"
NCT00534287:I.1005,"Effective contraception in fertile women"
NCT00534287:I.2001,"Age<18 years"
NCT00534287:I.2002,"Pregnancy, Gestation"
NCT00534287:I.2003,"Breast feeding, Nursing"
NCT00534287:I.2004,"Pretreatment with meropenem, imipenem, or ertapenem within the last 4 weeks (>1 daily dosage)"
NCT00534287:I.2005,"Pretreatment with moxifloxacin,ciprofloxacin, or levofloxacin within the last 4 weeks (>1 daily dosage)"
NCT00534287:I.2006,"Pretreatment with a pseudomonas effective cephalosporin (cefepime, ceftazidim, cefpirom) or piperacillin within the last 48 hours (>1 daily dosage)."
NCT00534287:I.2007,"Pretreatment with other chinolones within the last 4 weeks (>1 daily dosage)"
NCT00534287:I.2008,"Presence of infection where guidelines recommend another antimicrobial therapy than the study medication (i.e. endocarditis)"
NCT00534287:I.2009,"Evidence or strong clinical suspicion of a microorganism where the study medication is known to be ineffective (i.e. tuberculosis, MRSA- or VRE-infection)"
NCT00534287:I.2010,"Known allergy against meropenem or moxifloxacin"
NCT00534287:I.2011,"Tendon disease or injury due to past quinolone therapy"
NCT00534287:I.2012,"Congenital or acquired prolongation of QT-interval"
NCT00534287:I.2013,"Concomitant medication which prolongs the QT-interval"
NCT00534287:I.2014,"Electrolyte imbalance, especially uncorrected hypokalemia"
NCT00534287:I.2015,"Clinically relevant bradycardia"
NCT00534287:I.2016,"Clinically relevant cardiac dysfunction with reduced left-ventricular ejection fraction"
NCT00534287:I.2017,"Symptomatic arrhythmias in the medical history"
NCT00534287:I.2018,"Significant hepatic impairment (Child-Pugh C) or elevation of liver enzymes>5x the upper normal range"
NCT00534287:I.2019,"No commitment to full patient support (i.e. DNR order)"
NCT00534287:I.2020,"Patient's death is considered imminent due to coexisting disease"
NCT00534287:I.2021,"Concomitant participation in another study or study participation within the last 30 days."
NCT00534287:I.2022,"Relationship of the patient to study team member (i.e. colleague, relative)"
NCT00539487:I.1001,"age at least 18 Years"
NCT00539487:I.1002,"patients with essential hypertension aged>/= 18 years with one of the following risk factors: history of coronary artery disease or stroke/TIA or peripheral artery disease or diabetes mellitus."
NCT00539487:I.2001,"according to SPC"
NCT00543803:I.1001,"age at least 18 Years"
NCT00543803:I.1002,"male and female adult HIV type 1 infected patients, who have either not been treated previously, whose previous combination treatment with PIs has failed, or who have to switch their previous treatment from protease inhibitors (PI) or non-nucleoside reverse transcriptase inhibitors (NNRT)I due to side effects or intolerability after achieving suppression of viral load below the limit of detection."
NCT00543803:I.1003,"Viramune (nevirapine) is indicated as part of combination therapy for the antiviral treatment of HIV-1 infected patients with advanced or progressive immunodeficiency."
NCT00543803:I.1004,"Truvada (tenofovir and emtricitabine) is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults."
NCT00543803:I.2001,"Age<18 years"
NCT00543803:I.2002,"Pregnant female patients"
NCT00543803:I.2003,"Hypersensitivity to the active substance or to any of the excipients of Viramune (nevirapine) or Truvada (tenofovir and emtricitabine)."
NCT00543803:I.2004,"Viramune (nevirapine) should not be readministered to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine."
NCT00543803:I.2005,"Viramune (nevirapine) should not be used in patients with severe hepatic impairment (Child-Pugh C) or pre-treatment aspartine transaminase (ASAT) or alanine transaminase (ALAT)>5 upper limit normal (ULN) until baseline ASAT/ALAT are stabilised<5 ULN."
NCT00543803:I.2006,"Viramune (nevirapine) should not be readministered in patients who previously had ASAT or ALAT>5 ULN during Viramune (nevirapine) therapy and had recurrence of liver function abnormalities upon readministration of Viramune (nevirapine)"
NCT00543803:I.2007,"Herbal preparations containing St Johns wort (Hypericum perforatum) must not be used while taking Viramune (nevirapine) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine"
NCT00543803:I.2008,"The available pharmacokinetic data suggest that the concomitant use of rifampicin and Viramune (nevirapine) is not recommended."
NCT00545077:I.1001,"age 18 Years to 80 Years"
NCT00545077:I.1002,"Before starting the specific protocol procedures, the written informed consent must be obtained and documented."
NCT00545077:I.1003,"Women>=18 years."
NCT00545077:I.1004,"Capacity to comply with all the protocol requirements."
NCT00545077:I.1005,"Functional ECOG status<= 1."
NCT00545077:I.1006,"Life expectancy>= 24 weeks."
NCT00545077:I.1007,"Histologically confirmed breast adenocarcinoma, with measurable or non-measurable, locally advanced or metastatic (stage IV) disease. In the event that the patient only has locally advanced disease, she will not be able to undergo curative local treatment. Patients with metastasis confined to the bone can be chosen, but the disease must be confirmed by radiology, CT scan or NMR if there is any doubt after a single bone scan."
NCT00545077:I.1008,"Patients with HER2-negative disease evaluated by IHC and FISH/CISH (IHC 0 or 1+, or 2+ and negative FISH). Patients with 3+ by IHC cannot be chosen regardless of the FISH/CISH status and those with positive FISH/CISH (>2 amplifications) cannot be chosen either, regardless of the IHC findings."
NCT00545077:I.1009,"Positive hormone receptors (estrogen receptor [ER] and/or progesterone receptor [PgR]) evaluated by a local or central laboratory, according to the criteria of the participating institution."
NCT00545077:I.1010,"Patients who are candidates for receiving first-line treatment with letrozole."
NCT00545077:I.1011,"Patients may have received (neo)adjuvant chemotherapy, provided that the last dose of the latter was received at least 12 months before randomization . Patients must be recovered from toxicity."
NCT00545077:I.1012,"The patients are allowed to have received adjuvant radiotherapy, provided that it was completed at least 6 weeks before randomization and the patient has recovered from the reversible acute effects of the radiation. The previous administration of radiotherapy to palliate the pain of bone metastases is authorized, provided that:"
NCT00545077:I.1013,"Not more than 30% of bone marrow has been irradiated."
NCT00545077:I.1014,"The patient has recovered from the reversible acute effects of the radiation."
NCT00545077:I.1015,"The patient has at least one metastatic location which has not been irradiated  and which may be evaluated for progression, or a clear progression of the bone  disease has been objectified after the end of the palliative radiotherapy."
NCT00545077:I.2001,"Evolutionary disease requiring an immediate treatment with cytotoxic chemotherapy according to the investigator's judgment."
NCT00545077:I.2002,"Patients with locally advanced breast cancer who are expected to undergo surgery or curative radiotherapy."
NCT00545077:I.2003,"Previous chemotherapy or hormonotherapy for the metastatic disease. Patients may have received neoadjuvant chemotherapy or neoadjuvant hormonotherapy with curative intention as a part or as an alternative to an adjuvant treatment. For the previous neoadjuvant hormonotherapy the same premises than for the adjuvant hormonotherapy are valid."
NCT00545077:I.2004,"Previous therapy with anti-VEGF or VEGFR tyrosine-kinase inhibitors."
NCT00545077:I.2005,"History of another pathology that may affect the development of the protocol or the interpretation of results. It is considered that patients who have suffered from a skin carcinoma that is not melanoma, cervical carcinoma in situ or another neoplasia treated with a curative intention and with a disease-free interval exceeding 5 years can be chosen."
NCT00545077:I.2006,"Evidence of CNS metastasis. A CT scan or brain NMR must be done within the 4 weeks before the randomization in case of suspecting brain metastasis."
NCT00545077:I.2007,"History or evidence in the physical or neurological examination of CNS pathology unrelated to cancer unless it is suitable treated with standard therapy (e.g. uncontrolled convulsions)."
NCT00545077:I.2008,"History of peripheral neuropathy NCI CTCAE grade>2 at the time of randomization."
NCT00545077:I.2009,"Patients subjected to major surgical procedures, open biopsies or those having significant trauma injuries within the 28 days prior to randomization, or patients who are expected to undergo a major surgical procedure that must necessarily be performed within the course of the study."
NCT00552019:I.1001,"age at least 18 Years"
NCT00552019:I.1002,"active anterior or panuveitis with keratoprecipitates"
NCT00552019:I.2001,"Chandler syndrome"
NCT00554502:I.1001,"age 18 Years to 70 Years"
NCT00554502:I.1002,"Male or female patients from 18-70 years with histologically proven primary IgAN with typical mesangioproliferative features. Diagnosis has to be made by a neuropathologist."
NCT00554502:I.1003,"Proteinuria above 0.75 g/day within 12 weeks prior to or at the first visit in the run-in phase (month -6)and presence of at least one further risk factor for the development of end stage renal disease  1. arterial hypertension, defined as ambulatory blood pressure>140/90 mm Hg or the  use of antihypertensive medication or  2. impaired renal function, defined as creatinine clearance or estimated GFR<90  ml/min."
NCT00554502:I.2001,"Known allergy or intolerance to study medication (except in case of ACE-inhibitor, in which case a change to an angiotensin receptor blocker is possible)."
NCT00554502:I.2002,"Women who are pregnant or breastfeeding and women without sufficient contraception."
NCT00554502:I.2003,"Any prior immunosuppressive therapy."
NCT00554502:I.2004,"Variants of primary IgAN (e.g. rapidly progressive IgAN with crescents in>50% of glomeruli or minimal change GN with glomerular IgA deposits)."
NCT00554502:I.2005,"Significant liver dysfunction (more than three fold increased GPT compared to norm)"
NCT00554502:I.2006,"Contraindication for immunosuppressive therapy, like"
NCT00554502:I.2007,"acute or chronic infectious disease incl. hepatitis and HIV positive patients"
NCT00554502:I.2008,"Malignant Neoplasms"
NCT00554502:I.2009,"leukocytopenia, thrombocytopenia or known allergy against prednisolone,  cyclophosphamide or azathioprine"
NCT00554502:I.2010,"active intestinal bleeding, active gastric or duodenal ulcer"
NCT00554502:I.2011,"Need of permanent immunosuppression, (e.g. transplanted patients,  steroid-dependent inflammatory diseases)"
NCT00554502:I.2012,"Secondary IgAN or diseases associated with glomerular deposits of IgA."
NCT00554502:I.2013,"Additional other chronic renal disease."
NCT00554502:I.2014,"Creatinine clearance below 30 ml/min (mean of 3 measurements)."
NCT00554502:I.2015,"Alcohol or drug abuse"
NCT00554502:I.2016,"Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study"
NCT00554502:I.2017,"Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study"
NCT00554502:I.2018,"Participation in a parallel clinical trial or participation in another clinical trial within the last 3 months."
NCT00554502:I.2019,"Subjects who are in any state of dependency to the sponsor or the investigators."
NCT00554502:I.2020,"Employees of the sponsor or the investigators."
NCT00554502:I.2021,"Subjects who have been committed to an institution by legal or regulatory order."
NCT00556270:I.1001,"age at least 18 Years"
NCT00556270:I.1002,"Patients with severe, chronic pain"
NCT00556270:I.2001,"Hypersensitivity of fentanyl"
NCT00556270:I.2002,"Co-administration of monoaminooxidase-inhibitors"
NCT00556270:I.2003,"Pregnancy, Gestation"
NCT00556270:I.2004,"Ventilatory Depression"
NCT00556270:I.2005,"Chronic Obstructive Pulmonary Disease"
NCT00556270:I.2006,"Drug abuse"
NCT00556270:I.2007,"Impairment of CNS functions"
NCT00556270:I.2008,"Other criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)"
NCT00558584:I.1001,"age 18 Years to 65 Years"
NCT00558584:I.1002,"Dilated cardiomyopathy"
NCT00558584:I.1003,"LVEF<= 40% determined by contrast echocardiography"
NCT00558584:I.1004,"NYHA class II - IV"
NCT00558584:I.1005,"Age 18 - 65"
NCT00558584:I.1006,"Disease duration: symptomatic heart failure>1 year and<5 years prior to screening date"
NCT00558584:I.1007,"Treatment with ACE inhibitors or angiotensin II receptor blockers (ARB), beta-blockers, and aldosterone antagonists (the latter at the discretion of the attending physician), for at least 6 months and at stable doses for at least 2 months prior to screening date."
NCT00558584:I.1008,"Informed Consent"
NCT00558584:I.2001,"NYHA class IV patients who are bed-ridden and dependent upon parenteral medication"
NCT00558584:I.2002,"Cardiac insufficiency resulting from another basic disease (e.g. coronary artery disease,>= 50% stenosis of major vessel as ascertained by coronary angiography performed more recent than three years before screening date, hypertensive heart disease, or valvular defects>second degree"
NCT00558584:I.2003,"History of - myocardial infarction"
NCT00558584:I.2004,"Acute myocarditis according to Dallas criteria"
NCT00558584:I.2005,"Endocrine disorder excluding insulin-dependent diabetes mellitus"
NCT00558584:I.2006,"Implanted cardiac defibrillator (ICD)<1 month before screening date"
NCT00558584:I.2007,"Cardiac resynchronization therapy (CRT)<6 months before screening date"
NCT00558584:I.2008,"I.v. medication with inotropic drugs, vasodilators or repeated (>1/day) i.v. administration of diuretics."
NCT00558584:I.2009,"Active infectious disease, or signs of ongoing infection with CRP>10mmol/L"
NCT00558584:I.2010,"Impaired renal function (serum creatinine>220 µmol/L)"
NCT00558584:I.2011,"Any disease requiring immunosuppressive drugs"
NCT00558584:I.2012,"Anaemia (haemoglobin below 90 g/L) due to other causes than CHF"
NCT00558584:I.2013,"Pregnancy or lactation, or childbearing potential without appropriate contraception"
NCT00558584:I.2014,"Alcohol or drug abuse"
NCT00558584:I.2015,"Presence of a malignant tumour, or remission of malignancy<5 years"
NCT00558584:I.2016,"Suspected poor capability to follow instructions and cooperate"
NCT00558584:I.2017,"Another life-threatening disease with poor prognosis (survival<2 years)"
NCT00558584:I.2018,"Participation in any other clinical study within<30 days prior to screening date"
NCT00558584:I.2019,"Previous treatments with IA or immunoglobulin"
NCT00558584:I.2020,"Contraindications for application of echocardiography contrast agent (Luminity(R) according to Luminity(R) specifications, including cardiac shunts, pulmonary vascular compromise)"
NCT00560651:I.1001,"Patients diagnosed with keratokonus and treated with corneal cross Linking in Germany"
NCT00560651:I.2001,"Non-ectatic conditions"
NCT00560794:I.1001,"age at least 18 Years"
NCT00560794:I.1002,"B-precursor ALL patients in complete hematological remission with molecular failure or molecular relapse starting at any time after consolidation I of front-line therapy within GMALL standards or at any time outside GMALL standards."
NCT00560794:I.1003,"Patients must have a molecular marker for evaluation of minimal residual disease which is either Bcr/abl at any detection level or individual rearrangements of immunoglobulin or TCR-genes measured by an assay with a sensitivity of minimum 10-4: At least one individual marker at a quantitative level 10-4."
NCT00560794:I.1004,"ECOG performance status finding<2"
NCT00560794:I.1005,"Ability to understand and willingness to sign a written informed consent"
NCT00560794:I.1006,"Signed and dated written informed consent is available"
NCT00560794:I.2001,"Current extra medullar involvement"
NCT00560794:I.2002,"History of or current relevant CNS pathology (except migraine/headache and/or previous infiltration of cerebrospinal fluid (CSF) by ALL)"
NCT00560794:I.2003,"Current infiltration of cerebrospinal fluid by ALL"
NCT00560794:I.2004,"History of or current autoimmune disease"
NCT00560794:I.2005,"Autologous stem cell transplantation within 6 weeks prior to study entry"
NCT00560794:I.2006,"Any prior allogeneic stem cell transplantation"
NCT00560794:I.2007,"Cancer chemotherapy within 4 weeks prior to study treatment (except for intrathecal prophylaxis and/or low dose maintenance therapy such as vincalkaloids, mercaptopurine, methotrexate, steroids)"
NCT00560794:I.2008,"Radiotherapy within 4 weeks prior to study treatment"
NCT00560794:I.2009,"Therapy with monoclonal antibodies (Rituximab, MabCampath) within 6 weeks prior to study treatment"
NCT00560794:I.2010,"Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation"
NCT00560794:I.2011,"Presence of human anti-murine antibodies (HAMA)"
NCT00560794:I.2012,"Abnormal bone marrow, renal or hepatic function"
NCT00560794:I.2013,"Indication for a hypercoagulative state"
NCT00560794:I.2014,"History of malignancy other than ALL within 5 years prior to study entry, with the exception of basal cell carcinoma of the skin or cervix carcinoma in situ"
NCT00560794:I.2015,"Active severe infection, any other concurrent disease or medical condition that are deemed to interfere with the conduct of the study as judged by the investigator"
NCT00560794:I.2016,"Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti-HCV positive"
NCT00560794:I.2017,"Pregnant or nursing women"
NCT00560794:I.2018,"Women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least 3 months thereafter or male patients not willing to ensure effective contraception dur-ing participation in the study and at least three months thereafter"
NCT00561925:I.1001,"age at least 18 Years"
NCT00561925:I.1002,"Signed informed consent in accordance with Good Clinical Practice and local regulatory requirements prior to trial participation"
NCT00561925:I.1003,"HIV-1 infected males or females>= 18 years of age with positive serology (ELISA) confirmed by Western blot"
NCT00561925:I.1004,"No previous antiretroviral treatment"
NCT00561925:I.1005,"Males with CD4+ counts>50<400 cells/ml or females with CD4+ counts>50-<250 cells/ml"
NCT00561925:I.1006,"Adequate renal function defined as a calculated creatinine clearance (CLCr)>= 50 mL/min according to the Cockcroft-Gault formula as follows: Male: (140 age in years) x (weight in kg) divided by 72 x (serum creatinine in mg/dl) = CLCr (mL/min). Female: (140 age in years) x (weight in kg) divided by 72 x (serum creatinine in mg/dl) x 0.85 = CLCr (mL/min)."
NCT00561925:I.1007,"Karnofsky performance status (assessment scale)"
NCT00561925:I.1008,"An HIV-1 viral load of 1,000 copies/mL"
NCT00561925:I.1009,"Willingness to initiate CD4+ cell count-guided chemoprophylaxis to prevent important opportunistic infections as defined in Appendix 10.2"
NCT00561925:I.1010,"Willingness to abstain from ingesting substances which may alter plasma study drug levels by interaction with the cytochrome P450 system (listed in Appendix 10.3) during the study."
NCT00561925:I.1011,"For centers participating in the PK substudy only: Written informed consent in accordance with GCP and local legislation for participation in the PK substudy. Refusal to participate in the PK substudy is not an exclusion criterion for participation in the trial. Only study centers with previous experience and equipped in handling PK samples are eligible for participation in the substudy."
NCT00561925:I.2001,"Active drug abuse or chronic alcoholism at the investigator's discretion"
NCT00561925:I.2002,"Active hepatitis B or C disease, defined as HBsAg-positive and HBV-DNA-positive or HCV-RNA-positive"
NCT00561925:I.2003,"Female patients of child-bearing potential who: are pregnant at screening, are breast feeding, are planning to become pregnant are not willing to use a barrier method of contraception, or are not willing to use methods of contraception other than ethinyl estradiol containing oral contraceptives. Note: During participation in this study, females and males have to use barrier methods of contraception in addition or instead of ethinyl estradiol containing oral contraceptives."
NCT00561925:I.2004,"Laboratory parameters>DAIDS Grade 2"
NCT00561925:I.2005,"ALT/AST>DAIDS Grade 1"
NCT00561925:I.2006,"Hypersensitivity to any ingredients of the test products"
NCT00561925:I.2007,"Previous use of Viramune (nevirapine) or any other antiretroviral agents (does not include use of single dose NVP for the prevention of mother to child transmission)"
NCT00561925:I.2008,"Resistance to NNRTIs or either one of the components of Truvada (emtricitabine or tenofovir disoproxil fumarate) or lamivudine (3TC) based on HIV-1 genotypic resistance testing report obtained at screening"
NCT00561925:I.2009,"Patients who are receiving other concomitant treatments which are not permitted, as described in the prescribing information"
NCT00561925:I.2010,"Use of investigational medications (any experimental agent other than the study regimen) within 30 days before study entry or during the trial"
NCT00561925:I.2011,"Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2)"
NCT00561925:I.2012,"Patients who have been diagnosed with malignant disease"
NCT00561925:I.2013,"Patients who in the opinion of the investigator are not candidates for inclusion in the study"
NCT00561925:I.2014,"Patient with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma (KS), and/or any lymphoma"
NCT00561925:I.2015,"Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit"
NCT00562094:I.1001,"age at least 12 Years"
NCT00562094:I.1002,GERD
NCT00562094:I.1003,"Non-erosive reflux disease (NERD)"
NCT00562094:I.2001,"Criteria as defined in the Summary of Product Characteristics"
NCT00564993:I.1001,"age at least 14 Years"
NCT00564993:I.1002,"Written informed consent of the patient or patient's legal representatives"
NCT00564993:I.1003,"No participation in another AMG driven study within the past 4 weeks or during the whole duration of this study"
NCT00564993:I.1004,"Patients with Tetralogy of Fallot after corrective surgery"
NCT00564993:I.1005,"group A (n=45): Adolescents>= 14 years or adults with Tetralogy of Fallot after  corrective surgery and necessary re-intervention (pulmonary valve replacement  because of pulmonary insufficiency"
NCT00564993:I.1006,"group B (n=35): Adolescents>= 14 years or adults with Tetralogy of Fallot after  corrective surgery and good result of repair and good right ventricular function"
NCT00564993:I.2001,"pregnancy or lactation"
NCT00564993:I.2002,"women of child-bearing age who are sexually active without practising highly effective methods of contraception (a urine/serum pregnancy test may be requested at the discretion of the investigator)"
NCT00564993:I.2003,"any diseases or impairment that, in the opinion of the investigator, would justify to exclude a subject from participation"
NCT00564993:I.2004,"substance abuse (alcohol, medicines, drugs)"
NCT00564993:I.2005,"other medical, psychological or social circumstances that would adversely affect a patient's ability to participate reliably in the study or increase the risk to themselves or others if they participated"
NCT00564993:I.2006,"insufficient compliance"
NCT00564993:I.2007,"disagreement with storage&transfer of anonymized disease data within this study."
NCT00564993:I.2008,"Persons who are detained officially or legally to an official institution"
NCT00564993:I.2009,"contraindication against pharmacological stress testing (ventricular tachycardia or severe arrhythmia, profound pulmonary stenosis and hypertension of the pulmonary artery)"
NCT00564993:I.2010,"Coronary artery disease (CAD)"
NCT00564993:I.2011,"atrial fibrillation or flutter"
NCT00564993:I.2012,"DORV (if there is another VSD than subaortic)"
NCT00564993:I.2013,"associated severe heart defects"
NCT00564993:I.2014,"associated other severe (=hemodynamic significantly) valvular defects except for pulmonary insufficiency"
NCT00564993:I.2015,"Other clinically relevant diseases, such as malignant tumour or florid diseases (as considered by the investigating physician)"
NCT00564993:I.2016,"MRI contraindication, e.g. cardiac pacemaker, implanted neurostimulators and other magnetisable foreign bodies"
NCT00564993:I.2017,"Patient is not able to perform spiroergometry (bicycle/treadmill) or existing contraindications"
NCT00564993:I.2018,"Patients with Type I or II diabetes"
NCT00564993:I.2019,"prohibited concomitant medication: MAO-inhibitors"
NCT00564993:I.2020,"Treatment with beta- or alpha-blocker"
NCT00564993:I.2021,"Treatment with high doses of ACE-inhibitors or inhibitors of the AT-receptor and permanent treatment with nitrates (in the investigating physician's risk assessment)"
NCT00564993:I.2022,"Anticoagulation treatment (risk-benefit decision by the investigating physician, as there may be additional inhibition of platelet aggregation with dobutamine)"
NCT00564993:I.2023,"Treatment with diuretics (risk-benefit decision by the investigating physician, as there may be enhancement of the hypokalemia by administration of dobutamine). If necessary verification of the serum K+ -level before exposure to dobutamine"
NCT00564993:I.2024,"all contraindications against the study medication described in the SMPC"
NCT00574249:I.1001,"age at least 18 Years"
NCT00574249:I.1002,"Subject had a clinical diagnosis of chronic plaque psoriasis for at least 6 months, and has moderate to severe plaque psoriasis"
NCT00574249:I.1003,"Subject must have been treated and failed to respond to, or has a contraindication to, or is intolerant to at least two different systemic therapies, one of which must be cyclosporine, or methotrexate or oral PUVA"
NCT00574249:I.1004,"Subject is judged to be in generally good health as determined by the principal investigator"
NCT00574249:I.2001,"Subject has previous exposure to adalimumab"
NCT00574249:I.2002,"Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy"
NCT00574249:I.2003,"Subject is taking or requires oral or injectible corticosteroids"
NCT00574249:I.2004,"Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced or medication-exacerbated psoriasis or new onset guttate psoriasis"
NCT00574249:I.2005,"Subject considered by the investigator, for any reason, to be an unsuitable candidate"
NCT00574249:I.2006,"Female subject who is pregnant or breast-feeding or considering becoming pregnant"
NCT00574249:I.2007,"Calcium Metabolism Disorders"
NCT00586794:I.1001,"age at least 14 Years"
NCT00586794:I.1002,"Written informed consent obtained"
NCT00586794:I.1003,"No participation in another AMG driven study attendancing this treatment protocol"
NCT00586794:I.1004,"Presence of cyanosis with<93 % arterial oxygen saturation (measured by transcutaneous pulse oximetry)"
NCT00586794:I.1005,"Clinical indication for the invasive diagnostic procedures planned for the study is given. This is evaluated on the basis of observation before, during and after medicinal therapy)"
NCT00586794:I.1006,"Presence of PAH as diagnosed by invasive methods with Rp:Rs>0.5 measured at rest, before testing of pulmonary vasodilatory reserve"
NCT00586794:I.1007,Diagnosis
NCT00586794:I.1008,"non-corrected large congenital shunting defect at atrial, ventricular or  arterial level:"
NCT00586794:I.1009,"Partial anomalous pulmonary venous drainage, Partial Anomalous Pulmonary Venous Return"
NCT00586794:I.1010,"Atrial Septal Defects"
NCT00586794:I.1011,"Atrial Septal Defect Sinus Venosus, Sinus venosus atrial septal defect"
NCT00586794:I.1012,"Ventricular Septal Defects"
NCT00586794:I.1013,"Atrioventricular septal defect, Atrioventricular septal defect and common atrioventricular junction"
NCT00586794:I.1014,TAC
NCT00586794:I.1015,"Aortopulmonary window, Aortopulmonary septal defect"
NCT00586794:I.1016,"Persistent ductus arteriosus, Patent ductus arteriosis"
NCT00586794:I.1017,"combinations thereof"
NCT00586794:I.1018,"Surgically corrected shunting defect (diagnoses as above) with significant  residual defect"
NCT00586794:I.1019,"Other diagnoses with univentricular physiology/ hemodynamics."
NCT00586794:I.2001,"pregnancy or lactation"
NCT00586794:I.2002,"women of child-bearing age who are sexually active without practising highly effective methods of contraception"
NCT00586794:I.2003,"any diseases or impairment that, in the opinion of the investigator exclude a subject from participation"
NCT00586794:I.2004,"substance abuse (alcohol, medicines, drugs)"
NCT00586794:I.2005,"other medical, psychological or social circumstances that would adversely affect a patient's ability to participate reliably in the study or increase the risk to themselves or others if they participated"
NCT00586794:I.2006,"insufficient compliance"
NCT00586794:I.2007,"missing willingness to storaging and transferring pseudonymous disease data within this study."
NCT00586794:I.2008,"subjects who are not able to perform Cardio-Pulmonary Exercise Testing (CPX)."
NCT00586794:I.2009,"pulmonary hypertension secondary to any etiology other than those specified in the inclusion criteria"
NCT00586794:I.2010,"subjects with known intolerance of NO and iloprost or their constituents"
NCT00586794:I.2011,"acute decompensated heart failure within the 7 days before the invasive diagnostic procedure"
NCT00586794:I.2012,"clinically significant haemoptysis within the last 6 months"
NCT00586794:I.2013,"hemodynamic instability which would represent an unjustifiable risk during testing of pulmonary arterial vasoreagibility"
NCT00586794:I.2014,"arterial hypotension (as defined by age-specific values)"
NCT00586794:I.2015,Anaemia
NCT00586794:I.2016,"decompensated symptomatic policythemia; (details: 4.2.2. exclusion criteria)"
NCT00586794:I.2017,Thrombocytopenia
NCT00586794:I.2018,"secondary impairment of organic function:"
NCT00586794:I.2019,"impairment of renal function (GFR<30 ml/min/1,73 m2 BSA)"
NCT00586794:I.2020,"impairment of hepatic function (ALT and/or AST>3 x ULN and bilirubin ? 2 mg/dl)"
NCT00586794:I.2021,"other sources of pulmonary blood flow which prohibit measurement of the blood flow into the lungs and therefore of the pulmonary vascular resistance:"
NCT00586794:I.2022,"Glenn shunt, Anastomosis of superior vena cava to pulmonary artery"
NCT00586794:I.2023,"BT - Blalock-Taussig shunt, Subclavian to pulmonary artery shunt operation"
NCT00586794:I.2024,"significant number of MAPCAs; (details: 4.2.2. exclusion criteria)"
NCT00586794:I.2025,"Obstruction of pulmonary outflow tract"
NCT00586794:I.2026,"obstruction of pulmonary venous return"
NCT00586794:I.2027,"mitral valve dysfunction"
NCT00586794:I.2028,"Left heart diseases:"
NCT00586794:I.2029,"aortic or mitral valve disease (more severe than ""mild"")"
NCT00586794:I.2030,"restrictive or congestive cardiomyopathy"
NCT00586794:I.2031,"PCWP/LVEDP>15 mmHg"
NCT00586794:I.2032,"symptomatic coronary artery disease"
NCT00586794:I.2033,"Significant valvular diseases other than tricuspid or pulmonary regurgitation (these are not exclusion criteria; details: 4.2.2. exclusion criteria)."
NCT00586794:I.2034,"PERICARDIAL CONSTRICTION"
NCT00586794:I.2035,"History of stroke, myocardial infarction or life-threatening arrhythmia within the 6 months before screening"
NCT00586794:I.2036,"Bronchopulmonary dysplasia (BPD) and other chronic lung diseases"
NCT00586794:I.2037,"History of significant pulmonary embolism"
NCT00586794:I.2038,"Other relevant diseases (e.g. HIV, diabetes mellitus requiring medical treatment)"
NCT00586794:I.2039,"Subjects with trisomy 21 (reproducibility of 6-MWT and CPX doubtful; communication as to side effects and subjective quality of life doubtful)"
NCT00586794:I.2040,"all contraindications against the study medication (see also ""4.2.3 concomitant medication"")"
NCT00586794:I.2041,"hypersensitivity against the active ingredients as well as supplementaries"
NCT00586794:I.2042,"patients who lost vision on one eye due to a non arteriitic anterior ischaemic neuropathy of the opticus (NAION)."
NCT00586794:I.2043,"Prohibited concomitant medication:"
NCT00586794:I.2044,"Any medication listed below which has not been discontinued at least 30 days prior to screening. Specific pulmonary vasodilators during cardiac catheterization are allowed."
NCT00586794:I.2045,"Unspecified concomitant medication"
NCT00586794:I.2046,"Other significant medication (a.o. chronic intake of systemic immunosuppression as e.g. systemic glucocorticoids, cytostatic drugs, ciclosporin)"
NCT00586794:I.2047,"Instable medication (details: 4.2.5 prohibited concomitant medication):"
NCT00586794:I.2048,"begin of a new medication regimen within the last 30 days before screening"
NCT00586794:I.2049,"change in the dosage of existing medication within the last 7 days before cardiac catheterization"
NCT00586794:I.2050,"Existing anti-pulmonary hypertensive medication (in any form) with:"
NCT00586794:I.2051,"PDE-5 antagonists (e.g. sildenafil)"
NCT00586794:I.2052,"prostanoids (e.g. iloprost, prostacyclin, beraprost) In case the patient is stable and on Bosentan therapy at least for 6 months. Bosentan (Tracleer) is unprohibited as concomitant medication."
NCT00586794:I.2053,"Other medication with vascular action:"
NCT00586794:I.2054,"Adrenergic alpha-Antagonists"
NCT00586794:I.2055,"L-arginin (acts through NO axis)"
NCT00586794:I.2056,"ritonavir, nicorandil (act through K+ channels)"
NCT00586794:I.2057,"Medication that is not compatible with sildenafil or interferes with the metabolism:"
NCT00586794:I.2058,"cytochrome P450-CYP2C9 and CYP3A4 inhibitors (e.g. erythromycin/ketoconazole/itraconazole/protease inhibitors)"
NCT00586794:I.2059,"any existing medication that, in the opinion of the investigator, may interfere with sildenafil treatment."
NCT00598442:I.1001,"age at least 18 Years"
NCT00598442:I.1002,"Chronic Renal Failure with an estimated glomerular filtration rate<60 mL/min/1.73m2 and not expected to begin dialysis for at least 12 weeks."
NCT00598442:I.1003,"Two consecutive Hgb values>=8.0 g/dL and<11.0 g/dL within 4 weeks prior to randomization."
NCT00598442:I.2001,"Females who are pregnant or breast-feeding."
NCT00598442:I.2002,"Treatment with an ESA in the 12 weeks prior to randomization."
NCT00598442:I.2003,"Known intolerance to any ESA, parenteral iron supplementation, or PEGylated molecule."
NCT00598442:I.2004,"Prior chronic hemodialysis or chronic peritoneal dialysis treatment."
NCT00598442:I.2005,"Known bleeding or coagulation disorder."
NCT00598442:I.2006,"Known hematologic disease or cause of anemia other than renal disease."
NCT00598442:I.2007,"Poorly controlled hypertension."
NCT00598442:I.2008,"Evidence of active malignancy within one year prior to randomization"
NCT00598442:I.2009,"A scheduled kidney transplant."
NCT00606450:I.1001,"age at least 18 Years"
NCT00606450:I.1002,"Must understand and voluntarily sign an informed consent form"
NCT00606450:I.1003,"Must be in good health as judged by the investigator"
NCT00606450:I.1004,"Must be able to adhere to the study visit schedule and other protocol requirements"
NCT00606450:I.1005,"Must have a>= 6 month history of moderate-to-severe plaque-type psoriasis"
NCT00606450:I.1006,"Must have a PASI score>=10 and BSA>=10%"
NCT00606450:I.1007,"Must meet specific laboratory criteria"
NCT00606450:I.1008,"Must be a candidate for photo/systemic therapy"
NCT00606450:I.1009,"Women of childbearing potential must have a negative pregnancy test"
NCT00606450:I.2001,"Must not have clinically significant underlying disease processes"
NCT00606450:I.2002,"Must not be pregnant or lactating females"
NCT00606450:I.2003,"Must not have any condition, including lab abnormalities, which places the subject at unacceptable risk if the subject were to participate in the study or confounds the ability to interpret data from the study"
NCT00606450:I.2004,"Must not have a history of active mycobacterium tuberculosis infection within 3 years prior to the screening visit"
NCT00606450:I.2005,"Must not have a history of incompletely treated active of latent mycobacterium tuberculosis infection"
NCT00606450:I.2006,"Must not have a known history of exposure to an infectious case of mycobacterium tuberculosis within 2 years prior to the screening visit"
NCT00606450:I.2007,"Must not be an immigrant from a high-incidence country for mycobacterium tuberculosis disease within 2 years prior to the screening visit"
NCT00606450:I.2008,"Must not have current erythrodermic, guttate, or pustular psoriasis"
NCT00606450:I.2009,"Must not have a clinical history of failure to adequately respond to treatment in the investigator's opinion to one or more treatment courses of cyclosporine or the following biologic therapies: alefacept, etanercept, efalizumab, infliximab or adalimumab"
NCT00606450:I.2010,"Must not use topical therapy within 14 days of randomization"
NCT00606450:I.2011,"Must not use systemic therapy for psoriasis within 28 days of randomization"
NCT00606450:I.2012,"Must not use phototherapy within 28 days of randomization"
NCT00606450:I.2013,"Must not use adalimumab or infliximab within 3 months of randomization"
NCT00606450:I.2014,"Must not use etanercept or efalizumab within 56 days of randomization"
NCT00606450:I.2015,"Must not use alefacept within 6 months of randomization"
NCT00606723:I.1001,"age up to 21 Years"
NCT00606723:I.1002,"Children, adolescents and young adults aged 0-21 years, male and female"
NCT00606723:I.1003,"Patients suffering from refractory de novo AML"
NCT00606723:I.1004,"Patients with relapsed AML"
NCT00606723:I.1005,"Secondary Acute Myeloid Leukemia"
NCT00606723:I.2001,"Severely impaired functional performance"
NCT00606723:I.2002,"Severe renal impairment"
NCT00606723:I.2003,"Pregnancy, Gestation"
NCT00606723:I.2004,"Current participation in another clinical trial"
NCT00617214:I.1001,"age 18 Years to 65 Years"
NCT00617214:I.1002,"Outpatients suffering from schizophrenia, schizoaffective disorder, schizophreni-form disorder, delusional disorder or psychotic disorder not otherwise specified"
NCT00617214:I.1003,"Current stable treatment with Seroquel according to SmPC since at least 2 months"
NCT00617214:I.1004,"Given consent to take part in an integrated care program prior to study start. Written informed consent to take part in this NIS"
NCT00617214:I.2001,"Presence of any contraindication as described in the SmPC"
NCT00617214:I.2002,"Cancellation of participation in the integrated care program"
NCT00617669:I.1001,"18 Years and older"
NCT00617669:I.1002,male
NCT00617669:I.1003,"Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has spread to the bone (bone metastasis)"
NCT00617669:I.1004,"Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment"
NCT00617669:I.1005,"Currently receiving treatment with surgical or medical castration"
NCT00617669:I.2001,"Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial"
NCT00617669:I.2002,"Suffering from heart failure or had a myocardial infarction within last 6 months"
NCT00617669:I.2003,"A history of epilepsy or seizures"
NCT00622700:I.1001,"age 18 Years to 55 Years"
NCT00622700:I.1002,"First acute or subacute, well-defined neurological event consistent with demyelination (i.e. optic neuritis confirmed by an ophthalmologist, spinal cord syndrome, brainstem/cerebellar syndromes),"
NCT00622700:I.1003,"Onset of MS symptoms occurring within 90 days of randomization,"
NCT00622700:I.1004,"A screening MRI scan with 2 or more T2 lesions at least 3 mm in diameter that are characteristic of MS."
NCT00622700:I.2001,"Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease,"
NCT00622700:I.2002,"Significantly impaired bone marrow function,"
NCT00622700:I.2003,"Pregnancy or nursing,"
NCT00622700:I.2004,"Alcohol or drug abuse,"
NCT00622700:I.2005,"Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment"
NCT00622700:I.2006,"Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study."
NCT00623727:I.1001,"age 12 Years to 70 Years"
NCT00623727:I.1002,"male, male gender"
NCT00623727:I.1003,"Subjects with severe hemophilia A (<1% factor VIII [FVIII]:C)"
NCT00623727:I.1004,"Subjects with>= 150 exposure days (EDs) with any FVIII in total"
NCT00623727:I.1005,"Subjects who have been on-demand treatment with a minimum of 1 relevant bleed per month or have been on secondary prophylaxis treatment with not more than a 3x/week schedule"
NCT00623727:I.1006,"Subjects with bleeding events and/or treatments during the last 6 months prior to study entry which are documented in the subjects medical records"
NCT00623727:I.1007,"Subjects with no measurable inhibitor activity"
NCT00623727:I.1008,"Subjects with no history of FVIII inhibitor antibody formation"
NCT00623727:I.1009,"Written informed consent by subject and parent / legal representative, if<18 years"
NCT00623727:I.2001,"Subjects who are receiving primary prophylaxis"
NCT00623727:I.2002,"Subjects on prophylaxis with documented requirements of>75 IU/kg/week"
NCT00623727:I.2003,"Subjects with any other bleeding disease beside hemophilia A (i.e., von Willebrand disease)"
NCT00623727:I.2004,"Renal dysfunction"
NCT00623727:I.2005,"Elevated hepatic transaminases"
NCT00623727:I.2006,"Subjects on treatment with immunomodulatory agents within the last 3 months prior to study entry or during the study"
NCT00623727:I.2007,"Subjects with known hypersensitivity to the active substance, mouse or hamster protein, liposomes or polyethyleneglycol (PEG)"
NCT00623727:I.2008,"Subjects who require any pre-medication for FVIII injections"
NCT00624338:I.1001,"age at least 16 Years"
NCT00624338:I.1002,"Disease history of at least six months meeting at least 4 ACR criteria for SLE"
NCT00624338:I.1003,"BILAG flare A or B at screening requiring a change in corticosteroids"
NCT00624338:I.1004,"a positive ANA or anti-dsDNA at screening"
NCT00624338:I.1005,"Female subjects must be willing to avoid pregnancy"
NCT00624338:I.2001,"Active moderate to severe glomerulonephritis (kidney impairment)"
NCT00624338:I.2002,"Active central nervous system SLE deemed to be severe/progressive"
NCT00624338:I.2003,"Previous treatment with rituximab, abatacept, or belimumab"
NCT00624338:I.2004,"History of demyelinating disease or optic neuritis"
NCT00625898:I.1001,"age at least 18 Years"
NCT00625898:I.1002,"Life expectancy of at least 10 years, excluding their diagnosis of breast cancer."
NCT00625898:I.1003,"Women who have had breast reconstruction utilizing tissue expanders must be in agreement with delaying surgery to replace the tissue expanders with permanent implants until 3 months following the last dose of bevacizumab"
NCT00625898:I.1004,"Women of reproductive potential must agree to use an effective non-hormonal method of contraception (for example condoms, some intrauterine devices, diaphragms, vasectomized partner, or abstinence) during therapy and for at least 6 months after the last dose of bevacizumab and/or trastuzumab."
NCT00625898:I.1005,"Submission of tumor samples from the breast surgery for central HER2 testing is required for all patients prior to enrollment in the BETH Trial"
NCT00625898:I.1006,"Signed and dated IRB/EC-approved consent"
NCT00625898:I.1007,"ECOG performance status finding<= 1"
NCT00625898:I.1008,"The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination."
NCT00625898:I.1009,"The breast cancer must be HER2-positive based on test results as follows: Local testing (if available) should demonstrate that the tumor is IHC 2+ or 3+ or is considered to be HER2-positive for gene amplification by FISH, CISH, or other in situ hybridization (ISH) method. If local ISH test results are considered equivocal, the tumor can be submitted for central HER2 testing. (If local testing is not possible, the tumor can be submitted for central HER2 testing.) Central testing (a requirement for ALL patients) must demonstrate that the tumor is HER2-positive which is defined as FISH-positive and/or IHC 3+."
NCT00625898:I.1010,"All of the following staging criteria (according to the 6th edition of the AJCC Cancer Staging Manual) must be met: By pathologic evaluation, primary tumor must be pT1-3. By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b. If pN0, at least one of the following criteria must be met: Pathologic tumor size>2.0 cm. ER negative and PgR negative. Histologic and/or nuclear grade 2 (intermediate) or 3 (high). Or Age<35 years."
NCT00625898:I.1011,"Patients must have undergone either a total mastectomy or breast conserving surgery (lumpectomy)."
NCT00625898:I.1012,"For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional operative procedures may be performed to obtain clear margins. If tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. (Patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection.)"
NCT00625898:I.1013,"For patients who undergo mastectomy, margins must be free of gross residual tumor. Patients with microscopic positive margins are eligible."
NCT00625898:I.1014,"Patients must have completed one of the following procedures for evaluation of pathologic nodal status: Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes if the sentinel node (SN) is positive. Sentinel lymphadenectomy alone if pathologic nodal staging based on sentinel lymphadenectomy is pN0, pN1mi or pN1b. Or Axillary lymphadenectomy without SN isolation procedure."
NCT00625898:I.1015,"The interval between the last surgery for breast cancer (treatment or staging) and randomization must be at least 28 days but no more than 84 days."
NCT00625898:I.1016,"Patients must have ER analysis performed on the primary tumor prior to randomization. If ER analysis is negative, then PgR analysis must also be performed."
NCT00625898:I.1017,"The most recent postoperative blood counts, performed within 6 weeks prior to randomization, must meet the following criteria: ANC must be>= 1200/mm3. Platelet count must be>= 100,000/mm3. And Hemoglobin must be>= 10 g/dL."
NCT00625898:I.1018,"and alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab"
NCT00625898:I.1019,"Patients with AST or alkaline phosphatase>ULN are eligible for inclusion in the study if liver imaging (CT, MRI, PET scan, or PET-CT scan performed within 3 months prior to randomization) does not demonstrate metastatic disease and the requirements for evidence of adequate hepatic function are met."
NCT00625898:I.1020,"Patients with alkaline phosphatase that is>ULN but<= 2.5 x ULN are eligible for inclusion in the study if a bone scan,PET scan, or PET-CT scan (performed within 3 months prior to randomization) does not demonstrate metastatic disease."
NCT00625898:I.1021,"The following criteria for renal function must be met based on the results of the most recent postoperative tests performed within 6 weeks prior to randomization: Serum creatinine must be<= ULN for the lab. Measured or calculated creatinine clearance must be>60 mL/min."
NCT00625898:I.1022,"A urine sample must be tested for protein by determination of the urine protein/creatinine (UPC) ratio or by urine dipstick. UPC ratio must be<1.0. Urine dipstick must indicate 0-1+ protein. If dipstick reading is>= 2+, determine the UPC ratio, which must be<1.0, or collect a 24-hour urine specimen, which must demonstrate<1.0 g of protein per 24 hours."
NCT00625898:I.1023,"LVEF assessment must be performed within 3 months prior to randomization. The LVEF must be>= 55% regardless of the cardiac imaging facility's lower limit of normal (LLN)."
NCT00625898:I.1024,"supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication"
NCT00625898:I.2001,"Inflammatory Breast Carcinoma, Mastitis carcinomatosa"
NCT00625898:I.2002,"Definitive clinical or radiologic evidence of metastatic disease. (Chest imaging [mandatory for all patients] and other imaging [if required]must have been performed within 3 months prior to randomization.)"
NCT00625898:I.2003,"Synchronous or previous contralateral invasive breast cancer (Patients with synchronous or previous contralateral DCIS or LCIS are eligible)."
NCT00625898:I.2004,"History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral DCIS treated with excision and RT. (Patients with history of ipsilateral LCIS are eligible.)"
NCT00625898:I.2005,"History of non-breast malignancies within the 5 years prior to study entry, except for the following: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin."
NCT00625898:I.2006,"Previous therapy with anthracyclines, taxanes, carboplatin, trastuzumab, or bevacizumab for any malignancy."
NCT00625898:I.2007,"RT, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to randomization."
NCT00625898:I.2008,"Continued therapy with any hormonal agent such as raloxifene or tamoxifen (or other SERM) or an aromatase inhibitor. (Patients are eligible if these medications are discontinued prior to randomization.)"
NCT00625898:I.2009,"Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy, etc. Patients are eligible if these medications are discontinued prior to randomization."
NCT00625898:I.2010,"Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens. This includes but is not confined to: Active cardiac disease - angina pectoris that requires the use of anti-anginal medication. Ventricular arrhythmias except for benign premature ventricular contractions. Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication. Conduction abnormality requiring a pacemaker. Valvular disease with documented compromise in cardiac function. And symptomatic pericarditis. History of cardiac disease - myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function. History of documented CHF. And documented cardiomyopathy."
NCT00625898:I.2011,"Uncontrolled hypertension defined as systolic blood pressure (BP)>150 mmHg or diastolic BP>90 mmHg, with or without anti-hypertensive medication. (BP must be assessed within 28 days prior to randomization.) Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria."
NCT00625898:I.2012,"History of hypertensive crisis or hypertensive encephalopathy."
NCT00625898:I.2013,"History of TIA or CVA."
NCT00625898:I.2014,"History of any arterial thrombotic event within 12 months before randomization."
NCT00625898:I.2015,"Symptomatic peripheral vascular disease"
NCT00625898:I.2016,"Intrinsic lung disease resulting in dyspnea"
NCT00625898:I.2017,"Brittle diabetes"
NCT00625898:I.2018,"Active infection or chronic infection requiring chronic suppressive antibiotics."
NCT00625898:I.2019,"Any significant bleeding within 6 months before randomization, exclusive of menorrhagia in premenopausal women."
NCT00625898:I.2020,"Non-healing wound, skin ulcers, or incompletely healed bone fracture."
NCT00625898:I.2021,"Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy."
NCT00625898:I.2022,"Anticipation of need for major surgical procedures during study therapy and for at least 3 months following completion of bevacizumab."
NCT00625898:I.2023,"Gastroduodenal ulcer(s) documented by endoscopy to be active within 6 months before randomization."
NCT00625898:I.2024,"History of GI perforation, abdominal fistulae, or intra-abdominal abscess."
NCT00625898:I.2025,"Known bleeding diathesis or coagulopathy."
NCT00625898:I.2026,"Requirement for therapeutic doses of coumadin or equivalent."
NCT00625898:I.2027,"Sensory/motor neuropathy>= grade 2, as defined by the NCI CTCAE v3.0."
NCT00625898:I.2028,"Conditions that would prohibit administration of corticosteroids."
NCT00625898:I.2029,"Chronic daily treatment with corticosteroids (dose of>10 mg/day methylprednisolone equivalent) (excluding inhaled steroids)."
NCT00625898:I.2030,"History of hypersensitivity reaction to drugs formulated with polysorbate 80."
NCT00625898:I.2031,"Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 14 days prior to randomization according to institutional standards for women of child-bearing potential.)"
NCT00625898:I.2032,"Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up."
NCT00625898:I.2033,"Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements."
NCT00625898:I.2034,"Use of any investigational product within 4 weeks prior to enrollment in the study."
NCT00626548:I.1001,"18 Years and older"
NCT00626548:I.1002,Male
NCT00626548:I.1003,"Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT spread to the other parts of the body (metastases). Patients with lymph node involvement may be eligible if specified criteria is met."
NCT00626548:I.1004,"Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment"
NCT00626548:I.1005,"Currently receiving treatment with surgical or medical castration"
NCT00626548:I.2001,"Currently using opiate based pain killers for cancer related pain"
NCT00626548:I.2002,"Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial"
NCT00626548:I.2003,"Suffering from heart failure or had a myocardial infarction within last 6 months"
NCT00626548:I.2004,"A history of epilepsy or seizures"
NCT00628745:I.1001,"age at least 18 Years"
NCT00628745:I.1002,"Written informed consent."
NCT00628745:I.1003,"Patient has confirmed: genotyped TTR mutation with or without a diagnosis of TTR-associated amyloidosis (e.g., ATTR-PN, ATTR-CM), or Wild-type TTR-associated amyloidosis with cardiomyopathy (wild-type ATTR-CM)."
NCT00628745:I.1004,
NCT00628745:I.1005,"A. Presence of amyloid in cardiac biopsy tissue confirmed as TTR amyloid by immunohistochemistry and genotyped confirmation that patient does not possess a known mutation in TTR gene (i.e., is a carrier of wild-type allele only) via genetic testing"
NCT00628745:I.1006,"B. Evidence of cardiac involvement by echocardiogram as defined by mean left ventricle wall thickness of>12 mm, and presence of amyloid in non-cardiac tissue confirmed as TTR amyloid by immunohistochemistry, and genotyped confirmation that patient does not possess a known mutation in TTR gene (i.e., is a carrier of wild-type allele only) via genetic testing."
NCT00628745:I.2001,"Patient has primary or secondary amyloidosis."
NCT00630864:I.1001,"age 18 Years to 75 Years"
NCT00630864:I.1002,"Patient has amyloid documented by biopsy (in accordance with institutional site standard of care)."
NCT00630864:I.1003,"Patient has documentation of one of the following targeted TTR mutations: Ser77Tyr, Thr60Ala, Tyr114Cys, Leu58His, Glu89Gln, Ser77Phe, Thr49Ala, Ile107Val, Val30Ala, Gly47Ala, Gly47Glu, Leu55Arg, Lys70Asn, Ile84Thr, Ile107Met. Patients with mutations other than those listed may be enrolled only after approval by the Sponsor."
NCT00630864:I.1004,"Patient has peripheral and/or autonomic neuropathy and/or cardiomyopathy with a Karnofsky Performance Status>= 50."
NCT00630864:I.1005,"If female, patient is post-menopausal, surgically sterilized, or willing to use two acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study and for 3 months from the end of the study. (A condom alone is not considered an acceptable method of birth control.) If male with a female partner of childbearing potential, willing to use two acceptable methods of birth control for the duration of the study. For both females and males, acceptable birth control must be used for at least 3 months after the last dose of study medication."
NCT00630864:I.1006,"Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements."
NCT00630864:I.2001,"Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as>3-4 times/month (ibuprofen and nimesulide will be permitted)."
NCT00630864:I.2002,"Patient has primary or secondary amyloidosis."
NCT00630864:I.2003,"Patient has TTR-associated amyloidosis with V30M mutation."
NCT00630864:I.2004,"If female, patient is pregnant or breast feeding."
NCT00630864:I.2005,"Patient has received prior liver transplantation."
NCT00630864:I.2006,"Patient is expected to undergo liver transplantation within 12 months after enrollment."
NCT00630864:I.2007,"Patient with positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV)."
NCT00630864:I.2008,"Patient has renal insufficiency (creatinine clearance<30 ml/min)."
NCT00630864:I.2009,"Patient has liver function test abnormalities: alanine transaminases (ALT) and/or aspartate transaminases (AST)>2 times upper limit of normal (ULN) that in the medical judgment of the investigator are due to reduced liver function or active liver disease."
NCT00630864:I.2010,"Patient has a New York Heart Association (NYHA) Functional Classification>=  III."
NCT00630864:I.2011,"Patient has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic inflammatory diseases)."
NCT00630864:I.2012,"Patient has prior non-amyloid cardiac disease such as: myocardial infarction due to obstructive coronary artery disease, active non-amyloid cardiomyopathy (e.g., symptomatic left ventricular dysfunction from any cause other than amyloid, patients with a primary diagnosis of symptomatic valvular heart disease)"
NCT00630864:I.2013,"Patient has a co-morbidity anticipated to limit survival to<12 months."
NCT00630864:I.2014,"Patient has received an investigational drug/device and/or participated in another clinical investigational study within 60 days before Baseline (Day 0)."
NCT00632749:I.1001,"age at least 18 Years"
NCT00632749:I.1002,"Male or female adult with previously untreated acute myeloid leukaemia (AML)"
NCT00632749:I.1003,"Confirmed diagnosis of AML according to the WHO definition (except for acute promyelocytic leukaemia, APL)"
NCT00632749:I.1004,"Patient is considered ineligible for intensive treatment"
NCT00632749:I.1005,"Patient is eligible for low-dose cytarabine (LD-Ara-C) treatment"
NCT00632749:I.1006,"Life expectancy>3 months"
NCT00632749:I.1007,"Eastern co-operative oncology group (ECOG, R01-0787) performance score<=2 at screening"
NCT00632749:I.1008,"Signed written informed consent consistent with international conference on harmonisation good clinical practice (ICH-GCP) and local legislation"
NCT00632749:I.2001,"Patient with APL (AML subtype M3 according to the French-American-British (FAB) classification)."
NCT00632749:I.2002,"Relapsed or treatment refractory AML."
NCT00632749:I.2003,"Hypersensitivity to one of the trial drugs or the excipients."
NCT00632749:I.2004,"Other malignancy requiring treatment."
NCT00632749:I.2005,"Known central nervous system involvement."
NCT00632749:I.2006,"Aspartate amino transferase (AST) or alanine amino transferase (ALT)>2.5 times the upper limit of normal (ULN)."
NCT00632749:I.2007,"INR>1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin)."
NCT00632749:I.2008,Bilirubin
NCT00632749:I.2009,"Serum Creatinine Measurement"
NCT00632749:I.2010,"LVEF (Left ventricular ejection fraction)<50% in echocardiography or clinical congestive heart failure New York Heart Association (NYHA) grade III or IV."
NCT00632749:I.2011,"Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia."
NCT00632749:I.2012,"Psychiatric illness or social situation that would limit compliance with trial requirements."
NCT00632749:I.2013,"Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug (i.e. other chemo- or immunotherapy, see also section 4.2.2)."
NCT00632749:I.2014,"Contraindications for cytarabine treatment according to the summary of product characteristics (SPC)."
NCT00632749:I.2015,"Patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.)."
NCT00632749:I.2016,"Pregnant or nursing female patients."
NCT00632749:I.2017,"Patient unable to comply with the protocol."
NCT00635492:I.1001,"age at least 18 Years"
NCT00635492:I.1002,"diagnosed with type 2 diabetes"
NCT00635492:I.1003,"have had a treatment decision made within the normal course of care to initiate either insulin or exenatide for the treatment of type 2 diabetes"
NCT00635492:I.1004,"have not previously been treated with either insulin or exenatide"
NCT00635492:I.1005,"are not simultaneously participating in another study which includes an investigational drug or procedure at study entry"
NCT00635492:I.1006,"have been fully informed and given their written consent for use of their data"
NCT00635492:I.1007,"have sufficient understanding of the primary language of their country such that they will be able to complete the questionnaires."
NCT00637377:I.1001,"age at least 50 Years"
NCT00637377:I.1002,"Signed informed consent."
NCT00637377:I.1003,"Men and women>/=50 years of age."
NCT00637377:I.1004,"Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye."
NCT00637377:I.1005,"ETDRS best-corrected visual acuity of: 20/40 to 20/320 (letter score of 73 to 25) in the study eye at 4 meters."
NCT00637377:I.1006,"Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures."
NCT00637377:I.1007,"informed consent"
NCT00637377:I.2001,"Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD, except dietary supplements or vitamins."
NCT00637377:I.2002,"Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye."
NCT00637377:I.2003,"Any prior treatment with anti-VEGF agents in the study eye."
NCT00637377:I.2004,"Total lesion size>12 disc areas (30.5 mm, including blood, scars and neovascularization) as assessed by FA in the study eye."
NCT00637377:I.2005,"Subretinal hemorrhages that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye (if the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible CNV)."
NCT00637377:I.2006,"Scar or fibrosis making up>50% of the total lesion in the study eye."
NCT00637377:I.2007,"Scar, fibrosis, or atrophy involving the center of the fovea in the study eye."
NCT00637377:I.2008,"Presence of retinal pigment epithelial tears or rips involving the macula in the study eye."
NCT00637377:I.2009,"History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye."
NCT00637377:I.2010,"Presence of other causes of CNV in the study eye."
NCT00637377:I.2011,"Prior vitrectomy in the study eye."
NCT00637377:I.2012,"History of retinal detachment or treatment or surgery for retinal detachment in the study eye."
NCT00637377:I.2013,"Any history of macular hole of stage 2 and above in the study eye."
NCT00637377:I.2014,"Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of Day 1, as long as it is unlikely to interfere with the injection."
NCT00637377:I.2015,"History or clinical evidence of diabetic retinopathy, diabetic macular edema or any retinal vascular disease other than AMD in either eye."
NCT00639483:I.1001,"age 18 Years to 50 Years"
NCT00639483:I.1002,"Diagnosis of schizophrenia (according to Diagnostic and Statistical Manual of Mental Disorders [DSM]-IV-TR criteria and made by a specialist in psychiatry) and acute exacerbation of schizophrenia requiring hospitalization"
NCT00639483:I.1003,"Total PANSS score of ?60 at screening"
NCT00639483:I.1004,"History of schizophrenia of ?10 years (from onset of prodromal symptoms)"
NCT00639483:I.2001,"Axis-I DSM-IV-TR diagnosis other than schizophrenia"
NCT00639483:I.2002,"Less than a full cycle has lapsed at time of screening following the last injection of a depot antipsychotic"
NCT00639483:I.2003,"Currently taking celecoxib or other selective cyclo-oxygenase 2 inhibitors, or other antiinflammatory medication"
NCT00640016:I.1001,"age 18 Years to 80 Years"
NCT00640016:I.1002,"Informed consent"
NCT00640016:I.1003,"Female infertility or Contraceptive methods"
NCT00640016:I.1004,"partner using condom and subject using spermicide, diaphragm, intra-uterine device or contraceptive sponge) for 1 month prior to Visit 1 (screening visit) or longer if requested by the investigator. Women of childbearing potential must continue to practice birth control during the study and for at least 2 months after completing the study. Women of childbearing potential must have a negative pregnancy test at screening and Visit 2, 5, 7 and 9."
NCT00640016:I.1005,"Uncontrolled (refractory) asthma despite optimal treatment"
NCT00640016:I.1006,"subjects will have Global Initiative for Asthma (GINA 2006) clinical features of uncontrolled asthma despite treatment with a minimum dose of 800 µg beclomethasone dipropionate or equivalent inhaled corticosteroid per day plus one or more additional controller i.e. long-acting b-agonist, leukotriene antagonist or theophylline. Oral corticosteroids (not parenteral) as additional treatment at any dose are acceptable. The dose of inhaled and oral corticosteroids must have been stable within 4 weeks preceding Visit 1 (screening visit) and will be expected to remain stable for the duration of the study. If subjects are on single inhaler combination products at Visit 1 (e.g. fluticasone/salmeterol - Advair/Seretide or Symbicort (budesonide/formoterol) SMART) they must receive the two components as two separate inhaler medications for the purpose of the trial. This will facilitate withholding the long-acting b-agonist component before lung function and challenge testing (see Section 9.5.7). The GINA 2006 [14] levels of asthma control and treatment are described in Appendix 3."
NCT00640016:I.1007,"A forced expiratory volume in 1 second (FEV1) acceptable for AHR challenge tests (>= 60% of predicted normal) on the challenge days."
NCT00640016:I.1008,"A provocative concentration of methacholine causing a 20% fall in FEV1 (PC20)<= 4 mg/mL."
NCT00640016:I.1009,"Aged 18-80 years and are ambulatory and able to travel to the clinic.7. A 12-lead electrocardiogram (ECG) with no-clinically significant abnormalities."
NCT00640016:I.1010,"Clinical chemistry, haematology and urinalysis results within the laboratory reference ranges or deemed not clinically significant by the Investigator."
NCT00640016:I.1011,"Body weight (observable entity)"
NCT00640016:I.1012,"No other clinically significant abnormality on history and clinical examination (see also Exclusion Criteria)."
NCT00640016:I.1013,"Able to comply with the requirements of the protocol."
NCT00640016:I.2001,"Experienced a severe exacerbation within 28 days preceding Visit 1."
NCT00640016:I.2002,"Onset of uncontrolled seasonal allergy symptoms within 28 days preceding Visit 1. Subjects with a history of allergic rhinitis, seasonal allergy or oesophagitis must be optimally controlled and remain on a stable treatment regimen during the study."
NCT00640016:I.2003,"Participation in another study within five half lives or three months of the start of this study, whichever is the longer. This does not apply to methodological or observational studies in which no investigational medicinal product (IMP) was given."
NCT00640016:I.2004,"Lower respiratory tract infection within six weeks of Visit 1.5."
NCT00640016:I.2005,"Current smokers or ex-smokers with>10 pack-years (number of pack years = (number of cigarettes per day/20) x number of years smoked, e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)."
NCT00640016:I.2006,"Blood donation (>550 mL) in the previous two months."
NCT00640016:I.2007,"Excessive intake of alcohol (as judged by the Investigator) or evidence of drug or solvent abuse."
NCT00640016:I.2008,"Subjects with a physician-diagnosis of any other significant lung disease, including a primary diagnosis of chronic obstructive pulmonary disease or bronchiectasis, or lung cancer, sarcoidosis, tuberculosis, pulmonary fibrosis and cystic fibrosis."
NCT00640016:I.2009,"Concurrent medication from Visit 1 (screening visit) and for the duration of the study with any of the prohibited medications."
NCT00640016:I.2010,"Significant, uncontrolled disease including serious psychological disorders, chronic renal failure, uncontrolled hypertension"
NCT00640016:I.2011,"hypertension heart disease psoriasis or stroke"
NCT00640016:I.2012,"Onset of uncontrolled seasonal allergy symptoms within 28 days preceding Visit 1. Subjects with a history of allergic rhinitis, seasonal allergy or oesophagitis must be optimally controlled and remain on a stable treatment regimen during the study."
NCT00640016:I.2013,"Any factor which, in the opinion of the Investigator, would jeopardise the evaluation or safety or be associated with poor adherence to the protocol (i.e. inability to complete study diary, perform PEF measurements)."
NCT00640016:I.2014,"The subject's primary care physician recommends the subject should not take part in the study."
NCT00640016:I.2015,"Known hypersensitivity to CAT-354 or its components, to the challenge agents used in the study or to related drugs."
NCT00641056:I.1001,"age at least 18 Years"
NCT00641056:I.1002,"Has type 2 diabetes and at least 18 years of age at screening."
NCT00641056:I.1003,"Hemoglobin A1c (HbA1c) of 7.1% to 11.0%, inclusive, at screening."
NCT00641056:I.1004,"Body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening."
NCT00641056:I.1005,"Have a history of stable body weight (not varying by>5% for at least 3 months prior to screening)."
NCT00641056:I.1006,"Have been treated with metformin(Met) for at least 3 months and have been taking a stable dose for at least 8 weeks prior to screening OR"
NCT00641056:I.1007,"Have been treated with metformin(Met) for at least 3 months and have been taking a stable dose for at least 8 weeks prior to screening and have been treated with SU for at least 3 months and have been taking a stable dose of at least an optimally effective dose of brand of SU for 8 weeks prior to screening."
NCT00641056:I.2001,"Have had a clinically significant history of cardiac disease or presence of active cardiac disease within the year prior to inclusion in the study, including myocardial infarction, clinically significant arrhythmia, unstable angina, moderate to severe congestive heart failure, coronary artery bypass surgery, or angioplasty. or is expected to require coronary artery bypass surgery or angioplasty during the course of the study."
NCT00641056:I.2002,"Have clinical signs or symptoms of liver disease, acute or chronic hepatitis."
NCT00641056:I.2003,"Have a history of renal transplantation or are currently receiving renal dialysis."
NCT00641056:I.2004,"Have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years."
NCT00641056:I.2005,"Have had>3 episodes of major hypoglycemia within 6 months prior to screening."
NCT00641056:I.2006,"Have any contraindication for the oral antidiabetic agent which they use."
NCT00641056:I.2007,"Have a known allergy or hypersensitivity to insulin glargine, exenatide once weekly, or excipients contained in these agents."
NCT00641056:I.2008,"Are known to have active proliferative retinopathy."
NCT00641056:I.2009,"Have been treated with drugs that promote weight loss (e.g., Xenical [orlistat], Meridia [sibutramine], Acomplia [rimonabant], Acutrim [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening."
NCT00641056:I.2010,"Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening:"
NCT00641056:I.2011,"Insulin, regular insulin"
NCT00641056:I.2012,"Thiazolidinediones (e.g., Actos [pioglitazone] or Avandia [rosiglitazone])"
NCT00641056:I.2013,"Alpha-glucosidase inhibitors (e.g., Glyset [miglitol] or Precose [acarbose])"
NCT00641056:I.2014,"Meglitinides (e.g., Prandin [repaglinide] or Starlix [nateglinide])."
NCT00641056:I.2015,"Byetta (exenatide BID formulation)"
NCT00641056:I.2016,"Dipeptidyl peptidase (DPP)-4 inhibitors (e.g., Januvia [sitagliptin], Galvus  [vildagliptin])"
NCT00641056:I.2017,"Symlin, Pramlintide Acetate"
NCT00641056:I.2018,"Organ Transplantation, Organ Transplant"
NCT00641056:I.2019,"Have donated blood within 30 days of screening."
NCT00641056:I.2020,"Have previously completed or withdrawn from this study or any other study investigating exenatide once weekly."
NCT00641056:I.2021,"Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry."
NCT00641056:I.2022,"Are currently enrolled in any other clinical study."
NCT00642941:I.1001,"age at least 2 Years"
NCT00642941:I.1002,"progressive, recurrent or refractory Ewing's sarcoma, or recurrent or refractory osteosarcoma, synovial sarcoma, rhabdomyosarcoma, or other sarcomas of the following sub-types: alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma and myxoid liposarcoma."
NCT00642941:I.2001,"clinically significant unrelated systemic illness which would compromise the patient's ability to tolerate the investigational agent, or interfere with the study procedures or results"
NCT00642941:I.2002,"known hypersensitivity to any of the components of R1507 or prior hypersensitivity reactions to monoclonal antibodies"
NCT00642941:I.2003,"current or previous treatment (within last 6 months) with chronic pharmacological doses of corticosteroids, immunosuppressive agents or medications that inactivate or may interfere with the pharmacological activity of R1507"
NCT00642941:I.2004,"current or prior therapy with IGF inhibitor (monoclonal or specific kinase inhibitor)"
NCT00642941:I.2005,"history of solid organ transplant"
NCT00642941:I.2006,"other malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer."
NCT00643565:I.1001,"age 6 Months to 18 Years"
NCT00643565:I.1002,"childhood and adolescent patients"
NCT00643565:I.1003,"metastatic rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma"
NCT00643565:I.1004,"adequate bone marrow function"
NCT00643565:I.1005,"adequate renal and liver function"
NCT00643565:I.1006,"adequate blood clotting"
NCT00643565:I.2001,"previous malignant tumors"
NCT00643565:I.2002,"tumor invading major blood vessels"
NCT00643565:I.2003,"prior systemic anti-tumor treatment"
NCT00655252:I.1001,"age at least 18 Years"
NCT00655252:I.1002,"metastatic renal cancer, intolerant of or failed sunitinib and/or sorafenib"
NCT00655252:I.1003,"Adequate bone marrow function, liver function, renal function"
NCT00655252:I.1004,"Adequate birth control"
NCT00655252:I.1005,"Other protocol-defined inclusion criteria may apply"
NCT00655252:I.2001,"Previously received RAD001 or other mTOR inhibitors, known hypersensitivity to rapamycin, chronic systemic treatment with corticosteroids or immunosuppressive agents (prednisone<= 20 mg/day for adrenal insufficiency OK"
NCT00655252:I.2002,"Topical or inhaled steroids OK)"
NCT00655252:I.2003,"Active bleeding"
NCT00655252:I.2004,"Uncontrolled angina, CHF, heart attack<= 6 months, uncontrolled diabetes"
NCT00655252:I.2005,"Other protocol-defined exclusion criteria may apply"
S.NCT00661609:I.1001,"Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra)."
S.NCT00661609:I.1002,"Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy"
S.NCT00661609:I.1003,"Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting."
S.NCT00661609:I.1004,"Ambulatory and capable of all selfcare more than 50% of waking hours"
S.NCT00661609:I.2001,"Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study medication; 6 weeks if prior systemic mitomycin, nitrosourea, or suramin."
S.NCT00661609:I.2002,"Inadequate bone marrow reserve"
S.NCT00661609:I.2003,"Inadequate liver function in the presence of liver metastases"
S.NCT00661609:I.2004,"Impaired renal function"
NCT00661609:I.1001,"Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra)"
NCT00661609:I.1002,"Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy"
NCT00661609:I.1003,"Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting"
NCT00661609:I.1004,"Ambulatory and capable of all selfcare more than 50% of waking hours"
NCT00661609:I.2001,"Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study medication, 6 weeks if prior systemic mitomycin, nitrosourea, or suramin."
NCT00661609:I.2002,"Inadequate bone marrow reserve"
NCT00661609:I.2003,"Inadequate liver function in the presence of liver metastases"
NCT00661609:I.2004,"Impaired renal function"
NCT00662714:I.1001,"age at least 10 Years"
NCT00662714:I.1002,"Diagnosed cystic fibrosis"
NCT00662714:I.1003,"Newly diagnosed Diabetes mellitus in the screening"
NCT00662714:I.2001,"Diabetic keto-acidosis (blood glucose>350 mg/dl and arterial pH<7.25)"
NCT00662714:I.2002,"Already treated Diabetes mellitus by oral antidiabetic medication or insulin"
NCT00662714:I.2003,"Systemic steroid therapy during the last 3 months"
NCT00662714:I.2004,"Transplantation (status post TX or on the waiting list for TX)"
NCT00662714:I.2005,"Beginning pulmonary insufficiency, FEV1<35% at pulmonary function test in stable condition"
NCT00662714:I.2006,"Pregnancy, Gestation"
NCT00662714:I.2007,"Already diagnosed and treated diabetes mellitus"
NCT00662714:I.2008,"Patients with diabetic keto-acidosis (blood glucose>350 mg/dl and arterial pH<7.25) with or without diabetic coma"
NCT00662714:I.2009,"Severe liver insufficiency (chronic hepatitis B, AST or ALT twice the upper limit of normal, Quick's value<70% which is a contraindication to use Repaglinide)"
NCT00662714:I.2010,"Treatment with an indispensable important drug which contraindicates Repaglinide"
NCT00662714:I.2011,"PEG/ gastric tube/ total parenteral alimentation for more than 4 weeks during the study"
NCT00662714:I.2012,"CF-patients with type 1 diabetes"
NCT00662714:I.2013,"Not patient's consent to randomisation and therapeutic trial"
NCT00662714:I.2014,"Participation on other medical trial"
NCT00662922:I.1001,"age 18 Years to 80 Years"
NCT00662922:I.2001,"clinical diagnosis of diabetes mellitus"
NCT00662922:I.2002,"brain injury of any kind prior to or upon ICU-admission"
NCT00662922:I.2003,"pre-existing mental or psychiatric disorder"
NCT00662922:I.2004,"terminal kidney or liver failure prior admission"
NCT00662922:I.2005,"Drug abuse"
NCT00662922:I.2006,"CPR>5 min"
NCT00662922:I.2007,"Human immunodeficiency virus"
NCT00662922:I.2008,syphilis
NCT00663364:I.1001,"age at least 18 Years"
NCT00663364:I.1002,Eczema
NCT00663364:I.1003,"Willing to apply skin care for 2 to 4 weeks, twice daily"
NCT00663364:I.1004,"Willing to fulfill questionnaires / home diaries: self-perception of roughness of the skin, desquamation of the skin, lack of skin brightness, feelings of tension and itching"
NCT00663364:I.2001,"Participation in any other research study during the previous 4 weeks."
NCT00663364:I.2002,"Previous participation in this study."
NCT00663364:I.2003,"Concurrent participation in any other research study involving an investigational product."
NCT00663364:I.2004,"Current need for the use of topical steroids."
NCT00663364:I.2005,"History of skin disease or allergy likely to interfere with the study or known sensitivity to the test product or its ingredients."
NCT00663364:I.2006,"Subjects considered unable or unlikely to fulfill diaries."
NCT00663364:I.2007,"Employees of (CRO) or Stiefel Laboratories, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee."
NCT00663364:I.2008,"History of neoplastic disease"
NCT00663364:I.2009,"Recent immunization (<10 days prior to the use of the test product)."
NCT00663858:I.1001,"age at least 50 Years"
NCT00663858:I.1002,"Benign Prostatic Hyperplasia, based on medical history"
NCT00663858:I.1003,"Voiding symptoms"
NCT00663858:I.2001,"Urgent need for prostate surgery or prior surgical treatment of the prostate or bladder"
NCT00663858:I.2002,"Major organ dysfunction"
NCT00663858:I.2003,"Eczema (atopic dermatitis) treated during the last 6 months"
NCT00663858:I.2004,"Current or recent treatment with sexual hormone drugs or 5 alpha reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior randomization or with alpha blockers or saw palmetto within the last 6 weeks prior to randomization"
NCT00663858:I.2005,"Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy"
NCT00663858:I.2006,"History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months"
NCT00669708:I.1001,"age at least 18 Years"
NCT00669708:I.1002,"itch over VAS 3"
NCT00669708:I.2001,"Pregnant or lactating women"
NCT00669708:I.2002,"Drug abuse"
NCT00669708:I.2003,"active psychosomatic and psychiatric disease"
NCT00669708:I.2004,"active cancer"
NCT00669708:I.2005,"topical application of tacrolimus, pimecrolimus, corticosteroids or capsaicin two weeks before study start"
NCT00669708:I.2006,"intake of antihistamines, corticosteroids, cyclosporine A and other immunosuppressants, naltrexone, UV-therapy two weeks before study start"
NCT00669708:I.2007,"participation in any other research study during the previous 4 weeks"
NCT00673647:I.1001,"age at least 16 Years"
NCT00673647:I.1002,"Cannabis Use Disorders"
NCT00673647:I.1003,"motivation to change cannabis use"
NCT00673647:I.1004,"current (12 mth) regular cannabis use (at least 2 days a week)"
NCT00673647:I.1005,"informed consent to the study procedures and assessments"
NCT00673647:I.2001,"current alcohol or any illicit drug dependence syndrome according to DSM-IV other than due to cannabis"
NCT00673647:I.2002,"lifetime history of any psychotic disorder"
NCT00673647:I.2003,"current severe episode of Major depression"
NCT00673647:I.2004,"current panic-agoraphobic disorder (severe)"
NCT00673647:I.2005,"severe learning disability, brain damage or pervasive developmental disorder"
NCT00673647:I.2006,"currently acute suicidality"
NCT00673647:I.2007,"not fluent in german language"
NCT00673647:I.2008,"any other current treatment for cannabis use disorders"
NCT00679419:I.1001,"age at least 18 Years"
NCT00679419:I.1002,"Women and men"
NCT00679419:I.1003,"Patients with actually performed interventional coronary angiography and there a documented coronary heart disease, defined as at least one documented stenosis>= 50 % in at least one main coronary vessel (Main stem RCX, RIVA, RCA)"
NCT00679419:I.1004,"European/Caucasian descent (European/Caucasian parents and grandparents)"
NCT00679419:I.1005,"Availability of an urine, serum- and EDTA blood sample of the patient"
NCT00679419:I.1006,"Documented consent of patients for handling of personal medical data, including a genetic analysis"
NCT00679419:I.2001,"Patients who have been already recruited into this registry"
NCT00679419:I.2002,"Patients with organ transplantations, apart from kidney transplantations"
NCT00679419:I.2003,"Immunosuppressive therapy, apart from immunosuppressive therapy after kidney transplantation"
NCT00679419:I.2004,"Polycystic Kidney Diseases"
NCT00679419:I.2005,"Pregnant and breastfeeding patients"
NCT00679419:I.2006,"Known malignant tumor"
NCT00679731:I.1001,"age at least 18 Years"
NCT00679731:I.1002,"Diagnosis of Psoriasis for 6 MO.. BSA 10%, PASI>= 12, PGA>= 3"
NCT00679731:I.2001,"Previous exposure to anti-IL 12"
NCT00680550:I.1001,"age at least 18 Years"
NCT00680550:I.1002,"Patient implanted or scheduled for an implant with a Reveal XT Insertable Cardiac Monitor System for arrhythmia diagnosis or monitoring"
NCT00680550:I.1003,"Patient must be willing to sign a Patient Data Release Form (or Informed Consent where applicable)"
NCT00680550:I.2001,"Enrollment outside a 30-day window from the planned/performed Reveal XT implant procedure (from 15 days pre-implant until 15 days post implant)"
NCT00680550:I.2002,"Patient is implanted with a pacemaker, ICD, CRT-device or an implantable hemodynamic monitoring system"
NCT00680550:I.2003,"Unwillingness or inability to cooperate or give written informed consent or, if the patient is a minor and the legal guardian refuses to give consent"
NCT00682396:I.1001,"age 18 Years to 65 Years"
NCT00682396:I.1002,"Disease: cytologically proven"
NCT00682396:I.1003,"primary or therapy related myelodysplastic syndrome (MDS) either as"
NCT00682396:I.1004,"refractory anaemia (RA) according FAB or RA with or without dysplasia  according WHO"
NCT00682396:I.1005,"refractory anaemia with ringsideroblasts (RARS) according FAB or RARS with  or without dysplasia according WHO"
NCT00682396:I.1006,"refractory anaemia with excess of blasts (RAEB) according FAB or RAEB I or  RAEB II according WHO"
NCT00682396:I.1007,"refractory anaemia with excess of blast in transformation (RAEB-T)  according FAB"
NCT00682396:I.1008,"CMML (dysplastic type) according WHO"
NCT00682396:I.1009,"Secondary Acute Myeloid Leukemia"
NCT00682396:I.1010,"Blast count<20 percent in bone marrow with or without chemotherapy at time of transplantation"
NCT00682396:I.1011,"Patient eligible for standard and dose-reduced conditioning as per local guideline"
NCT00682396:I.1012,"Patient age 18-60 years if donor is a HLA-matched UNRELATED donor (HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1) (one mismatch allowed)"
NCT00682396:I.1013,"Patient age 18-65 years if donor is a HLA-matched RELATED donor (HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1)(one antigen-mismatch allowed)"
NCT00682396:I.1014,"no major organ dysfunction"
NCT00682396:I.1015,"written informed consent of the patient"
NCT00682396:I.2001,"Blasts>20% in bone marrow at time of transplantation"
NCT00682396:I.2002,"no written informed consent"
NCT00682396:I.2003,"Central nervous system (CNS) involvement status"
NCT00682396:I.2004,"Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as"
NCT00682396:I.2005,"total bilirubin, SGPT or SGOT>2 times upper the normal level"
NCT00682396:I.2006,"LVEF - Left ventricular ejection fraction"
NCT00682396:I.2007,"Creatinine clearance (CrCl)  measurement"
NCT00682396:I.2008,"DLCO<35% and/or receiving supplementary continuous oxygen"
NCT00682396:I.2009,"Positive serology for HIV"
NCT00682396:I.2010,"pregnant or lactating women"
NCT00682396:I.2011,"patients with a life-expectancy of<6 months because of another debilitating disease"
NCT00682396:I.2012,"serious psychiatric or psychological disorders"
NCT00682396:I.2013,"invasive fungal infection at time of registration"
NCT00683930:I.1001,"age 18 Years to 70 Years"
NCT00683930:I.1002,"Adulthood (qualifier value)"
NCT00683930:I.1003,"Diagnosis of mild to moderate pemphigus vulgaris within the past 12 months, requiring high dose corticosteroids"
NCT00683930:I.2001,"Female patients who are pregnant, breastfeeding, or lactating"
NCT00683930:I.2002,"Regularly scheduled plasma exchange (PE) or intravenous immunoglobulin (IVIG) treatment, or PE or IVIG treatment within 8 weeks prior to randomization"
NCT00683930:I.2003,"CellCept or other immunosuppressive therapy, except corticosteroids, exceeding 2 weeks total duration and within 8 weeks prior to randomization"
NCT00683930:I.2004,"Use of PV therapies other than those noted above, within 4 weeks prior to randomization"
NCT00683930:I.2005,"Use of topical corticosteroids within 2 weeks prior to randomization"
NCT00684619:I.1001,"age at least 18 Years"
NCT00684619:I.1002,"T-ALL, T-NHL"
NCT00684619:I.1003,"cytological treatment failure / relapse"
NCT00684619:I.1004,"molecular treatment failure / relapse"
NCT00684619:I.1005,"no promising therapy alternatives with approved medication available"
NCT00684619:I.1006,"no CNS-manifestation, requiring intrathecal therapy or CNS-radiation"
NCT00684619:I.1007,"no convulsive disease or neurotoxicity>grade III in patients history"
NCT00684619:I.1008,"written informed consent"
NCT00684619:I.1009,"no cytostatic therapy in the last 10 days"
NCT00684619:I.1010,"no pregnancy or breastfeeding"
NCT00684619:I.1011,"Contraception, Birth control"
NCT00684619:I.1012,"recovery of toxicities of previous chemotherapy - except leukemia-related changes like bone marrow suppression or pathological transaminases in liver manifestation"
NCT00684619:I.2001,"Severe psychiatric illness"
NCT00684619:I.2002,"uncontrolled or severe cardiac disease or infection"
NCT00684619:I.2003,"active secondary neoplasms - except skin cancer (no melanoma)"
NCT00688753:I.1001,"Age at least 18 Years"
NCT00688753:I.1002,"Patients with metastatic papillary renal cell carcinoma, type I or II"
NCT00688753:I.1003,"Patients with at least one measurable lesion"
NCT00688753:I.1004,"ECOG performance status finding<= 1"
NCT00688753:I.1005,"Adequate bone marrow function"
NCT00688753:I.1006,"Adequate liver function"
NCT00688753:I.1007,"Adequate renal function"
NCT00688753:I.1008,"Adequate lipid profile"
NCT00688753:I.2001,"Patients who had radiation therapy within 28 days prior to start of study."
NCT00688753:I.2002,"Patients who have received prior systemic treatment for their metastatic RCC."
NCT00688753:I.2003,"Patients who received prior therapy with VEGF pathway inhibitor."
NCT00688753:I.2004,"Patients who have previously received systemic mTOR inhibitors."
NCT00688753:I.2005,"Patients with a known hypersensitivity everolimus or other rapamycins or to its excipients."
NCT00688753:I.2006,"Patients with uncontrolled central nervous system (CNS) metastases."
NCT00688753:I.2007,"Patients receiving chronic systemic treatment with corticosteroids or another immunosuppressive agent."
NCT00688753:I.2008,"Patients with a known history of HIV seropositivity."
NCT00688753:I.2009,"Autoimmune Hepatitis"
NCT00688753:I.2010,"Patients with an active, bleeding diathesis."
NCT00688753:I.2011,"Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study."
NCT00688753:I.2012,"Patients who have a history of another primary malignancy and off treatment ? 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the uterine cervix."
NCT00688753:I.2013,"Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods."
NCT00688753:I.2014,"Patients who are using other investigational agents or who had received investigational drugs ? 4 weeks prior to study treatment start."
NCT00688753:I.2015,"Patients unwilling to or unable to comply with the protocol."
NCT00689936:I.1001,"Must understand and voluntarily sign informed consent form"
NCT00689936:I.1002,"Age ? 18 years at the time of signing consent"
NCT00689936:I.1003,"Previously untreated, symptomatic multiple myeloma as defined by the 3 criteria below:"
NCT00689936:I.1004,"MM diagnostic criteria (all 3 required)"
NCT00689936:I.1005,"Monoclonal plasma cells in the bone marrow ?10% and/or presence of a biopsy-proven plasmacytoma"
NCT00689936:I.1006,"Monoclonal protein present in the serum and/or urine"
NCT00689936:I.1007,"Myeloma-related organ dysfunction (at least one of the following) [C] Calcium elevation in the blood (serum calcium>10.5 mg/dl or upper limit of normal) [R] Renal insufficiency (serum creatinine>2 mg/dl) [A] Anemia (hemoglobin<10 g/dl or 2 g<laboratory normal) [B] Lytic bone lesions or osteoporosis"
NCT00689936:I.1008,"AND have measurable disease by protein electrophoresis analyses as defined by the following"
NCT00689936:I.1009,"IgG multiple myeloma: Serum monoclonal paraprotein (M-protein) level ? 1.0 g/dl or urine M-protein level ? 200 mg/24 hours"
NCT00689936:I.1010,"IgA multiple myeloma: Serum M-protein level ? 0.5 g/dl or urine M-protein level ? 200 mg/24 hours"
NCT00689936:I.1011,"IgM multiple myeloma (IgM M-protein plus lytic bone disease documented by skeletal survey plain films): Serum M-protein level ? 1.0 g/dl or urine M-protein level ? 200mg/24hours"
NCT00689936:I.1012,"IgD multiple myeloma: Serum M-protein level ? 0.05 g/dl or urine M-protein level ? 200 mg/24 hours"
NCT00689936:I.1013,"Light chain multiple myeloma: Serum M-protein level ? 1.0 g/dl or urine M-protein level ? 200 mg/24 hours"
NCT00689936:I.1014,"AND are at least 65 years of age or older or, if younger than 65 years of age, are not candidates for stem cell transplantation because"
NCT00689936:I.1015,"The patient declines to undergo stem cell transplantation or"
NCT00689936:I.1016,"Stem cell transplantation is not available to the patient due to cost or other reasons"
NCT00689936:I.1017,"ECOG performance status finding<= 2"
NCT00689936:I.1018,"Able to adhere to the study visit schedule and other protocol requirements"
NCT00689936:I.1019,"Females of child-bearing potential (FCBP)^2"
NCT00689936:I.1020,"Must agree to undergo two medically supervised pregnancy tests prior to starting study therapy with either Rd or MPT. The first pregnancy test will be performed within 10-14 days prior to the start of Rd or MPT and the second pregnancy test will be performed within 24 hours prior to the start of Rd or MPT. She must also agree to ongoing pregnancy testing during the course of the study and after the end of study therapy. This applies even if the patient practices complete and continued sexual abstinence."
NCT00689936:I.1021,"Must commit to either continued abstinence from heterosexual intercourse (which must be reviewed on a monthly basis) or agree to use and be able to comply with effective contraception without interruption, 28 days prior to starting study drug, during the study therapy (including during periods of dose interruptions), and for 28 days after discontinuation of study therapy."
NCT00689936:I.1022,"male, male gender"
NCT00689936:I.1023,"Must agree to use a condom during sexual contact with a FCBP, even if they have had a vasectomy, throughout study drug therapy, during any dose interruption and after cessation of study therapy."
NCT00689936:I.1024,"Must agree to not donate semen during study drug therapy and for a period after end of study drug therapy"
NCT00689936:I.1025,"All patients must"
NCT00689936:I.1026,"Have an understanding that the study drug could have a potential teratogenic risk"
NCT00689936:I.1027,"Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy."
NCT00689936:I.1028,"Agree not to share study medication with another person. All FCBP and male patients must be counseled about pregnancy precautions and risks of fetal exposure"
NCT00689936:I.2001,"Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid [i.e.,<= the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 14 days of randomization])."
NCT00689936:I.2002,"Any serious medical condition that places the patient at an unacceptable risk if he or she participates in this study. Examples of such a medical condition are, but are not limited to, patient with unstable cardiac disease as defined by: Cardiac events such as MI within the past 6 months, NYHA heart failure class III-IV, uncontrolled atrial fibrillation or hypertension; patients with conditions requiring chronic steroid or immunosuppressive treatment, such as rheumatoid arthritis, multiple sclerosis and lupus, that likely need additional steroid or immunosuppressive treatments in addition to the study treatment."
NCT00689936:I.2003,"Pregnant or lactating females"
NCT00689936:I.2004,"Any of the following laboratory abnormalities"
NCT00689936:I.2005,"Absolute Neutrophil Count"
NCT00689936:I.2006,"Untransfused platelet count<50,000 cells/µL (50 x 10^9/L)"
NCT00689936:I.2007,"Serum SGOT/AST or SGPT/ALT>3.0 x upper limit of normal (ULN)"
NCT00689936:I.2008,"Renal failure requiring hemodialysis or peritoneal dialysis."
NCT00689936:I.2009,"Prior history of malignancies, other than multiple myeloma, unless the patient has been free of the disease for ? 3 years. Exceptions include the following:"
NCT00689936:I.2010,"Basal cell carcinoma"
NCT00689936:I.2011,"Spinous cell carcinoma"
NCT00689936:I.2012,"Carcinoma in situ of uterine cervix"
NCT00689936:I.2013,"Stage 0 Breast Carcinoma"
NCT00689936:I.2014,"Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)"
NCT00689936:I.2015,"Patients who are unable or unwilling to undergo antithrombotic therapy."
NCT00689936:I.2016,"Peripheral neuropathy of>grade 2 severity."
NCT00689936:I.2017,"Known HIV positivity or active infectious hepatitis, type A, B, or C. Primary AL (immunoglobulin light chain) amyloidosis and myeloma complicated by amyloidosis."
NCT00689936:I.2018,"A variety of other types of end organ dysfunctions can occasionally occur and lead to a need for therapy. Such dysfunction is sufficient to support classification as myeloma if proven to be myeloma-related."
NCT00689936:I.2019,"A FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal (i.e., amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)."
NCT00699283:I.1001,"age 16 Years to 75 Years"
NCT00699283:I.1002,"Age between 16 and 75 years"
NCT00699283:I.1003,"Well-characterized focal epilepsy or epileptic syndrome."
NCT00699283:I.1004,"Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period."
NCT00699283:I.1005,"Subjects on a stable dose of at least 1 but no more than 2 concomitant AEDs with the second AED<= 50% of the minimum recommended maintenance dose."
NCT00699283:I.2001,"Seizure type IA non-motor as only seizure type."
NCT00699283:I.2002,"History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline."
NCT00699283:I.2003,"Other serious uncontrolled disease."
NCT00699335:I.1001,"Age at least 18 Years"
NCT00699335:I.1002,"Outpatients with severe, chronic pain"
NCT00699335:I.2001,"Hypersensitivity to fentanyl"
NCT00699335:I.2002,"Co-administration of monoamineoxidase-inhibitors"
NCT00699335:I.2003,"Pregnancy, Gestation"
NCT00699335:I.2004,"Ventilatory Depression"
NCT00699335:I.2005,"Chronic Obstructive Pulmonary Disease"
NCT00699335:I.2006,"Drug abuse"
NCT00699335:I.2007,"Impairment of CNS functions"
NCT00699335:I.2008,"Other criteria as defined in the Summary of Product Characteristics (Chapter 4.3)"
NCT00700102:I.1001,"Age at least 18 Years"
NCT00700102:I.1002,"Adult (person)"
NCT00700102:I.1003,"metastatic colorectal cancer and disease progression"
NCT00700102:I.1004,"previously treated with first-line chemotherapy plus Avastin"
NCT00700102:I.1005,"ECOG performance status finding<=2"
NCT00700102:I.2001,"Diagnosis of progression of disease more than 3 months after last Avastin administration"
NCT00700102:I.2002,"first line patients with progression-free survival in first line of<3 months"
NCT00700102:I.2003,"Patients receiving less than 3 consecutive months of Avastin in first-line therapy"
NCT00700102:I.2004,"Past or current history (within the last 2 years prior to treatment start) of other malignancies, except for curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix"
NCT00700102:I.2005,"clinically significant cardiovascular disease within 6 months prior to start of study treatment"
NCT00700102:I.2006,"Known CNS disease, except for treated CNS metastases as defined by protocol"
NCT00700141:I.1001,"age at least 18 Years"
NCT00700141:I.1002,Hemorrhage
NCT00700141:I.1003,"Patients undergoing total or subtotal thyroidectomy"
NCT00700141:I.2001,"Contraindications, such as hypersensitivity to the active pharmaceutical ingredient or to another ingredient"
NCT00701714:I.1001,"Age at least 18 Years"
NCT00701714:I.1002,"Known chronic renal insufficiency of at least 4 weeks duration. CKD stage at least 3 or higher"
NCT00701714:I.1004,"Patients who are naive to ESA treatment or previously ESA treated after 3 months of ESA-free period (i.v. or s.c.)"
NCT00701714:I.1005,"Patients with symptomatic anemia, defined as Hb level below 11.0 g/dL and not lower than or equal to 7.5 g/dL on at least 2 visits during the screening period"
NCT00701714:I.1006,"Adequate iron status, serum ferritin>= 100 µg/L or transferrin saturation>= 20%"
NCT00701714:I.1007,"Ability to follow study instructions and likely to complete all required visits and compliant with subcutaneous administration"
NCT00701714:I.1008,"Written informed consent of the patient."
NCT00701714:I.2001,"Anemia of non-renal causes"
NCT00701714:I.2002,"Therapy with immunosuppressants (other than corticosteroids for chronic treatment) within 3 months before screening and during the study for patients with renal allograft in place or other chronic conditions (e.g. lupus erythematosus, rheumatic arthritis)"
NCT00701714:I.2003,"Patients previously treated with chronic dialysis within the last 6 months (exception: one session of acute dialysis)"
NCT00701714:I.2004,"Patients with acute deterioration of renal function during the screening phase according to the investigator's judgment"
NCT00701714:I.2005,"Patients receiving any RBC/whole blood transfusion during the screening period"
NCT00701714:I.2006,"Primary hematological disorder (e.g. myeloma, myelodysplastic syndrome, sickle cell anemia, hematological malignancy, hemolytic anemia)"
NCT00701714:I.2007,"Evidence of uncontrolled diabetes mellitus (HbA1c>10 % at visit -2)"
NCT00701714:I.2008,"Evidence of severe hepatic dysfunction (e.g. ALT and/or AST above 2x upper limit of normal range. Or gamma-GT above 3x upper limit of normal range)"
NCT00701714:I.2009,"Clinical evidence of current uncontrolled or symptomatic hyperparathyroidism, defined as parathyroid hormone>500 ng/L at visit -2."
NCT00701714:I.2010,"Uncontrolled hypertension, defined as a systolic blood pressure of>= 160 mmHg and a diastolic blood pressure measurement>= 100 mmHg (average of two values with at least one day between measurements)"
NCT00701714:I.2011,"Congestive heart failure and/or angina pectoris [New York Heart Association (NYHA) class III and IV]"
NCT00701714:I.2012,"History of stroke or myocardial infarction during the last 6 months prior to visit -2"
NCT00701714:I.2013,"Ongoing treatment with phenprocoumon or other cumarin derivates"
NCT00701714:I.2014,"Thrombocytopenia (platelet count<100.000/µL) or leucopenia (white blood cell count<2.000/µL)"
NCT00701714:I.2015,"Gastrointestinal bleeding within the last 6 months prior to visit -2 or hemolysis"
NCT00701714:I.2016,"Evidence of acute or chronic infection by a C-reactive protein value of>30 mg/L"
NCT00701714:I.2017,"Suspicion or known PRCA (pure red cell aplasia)"
NCT00701714:I.2018,"Previously diagnosed HIV or acute hepatitis infection"
NCT00701714:I.2019,"History of epilepsy or epileptic seizures or treatment for epilepsy within the past 6 months prior to screening"
NCT00701714:I.2020,"Planned major surgery (with expected high blood loss) during the next 3 months or major surgery within the previous 3 months (except laser photocoagulation, access surgery)"
NCT00701714:I.2021,"Clinical evidence of active malignant diseases within the last 5 years (except non-melanoma skin cancer)"
NCT00701714:I.2022,"Pregnancy, breastfeeding women or women not using a highly effective birth control method (e.g. implants, injectables, combined oral contraceptives, IUD, sexual abstinence, vasectomised partner)"
NCT00701714:I.2023,"Known history of severe drug related allergies (e.g. anaphylactic shock)"
NCT00701714:I.2024,"Known allergy to one of the ingredients of the test product or hypersensitivity to mammalian-derived products"
NCT00701714:I.2025,"Known or suspicion of any non-compliance with respect to subcutaneous treatment"
NCT00701714:I.2026,"Simultaneous participation in another clinical study or participation in a study in the month preceding visit-2 or previously randomized in this study"
NCT00701714:I.2027,"Participation in another ESA study in the 3 months preceding visit -2"
NCT00701714:I.2028,"Any other condition which at the investigator's discretion may put the patient at risk or which may confound the study results."
NCT00701766:I.1002,"Older than 60 years"
NCT00701766:I.1003,"Patient with confirmed AML (except for APL) according to the WHO definition who relapsed after or are refractory to prior chemotherapy"
NCT00701766:I.1004,"White Blood Cell Count procedure (WBC)"
NCT00701766:I.1005,"Patient not eligible for intensive treatment options"
NCT00701766:I.1006,"Life expectancy>= 2 months"
NCT00701766:I.1007,"ECOG performance status finding<= 2"
NCT00701766:I.1008,"Signed written informed consent consistent with international conference on harmonisation - good clinical practice (ICH-GCP) and local legislation"
NCT00701766:I.2001,"Patient with acute promyelocytic leukaemia (APL, AML of the French-American-British (FAB) classification subtype M3)"
NCT00701766:I.2002,"Hypersensitivity to the trial drug or the excipients"
NCT00701766:I.2003,"Secondary malignancy requiring therapy"
NCT00701766:I.2004,"Central nervous system (CNS) involvement status"
NCT00701766:I.2005,"Aspartate amino transferase (AST) or alanine amino transferase (ALT)>2.5 times the upper limit of normal, or AST or ALT>5 times the upper limit of normal in case of known liver involvement"
NCT00701766:I.2006,"Bilirubin>1.5 mg/dl (>26 mcmol/l, SI unit equivalent)"
NCT00701766:I.2007,"Serum Creatinine Measurement"
NCT00701766:I.2008,"Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia"
NCT00701766:I.2009,"Psychiatric illness or social situation that would limit compliance with trial requirements"
NCT00701766:I.2010,"Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug"
NCT00701766:I.2011,"Chemotherapy (except hydroxyurea) or immunotherapy or treatment with any other investigational drug within the past four weeks prior to treatment with the trial drug"
NCT00701766:I.2012,"Persistence of toxicities of prior anti-leukaemia therapies which are deemed to be clinically relevant"
NCT00701766:I.2013,"Patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.)"
NCT00701766:I.2014,"Patient unable to comply with the protocol"
NCT00717366:I.1001,"age 5 Years to 17 Years"
NCT00717366:I.1002,"children aged 5-17 years with clinically stable chronic renal anemia"
NCT00717366:I.1003,"hemodialysis for>=8 weeks"
NCT00717366:I.1004,"intravenous stable maintenance epoetin alfa, epoetin beta or darbepoetin alfa for>= 8 weeks before screening"
NCT00717366:I.1005,"stable maintenance epoetin alfa, epoetin beta or darbepoetin alfa with no more than one dose change<=25% during the 2 weeks of screening."
NCT00717366:I.2001,"overt gastrointestinal bleeding, or bleeding episode necessitating transfusion within 8 weeks before screening"
NCT00717366:I.2002,"red blood cell transfusions within 8 weeks before screening"
NCT00717366:I.2003,"active malignant disease."
NCT00717457:I.1001,"age 18 Years to 75 Years"
NCT00717457:I.1002,"Adult (person)"
NCT00717457:I.1003,"type 2 diabetes receiving metformin and/or pioglitazone or rosiglitazone for at least 12 weeks"
NCT00717457:I.1004,"HbA1c>=7.0% and<=10% at screening"
NCT00717457:I.1005,"BMI>=25kg/m2 (>23kg/m2 for Asians) and<=45kg/m2 at screening"
NCT00717457:I.1006,"stable weight +/- 5% for at least 12 weeks prior to screening."
NCT00717457:I.2001,"history of type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes"
NCT00717457:I.2002,"history of acute metabolic diabetic complications within the previous 6 months"
NCT00717457:I.2003,"evidence of clinically significant diabetic complications"
NCT00717457:I.2004,"Proliferative diabetic retinopathy"
NCT00717457:I.2005,"myocardial infarction (MI), coronary artery bypass surgery, post-transplantation cardiomyopathy (PTCM) or stroke within the past 6 months"
NCT00717457:I.2006,"any abnormality in clinical laboratory test or ECG, which precludes safe involvement in the study as judged by the investigator"
NCT00717457:I.2007,"known hemoglobinopathy or chronic anemia"
NCT00717457:I.2008,"clinically significant gastrointestinal disease."
NCT00717470:I.1001,"age at least 18 Years"
NCT00717470:I.1002,"End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation (unless the graft was lost from rejection within 12 months)"
NCT00717470:I.1003,"Receiving a kidney transplant from a cadaveric or living (non HLA identical) donor with compatible ABO blood type"
NCT00717470:I.1004,"Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study"
NCT00717470:I.2001,"Receiving or having previously received an organ transplant other than a kidney"
NCT00717470:I.2002,"Cold ischemia time of the donor kidney>30 hours"
NCT00717470:I.2003,"Receiving a graft from a non-heart-beating donor other than of Maastricht category 3 (withdrawn of support awaiting cardiac arrest)"
NCT00717470:I.2004,"Significant liver disease, defined as having continuously elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin levels>= 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor"
NCT00717470:I.2005,"Requiring initial sequential or parallel therapy with immunosuppressive antibody preparation(s)"
NCT00717470:I.2006,"Requiring ongoing dosing with a systemic immunosuppressive drug prior to transplantation."
NCT00717470:I.2007,"Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer"
NCT00717470:I.2008,"Pregnant woman or breast-feeding mother"
NCT00717470:I.2009,"Subject or donor known to be HIV positive"
NCT00717470:I.2010,"Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, basiliximab or mycophenolate mofetil or any of the product excipients"
NCT00717470:I.2011,"Diagnosis of new-onset malignancy prior to transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully"
NCT00717470:I.2012,"Currently participating in another clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment"
NCT00717470:I.2013,"Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator"
NCT00722566:I.1001,"age at least 18 Years"
NCT00722566:I.1003,"Diagnosis of multiple myeloma"
NCT00722566:I.1004,"Measurable, secretory multiple myeloma defined as serum monoclonal IgG of ?10 g/L, serum monoclonal IgA or IgE ?5 g/L, or serum monoclonal IgD ?0.5g/L; or urine M-protein of ?200 mg/24 hr"
NCT00722566:I.2001,"Previous treatment with VELCADE"
NCT00722566:I.2002,"More than 3 previous lines of therapy (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a greater than 6 month treatment-free interval)"
NCT00722566:I.2003,"Peripheral neuropathy or neuropathic pain of NCI CTCAE Grade ?2"
NCT00722566:I.2004,"Any of the following within 3 weeks prior to randomization:"
NCT00722566:I.2005,"antineoplastic or experimental therapy, corticosteroid use above 10mg a day (prednisone or equivalent), or plasmapheresis"
NCT00722566:I.2006,"Any of the following within 2 weeks prior to randomization:"
NCT00722566:I.2007,"radiation therapy, major surgery (kyphoplasty is not considered major surgery)"
NCT00722566:I.2008,"Prior malignancy other than multiple myeloma diagnosed or treated within the last 2 years, with the exception of completely resected carcinoma in situ or basal/squamous carcinoma of the skin"
NCT00724022:I.1001,"age 18 Years to 75 Years"
NCT00724022:I.1002,"Post mortal kidney donation or living donation"
NCT00724022:I.1003,"Primary and secondary renal transplantation, unless the graft was lost due to severe rejection within the first year"
NCT00724022:I.1004,"PRA level<= 20%."
NCT00724022:I.1005,AB0-compatible
NCT00724022:I.1006,"Negative crossmatch"
NCT00724022:I.1007,"Patient's Signature on Informed Consent Form"
NCT00724022:I.1008,"Women of child-bearing age must agree to an efficient contraception"
NCT00724022:I.2001,"Third or multiple transplantation"
NCT00724022:I.2002,"Transplantation per a non-heart beating donor"
NCT00724022:I.2003,"HLA-identical living donation"
NCT00724022:I.2004,"Incompatibility to study medication (allergy, intolerance, hypersensitivity)"
NCT00724022:I.2005,"Patients with existing malignant underlying disease or tumour anamnesis<5 years. Exception: basaloma or squamous cell carcinoma of the skin after successful therapy"
NCT00724022:I.2006,"Female patients who do not use a safe method of contraception"
NCT00724022:I.2007,"Patients with clinically significant, uncontrolled infectious diseases (incl. HIV) and/or severe diarrhoea, emesis, active malabsorption of the upper gastrointestinal tract or active peptic ulcer"
NCT00724022:I.2008,"Patients currently, resp. within the last 30 days, participating in other studies"
NCT00724022:I.2009,"Primary focal-sclerosing glomerulonephritis and membranoproliferative glomerulonephritis as an underlying disease"
NCT00724022:I.2010,"Autoimmune disease as underlying disease (collagen diseases, colitis, HUS, SLE) which might require chronic cortisone therapy"
NCT00724022:I.2011,"Additional disease requiring temporary or chronic cortisone therapy (including inhalation medicine)"
NCT00724022:I.2012,"Chronic hepatitis B and hepatitis C infection"
NCT00724022:I.2013,"Thrombopenia<70.000/mm3 or leukopenia<2.500/mm3 or neutropenia<1500/ mm3."
NCT00724022:I.2014,"Patients with hepatocirrhosis Child B or C or another severe disease of the liver"
NCT00724022:I.2015,"Patients with symptoms of a significant somatic or psychiatric / mental illness. Patients who are not able to realize nature, relevance and consequences of the clinical trial and who are not able to comply, to cooperate and communicate adequately and to follow the instructions of the study or even to give their informed consent (according to § 40 article 4 and § 41 article 2 and 3 AMG)."
NCT00724022:I.2016,"Patients who possibly depend on the sponsor or the trial physician"
NCT00724022:I.2017,"Patients with signs of drug abuse or alcohol abuse"
NCT00724022:I.2018,"Patients taking additional medicines with known interactions with the immune suppressive substances (MMF and tacrolimus) that preclude an adequate control of the immunosuppression"
NCT00724022:I.2019,"Cold ischemia time of donor kidney>30 hours"
NCT00724022:I.2020,"Pregnant or nursing patients"
NCT00728351:I.1001,"age 18 Years to 78 Years"
NCT00728351:I.1002,"History of T2DM treated with Metformin"
NCT00728351:I.2001,"Plasma fasting glucose level"
NCT00729235:I.1001,"Age at least 18 Years"
NCT00729235:I.1002,"Biventricular Tachycardias"
NCT00729235:I.1003,"Patient has been prescribed the implantation or replacement of a CRT-ICD system accordingly to the relevant currently-approved ACC/AHA15 (August 2005, Appendix §  M.10) or ESC 16 (Update 2005, Appendix § M.11) guidelines or any relevant currently-approved local guidelines for the implantation or replacement of CRT-ICD."
NCT00729235:I.1004,"Patient's Signature on Informed Consent Form"
NCT00729235:I.2001,"Clinical history of symptomatic or not symptomatic slow VT"
NCT00729235:I.2002,"Permanent atrial fibrillation"
NCT00729235:I.2003,"Any contraindication to the implant or replacement of CRT-ICD"
NCT00729235:I.2004,"Pt is unable to attend the scheduled f-up visits at the implanting Centre"
NCT00729235:I.2005,"Pt is already included in another ongoing clinical study"
NCT00729235:I.2006,"Pt is unable to understand the objectives of the ITAC04 study"
NCT00729235:I.2007,"Pt refuses to cooperate"
NCT00729235:I.2008,"Pt is unable or refuses to provide informed consent"
NCT00729235:I.2009,"Minor (person)"
NCT00729235:I.2010,"Pt has life expectancy of less than 1 year"
NCT00729235:I.2011,"Pt is pregnant."
NCT00729703:I.1001,"age at least 18 Years"
NCT00729703:I.1002,"Patient has been prescribed the implantation for an ICD system accordingly to the relevant currently-approved ACC/AHA guidelines 1 or ESC guidelines 35 or any relevant currently-approved local guidelines for the implantation of an ICD-system"
NCT00729703:I.1003,"Impaired left ventricular function demonstrated by a left-ventricular ejection fraction (LVEF)<= 40 %, measured by angio-scintigraphy, echocardiography, or contrast ventriculogram."
NCT00729703:I.1004,"An optimal (as determined by the enrolling physician) medical regimen."
NCT00729703:I.1005,"Patient's Signature on Informed Consent Form"
NCT00729703:I.2001,"Any generally accepted indication for standard cardiac pacing, or any contraindication for standard cardiac pacing."
NCT00729703:I.2002,"Any indication for CRT accordingly to the relevant currently-approved ACC/AHA1 or ESC35 guidelines for the implantation of a CRT system."
NCT00729703:I.2003,"Any contraindication for ICD therapy and the implant of a dual chamber ICD."
NCT00729703:I.2004,"ICD replacement"
NCT00729703:I.2005,"Chronic atrial arrhythmias or cardioversion for atrial fibrillation within the past month."
NCT00729703:I.2006,"A PR interval>250 ms or AR interval>300 ms measured at implant."
NCT00729703:I.2007,"Idiopathic hypertrophic subaortic stenosis"
NCT00729703:I.2008,"Acute myocarditis"
NCT00729703:I.2009,"Unstable coronary symptoms or myocardial infarction within the last month."
NCT00729703:I.2010,"Recent (within the last month) or planned cardiac revascularization or coronary angioplasty."
NCT00729703:I.2011,"Recently performed (in the last month) or planned cardiac surgery"
NCT00729703:I.2012,"Already included in another clinical study."
NCT00729703:I.2013,"Life expectancy less than 24 months."
NCT00729703:I.2014,"Inability to understand the purpose of the study or refusal to cooperate."
NCT00729703:I.2015,"Inability or refusal to provide informed consent and, if not part of the informed consent, a Health Insurance Portability and Accountability Act (HIPAA) authorization."
NCT00729703:I.2016,"Unavailability for scheduled follow-up at the implanting or cooperating center."
NCT00729703:I.2017,"Age<18 years"
NCT00729703:I.2018,"Pregnancy, Gestation"
NCT00731289:I.1001,"Age 35 Years to 80 Years"
NCT00731289:I.1003,"radiographically verified degenerative osteoarthritis of the knee (grade II or III according to the Kellgren and Lawrence classification)"
NCT00731289:I.1004,"pain of at least 40 mm on a 100 mm visual analogue scale (VAS) at initial examination"
NCT00731289:I.1005,"persisting pain for at least 6 months"
NCT00731289:I.1006,"Lequesne index - knee (assessment scale)"
NCT00731289:I.1007,"good physical and mental status"
NCT00731289:I.1008,"good compliance and agreement to participate in this study"
NCT00731289:I.2001,"non-degeneratively induced osteoarthritis"
NCT00731289:I.2002,"Rheumatoid Arthritis"
NCT00731289:I.2003,"ligamentous instability or complete resection of the meniscus"
NCT00731289:I.2004,"Sudeck's atrophy, Reflex Sympathetic Dystrophy"
NCT00731289:I.2005,"operations of the affected knee within the last three months"
NCT00731289:I.2006,"varus or valgus deformity of>15 degrees"
NCT00731289:I.2007,"patellofemoral arthritis"
NCT00731289:I.2008,"intraarticular therapy of the affected joint within the last 6 months with hyaluronan and three months with glucocorticoids"
NCT00731289:I.2009,"severe systemic diseases (tumor, exacerbated diabetes mellitus, hyperthyroidism)"
NCT00731289:I.2010,"anti-thrombotic medication or regular medication with NSAID/psychiatric pharmaceuticals"
NCT00731289:I.2011,"Communicable Diseases"
NCT00731289:I.2012,"Alcohol abuse"
NCT00731289:I.2013,"Drug abuse"
NCT00731289:I.2014,"psychiatric diseases or suicidal tendencies"
NCT00731289:I.2015,"involvement in another study"
NCT00731289:I.2016,Non-compliant
NCT00731289:I.2017,"acute hemarthrosis or joint effusion"
NCT00731289:I.2018,"allergic predisposition"
NCT00731289:I.2019,"skin infections or skin diseases around the knee"
NCT00733343:I.1001,"age at least 22 Years"
NCT00733343:I.1002,"Chronic heart failure (at least 12 weeks since diagnosis) according to the current applicable guidelines (ESC, ACC/AHA)"
NCT00733343:I.1003,"Left ventricular systolic dysfunction (LVEF<= 45% by imaging method such as echocardiography, radionuclide angiography, left ventriculography, or cardiac magnetic resonance imaging) documented less than 12 weeks before randomisation"
NCT00733343:I.1004,"NYHA class III or IV at the time of inclusion or NYHA class II with at least one hospitalisation for HF in the last 24 months"
NCT00733343:I.1005,"No hospitalisation for heart failure for at least 4 weeks prior to inclusion"
NCT00733343:I.1006,"Optimised medical treatment according to applicable guidelines with no new class of disease modifying drug for more than 4 weeks prior to randomisation. In case of no beta blockers or ACE inhibitors/ ARB antagonists the reasons must be documented"
NCT00733343:I.1007,"SDB (AHI>15/h with>= 50% central events and a central AHI>= 10/h, derived from polygraphy or polysomnography (based on total recording time (TRT)), documented less than 4 weeks before randomisation. Flow measurement has to be performed with nasal cannula"
NCT00733343:I.1008,"Patients for whom the use of AutoSet CS2/VPAP Adapt may be contra-indicated because of symptomatic hypotension or significant intravascular volume depletion or pneumothorax or pneumomediastinum"
NCT00733343:I.1009,"Patient is able to fully understand study information and signed informed consent"
NCT00733343:I.2001,"Significant COPD with Forced Expiratory Volume within one second (FEV1)<50% (European Respiratory Society criteria) in the last four weeks before randomisation"
NCT00733343:I.2002,"Oxygen saturation at rest during the day<= 90% at inclusion"
NCT00733343:I.2003,"Current use of Positive Airway Pressure (PAP) - therapy"
NCT00733343:I.2004,"Life expectancy<1 year for diseases unrelated to chronic HF"
NCT00733343:I.2005,"Cardiac surgery, Percutaneous coronary intervention (PCI), Myocardial Infarction (MI) or unstable angina within 6 months prior to randomisation"
NCT00733343:I.2006,"CRT-implantation or ICD-implantation scheduled or within 6 months prior to randomisation"
NCT00733343:I.2007,"Transient ischemic attack (TIA) or Stroke within 3 months prior to randomisation"
NCT00733343:I.2008,"Primary hemodynamically significant uncorrected valvular heart disease, obstructive or regurgitant, or any valvular disease expected to lead to surgery during the trial"
NCT00733343:I.2009,"Acute myocarditis/pericarditis within 6 months prior to randomisation"
NCT00733343:I.2010,"Untreated or therapy refractory Restless legs-Syndrome (RLS) according to criteria listed in Appendix IX at the time of study entry"
NCT00733343:I.2011,"Pregnancy, Gestation"
NCT00740103:I.1001,"Age at least 18 Years"
NCT00740103:I.1002,"Crohn's Disease"
NCT00740103:I.1003,"Patients satisfactorily completing study CNI-1493-04 were eligible for participation in this study. Satisfactory completion was defined as follows:"
NCT00740103:I.1004,"The patient met all eligibility criteria for participation in study CNI-1493-04 or was granted an exemption by the medical monitor for factors indicating ineligibility"
NCT00740103:I.1005,"The patient received at least 2 of the 3 planned doses of study medication."
NCT00740103:I.1006,"The patient had no adverse event>grade 2 felt to be possibly, probably or definitely related to study medication."
NCT00740103:I.1007,"The patient underwent all required evaluations, both for safety and efficacy, at baseline and day 29 and, for patients enrolling between days 43 and 57 of study CNI-1493-CD-04, at least one full later evaluation, ie the procedures required at day 43 and/or 57."
NCT00740103:I.1008,"At baseline for study CNI-1493-CD-05, patients were to meet the same concomitant medication criteria as for study CNI-1493-CD-04:"
NCT00740103:I.1009,"Patients receiving medications for CD were to be on each medication for at least 8 weeks prior to screening and on stable doses of each for at least 2 weeks prior to baseline assessments, with the following exceptions:"
NCT00740103:I.1010,"those on methotrexate were to be on a stable dose for at least 4 weeks and  must not be receiving>25mg/week"
NCT00740103:I.1011,"those on azathioprine or 6-mercaptopurine on a stable dose for at least 10  weeks"
NCT00740103:I.1012,"those on corticosteroids were to have been on them for at least 2 weeks and  on a stable for those 2 weeks. They were not to be receiving>20  mg/day prednisone (or equivalent)."
NCT00740103:I.1013,"those on mesazaline were to have been on for at least 6 weeks and on a  stable dose for at least 2 weeks"
NCT00740103:I.1014,"those on antibiotics for CD were to have been on for at least 2 weeks and  on a stable dose for those 2 weeks"
NCT00740103:I.1015,"Patients who were not using other CD medications were to have stopped any previous use of these agents at least 4 weeks prior to baseline assessment for study CNI-1493-CD-05."
NCT00740103:I.1016,"Patients were required to sign informed consent specifically for this study, in addition to the consent for study CNI-1493-CD-04."
NCT00740103:I.1017,"Men and women of childbearing potential were to be using a barrier method (diaphragm or condom) of contraception and continue doing so for at least 3 months after last study medication. It was strongly recommended that two forms be used."
NCT00740103:I.1018,"Patients were to be able to adhere to the study visit schedule and/or protocol requirements."
NCT00740103:I.2001,"Only patients completing CD04 were eligible and must not have met any of the exclusion criteria for that study."
NCT00740831:I.1001,"age 18 Years to 50 Years"
NCT00740831:I.1002,"Be a pre-menopausal woman between 18 and 50 years inclusive."
NCT00740831:I.1003,"Have excessive uterine bleeding due to myoma"
NCT00740831:I.1004,"Have a myomatous uterus with at least one myoma of>= 3 cm diameter in size"
NCT00740831:I.1005,"Be eligible for one surgical procedure: e.g. hysterectomy, myomectomy or others."
NCT00740831:I.1006,"If of childbearing potential the subject must be practicing a non-hormonal method of contraception."
NCT00740831:I.1007,"Body mass index>= 18 and<= 40"
NCT00740831:I.2001,"Has a history of or current uterine, cervical, ovarian or breast cancer."
NCT00740831:I.2002,"Has a history of or current endometrium atypical hyperplasia or adenocarcinoma."
NCT00740831:I.2003,"Has a known severe coagulation disorder."
NCT00740831:I.2004,"Has a history of or current treatment for myoma with a Selective Progesterone Receptor Modulator (SPRM) or a GnRH-agonist."
NCT00740831:I.2005,"Has a history of or known current osteoporosis."
NCT00740831:I.2006,"Has abnormal hepatic function at study entry."
NCT00740831:I.2007,"Has a positive pregnancy test at baseline or is nursing or planning a pregnancy during the course of the study."
NCT00740831:I.2008,"Has a current (within twelve months) problem with alcohol or drug abuse."
NCT00740831:I.2009,"Is currently enrolled in an investigational drug or device study or has participated in such a study within the last 30 days."
NCT00749723:I.1001,"age 3 Months to 30 Years"
NCT00749723:I.1002,"Histologically confirmed Medulloblastoma, cerebral PNET or Ependymoma"
NCT00749723:I.1003,"Refractory or relapsed disease"
NCT00749723:I.1004,"Measurable disease by MRI or detection of tumor cells in cerebrospinal fluid"
NCT00749723:I.1005,"Performance status ECOG>= 3 or Karnofsky Status>= 40%"
NCT00749723:I.1006,"Life expectancy>= 8 weeks"
NCT00749723:I.1007,"Absolute leukocyte count>= 2.0 x 10^9 /l"
NCT00749723:I.1008,"Hemoglobin, Hemoglobin Measurement"
NCT00749723:I.1009,"Platelet count - finding"
NCT00749723:I.1010,"Creatinine no greater than 1.5 times UNL"
NCT00749723:I.1011,"No overt renal disease"
NCT00749723:I.1012,"Bilirubin<2.5 times UNL"
NCT00749723:I.1013,"AST and ALT<5 times UNL"
NCT00749723:I.1014,"No overt hepatic disease"
NCT00749723:I.1015,"No overt pulmonary disease"
NCT00749723:I.1016,"No overt cardiovascular disease"
NCT00749723:I.1017,"Not pregnant or nursing"
NCT00749723:I.1018,"Negative Pregnancy Test"
NCT00749723:I.1019,"Fertile patients must use effective contraception"
NCT00749723:I.1020,"No uncontrolled infection prior concurrent therapy"
NCT00749723:I.1021,">2 weeks since prior systemic chemotherapy"
NCT00749723:I.1022,">4 weeks since prior radiotherapy"
NCT00749723:I.1023,"No other concurrent anticancer or experimental drugs"
NCT00749723:I.1024,"Examination of lumbar CSF"
NCT00749723:I.1025,"Cranial and spinal MRI within 14 days prior to start of treatment"
NCT00750282:I.1001,"Age at least 55 Years"
NCT00750282:I.1002,"Is a man or woman and is>55 of age, whereby females must be without  childbearing potential (confirmed by either: age>/= 60. Or history of  hysterectomy, or last spontaneous bleeding at least 2 years prior to the study  start)"
NCT00750282:I.1003,"Has at least 6 years of education"
NCT00750282:I.1004,"Is able to provide informed consent, understand the information provided on the  purpose and conduct of the trial and to comply with study procedures"
NCT00750282:I.1005,"Possesses a general health that permits adequate compliance with all study  procedures"
NCT00750282:I.1006,"The subject, or the subject and caregiver (for probable AD patients) will be  compliant and have a high probability of completing the study"
NCT00750282:I.1007,"Informed consent has been signed and dated (with time) by the subject and/or the  subject's caregiver (for probable AD patients)"
NCT00750282:I.1008,"Healthy Subject"
NCT00750282:I.1009,"Has no evidence of cognitive impairment"
NCT00750282:I.1010,"Has MRI brain scan that has been judged as normal (age-appropriate)"
NCT00750282:I.1011,"Alzheimer's Disease"
NCT00750282:I.1012,"Presents with positive assessment for dementia of Alzheimer's type"
NCT00750282:I.1013,"Does not fulfill the criteria DLB or VaD"
NCT00750282:I.1014,"MRI brain scan findings that do not reveal changes indicative of stroke and/or  generalized cerebrovascular disease"
NCT00750282:I.1015,"Has a caregiver that is willing and able to attend all study visits and perform  the psychometric tests requiring the presence of a caregiver"
NCT00750282:I.2001,"Has any contraindication to MRI examination scan"
NCT00750282:I.2002,"Is scheduled for surgery and/or another invasive procedure within the time period of up to 24 hours following IMP application"
NCT00750282:I.2003,"Is allergic to the IMP or any of its constituents and/or has a history of severe allergic reactions to drugs or allergens (e.g. patients / volunteers with allergic asthma)"
NCT00750282:I.2004,"is critically ill and/or medically unstable and whose clinical course during the observation period is unpredictable"
NCT00750282:I.2005,"Has a history of exposure to any radiation>15 mSv/year (e.g. occupational or radiation therapy)"
NCT00750282:I.2006,"Is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy)"
NCT00750282:I.2007,"Has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical"
NCT00750282:I.2008,"Has a brain tumor or other intracranial lesion, a disturbance of CSF circulation (e.g., normal pressure hydrocephalus) and/or a history of head trauma or brain surgery"
NCT00750282:I.2009,"Has an inflammatory or infectious CNS disease, e.g. multiple sclerosis, HIV, syphilis, or Creutzfeldt-Jacob disease"
NCT00750282:I.2010,"Has a history, physical, laboratory or imaging findings indicative of a neurological or psychiatric illness"
NCT00750282:I.2011,"Has another disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function)"
NCT00750282:I.2012,"Has a history of alcohol or drug abuse"
NCT00750282:I.2013,"Has history of severe persistent depression"
NCT00752388:I.1001,"age at least 30 Years"
NCT00752388:I.1002,"PD patients attending one of the participating neurologist practices during 2 fixed weeks in November 2008"
NCT00752388:I.1003,"Idiopathic PD with or without fluctuations"
NCT00752388:I.1004,"Male or female PD patients aged at least 30"
NCT00752388:I.1005,"Ability to reliably complete self-rating scales (WHO-5, MDI) ), according to the physician's judgement."
NCT00752388:I.1006,"Written informed consent by the patient for study participation."
NCT00752388:I.2001,"PD Patients who only attend the practice to get a prescription and are not seen by the doctor on that day"
NCT00752388:I.2002,"Patients who are not able to understand the questionnaires (e.g. due to mental impairment or language problems)."
NCT00754559:I.1001,"age at least 18 Years"
NCT00754559:I.1002,"Adult (person)"
NCT00754559:I.1003,"rheumatoid arthritis of>=6 months duration diagnosed according to the revised 1987 ACR criteria"
NCT00754559:I.1004,"Disease activity score using 28 joint count"
NCT00754559:I.1005,"At screening either ESR>=28 mm/h or CRP>=1 mg/dL"
NCT00754559:I.1006,"Having received permitted DMARDs>= 1. Current DMARD therapy must have been at a stable dose for at least 8 weeks prior to baseline."
NCT00754559:I.2001,"major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following screening"
NCT00754559:I.2002,"functional class IV as identified by the ACR classification of functional status in RA"
NCT00754559:I.2003,"rheumatoid autoimmune disease other than RA"
NCT00754559:I.2004,"prior history of or current inflammatory joint disease other than RA."
NCT00757523:I.1001,"age 12 Years to 45 Years"
NCT00757523:I.1002,"Males or females 12 to 45 years of age, inclusive, in good general health."
NCT00757523:I.1003,"Clinical diagnosis of acne vulgaris"
NCT00757523:I.1004,"Capable of understanding and willing to provide signed and dated written voluntary informed consent"
NCT00757523:I.1005,"Female subjects of childbearing potential must have a negative pregnancy test at baseline. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception"
NCT00757523:I.1006,"Subjects who have been treated with estrogens, androgens, or anti-androgenic agents for more than 12 consecutive weeks prior to the first dose of study product are allowed to enroll as long as they do not expect to change dose, drug, or discontinue use during the study."
NCT00757523:I.1007,"The ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study."
NCT00757523:I.2001,"Female subjects who are pregnant, trying to become pregnant, or who are lactating."
NCT00757523:I.2002,"Any clinically relevant finding at their baseline physical examination or medical history such as severe systemic diseases or diseases of the facial skin other than acne vulgaris."
NCT00757523:I.2003,"Facial hair that may obscure the accurate assessment of acne grade."
NCT00757523:I.2004,"History or presence of regional enteritis or inflammatory bowel disease (eg, ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of antibiotic-associated colitis) or similar symptoms."
NCT00757523:I.2005,"Used topical antibiotics on the face or systemic antibiotics within the past 2 and 4 weeks, respectively."
NCT00757523:I.2006,"Used topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra articular or intra-lesional (other than for facial acne lesions) steroids is acceptable."
NCT00757523:I.2007,"Used systemic retinoids within the past 6 months."
NCT00757523:I.2008,"Using drugs known to be photosensitizers (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the possibility of increased phototoxicity."
NCT00757523:I.2009,"Using neuromuscular blocking agents. Clindamycin has neuromuscular blocking activities, which may enhance the action of other neuromuscular blocking agents."
NCT00757523:I.2010,"Used topical anti-acne medications (eg, BPO, retinoids, azelaic acid, resorcinol, salicylates, sulfacetamide sodium and derivatives, glycolic acid) within the past 2 weeks."
NCT00757523:I.2011,"Used any investigational therapy within 4 weeks of study day 1."
NCT00757523:I.2012,"Using the following types of facial products: astringents, toners, abradants, facials, peels containing glycolic or other acids, masks, washes or soaps containing BPO, sulfacetamide sodium or salicylic acid, non-mild facial cleansers, or moisturizers that contain retinol, salicylic acid, or alpha- or beta-hydroxy acids."
NCT00757523:I.2013,"Using medications that are reported to exacerbate acne (eg, mega-doses of certain vitamins such as vitamin D, vitamin A, and vitamins B2, B6, and B12, haloperidol, halogens such as iodide and bromide, lithium, hydantoin, and phenobarbital) as these may impact efficacy assessments"
NCT00757523:I.2014,"Have had a facial procedure (chemical or laser peel, microdermabrasion, artificial ultraviolet [UV] therapy) performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks."
NCT00757523:I.2015,"Have a known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, adapalene, clindamycin, BPO, or excipients of the study medication."
NCT00757523:I.2016,"Employees of a clinical research organization involved in the study, or Stiefel Laboratories, or an immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of an employee."
NCT00757523:I.2017,"Have a member of the same household in this trial."
NCT00759174:I.1001,"age at least 45 Years"
NCT00759174:I.1002,"Optic Neuropathy, Ischemic"
NCT00759174:I.1003,"male, male gender"
NCT00759174:I.1004,"Experienced abrupt visual change in only 1 eye"
NCT00759174:I.2001,"Pain determined by an ophthalmologist to be consistent with an inflammatory/arteritic process or optic neuritis"
NCT00759174:I.2002,"History of NAION or optic neuritis."
NCT00759174:I.2003,"Participation in other studies within 60 days prior to entry in the study."
NCT00761280:I.1001,"age 18 Years to 70 Years"
NCT00761280:I.1002,"The patient has provided written informed consent prior to any study-related procedure."
NCT00761280:I.1003,"The patient has a present diagnosis of AA or secondary GBM."
NCT00761280:I.1004,"The patient has a measurable lesion (>1 ccm in volume, central MRI review)."
NCT00761280:I.1005,"The lesion (or sum of lesions) does not exceed 50 ccm in volume (central MRI review)."
NCT00761280:I.1006,"The tumor is localized supratentorially (central MRI review)."
NCT00761280:I.1007,"All patients have recurrent or refractory disease, i.e. disease has progressed after prior surgery and radiotherapy at any time of the disease course or stage. Secondary GBM patients have progressed after a previous diagnosis of A and/or AA."
NCT00761280:I.1008,"The patient has not received more than one chemotherapy regimen. Radiation with concomitant chemotherapy, followed by adjuvant chemotherapy, is considered as one chemotherapy regimen."
NCT00761280:I.1009,"The patient is eligible for chemotherapy."
NCT00761280:I.1010,"The patient is on a maximum dose of 4 mg/day dexamethasone or equivalent doses for other corticosteroids, which has been stable or decreasing for at least 3 weeks prior to Screening."
NCT00761280:I.1011,"The patient is male or a non-pregnant, non-lactating female."
NCT00761280:I.1012,"Females of childbearing potential must have a negative beta-HCG pregnancy test at Screening."
NCT00761280:I.1013,"Females of childbearing potential and males must practice strict birth control."
NCT00761280:I.1014,"The patient must have recovered from acute toxicity caused by any previous therapy."
NCT00761280:I.1015,"The patient has a life expectancy of at least 3 months."
NCT00761280:I.1016,"Karnofsky performance status (assessment scale)"
NCT00761280:I.1017,"The patient shows adequate organ functions as assessed by the following screening laboratory values:"
NCT00761280:I.1018,"Adequate renal function determined by serum creatinine and urea<2 times the upper limit of normal"
NCT00761280:I.1019,"Adequate liver function with ALT, AST and AP<3 times the upper limit of normal, and bilirubin<2.5 mg/dL"
NCT00761280:I.1020,"INR<1.5 and aPTT<1.5 x ULN"
NCT00761280:I.1021,Hemoglobin
NCT00761280:I.1022,"Platelet count - finding"
NCT00761280:I.1023,"White Blood Cell Count procedure (WBC)"
NCT00761280:I.1024,"ANC>1.5 x 10E9/L (or WBC>3.0 x 10E9/L)"
NCT00761280:I.2001,"Patient unable or not willing to comply with the protocol regulations."
NCT00761280:I.2002,"The investigator deems it necessary to surgically (re-)resect the present tumor (NOTE: the patient might still be eligible for randomization at a later timepoint)."
NCT00761280:I.2003,"Tumor surgery, tumor debulking, or other neurosurgery within 3 months prior to randomization. If a<=48-hour routine post-surgery MRI (in accordance with study specifications) qualifies the patient for study participation, the patient can be randomized 30 ± 7 days post-surgery."
NCT00761280:I.2004,"Radiotherapy or stereotactic (gamma knife) radiosurgery within 3 months prior to randomization."
NCT00761280:I.2005,"Prior interstitial brachytherapy of the brain with permanent implants. Prior interstitial brachytherapy of the brain with removable implants within 3 months prior to randomization."
NCT00761280:I.2006,"Chemotherapy, hormone therapy, or any other therapy with established or suggested anti-tumor effects within 4 weeks (nitrosoureas: 6 weeks) prior to randomization."
NCT00761280:I.2007,"Prior anti-TGF-beta 2 targeted therapy."
NCT00761280:I.2008,"Screening MRI shows a mass effect caused by the tumor defined as significant compression of the ventricular system and/or a midline shift (>= 3 mm, central MRI review). Compression of the ventricular system and/or a midline shift>= 3 mm only due to the presence of (a) cyst(s) or scarring processes does not exclude an individual from the study."
NCT00761280:I.2009,"Participation in another clinical study with another investigational medicinal product within 30 days prior to randomization."
NCT00761280:I.2010,"History of a second independent malignant disorder within 5 years, except for carcinoma in situ of the cervix and basal cell carcinoma."
NCT00761280:I.2011,"Seizures, poorly controlled"
NCT00761280:I.2012,"Clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure, unstable angina, or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomization."
NCT00761280:I.2013,"Known HIV, HBV or HCV infection."
NCT00761280:I.2014,"Acute viral, bacterial, or fungal infection."
NCT00761280:I.2015,"Acute medical problems that may be considered to become an unacceptable risk, or any conditions, which might be contraindications for starting study treatment."
NCT00761280:I.2016,"Presence of high risk for pulmonary toxicities, defined as:"
NCT00761280:I.2017,"Lung function: vital capacity ? 70%"
NCT00761280:I.2018,"Status following sequential or concomitant thoracic irradiation"
NCT00761280:I.2019,"Increased risk for a pulmonary toxicity induced by BCNU (Carmustine) or CCNU (Lomustine). Risk factors include smoking, presence of a respiratory condition, pre-existing radiographic pulmonary abnormalities, exposure to agents that cause lung damage."
NCT00761280:I.2020,"History of allergies to reagents used in this study."
NCT00761280:I.2021,"Drug abuse or extensive use of alcohol."
NCT00761280:I.2022,"Clinically relevant psychiatric disorders / legal incapacity or a limited legal capacity."
NCT00761280:I.2023,"Concomitant treatment with yellow fever vaccine."
NCT00761787:I.1001,"age at least 18 Years"
NCT00761787:I.1002,"Cardiac Allograft Rejection"
NCT00761787:I.1003,"New and existing allograft recipients"
NCT00761787:I.1004,"All patients (age>= 18 years) receiving post-transplant care at the enrolling centers"
NCT00761787:I.2001,"Concurrent enrollment in a double-blind drug trial (immunosuppressive drugs)."
NCT00766779:I.1001,"age 60 Years to 75 Years"
NCT00766779:I.1002,"primary or secondary AML as defined by WHO or refractory anemia with excess of blasts (RAEB)"
NCT00766779:I.1003,"First complete remission following one or two cycles of induction chemotherapy"
NCT00766779:I.1004,"Chemotherapy was administered according to current participating cooperative group protocols"
NCT00766779:I.1005,"Karnofsky performance status (assessment scale)"
NCT00766779:I.1006,"Written informed consent"
NCT00766779:I.2001,"AML FAB M3"
NCT00766779:I.2002,"HIV Seropositivity"
NCT00766779:I.2003,"Participation in another clinical trial without prior consent of the coordinating investigator, patients may exceptionally take part in a further study only if"
NCT00766779:I.2004,"The second study exclusively concerns induction therapy"
NCT00766779:I.2005,"Consolidation cycle one and two are given according to the accredited study  group policy"
NCT00766779:I.2006,"No investigational drugs are used post registration for the HCT vs CT in elderly  AML study."
NCT00766779:I.2007,"Documentation for the HCT vs CT in elderly AML study is not compromised. Second  hand data from foreign study is not accepted"
NCT00770445:I.1001,"age 30 Years to 75 Years"
NCT00770445:I.1002,"Has Diabetes Mellitus type 2."
NCT00770445:I.1003,"Hemoglobin, Glycosylated"
NCT00770445:I.1004,"Treatment with the following insulins with or without Oral Antidiabetic Therapy since 3 months:"
NCT00770445:I.1005,"Long acting basal insulin analogs"
NCT00770445:I.1006,"Neutral protamine hagedorn insulin"
NCT00770445:I.1007,"Combination insulin with 1-2 daily doses except intensified insulin therapies."
NCT00770445:I.1008,"Body mass index"
NCT00770445:I.1009,"Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."
NCT00770445:I.2001,"Has a history of type 1 diabetes mellitus."
NCT00770445:I.2002,"Has uncontrolled hypertension (systolic blood pressure>160mmHg and/or diastolic blood pressure>95mmHg) or change of antihypertensive treatment within the last 2 weeks."
NCT00770445:I.2003,"Acute infection"
NCT00770445:I.2004,"Has anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structure."
NCT00770445:I.2005,"Has a history of severe or multiple allergies."
NCT00770445:I.2006,"History of drug or alcohol abuse in the past 5 years"
NCT00770445:I.2007,"A history of significant cardiovascular (New York Heart Association stage I - IV), respiratory, gastrointestinal, hepatic (Alanine Aminotransferase and/or Aspartate Aminotransferase>2.5 times the upper limit of the normal reference range), renal (serum creatinine>1.2 mg/dL in women and>1.5 mg/dL in men, Glomerular Filtration Rate<60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator"
NCT00770445:I.2008,"History of macular edema."
NCT00770445:I.2009,"State after kidney transplantation."
NCT00770445:I.2010,"Serum Potassium Measurement"
NCT00770445:I.2011,"History of primary hyperaldosteronism."
NCT00770445:I.2012,"Acute myocardial infarction, open heart surgery or cerebral event (stroke/ Transitory Ischemic Attack) within the previous 12 months."
NCT00770445:I.2013,"Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:"
NCT00770445:I.2014,"Pre-treatment with gemfibrozil within the last 12 weeks."
NCT00770445:I.2015,"Pre-treatment with rifampicin within the last 12 weeks."
NCT00770445:I.2016,"Treatment with thiazolidinediones within the past 3 months."
NCT00770445:I.2017,"If statin therapy applicable: Change of medication within the last 4 weeks."
NCT00770445:I.2018,"Has used non-steroidal anti-inflammatory agents including low dose ASA or  Cox-2-inhibitors if therapy has been initiated within the last 4 weeks."
NCT00770445:I.2019,"Treatment with any other investigational drug within 4 weeks before trial entry."
NCT00770445:I.2020,"Any elective surgery during study participation."
NCT00770445:I.2021,"Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit."
NCT00770445:I.2022,"History of dehydration, precoma diabeticorum or shock or diabetic ketoacidosis within the past year prior to screening visit."
NCT00770445:I.2023,"Acute or scheduled investigation with iodine containing radiopaque material."
NCT00770445:I.2024,"Uncontrolled unstable angina pectoris."
NCT00770445:I.2025,"Medical history of acute and clinically relevant pericarditis, myocarditis, endocarditis, recent pulmonary embolism, hemodynamic relevant aortic stenosis, aortic aneurysm."
NCT00770653:I.1001,"age 18 Years to 75 Years"
NCT00770653:I.1002,"Type 2 diabetes according to the American Diabetes Association Criteria."
NCT00770653:I.1003,"Treatment with individual maximal tolerated dose of metformin (850 - 2000 mg) as monotherapy within the last 12 weeks"
NCT00770653:I.1004,"Hemoglobin, Glycosylated"
NCT00770653:I.1005,"Dyslipidemia defined as high-density lipoprotein cholesterol<= 1.03 mmol/l (40 mg/dL) and/or triglycerides>= 1.7 mmol/l (150 mg/dL)."
NCT00770653:I.1006,"Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."
NCT00770653:I.2001,"Diabetes Mellitus, Insulin-Dependent"
NCT00770653:I.2002,"DIABETES MELLITUS, INSULIN-DEPENDENT, 2"
NCT00770653:I.2003,"Treatment or history of treatment with any insulin formulation other than emergency for more than 2 weeks."
NCT00770653:I.2004,"Treatment with other oral antidiabetic drugs in addition to metformin within the last 12 weeks."
NCT00770653:I.2005,"Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures."
NCT00770653:I.2006,"Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:"
NCT00770653:I.2007,"Heparin (and heparin-like drugs)"
NCT00770653:I.2008,"Cumarin, Coumarin anticoagulant"
NCT00770653:I.2009,"Phenprocoumon (substance)"
NCT00770653:I.2010,"Hirudin (substance)"
NCT00770653:I.2011,"Protein C (substance)"
NCT00770653:I.2012,"Fondaparinux (product)"
NCT00770653:I.2013,"Antithrombin III (substance)"
NCT00770653:I.2014,"Peroxisome Proliferation Activating Receptor (gamma) agonists"
NCT00770653:I.2015,"Treatment within the last 12 weeks with:"
NCT00770653:I.2016,Fibrates
NCT00770653:I.2017,"Gemfibrozil (product)"
NCT00770653:I.2018,"Nicotinic acid (substance)"
NCT00770653:I.2019,Rifampin
NCT00770653:I.2020,"Changes in dosage of any statin treatment to lower low-density lipoprotein  within 2 weeks before study entry and during study participation interval."
NCT00770653:I.2021,"Changes in dosage of any anticoagulant treatment with acetyl salicylic acid  and/or clopidogrel within 2 weeks before study entry and during study  participation interval."
NCT00770653:I.2022,"Start of statin and/or anticoagulant treatment during study participation  interval."
NCT00770653:I.2023,"History of severe or multiple allergies and/ or acute severe infections."
NCT00770653:I.2024,"Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit."
NCT00770653:I.2025,"Progressive fatal disease."
NCT00770653:I.2026,"Any elective surgery during study participation."
NCT00770653:I.2027,"History of drug or alcohol abuse within the last 5 years."
NCT00770653:I.2028,"A history of significant cardiovascular (New York Heart Association stage I - IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase and/or aspartate aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine>1.2 mg/dL in women and>1.5 mg/dL in men, glomerular filtration rate<60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator, history of macular edema."
NCT00770653:I.2029,"Blood donation within the last 30 days."
NCT00771927:I.1001,"age at least 16 Years"
NCT00771927:I.1002,"This study includes any subject 16 years or older who has an epilepsy diagnosis with partial on-set seizures, and whose seizure activity is uncontrolled on current therapy"
NCT00771927:I.1003,"Patients who are prescribed Vimpat or any other add-on AED may be included in the study."
NCT00771927:I.1004,"The initiation of an add-on AED therapy can not be more than 2 days before the patient's start of the study."
NCT00771927:I.2001,"No Information Available"
NCT00777127:I.1001,"Age at least 18 Years"
NCT00777127:I.1002,Immunocompetent
NCT00777127:I.1003,"A study treatment area must be identifiable: Minimum of 5 and maximum of 10 typical visible AKs in one contiguous area of up to 50 cm2 on the face or scalp. The eyelids, the inside of the nostrils or ears, or the lip area inside the vermilion border must not be part of this area."
NCT00777127:I.1004,"A positive histological finding for AK grade I or II (see Section 7.1.1.2). This will be determined from the most suspicious lesion in the STA and there from the most pathological area biopsied during screening visit. This analysis will be done by the central histopathological laboratory."
NCT00777127:I.1005,"Willingness to comply with the obligations of the study."
NCT00777127:I.2001,"History of allergic reaction to imiquimod, diclofenac, acetyl salicylic acid, other non steroidal anti-inflammatory drugs (NSAID), hyaluronic acid, or relevant excipients."
NCT00777127:I.2002,"Pregnancy, breast-feeding or planned pregnancy during the study. Women of child bearing potential not using a highly effective method of birth control defined as those which result in a low failure rate (i.e.<1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation or vasectomised partner."
NCT00777127:I.2003,"Presence of AK lesions in the STA with clinically marked hyperkeratosis or hypertrophy as seen in cutaneous horns."
NCT00777127:I.2004,"Any topical AK treatment including imiquimod or diclofenac, or any systemic AK treatment such as systemic retinoids, or any surgical AK treatment at the STA within the last 2 months prior to randomisation."
NCT00777127:I.2005,"Persisting AK lesion at screening visit following topical treatment with imiquimod or diclofenac in the STA."
NCT00777127:I.2006,"Topical treatment with imiquimod or diclofenac anywhere else on the body within the last 2 months prior to randomisation."
NCT00777127:I.2007,"Presence of any histologically confirmed skin tumour in the STA: in situ SCC including Bowen's disease, invasive SCC, basal cell carcinoma, or other malignant tumours."
NCT00777127:I.2008,"Any dermatological disease or condition that may exacerbate by treatment with imiquimod or diclofenac (e.g. rosacea, psoriasis, atopic dermatitis)."
NCT00777127:I.2009,"Any dermatological disease or condition in the STA that causes difficulty with examination (e.g. eczema)."
NCT00777127:I.2010,"Systemic immunomodulatory treatment such as interferon, azathioprine, cyclosporine, retinoids, any oral or injectable corticosteroids, or inhaled or nasal corticosteroids with dosages of>1200 µg/day beclomethasone or equivalent within 4 weeks before start of study treatment."
NCT00777127:I.2011,"History of any malignant tumour with high tumour burden or any systemic antitumour treatment (incl. radiotherapy)."
NCT00777127:I.2012,"History of any malignant skin tumour having metastasised or where metastasis could be expected."
NCT00777127:I.2013,"History of severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, metabolic, mental, neurological, or other disease within the last two years."
NCT00777127:I.2014,"Mentally Disabled Persons"
NCT00777127:I.2015,"Present or history of drug or alcohol abuse within the last 3 years."
NCT00777127:I.2016,"Exposure to an investigational product within the last 3 months."
NCT00777127:I.2017,"Lack of ability or willingness to give informed consent."
NCT00777127:I.2018,"Age below 18 years."
NCT00777127:I.2019,"Lack of willingness to have personal study related data collected, archived or transmitted according to protocol."
NCT00777127:I.2020,"Anticipated non-availability for study visits/procedures."
NCT00777127:I.2021,"Vulnerable subjects (such as persons kept in detention)."
NCT00778388:I.1001,"written informed consent obtained prior to study entry"
NCT00778388:I.1002,"healthy adults aged between 18 and 65 years"
NCT00778388:I.1003,"no clinically relevant pathological findings in any of the investigations at the Screening visit. Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance"
NCT00778388:I.1004,"In female subjects either childbearing potential terminated by surgery or a negative serum pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception"
NCT00778388:I.2001,"History of autoimmune diseases and malignancies"
NCT00778388:I.2002,"Active or passive vaccination 4 weeks before and during the entire study protocol"
NCT00778388:I.2003,"Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine"
NCT00778388:I.2004,"History of severe hypersensitivity reactions and anaphylaxis"
NCT00778388:I.2005,"Known hypersensitivity or allergic reactions to one of the components of the vaccine"
NCT00778388:I.2006,"Clinically significant diseases as judged by the investigator"
NCT00778388:I.2007,"Immunodeficiency due to immunosuppressive therapy"
NCT00778388:I.2008,"A family history of congenital or hereditary immunodeficiency"
NCT00778388:I.3001,"Informed Consent"
NCT00778388:I.3002,Age
NCT00778388:I.3003,"Healthy Subject"
NCT00778388:I.3004,pregnant
NCT00778388:I.3005,Contraception
NCT00778388:I.3006,"Serum pregnancy test (B-HCG)"
NCT00778388:I.3007,Diagnosis
NCT00778388:I.3008,"Autoimmune Disease"
NCT00778388:I.3009,"Malignant Neoplasms"
NCT00778388:I.3010,Vaccination
NCT00778388:I.3011,Enrollment
NCT00778388:I.3012,Hypersensitivity
NCT00778388:I.3013,"Immunomodulatory or immunosuppressive therapy"
NCT00778388:I.3014,"congenital immunodeficiency"
NCT00785330:I.1001,"age 18 Years to 65 Years"
NCT00785330:I.1002,"histology proven aggressive non Hodgkin's lymphoma and"
NCT00785330:I.1003,"primary progressive disease or"
NCT00785330:I.1004,"early relapse after<12 months of remission duration and at least one risk factor according to the international prognostic index (IPI) or"
NCT00785330:I.1005,"relapse or progression after high dose chemotherapy and autologous transplantation or"
NCT00785330:I.1006,"relapse or progression and lack of an autologous stem cell product."
NCT00785330:I.2001,"severe comorbidity or impaired organ function"
NCT00785330:I.2002,"Documented hypersensitivity to administered drug"
NCT00785330:I.2003,"HIV Seropositivity"
NCT00785330:I.2004,"active hepatitis"
NCT00785330:I.2005,"other active malignant disease"
NCT00786253:I.1001,"age 18 Years to 64 Years"
NCT00786253:I.1002,"male, male gender"
NCT00786253:I.1003,"Mild or mild to moderate ED (defined as>15 and<21 score points according to the Erectile Function Domain Score from IIEF as assessed at the randomisation visit)"
NCT00786253:I.1004,"History of at least one of the following conditions: Diabetes mellitus type 2, hypertension, peripheral arterial occlusive disease"
NCT00786253:I.1005,"Stable, heterosexual relationship for>6 months"
NCT00786253:I.2001,"Primary hypoactive sexual desire"
NCT00786253:I.2002,"History of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 months"
NCT00786253:I.2003,"Nitrate therapy."
NCT00787683:I.1001,"age 18 Years to 80 Years"
NCT00787683:I.1002,"Ventricular Arrhythmia"
NCT00787683:I.1003,"The patient is willing/able to undergo the study protocol appointments and procedures/questionnaires"
NCT00787683:I.1004,"Indication for implantation of single chamber ICD or dual chamber ICD according to European guidelines"
NCT00787683:I.2001,"Age<18 and>80 years"
NCT00787683:I.2002,"Expected non-compliance"
NCT00787683:I.2003,"Known drug or alcohol abuse"
NCT00787683:I.2004,"Life expectancy<1 year"
NCT00787683:I.2005,"New York Heart Association Class IV"
NCT00787683:I.2006,"Participation in another clinical study"
NCT00787683:I.2007,"Participation in another telemonitoring concept"
NCT00787683:I.2008,"Pregnant or breast-feeding woman"
NCT00787683:I.2009,"Uncontrolled hypertension"
NCT00787683:I.2010,"No mobile phone use possible in patient residence"
NCT00791492:I.1001,"age 18 Years to 75 Years"
NCT00791492:I.1002,"Familial Amyloid Polyneuropathy"
NCT00791492:I.1003,"Inclusion Criteria: Male and non-pregnant female patients meeting all of the following criteria are eligible for enrollment in this study:"
NCT00791492:I.1004,"Patient has completed the Month 18 visit of Study Fx-005."
NCT00791492:I.1005,"If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study. (A condom alone is not considered an acceptable method of birth control.) If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the duration of the study. For both females and males, acceptable birth control must be used for at least 3 months after the last dose of study medication."
NCT00791492:I.1006,"Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements."
NCT00791492:I.1007,"Patient agrees not to participate in another investigational drug or device study while participating in this open-label extension study."
NCT00791492:I.2001,"Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3-4 times/month (ibuprofen and nimesulide will be permitted)."
NCT00791492:I.2002,"If female, patient is pregnant or breast feeding."
NCT00791492:I.2003,"Patient has liver function test abnormalities: alanine transaminases (ALT) and/or aspartate transaminases (AST)>2 times upper limit of normal (ULN) that in the medical judgment of the investigator are due to reduced liver function or active liver disease."
NCT00796354:I.1001,"Age 18 Years to 80 Years"
NCT00796354:I.1003,"Written informed consent obtained."
NCT00796354:I.1004,"Females of child-bearing potential must employ an adequate method of contraception and must undergo a pregnancy test at Randomisation Visit."
NCT00796354:I.1005,"Willing, able and competent to complete the entire study and comply with study instructions."
NCT00796354:I.1006,"Patients>50 years old have to have undergone a colonoscopy or computerised tomography (CT) after the onset of their IBS-C symptoms or within the last 5 years."
NCT00796354:I.1007,"Patient has diagnosed IBS-C using Rome III criteria for the last 3 months, with symptom onset at least 6 months prior to diagnosis."
NCT00796354:I.2001,"History or evidence of organic disease in the large bowel, intestinal perforation or obstruction due to structural or functional disorder of the gut wall, ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, complicated diverticulitis, ulcerative colitis, toxic megacolon and occlusive or subocclusive syndrome."
NCT00796354:I.2002,"Abdominal pain of unknown cause, not related to IBS."
NCT00796354:I.2003,"History of - major abdominal surgery"
NCT00796354:I.2004,"IBS subtype other than IBS-C."
NCT00796354:I.2005,"Known allergy to polyethylene glycol (PEG) 3350 or known hypersensitivity to any of the active substances."
NCT00796354:I.2006,"Laxative, drug or alcohol abuse (recent history or within previous 12 months)."
NCT00796354:I.2007,"Pregnant or lactating females."
NCT00796354:I.2008,"Severe or acute disease within 2 weeks prior to the start of the study."
NCT00796354:I.2009,"Patients with type I or II diabetes."
NCT00796354:I.2010,"Use of other investigational drugs, prescribed or OTC medications affecting gastrointestinal function such as anticholinergics, prokinetics, drugs affecting motility, anthraquinones, opioids,ondansetron or other 5-HT3 antagonists."
NCT00796354:I.2011,"Incomplete Patient Diary Card during the run-in period."
NCT00796354:I.2012,"The occurrence of diarrhoea during the run-in period."
NCT00796354:I.2013,"Patients with abnormal laboratory tests, proctoscopy /abdominal ultrasound, colonoscopy, sigmoidoscopy or CT that requires further investigation."
NCT00796354:I.2014,"Patients with any condition, which, in the Investigator's may put the patient at significant risk, may confound the study results, or may interfere significantly with the results of the study."
NCT00796354:I.2015,"Participation in another clinical study of drugs or devices parallel to or less than 1 month before study entry, or previous participation in this study."
NCT00796354:I.2016,"Employees of the Investigator or study site with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator."
NCT00796757:I.1001,"age at least 18 Years"
NCT00796757:I.1002,"adult patients,>=18 years of age"
NCT00796757:I.1003,"metastatic RCC with majority (>50%) of conventional clear-cell type"
NCT00796757:I.1004,"prior total nephrectomy for primary RCC"
NCT00796757:I.1005,"at least one measurable or non-measurable lesions"
NCT00796757:I.1006,"ECOG performance score of 0 or 2."
NCT00796757:I.2001,"prior systemic treatment for metastatic RCC"
NCT00796757:I.2002,"current or previously treated but non-stable CNS metastases or spinal cord compression"
NCT00796757:I.2003,"major surgery (including open biopsy) or radiation therapy within 28 days prior to enrollment"
NCT00796757:I.2004,"significant cardiovascular disease within 6 months prior to enrollment."
NCT00798317:I.1001,"age at least 18 Years"
NCT00798317:I.1002,"Presence of focal vitreomacular adhesion (i.e., central vitreal adhesion within 6 mm OCT field surrounded by elevation of the posterior vitreous cortex) that in the opinion of the Investigator is related to decreased visual function (such as metamorphopsia, decreased visual acuity, or other visual complaint)"
NCT00798317:I.2001,"Any evidence of proliferative retinopathy (including PDR or other ischemic retinopathies involving vitreoretinal vascular proliferation) or exudative AMD or retinal vein occlusion in the study eye"
NCT00798317:I.2002,"Subjects with any vitreous hemorrhage or any other vitreous opacification which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either OCT and/or fluorescein angiogram in the study eye"
NCT00798317:I.2003,"Subjects with macular hole diameter>400 µm in the study eye"
NCT00798317:I.2004,"Aphakia in the study eye"
NCT00798317:I.2005,"High myopia (>8D) in study eye (unless prior cataract extraction or refractive surgery that makes refraction assessment unreliable for myopia severity approximation, in which case axial length>28 mm is an exclusion)."
NCT00803309:I.1001,"age at least 18 Years"
NCT00803309:I.1002,"Male and female patients with HCV-genotype 2/3 chronic hepatitis C documented by detectable plasma HCV RNA (>15 IU/mL) and positivity of anti-HCV antibodies"
NCT00803309:I.1003,"Compensated liver disease (Child-Pugh Grade A clinical classification)"
NCT00803309:I.1004,"Negative urine or blood pregnancy test (one of the both, for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug. Additionally, all fertile males and females must be using two forms of effective contraception during treatment and during the 7 months after treatment end. This includes using birth control pills (no interaction with investigational drugs), IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state. At least one contraception method must be of barrier method"
NCT00803309:I.1005,"Ongoing treatment with 1.5 µg/kg Peg-Interferon alpha-2b (PegIntron) and>10.6 mg/kg ribavirin (Rebetol)"
NCT00803309:I.1006,"No rapid virological response (HCV-RNA positive after week 4 of the ongoing therapy)"
NCT00803309:I.1007,"Willingness to give written informed consent and willingness to participate to and to comply with the study protocol"
NCT00803309:I.2001,"Women with ongoing pregnancy or breast feeding"
NCT00803309:I.2002,"Male partners of women who are pregnant"
NCT00803309:I.2003,"Positive tests at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, HBeAg, anti-HIV, HIV-RNA"
NCT00803309:I.2004,"History or other evidence of a medical condition associated with chronic liver disease other than HCV associated (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures)"
NCT00803309:I.2005,"History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease"
NCT00803309:I.2006,"Patients with liver cirrhosis with a lesion suspicious for hepatic malignancy on the screening"
NCT00803309:I.2007,"Absolute neutrophil count (ANC)<750 cells/mm3 at screening"
NCT00803309:I.2008,"Platelet count<50,000 cells/mm3 at screening"
NCT00803309:I.2009,"Hb<10 g/dl at screening"
NCT00803309:I.2010,"Dose modification of Peg-Interferon alpha-2b (PegIntron) or ribavirin (Rebetol) during the first 4 weeks of the ongoing therapy"
NCT00803309:I.2011,"Interferon alpha or ribavirin therapy at any time point before the actual ongoing treatment"
NCT00803309:I.2012,"<80% adherence to treatment of the ongoing treatment until randomization (week 20-22 of ongoing treatment)"
NCT00803309:I.2013,"Serum creatinine level>1.5 times the upper limit of normal at screening"
NCT00803309:I.2014,"History of severe psychiatric disease, especially depression (ICD 10 codes F30-F33). Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time. Patients are excluded if any history of suicidal attempts is evident. If hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease are documented, psychiatric consultation is mandatory. Patients with a mild or moderate psychiatric disease (ICD 10 codes F32.0, F32.1, F33.0, F33.1) are only allowed to be included into the trial if a regular monitoring by a psychiatrist is performed during the trial"
NCT00803309:I.2015,"History of a severe seizure disorder or current anticonvulsant use"
NCT00803309:I.2016,"History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis)"
NCT00803309:I.2017,"History or any other evidence of autoimmune diseases"
NCT00803309:I.2018,"History or other evidence of chronic pulmonary disease associated with functional limitation"
NCT00803309:I.2019,"History of significant cardiac disease that could be worsened by acute anemia (e.g. NYHA Functional Class III or IV, myocardial infarction within 6 months prior to treatment with Peg-Interferon/ribavirin therapy, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina)"
NCT00803309:I.2020,"Evidence of thyroid disease that is poorly controlled on prescribed medications"
NCT00803309:I.2021,"Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration)"
NCT00803309:I.2022,"History of major organ transplantation with an existing functional graft"
NCT00803309:I.2023,"History or other evidence of severe illness, malignancy or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study"
NCT00803309:I.2024,"History of any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study"
NCT00803309:I.2025,"Patients with evidence for tuberculosis"
NCT00803309:I.2026,"Drug abuse within 6 months prior to the first dose of study drug and excessive alcohol consumption. Patients on methadone/polamidone/buprenorphine programs are not excluded"
NCT00803309:I.2027,"Any investigational drug and/or participation in another clinical study prior 6 months to the actual ongoing antiviral treatment"
NCT00803309:I.2028,"Limited contractual capability"
NCT00804856:I.1001,"age at least 18 Years"
NCT00804856:I.1002,"Male or female adult with relapsed/refractory AML ineligible for intensive treatment (phase I part only)"
NCT00804856:I.1003,"Male or female adult with previously untreated AML ineligible for intensive treatment (phase IIa part only)"
NCT00804856:I.1004,"Confirmed diagnosis of AML according to the WHO definition (except for acute promyelocytic leukaemia, APL)"
NCT00804856:I.1005,"Patient is eligible for LD-Ara-C treatment"
NCT00804856:I.1006,"Life expectancy>3 months"
NCT00804856:I.1007,"Eastern co-operative oncology group (ECOG, R01-0787) performance score<=2 at screening"
NCT00804856:I.1008,"Signed written informed consent consistent with international conference on harmonisation, good clinical practice (ICH-GCP) and local legislation"
NCT00804856:I.2001,"Previously untreated AML (phase I part only)"
NCT00804856:I.2002,"Relapsed or treatment refractory AML (phase IIa part only)"
NCT00804856:I.2003,"Patient with APL (AML subtype M3 according to the French-American-British (FAB) classification)"
NCT00804856:I.2004,"Hypersensitivity to one of the trial drugs or the excipients"
NCT00804856:I.2005,"Other malignancy requiring treatment"
NCT00804856:I.2006,"Symptomatic central nervous system involvement"
NCT00804856:I.2007,"Clinically relevant QT prolongation (e.g. long QT syndrome, QTcF>470 ms)"
NCT00804856:I.2008,"Aspartate amino transferase (AST) or alanine amino transferase (ALT)>2.5 times the upper limit of normal (ULN), or AST or ALT>5 times the ULN in case of known leukaemia liver involvement"
NCT00804856:I.2009,"Prothrombin time (PT)>1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin)"
NCT00804856:I.2010,Bilirubin
NCT00804856:I.2011,"Serum Creatinine Measurement"
NCT00804856:I.2012,"Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris, cardiac arrhythmia or severe heart failure/cardiac insufficiency."
NCT00804856:I.2013,"Psychiatric illness or social situation that would limit compliance with trial requirements"
NCT00804856:I.2014,"Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug"
NCT00804856:I.2015,"Contraindications for cytarabine treatment according to the SPC"
NCT00804856:I.2016,"Female patients of childbearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial, i.e. combination of two forms of effective contraception (hormonal contraception, intrauterine device, condom with spermicide, etc.)."
NCT00804856:I.2017,"Male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second medically acceptable method of contraception during the trial"
NCT00804856:I.2018,"Pregnant or nursing female patients"
NCT00804856:I.2019,"Patient unable to comply with the protocol"
NCT00816660:I.1001,"Age 18 Years to 60 Years"
NCT00816660:I.1002,"Subject has voluntarily given written informed consent (before conduct of any study-related procedures)"
NCT00816660:I.1003,"The subject has hereditary type 3 VWD (<= 3 IU/dL VWF:Ag)or severe type 1 or type 2A VWD (VWF:RCo<= 10% and FVIII:C<20%)"
NCT00816660:I.1004,"The subject has a medical history of at least 25 exposure days to VWF/FVIII coagulation factor concentrates"
NCT00816660:I.1005,"Karnofsky performance status (assessment scale)"
NCT00816660:I.1006,"NOT APPLICABLE IN ITALY: Female subjects of child-bearing potential must have a negative pregnancy test and agree to practice contraception using a method of proven reliability from the day of screening until the study completion visit"
NCT00816660:I.1007,"APPLICABLE ONLY IN ITALY: Female subjects of child-bearing potential must have a negative pregnancy test and agree to practice non-hormonal-based contraception using a method of proven reliability (IUD acceptable) from the day of screening until 96 hours after the last investigational drug infusion"
NCT00816660:I.1008,"NOT APPLICABLE IN ITALY: The subject must agree not to be on any therapy (hormone-based contraception acceptable) interfering with coagulation factor pharmacokinetics until 96 hours after the last investigational drug infusion"
NCT00816660:I.1009,"APPLICABLE ONLY IN ITALY: The subject must agree not to be on any therapy interfering with coagulation factor pharmacokinetics until 96 hours after the last investigational drug infusion"
NCT00816660:I.2001,"The subject has been diagnosed with a hereditary or acquired coagulation disorder other than VWD (including qualitative and quantitative platelet disorders and/or an international normalized ratio (INR)>1.4)"
NCT00816660:I.2002,"The subject has been diagnosed with an ADAMTS13 deficiency with<10% ADAMTS13 activity"
NCT00816660:I.2003,"von Willebrand factor antibody"
NCT00816660:I.2004,"The subject has a history or presence of FVIII inhibitor with a titer>= 0.4 BU (by Nijmegen assay) or>= 0.6 BU (by Bethesda assay)"
NCT00816660:I.2005,"The subject has a known hypersensitivity to mouse or hamster proteins"
NCT00816660:I.2006,"The subject has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, food allergies or animal allergies"
NCT00816660:I.2007,"The subject has a medical history of a thromboembolic event"
NCT00816660:I.2008,"The subject is HIV positive with an absolute CD4 count<200/mm3"
NCT00816660:I.2009,"The subject has been diagnosed with cardiovascular disease (New York Heart Association (NYHA) classes 1-4)"
NCT00816660:I.2010,"The subject has been diagnosed with insulin-dependent diabetes mellitus"
NCT00816660:I.2011,"The subject has an acute illness (e.g. influenza, flu-like syndrome, allergic rhinitis/conjunctivitis)"
NCT00816660:I.2012,"The subject has been diagnosed with liver disease, as evidenced by, but not limited to, any of the following: serum ALT three times the upper limit of normal, hypoalbuminemia, portal vein hypertension (e.g. presence of otherwise unexplained splenomegaly, history of esophageal varices)"
NCT00816660:I.2013,"The subject has been diagnosed with renal disease, with a serum creatinine level>= 2 mg/dL"
NCT00816660:I.2014,"In the judgment of the investigator, the subject has another clinically significant concomitant disease (e.g. uncontrolled hypertension, diabetes type II) that may pose additional risks for the subject"
NCT00816660:I.2015,"The subject has been treated with an immunomodulatory drug, excluding topical treatment (e.g. ointments, nasal sprays) within 30 days before enrollment"
NCT00816660:I.2016,"The subject has been treated with drugs known to induce thrombotic thrombocytopenic purpura (TTP) (e.g. Adenosine diphosphate (ADP) receptor inhibitors (Clopidogrel, Ticlopidine)) within 60 days before enrollment"
NCT00816660:I.2017,"The subject is receiving or anticipates receiving another investigational and/or interventional drug within 30 days before enrollment"
NCT00816660:I.2018,"The subject is a lactating female"
NCT00816660:I.2019,"The subject has a history of drug or alcohol abuse within the last 5 years"
NCT00816660:I.2020,"The subject has a progressive fatal disease and/or life expectancy of<3 months"
NCT00816660:I.2021,"The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures"
NCT00816660:I.2022,"The subject suffers from a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude"
NCT00816660:I.2023,"Subject is in prison or compulsory detention by regulatory and/or juridical order"
NCT00820105:I.1002,"Age between 18 and 65 years"
NCT00820105:I.1003,"History of migraine"
NCT00820105:I.1004,"Aged<= 50 years at onset of migraine history"
NCT00820105:I.2001,"Cluster headache or chronic migraine headaches"
NCT00820105:I.2002,"Currently uses, or within 3 months of Screening, has used: sodium valproate or topiramate and any other drugs used specifically for migraine prophylaxis, for example beta-blockers, calcium channel blockers, tricyclic antidepressants, selective serotonin reuptake inhibitors"
NCT00820105:I.2003,"Unable to distinguish migraine headache from tension and other types of headache"
NCT00820105:I.2004,"Current history of psychiatric disorder requiring regular medication"
NCT00820105:I.2005,"History of alcohol abuse"
NCT00820105:I.2006,"Known clinically significant allergy or known hypersensitivity to drugs"
NCT00820105:I.2007,"History of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study"
NCT00820105:I.2008,"Pregnant or breast-feeding"
NCT00820365:I.1001,"age 18 Years to 70 Years"
NCT00820365:I.1002,"Established diagnosis of CD, confirmed by standard criteria (e.g. endoscopy, ultrasound, X-ray)"
NCT00820365:I.1003,"Patients must be in clinical remission (Crohn's Disease Activity Index [CDAI]<150 points) on steroid therapy for at least 2 weeks"
NCT00820365:I.1004,"Confirmed steroid-dependency of CD: patients who are either"
NCT00820365:I.1005,"unable to taper steroids completely within 3 months of starting steroids,  without recurrent active disease, or"
NCT00820365:I.1006,"who have a relapse within 2 months of stopping steroids"
NCT00820365:I.1007,"Individual threshold dose of previous relapses should be<= 20 mg/day Prednisolone or equivalent steroid dose"
NCT00820365:I.1008,"Patients with stable glucocorticosteroid therapy between 20 and 40 mg/day Prednisolone or equivalent steroid dose for the previous week"
NCT00820365:I.1009,"Established diagnosis of UC, confirmed by standard criteria (e.g. endoscopy, ultrasound, X-ray)"
NCT00820365:I.1010,"Patients must be in clinical remission (Clinical Activity Index [CAI]<4 points) on steroid therapy for at least 2 weeks"
NCT00820365:I.1014,"Individual threshold dose of previous relapses should be<= 20 mg/day Prednisolone or equivalent steroid dose"
NCT00820365:I.1015,"Patients with stable glucocorticosteroid therapy between 20 and 40 mg/day Prednisolone or equivalent steroid dose for the previous week (* The threshold dose is that dose at which the patient experienced the relapses)"
NCT00820365:I.1017,"Written informed consent"
NCT00820365:I.1018,"Negative pregnancy test at screening in females of child-bearing potential"
NCT00820365:I.1019,"Males willing to use condoms or to be sexually abstinent"
NCT00820365:I.1020,"Use of appropriate contraceptive methods for females of childbearing potential one month before, throughout the course of the study and one month after study termination. This must be a combination of the following:"
NCT00820365:I.1021,"a highly effective method of first choice = a method with a low failure rate  (i.e.<1% per year) like sexual abstinence, combined oral  contraceptives, implants, injectables, some Intra Uterine Devices (IUDs),  vasectomized partner  together with"
NCT00820365:I.1022,"a method of second choice like condom, diaphragm, or cup pessary"
NCT00820365:I.2001,"Short Bowel Syndrome"
NCT00820365:I.2002,"Ileostomy, colostomy or rectal pouch"
NCT00820365:I.2003,"Relapse during screening"
NCT00820365:I.2004,"History of or existence of active tuberculosis"
NCT00820365:I.2005,"History of or existence of urolithiasis"
NCT00820365:I.2006,"History of or existence of human immune deficiency virus (HIV), Hepatitis B or C"
NCT00820365:I.2007,"History of malignancy within the past five years (excluding basal cell carcinoma of the skin)"
NCT00820365:I.2008,"Previous opportunistic infection"
NCT00820365:I.2009,"History of serious drug sensitivity"
NCT00820365:I.2010,"Significant cardiac arrhythmia, bradycardia or tachycardia or any other significant finding in the electrocardiogram (ECG)"
NCT00820365:I.2011,"Congestive heart failure, CHF"
NCT00820365:I.2012,"Uncontrolled hypertension"
NCT00820365:I.2013,"Uncontrolled asthma"
NCT00820365:I.2014,"Kidney Disease"
NCT00820365:I.2015,"Renal insufficiency defined as glomerular filtration rate (GRF)<50 ml/min/1.73 m (estimated GRF according to Cockcroft-Gault)"
NCT00820365:I.2016,"Psychiatric disorder"
NCT00820365:I.2017,"Known or suspected immunodeficiency"
NCT00820365:I.2018,"Laboratory abnormalities: hemoglobin<8.5 g/dl, white blood cell count<3500/mm, platelet count<125 000/mm, clinically relevant elevation of liver enzymes, serum creatinine level>=1.4 mg/dl, hematuria (>=10 erythrocytes/field on dipsticks)"
NCT00820365:I.2019,"Pregnancy, lactation"
NCT00820365:I.2020,"History of alcohol and/or drug dependence"
NCT00820365:I.2021,"Heavy smoker (over 20 per day)"
NCT00820365:I.2022,"Use of prohibited drugs or treatments"
NCT00820365:I.2023,"Patient not able or not willing to follow study procedures due to physical or psychological limitations or language problems"
NCT00820365:I.2024,"Participation in another investigational drug or vaccine trial within the last three months or concurrently with this study"
NCT00820365:I.2025,"Vaccination with life attenuated viruses within 4 weeks prior to study start"
NCT00820365:I.2026,"Patient with any medical condition which, in the opinion of the investigator or his designee, could jeopardize or compromise the ability of the patient to participate in the trial"
NCT00820365:I.2027,"Patients possibly dependent on the investigator or the sponsor"
NCT00822159:I.1001,"age at least 50 Years"
NCT00822159:I.1002,"Patients with trochanteric or femoral neck fractures, classified as: AO 31-A1, AO 31-A2, AO 31-A3, AO 31-B1, AO 31-B2, AO 31-B3"
NCT00822159:I.1003,"Patients undergoing fixation with DHS (135° aiming device, anti-rotational K-wire)"
NCT00822159:I.1004,"Patients willing to participate in the study according to the clinical investigation plan"
NCT00822159:I.1005,"Patients able to understand and read country national language at an elementary level"
NCT00822159:I.1006,"Signed written informed consent by the patient or legal guardian"
NCT00822159:I.2001,"Bilateral hip fractures (at present or in the past)"
NCT00822159:I.2002,"Open hip fracture"
NCT00822159:I.2003,"Any previous surgical procedures of the hip (ipsilateral / contralateral)"
NCT00822159:I.2004,"More than 7 days between injury and surgery"
NCT00822159:I.2005,"Polytrauma (multiple injuries, whereof one or the combination of several injuries is life-threatening)"
NCT00822159:I.2006,"Patients being pregnant or breast-feeding"
NCT00822159:I.2007,"Pathological fracture"
NCT00822159:I.2008,"Active malignancy"
NCT00822159:I.2009,"Psychiatric disorders that would preclude reliable assessment (e.g. severe depression)"
NCT00822159:I.2010,"Drug or alcohol abuse"
NCT00822159:I.2011,"Patients having participated in any other device or drug related clinical trial within the previous month"
NCT00822393:I.1001,"age 18 Years to 70 Years"
NCT00822393:I.1002,"Patients with acute myeloid leukaemia acc. to WHO, 2001 (AML in complete remission at transplant, i.e. blast counts<5 % in bone marrow) or myelodysplastic syndrome acc. to WHO, 2001 (MDS with blast counts<20 % in bone marrow during disease history) indicated for allogeneic haematopoietic progenitor cell transplantation but considered to be at increased risk for standard conditioning therapies according to the following criteria:"
NCT00822393:I.1003,"patients aged>= 50 years at transplant and / or"
NCT00822393:I.1004,"patients with a HCT-CI score>2 [acc. to Sorror et al., 2005]"
NCT00822393:I.1005,"Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor (MUD). Donor selection is based on molecular high resolution typing (4 digits) of class II alleles of the DRB1 and DQB1 gene loci and molecular (at least) low resolution typing (2 digits) of class I alleles (i.e., antigens) of the HLA-A, B, and C gene loci. In case, no class I and class II completely identical donor (10 out of 10 gene loci) can be identified, one antigen disparity (class I) and/or one allele disparity (class II) between patient and donor are acceptable. Conversely, disparity of two antigens (irrespective of the involved gene loci) cannot be accepted. These definitions for the required degree of histocompatibility apply to the selection of related as well as of unrelated donors."
NCT00822393:I.1006,"Adult patients of both gender, age 18 - 70 years"
NCT00822393:I.1007,"Karnofsky performance status (assessment scale)"
NCT00822393:I.1008,"Written informed consent"
NCT00822393:I.1009,"Men capable of reproduction and women of childbearing potential must be willing to consent to using a highly effective method of birth control such as condoms, implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner while on treatment and for at least 6 months thereafter"
NCT00822393:I.2001,"Patients with acute promyelocytic leukaemia with t(15,17)(q22,q12) and in CR1"
NCT00822393:I.2002,"Patients considered contra-indicated for allogeneic HSCT due to severe concomitant illness (within three weeks prior to scheduled day -6):"
NCT00822393:I.2003,"patients with severe renal impairment like patients on dialysis or prior  renal transplantation or S-creatinine>3.0 x ULN or calculated  creatinine-clearance<60 ml/min"
NCT00822393:I.2004,"patients with severe pulmonary impairment, DLCO/or FEV1<50 % or severe  dyspnoea at rest or requiring oxygen supply"
NCT00822393:I.2005,"patients with severe cardiac impairment diagnosed by echocardiography and  LVEF<40 %"
NCT00822393:I.2006,"patients with severe hepatic impairment indicated by hyperbilirubinaemia>3  x ULN or ALT / AST>5 x ULN"
NCT00822393:I.2007,"Active malignant involvement of the CNS"
NCT00822393:I.2008,"HIV-positivity, active non-controlled infectious disease under treatment (no decrease of CRP or PCT) including active viral liver infection"
NCT00822393:I.2009,"Previous allogeneic HSCT"
NCT00822393:I.2010,"Pleural effusion or ascites>1.0 L"
NCT00822393:I.2011,"Pregnancy or lactation"
NCT00822393:I.2012,"Known hypersensitivity to treosulfan, busulfan and/or related ingredients"
NCT00822393:I.2013,"Participation in another experimental drug trial within 4 weeks prior to day -6 of the protocol"
NCT00822393:I.2014,"Non-cooperative behaviour or non-compliance"
NCT00822393:I.2015,"Psychiatric diseases or conditions that might compromise the ability to give informed consent"
NCT00823173:I.1001,"age at least 18 Years"
NCT00823173:I.1002,"Signed and dated informed consent."
NCT00823173:I.1003,"Patients with the typical presentation of HLA-B27 positive AAU (unilateral, painful anterior uveitis of sudden onset)."
NCT00823173:I.1004,"2+ anterior chamber cells according to the SUN Working Group criteria, as assessed by slit lamp biomicroscopy."
NCT00823173:I.1005,"Start of the typical first symptoms of the current attack, defined as the point in time when the patient felt the first sensation of the attack, within the last 72 hours before initiation of treatment with the study medication."
NCT00823173:I.1006,"Negative pregnancy test for females of childbearing potential (pre menopausal,<2 years post-menopausal, not surgically sterile)."
NCT00823173:I.1007,"Patients with a negative QuantiFERON TB Gold test result."
NCT00823173:I.1008,"Patients who currently have no clinically apparent symptoms of an HLA B27 associated acute extraocular disorder requiring systemic immunosuppressive therapy."
NCT00823173:I.1009,"Patients who are willing and able to cooperate with study requirements."
NCT00823173:I.2001,"IOP elevation requiring therapy."
NCT00823173:I.2002,"Uncontrolled diabetes mellitus and diabetic retinopathy."
NCT00823173:I.2003,"Patients with a single eye or a pinhole Snellen visual acuity 20/200 or worse in the non study eye."
NCT00823173:I.2004,"<= 1+ Anterior chamber cells (finding)"
NCT00823173:I.2005,"Patients with 3+ or 4+ anterior chamber cells or hypopyon."
NCT00823173:I.2006,"Patients in whom the time of the beginning of the current attack can not be determined."
NCT00823173:I.2007,"Patients exhibiting corneal ulceration or a history of recurrent herpetic keratitis or clinical evidence of herpetic dermatitis."
NCT00823173:I.2008,"Patients currently treated with topical corticosteroids."
NCT00823173:I.2009,"Patients treated with systemic immunosuppressive therapy within the last 2 months."
NCT00823173:I.2010,"Patients treated with a systemically administered TNF-alpha inhibitor within the last 2 months."
NCT00823173:I.2011,"Pregnant or breast-feeding women or women of childbearing potential, who with their partners refuse to use 2 reliable methods of contraception (including 1 barrier method) during the study."
NCT00823173:I.2012,"Male patients with a female partner who could become pregnant and who refuse, with their partner, to use 2 reliable methods of contraception (including 1 barrier method) during the study."
NCT00823173:I.2013,"Patients whose clinical presentation is suggestive for an active bacterial, viral or fungal infection anywhere in the body."
NCT00823173:I.2014,"Patients with history of recurrent infections, or a clinical presentation suggestive of a chronic infection requiring antimicrobial therapy (e.g. syphilis) including active episodes of serious viral infections by, e.g. herpes simplex, herpes zoster, cytomegalic or hepatitis viruses or clinical signs of fungal infections, such as histoplasmosis, aspergillosis or coccidiomycosis."
NCT00823173:I.2015,"Patients presenting with higher intraocular pressure in the uveitic eye than in the contralateral eye."
NCT00823173:I.2016,"Patients with known carrier status of human immunodeficiency virus, hepatitis B or hepatitis C."
NCT00823173:I.2017,"Patients with a history of demyelinating disease (multiple sclerosis) or optic neuritis."
NCT00823173:I.2018,"Patients with positive or unclear QuantiFERON TB Gold test result or history of high risk exposure to Mycobacterium tuberculosis."
NCT00823173:I.2019,"Patients with known coexisting malignancy."
NCT00823992:I.1001,"Age 18 Years to 75 Years"
NCT00823992:I.1002,"Adult (person)"
NCT00823992:I.1003,"type 2 diabetes mellitus, receiving metformin at a stable dose of>=1500mg/day for at least 12 weeks"
NCT00823992:I.1004,"HbA1c>=6.5% and<=9.5% at screening"
NCT00823992:I.1005,"BMI>=30 and<=50 kg/m2 at screening"
NCT00823992:I.1006,"stable weight +/-5% for at least 12 weeks prior to screening."
NCT00823992:I.2001,"history of type 1 diabetes or acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months"
NCT00823992:I.2002,"evidence of clinically significant diabetic complications"
NCT00823992:I.2003,"myocardial infarction, coronary artery bypass surgery, post-transplantation cardiomyopathy or stroke within the past 6 months."
NCT00824083:I.1001,"age 6 Years to 60 Years"
NCT00824083:I.1002,"CESS81/CESS86/EICESS92/EURO-E.W.I.N.G.99 trials participants of the German Society of Pediatric Hematology and Oncology (GPOH)"
NCT00824083:I.2001,"no complete remission (CR)"
NCT00824083:I.2002,"any kind of paralysis"
NCT00824083:I.2003,"<5years after diagnosis"
NCT00826059:I.1001,"age 40 Years to 85 Years"
NCT00826059:I.1002,"Age: Between 40 years and 80 years for male and 85 for female subjects"
NCT00826059:I.1003,"Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior Cerebral Artery territories"
NCT00826059:I.1004,"Imaging findings demonstrating signs of ischemia in the anterior circulation, consistent with the clinical diagnosis"
NCT00826059:I.1005,"Baseline NIHSS ? 7 and ? 18 within 2 hours prior to implantation."
NCT00826059:I.1006,"Ability to initiate treatment within 8- 24 hours from stroke onset"
NCT00826059:I.1007,"Signed informed consent from patient him/herself or legally authorized representative if applicable"
NCT00826059:I.2001,"Intracranial hemorrhage or hemorrhagic transformation"
NCT00826059:I.2002,"Massive stroke"
NCT00826059:I.2003,"Acute ischemic stroke in the posterior circulation"
NCT00826059:I.2004,"Minor stroke"
NCT00826059:I.2005,"Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke"
NCT00826059:I.2006,"Previous stroke in the last 6 months or pre-existing disability"
NCT00826059:I.2007,"Patients with bleeding propensity or any condition in the oral cavity that prevents implantation"
NCT00826059:I.2008,"Clinical signs and symptoms or imaging evidence of bilateral stroke."
NCT00826059:I.2009,"Known cerebral arteriovenous malformation, cerebral aneurysm."
NCT00826059:I.2010,"Clinical suspicion of septic embolus."
NCT00826059:I.2011,"Uncontrolled hypertension (systolic>185 mmHg and/or diastolic>110 mmHg)"
NCT00826059:I.2012,"Serious systemic infection."
NCT00826059:I.2013,"Women known to be pregnant or having a positive or indeterminate pregnancy test."
NCT00826059:I.2014,"Patients with other implanted neural stimulator/ electronic devices (pacemakers)."
NCT00826059:I.2015,"Life expectancy<1 year from causes other than stroke."
NCT00832039:I.1001,"age at least 18 Years"
NCT00832039:I.1002,"Severe sepsis or septic shock according to ACCP/SCCM criteria"
NCT00832039:I.1003,"Onset of severe sepsis or septic shock<24 h"
NCT00832039:I.1004,"Informed Consent"
NCT00832039:I.2001,"Pregnant or breast-feeding women"
NCT00832039:I.2002,"Fertile female women without effective contraception"
NCT00832039:I.2003,"Participation in interventional clinical trial within the last 30 days"
NCT00832039:I.2004,"Current participation in any study"
NCT00832039:I.2005,"Former participation in this trial"
NCT00832039:I.2006,"Selenium intoxication"
NCT00832039:I.2007,"No commitment to full patient support (i.e. DNR order)"
NCT00832039:I.2008,"Patient's death is considered imminent due to coexisting disease"
NCT00832039:I.2009,"Relationship of the patient to study team member (i.e. colleague, relative)"
NCT00832039:I.2010,"Infection where guidelines recommend a longer duration of antimicrobial therapy (i.e. endocarditis, tuberculosis, malaria etc)"
NCT00832039:I.2011,"Patient immunocompromised"
NCT00833924:I.1001,"age at least 18 Years"
NCT00833924:I.1002,"Abdominal aortic, aortoiliac, and iliac aneurysms of appropriate size"
NCT00833924:I.1003,"Vessels suitable for endovascular access and aneurysm repair"
NCT00833924:I.2001,"<18 years of age"
NCT00833924:I.2002,"Inability or refusal to give informed consent"
NCT00833924:I.2003,"Disease considerations that would compromise patient safety or study outcomes"
NCT00833924:I.2004,"Unsuitable arterial anatomy"
NCT00844064:I.1001,"age 18 Years to 75 Years"
NCT00844064:I.1002,"Written informed consent."
NCT00844064:I.1003,"Male or non-pregnant, non-lactating female."
NCT00844064:I.1004,"Pancreatic cancer: Histologically or cytologically confirmed diagnosis, stage IVA or IVB (AJCC, 1997)."
NCT00844064:I.1005,"Melanoma: Histologically or cytologically confirmed diagnosis, stage III or IV (AJCC, UICC)"
NCT00844064:I.1006,"Colorectal cancer: Histologically or cytologically confirmed diagnosis, stage III or IV (AJCC, UICC), excluded from the last cohort."
NCT00844064:I.1007,"Patient is not or no longer amenable to established forms of therapy."
NCT00844064:I.1008,"At least one measurable lesion."
NCT00844064:I.1009,"Karnofsky performance status of at least 80%."
NCT00844064:I.1010,"Recovery from acute toxicity caused by any previous therapy."
NCT00844064:I.1011,"Adequate organ function as assessed by the following laboratory values:"
NCT00844064:I.1012,"Serum creatinine and urea<2 times the upper limit of normal (ULN)."
NCT00844064:I.1013,"ALT and AST<3 ULN (in case of a liver metastasis:<5x ULN); alkaline phosphatase<3 ULN; and bilirubin<2.5 mg/dL."
NCT00844064:I.1014,"Prothrombin time<1.5 INR and PTT<1.5 times the upper limit of normal."
NCT00844064:I.1015,Hemoglobin
NCT00844064:I.1016,"Blood Platelets"
NCT00844064:I.1017,"White Blood Cell Count procedure (WBC)"
NCT00844064:I.1018,"Absolute Neutrophil Count, ANC"
NCT00844064:I.2001,"Patient unable to comply with the protocol regulations."
NCT00844064:I.2002,"Pregnant or lactating female."
NCT00844064:I.2003,"Antitumor radiation therapy within 12 weeks, tumor surgery within 4 weeks or any other therapy with established antitumor effects within 2 weeks prior to study entry."
NCT00844064:I.2004,"The patient takes or is likely to need other prohibited concomitant medication. Administration of corticosteroids should be strictly avoided during the course of the study."
NCT00844064:I.2005,"Patient's participation in another clinical trial with investigational medication within 30 days prior to study entry."
NCT00844064:I.2006,"History of brain metastases. In the case of suspected brain metastases a CT scan of the skull will be performed (not mandatory in asymptomatic patients)."
NCT00844064:I.2007,"Clinically significant cardiovascular abnormalities such as refractory hypertension, congestive heart failure, unstable angina, or poorly controlled arrhythmia, or a myocardial infarction within 6 months prior to treatment."
NCT00844064:I.2008,"Gastric or duodenal ulcers within 6 months before study entry or is at risk of gastrointestinal ulceration due to high consumption of NSAIDs."
NCT00844064:I.2009,"An active infection with HIV, HBV, or HCV."
NCT00844064:I.2010,"Clinically significant acute viral, bacterial, or fungal infection."
NCT00844064:I.2011,"Acute medical problems that may be considered to become an unacceptable risk, or any conditions that might be contraindications for starting study treatment."
NCT00844064:I.2012,"History of allergies to reagents used in this study."
NCT00844064:I.2013,"Drug abuse or extensive use of alcohol."
NCT00844064:I.2014,"Significant psychiatric disorders/ legal incapacity or limited legal capacity."
NCT00844064:I.2015,"History of Long QT Syndrome or QTc time ? 480 msec in screening/baseline ECGs. The average QTc time is to be calculated from three separate ECGs performed prior to start of infusion: two ECGs performed at Screening/Baseline (with a minimum 1-hour interval in between) and one performed within 1 hour prior to start of infusion."
NCT00844194:I.1001,"age at least 18 Years"
NCT00844194:I.1002,"Present with pain due to bilateral peripheral neuropathy (according to International Statistical Classification of Diseases and Related Health Problems 10 (ICD 10)."
NCT00844194:I.1003,"To qualify for the MDD+ cohort, patients need to meet the ICD-10 criteria for MDD. Furthermore, Hamilton rating scale for depression 17 (HAMD-17) scores need to match with the ICD-10 criteria for qualification of the MDD+ or MDD- groups."
NCT00844194:I.1004,"Male or female outpatients at least 18 years of age."
NCT00844194:I.1005,"Females with child bearing potential must test negative for a serum pregnancy test at Visit 1. Females of child-bearing potential (not surgically sterilized and between menarche and 1 year post-menopause) must agree to utilize medically acceptable and reliable means of birth control as determined by the investigator during the study and for 1 month following the last dose of the study. Examples of reliable methods include use of oral contraceptives or Depo-Clinovir Contraceptive Injection (sterile medroxyprogesterone acetate suspension, Pharmacia), partner with vasectomy, diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, or intrauterine devices. Women who are pregnant or breast-feeding may not participate in the study."
NCT00844194:I.1006,"Educational level and degree of understanding such that they can communicate intelligibly with the investigator and study coordinator."
NCT00844194:I.1007,"Judged to be reliable and agrees to keep all appointments for clinic visits, tests, and procedures required by the protocol."
NCT00844194:I.2001,"Have already a diagnosis of Depression and are currently treated with an antidepressant medication for depression, when entering the study."
NCT00844194:I.2002,"Suffer from pain that cannot be clearly differentiated from or conditions that interfere with the assessment of DPNPain."
NCT00844194:I.2003,"Had a historical exposure to drugs known to cause neuropathy, that could have been responsible for neuropathy."
NCT00844194:I.2004,"Have previously been treated with duloxetine (for DPNP or MDD)"
NCT00844194:I.2005,"Are judged to be at suicidal risk by the clinical investigator or as defined by a score of>= 2 on question 9 of the Beck Depression Inventory-II (BDI-II)."
NCT00844194:I.2006,"Had a history of substance abuse or dependence within the past year, excluding nicotine and caffeine."
NCT00851084:I.1001,"age at least 18 Years"
NCT00851084:I.1002,"Histologically proven adenocarcinoma of the colon or the rectum"
NCT00851084:I.1003,"Metastatic disease not amenable to potentially curative treatment"
NCT00851084:I.2001,"Prior therapy for metastatic cancer of the colon or the rectum"
NCT00851084:I.2002,"Prior treatment with angiogenesis inhibitors"
NCT00852670:I.1001,"age 18 Years to 60 Years"
NCT00852670:I.1002,"Adult males and females with moderate to severe plaque psoriasis who require systemic treatment and for whom participation in a placebo-controlled study of an investigational drug is justified."
NCT00852670:I.2001,"Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis."
NCT00852670:I.2002,"Systemic or topical treatments for psoriasis other than emollients."
NCT00852670:I.2003,"Ongoing bacterial, viral or fungal infections."
NCT00852670:I.2004,"History or presence of malignancy."
NCT00852670:I.2005,"Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients'risk from participating in the study."
NCT00855218:I.1001,"age at least 18 Years"
NCT00855218:I.1002,"Unresectable, multinodular asymptomatic tumor without vascular invasion or extrahepatic spread"
NCT00855218:I.1003,"Confirmed Diagnosis of HCC:"
NCT00855218:I.1004,"Cirrhotic subjects: Clinical diagnosis by AASLD criteria"
NCT00855218:I.1005,"HCC can be defined in cirrhotic subjects by one imaging technique (CT scan, MRI, or second generation contrast ultrasound) showing a nodule larger than 2 cm with contrast uptake in the arterial phase and washout in venous or late phases or two imaging techniques showing this radiological behavior for nodules of 1-2 cm in diameter."
NCT00855218:I.1006,"Cytohistological confirmation is required for subjects who do not fulfill these eligibility criteria."
NCT00855218:I.1007,"Non-cirrhotic subjects: For subjects without cirrhosis, histological or cytological confirmation is mandatory"
NCT00855218:I.1008,"Documentation of original biopsy for diagnosis is acceptable"
NCT00855218:I.1009,"Child Pugh class A without ascites"
NCT00855218:I.1010,"Adequate bone marrow, liver and renal function as assessed by central lab by means of the following laboratory requirements from samples within 7 days prior to randomization:"
NCT00855218:I.2001,"Patients on a liver transplantation list or with advanced liver disease as defined below:"
NCT00855218:I.2002,"Child Pugh B and C"
NCT00855218:I.2003,"Active gastrointestinal bleeding"
NCT00855218:I.2004,Encephalopathies
NCT00855218:I.2005,Ascites
NCT00855218:I.2006,"Lesions having previously been treated with local therapy such as resection of HCC, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI) or cryoablation can not be selected as the target lesions."
NCT00856284:I.1001,"age 18 Years to 80 Years"
NCT00856284:I.1002,"Has a diagnosis of type 2 diabetes mellitus."
NCT00856284:I.1003,"Must meet one of the following:"
NCT00856284:I.1004,"Has been inadequately controlled on a stable daily dose of>= 1500 mg (or  documented maximum tolerated dose) of metformin for at least 2 months prior to  Screening."
NCT00856284:I.1005,"Has been inadequately controlled (as defined by a glycosylated hemoglobin 7.5  10%, inclusive) on metformin<1500 mg without documented maximum tolerated dose."
NCT00856284:I.1006,"No treatment with antidiabetic agents other than metformin within 2 months prior to Screening (for Schedule A)/Pre-Screening (for Schedule B)."
NCT00856284:I.1007,"Has body mass index within 23kg/m2 and 45kg/m2 unless the subject is Asian or of Asian descent, for whom the allowable body mass index will be>= 20 kg/m2 and<= 35 kg/m2, inclusive."
NCT00856284:I.1008,"Has fasting C-peptide concentration at least 0.8 ng."
NCT00856284:I.1009,"If regularly using non-excluded medications, must be on a stable dose at least 4 wks prior to Screening/Pre-screening."
NCT00856284:I.1010,"Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant, lactating or intends to donate ova from Screening throughout the duration of the study."
NCT00856284:I.1011,"Must be able and willing to monitor their blood glucose concentrations with a home monitor, and comply with protocol requirements including scheduled clinic appointments."
NCT00856284:I.2001,"Systolic blood pressure>= 150 mmHg and/or diastolic pressure>= 90."
NCT00856284:I.2002,"Hemoglobin<= 12 g/dL for males and<= 10 g/dL for females at Screening Visit."
NCT00856284:I.2003,"Alanine aminotransferase>= 2.5 times the upper limit of normal at Screening Visit."
NCT00856284:I.2004,"Serum creatinine>= 1.5 mg/dL for males and 1.4 for females, or calculated creatinine clearance<60 L/min."
NCT00856284:I.2005,"Males intending to impregnate others or donate sperm before, during or within 1 month after participating in the study."
NCT00856284:I.2006,"A history of cancer other than squamous or basal cell carcinoma of the skin that has not been in full remission for at least 5 yrs."
NCT00856284:I.2007,"A history of laser treatment for diabetic retinopathy within 6 months of screening."
NCT00856284:I.2008,"Treated for diabetic gastric paresis, gastric banding, or gastric bypass."
NCT00856284:I.2009,"New York Heart Association Class III or IV heart failure."
NCT00856284:I.2010,"History of coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, stroke or transient ischemic attack within 3 months prior to screening."
NCT00856284:I.2011,"Known history of human immunodeficiency virus, hepatitis B or C."
NCT00856284:I.2012,"Alcohol or substance abuse within 2 years prior to screening."
NCT00856284:I.2013,"Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:"
NCT00856284:I.2014,"Any investigational drug within 30 days"
NCT00856284:I.2015,"Any investigational diabetic drug within 3 months"
NCT00856284:I.2016,"Any antidiabetic drug in the dipeptidyl peptidase-4 inhibitors or glucagon-like  peptide-1 mimetics classes within 90 days prior to Screening other than  metformin"
NCT00856284:I.2017,"Prior treatment with alogliptin."
NCT00856284:I.2018,"Weight-Loss Agents"
NCT00856284:I.2019,"Investigational antidiabetics"
NCT00856284:I.2020,"Oral or systemically injected glucocorticoids"
NCT00856284:I.2021,"A hypersensitivity allergy or anaphylactic reaction to any dipeptidyl peptidase-4 drug, metformin or glipizide."
NCT00856284:I.2022,"Has a documented history or concurrent signs of significant thyroid disease (eg, autoimmune thyroid diseases such as Graves disease and Hashimoto thyroiditis or active thyroid nodules)."
NCT00856622:I.1001,"age at least 18 Years"
NCT00856622:I.1002,"Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension."
NCT00856622:I.1003,"Patients currently on IOP reducing therapy: IOP>= 25mmHg (two IOP determinations at pre-study separated by at least one hour) OR Patients without IOP reducing therapy: IOP>= 30mmHg (two IOP determinations at pre-study separated by at least one hour)."
NCT00856622:I.2001,"History of acute angle closure or closed/barely open anterior chamber angle."
NCT00856622:I.2002,"Current use of contact lenses."
NCT00856622:I.2003,"Ocular surgery or argon laser trabeculoplasty (ALT) within three months prior to pre-study visit."
NCT00856622:I.2004,"Ocular inflammation/infection occurring within three months prior to pre-study visit."
NCT00856622:I.2005,"Hypersensitivity to benzalkonium chloride or to any other component of the study drug solutions."
NCT00856622:I.2006,"Other abnormal ocular condition or symptom preventing the patient from entering the study, according to the investigator's judgement."
NCT00856622:I.2007,"Cardiac failure, sinus bradycardia, second and third degree of atrioventricular block. (The routines for prescribing topical B-blocking agents will be followed."
NCT00856622:I.2008,"Bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary disease. (The routines for prescribing topical B-blocking agents will be followed)."
NCT00856622:I.2009,"Pregnancy, Gestation"
NCT00856622:I.2010,"Women of childbearing potential who has not used adequate contraceptive methods during the last three months."
NCT00856622:I.2011,"Inability to adhere to treatment/visit plan."
NCT00856622:I.2012,"Have participated in any other clinical study within one month prior to pre-study visit."
NCT00857012:I.1001,"age at least 18 Years"
NCT00857012:I.1002,"Postmenopausal women aged 18 years or older. Postmenopause is defined as Natural menopause with menses>1 year ago or Serum FSH (>20 IU/ l), and E2 levels in the postmenopausal range or patients who had bilateral oophorectomy"
NCT00857012:I.1003,"Histologically / cytologically confirmed primary diagnosis of early breast cancer (M0) with hormone sensitive tumour (ER+ve and/or PgR+ve)"
NCT00857012:I.1004,"Patients, who underwent breast cancer surgery and, if appl. radiation therapy and/or neo/adjuvant chemotherapy and have taken adjuvant endocrine treatment with anastrozole (upfront or following two to three years of tamoxifen) min 3 max 6 months"
NCT00857012:I.1005,"In case of a previous therapy with tamoxifen (switch-therapy), duration of tamoxifen treatment for at least two and up to three years."
NCT00857012:I.2001,"Patients with severe renal function disorders (Creatinine clearance<20 ml/min or Patients with moderate or severe disorders of hepatic function"
NCT00857012:I.2002,"Concomitant treatment with drugs known to affect sex hormonal status and tamoxifen"
NCT00857012:I.2003,"Patients with ductal carcinoma in situ (DCIS) without primary diagnosis of early breast cancer (M0)"
NCT00857012:I.2004,"Evidence of any significant clinical disorder or laboratory finding which in the opinion of the investigator, makes it undesirable for the patient to participate in the program"
NCT00858364:I.1001,"age at least 18 Years"
NCT00858364:I.1002,"Subjects with stage IV NSCLC (not recurrent or re-staged)."
NCT00858364:I.1003,"Expected to receive at least 2 additional cycles (at least 6 total weeks) of first line myelosuppressive cyclic chemotherapy after randomization. Subjects should not be expected to receive only maintenance chemotherapy."
NCT00858364:I.1004,"Eastern Cooperative Oncology Group performance status of 0 or 1 as assessed within 21 days prior to randomization."
NCT00858364:I.1005,"Life expectancy>6 months based on the judgment of the investigator and documented during screening."
NCT00858364:I.1006,"Hemoglobin level<= 11.0 g/dL as assessed by the local laboratory, sample obtained within 7 days prior to randomization (retest in screening is acceptable)."
NCT00858364:I.1007,"Adequate serum folate (>= 2 ng/mL) and vitamin B12 (>= 200 pg/mL) levels assessed by central laboratory (supplementation and retest acceptable) during screening."
NCT00858364:I.1008,"Subjects must have had a baseline scan (CT, MRI, or PET/CT) of the chest to assess disease burden before starting on first line chemotherapy for NSCLC and those images must have been reviewed by the investigator prior to randomization. If the scan was performed more than 28 days prior to randomization, an additional scan must be performed and reviewed by the investigator to confirm that the patient has not progressed before randomization."
NCT00858364:I.1009,"Before any study-specific procedure, the appropriate written informed consent must be obtained from the subject or a legally accepted representative ."
NCT00858364:I.2001,"Known primary benign or malignant hematologic disorder which can cause anemia."
NCT00858364:I.2002,"History of, or current active cancer other than NSCLC, with the exception of curatively resected non-melanomatous skin cancer, curatively treated cervical carcinoma in situ, or other primary solid tumors curatively treated with no known active disease present and no curative treatment administered for the last 3 years."
NCT00858364:I.2003,"Received any prior adjuvant or neoadjuvant therapy for NSCLC."
NCT00858364:I.2004,"Subjects with a history of brain metastasis ."
NCT00858364:I.2005,"Uncontrolled hypertension (systolic BP>160 mmHg or diastolic BP>100 mmHg), or as determined by the investigator during screening."
NCT00858364:I.2006,"History of neutralizing antibody activity to rHuEPO or darbepoetin alfa."
NCT00858364:I.2007,"Uncontrolled angina, uncontrolled heart failure, or uncontrolled cardiac arrhythmia as determined by the investigator at screening. Subjects with known myocardial infarction within 6 months prior to randomization."
NCT00858364:I.2008,"Subjects with a history of seizure disorder taking anti-seizure medication within 30 days prior to randomization."
NCT00858364:I.2009,"Clinically significant systemic infection or uncontrolled chronic inflammatory disease (eg, rheumatoid arthritis, inflammatory bowel disease) as determined by the investigator during screening."
NCT00858364:I.2010,"Known seropositivity for HIV or diagnosis of AIDS, positive for hepatitis B surface antigen, or seropositive for hepatitis C virus"
NCT00858364:I.2011,"History of pure red cell aplasia"
NCT00858364:I.2012,"History of deep venous thrombosis or embolic event (eg, pulmonary embolism) within 6 months prior to randomization."
NCT00858364:I.2013,"Transferrin saturation<20% and ferritin<50 ng/mL as assessed by the central laboratory during screening. Subjects must have both to be excluded (supplementation and retest acceptable)."
NCT00858364:I.2014,"Abnormal renal function (serum creatinine level>2X ULN) as assessed by the central laboratory during screening."
NCT00858364:I.2015,"Abnormal liver function (total bilirubin>2X ULN or liver enzymes ALT or AST>2.5X ULN for subjects without liver metastasis or>= 5X ULN for subjects with liver metastasis) as assessed by the central laboratory during screening. Subjects with documented Gilbert's Disease may be eligible."
NCT00858364:I.2016,"Erythrocyte Transfusion"
NCT00858364:I.2017,"Plan to receive any RBC transfusion between randomization and study day 1."
NCT00858364:I.2018,"Known previous treatment failure to ESAs (eg, rHuEPO, darbepoetin alfa)."
NCT00858364:I.2019,"ESA therapy within the 28 days prior to randomization."
NCT00858364:I.2020,"Known hypersensitivity to recombinant ESAs or the excipients contained within the investigational product."
NCT00858364:I.2021,"<30 days since receipt of any investigational product or device. Investigational use/receipt of a medicinal product or device that has been approved by the country's local regulatory authority for any indication is permitted."
NCT00858364:I.2022,"Subjects of reproductive potential who are pregnant, breast feeding or not willing to use effective contraceptive precautions during the study and for at least one month after the last dose of investigational product in the judgment of the investigator (including females of childbearing potential who are partners of male subjects)."
NCT00858364:I.2023,"Previously randomized to this study."
NCT00858364:I.2024,"Investigator has concerns regarding the ability of the subject to give written informed consent and/or to comply with study procedures (including availability for follow up visits."
NCT00866684:I.1001,"Age at least 18 Years"
NCT00866684:I.1002,"Recipients of renal allograft with current actinic keratosis I or II or successfully treated actinic keratosis III (inclusion possible immediately after completed wound healing from surgical excision), invasive squamous cell carcinoma (SCC), basal cell carcinoma and/or premalignant neoplastic skin lesions"
NCT00866684:I.1003,"Minimum period of 6 month after renal transplantation"
NCT00866684:I.1004,"Stable renal function and a calculated creatinine clearance of at least 40 ml/min"
NCT00866684:I.1005,"Written informed consent"
NCT00866684:I.1006,"Proteinuria<= 800 mg/d at time of enrolment"
NCT00866684:I.1007,"Successfully treated solid tumor (no recurrence or metastasis in the last 2 years)"
NCT00866684:I.2001,"Current Sirolimus- or Everolimus-intake"
NCT00866684:I.2002,"Instable graft function (creatinine clearance<40 ml/min)"
NCT00866684:I.2003,"Graft rejection"
NCT00866684:I.2004,Proteinuria
NCT00866684:I.2005,"Non-controlled hyperlipidemia (Cholesterol>7,8 mmol/l, Triglycerides>4)"
NCT00866684:I.2006,Leukocytopenia
NCT00866684:I.2007,Thrombocytopenia
NCT00866684:I.2008,"Pregnancy or breastfeeding"
NCT00866684:I.2009,"Women of childbearing age without highly effective contraception (= defined as those which result in a low failure rate (i.e. less than 1 % per year))"
NCT00866684:I.2010,"Known allergy to macrolides"
NCT00866684:I.2011,"Current participation in other studies"
NCT00866684:I.2012,"Refusal to sign informed consent form"
NCT00866684:I.2013,"Neoplasm other than defined as inclusion criteria"
NCT00866684:I.2014,"All contraindications to SRL (see package insert, appendix)"
NCT00866684:I.2015,"Persons who are detained officially or legally to an official institute"
NCT00867672:I.1001,"age at least 60 Years"
NCT00867672:I.1002,"Patients older than 60 years with acute myeloid leukemia according to FAB (>30 % bone marrow blasts) not qualifying for, or not consenting to, standard induction chemotherapy or immediate allografting"
NCT00867672:I.1003,"Life expectancy>3 months with successful treatment"
NCT00867672:I.1004,"Performance status ECOG 0, 1, 2"
NCT00867672:I.1005,"Age-adjusted normal cardiac, kidney, liver function (creatinine<1.5 mg/dl unless leukemia-related, total bilirubin<2.0 of upper normal limits)"
NCT00867672:I.1006,"Patients with>50 000 leukocytes/µl in whom initial cytoreduction according to protocol is effective"
NCT00867672:I.1007,"Written informed consent"
NCT00867672:I.2001,"AML of FAB subtype M3"
NCT00867672:I.2002,"Previous induction-type chemotherapy for MDS or AML"
NCT00867672:I.2003,"Previous treatment with DAC, 5-azacytidine, VPA or another HDAC inhibitor, or ATRA"
NCT00867672:I.2004,"low-dose chemotherapy (e.g.hydroxyurea, cytosine arabinoside, melphalan) within 8 weeks prior to DAC treatment, except for cytoreduction of leukocytosis>50 000/µl according to protocol"
NCT00867672:I.2005,"Patients with>50 000 leukocytes/µl in whom initial cytoreduction according to protocol is ineffective"
NCT00867672:I.2006,"Treatment with cytokines within previous 4 weeks"
NCT00867672:I.2007,"Concomitant use of any other investigational drug"
NCT00867672:I.2008,"Other malignancy that is not in remission (previous chemotherapy for other malignancies is not an exclusion criteria)"
NCT00867672:I.2009,"Cardiac insufficiency NYHA IV"
NCT00867672:I.2010,"Human immunodeficiency virus infection"
NCT00867672:I.2011,"Other uncontrolled active infection"
NCT00867672:I.2012,"Psychiatric disorder that interferes with treatment"
NCT00875667:I.1001,"age at least 18 Years"
NCT00875667:I.1002,"Biopsy proven mantle cell lymphoma"
NCT00875667:I.1003,"Patients who have progressed or relapsed after or are refractory to at least one, and up to three prior chemotherapy regimens, and who have documented progressive disease."
NCT00875667:I.1004,"ECOG performance score 0,1, or 2"
NCT00875667:I.1005,"Willing to follow pregnancy precaution"
NCT00875667:I.2001,"Abnormal Laboratory Test Result"
NCT00875667:I.2002,"Absolute Neutrophil Count, ANC"
NCT00875667:I.2003,"Platelet count - finding"
NCT00875667:I.2004,"Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT)>3.0 x upper limit or normal (ULN), except patients with documented liver involvement by lymphoma"
NCT00875667:I.2005,"Serum total bilirubin>1.5 x ULN, except in case of Gilbert's Syndrome and documented liver involvement by lymphoma."
NCT00875667:I.2006,"Estimation of creatinine clearance by Cockcroft-Gault formula (procedure)"
NCT00875667:I.2007,"History of active CNS lymphoma within the previous 3 months"
NCT00875667:I.2008,"Subjects not willing to take DVT prophylaxis"
NCT00875667:I.2009,"Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are sero-positive because of hepatitis B virus vaccine are eligible"
NCT00876031:I.1001,"age 6 Months to 21 Years"
NCT00876031:I.1002,"written informed consent for registration, randomisation, data collection/transfer, and tumour material asservation available"
NCT00876031:I.1003,"pathologically (including molecular pathology) proven diagnosis of rhabdomyosarcoma (RMS) or RMS-like soft tissue sarcoma (STS) and tumour material available for pathology review"
NCT00876031:I.1004,"Rhabdomyosarcoma of the High Risk Group, i.e.:"
NCT00876031:I.1005,"RME, N0, M0, IRS II&III,>5 cm or>10 years in EXT, HN-PM, OTH, UG-BP"
NCT00876031:I.1006,"RME, N1, M0, any IRS-group, any size or age"
NCT00876031:I.1007,"RMA, NO, M0, any IRS-group, any size or age  (exception: paratesticular RMA are not eligible) or"
NCT00876031:I.1008,"Rhabdomyosarcoma of the Very High Risk Group, i.e.:"
NCT00876031:I.1009,"RMA, N1, MO, IRS II&III, any size or age or"
NCT00876031:I.1010,"localised high-risk RMS-like Soft Tissue Sarcoma, i.e.:"
NCT00876031:I.1011,"EES, pPNET, UDS: any N, M0, any IRS-group, any size or age"
NCT00876031:I.1012,"Synovioma, malignant"
NCT00876031:I.1013,"no pre-existing illness preventing treatment (esp. those listed in the medicinal product information, e.g. cardiac, hepatic, metabolic, or renal dysfunction, hypersensitivity)"
NCT00876031:I.1014,"no previous malignant tumours"
NCT00876031:I.1015,"available for long term follow up through the treating centre"
NCT00876031:I.1016,"in remission (according to the CWS-2007-HR definition (see X7.1.8X)) at the time of randomisation after standard multimodal therapy e.g. according to the CWS-guidance"
NCT00876031:I.2001,"pregnant or lactating women"
NCT00876031:I.2002,"other medical condition precluding treatment with protocol therapy (e.g. HIV, psychiatric disorder, etc.)"
NCT00876031:I.2003,"for sexually active females and males in Arm B (O-TIE treatment): refusal to use effective contraception (e.g. oral, IUD)"
NCT00876733:I.1001,"age at least 18 Years"
NCT00876733:I.1002,"To construct a treatment option with Viramune (nevirapine) and antiretroviral, e.g. Combivir (fixed dose combination of Zidovudine and Lamivudine), Kivexa (fixed dose combination of Abacavir and Lamivudine) or Truvada (fixed dose combination of tenofovir and emtricitabine) in male and female adult HIV type 1 infected patients"
NCT00876733:I.1003,"HIV type 1 infected patients, who have either not been treated previously"
NCT00876733:I.1004,"HIV type 1 infected patients, whose previous combination treatment with protease inhibitors has failed"
NCT00876733:I.1005,"HIV type 1 infected patients, who have to switch their previous treatment from protease inhibitor or nucleosidaI reverse transcriptase inhibitor due to side effects or intolerability after achieving suppression of viral load below the limit of detection."
NCT00876733:I.1006,"Viramune (nevirapine) is indicated as part of combination therapy for the antiviral treatment of HIV-1 infected patients with advanced or progressive immunodeficiency."
NCT00876733:I.2001,"Age<18 years"
NCT00876733:I.2002,"Pregnant female patients"
NCT00876733:I.2003,"Hypersensitivity to the active substance or to any of the excipients of Viramune (nevirapine) or antiretroviral in combination with Viramune, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine)."
NCT00876733:I.2004,"Viramune (nevirapine) should not be readministered to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine."
NCT00876733:I.2005,"Viramune (nevirapine) should not be used in patients with severe hepatic impairment (Child-Pugh C) or pre-treatment GOT (Glutamic Oxaloacetic Transaminase) or GPT (Glutamic Pyruvate Transaminase)>5 upper limit of normal until baseline GOT/GPT are stabilised<5 upper limit of normal."
NCT00876733:I.2006,"Viramune (nevirapine) should not be readministered in patients who previously had GOT or GPT (Liver enzymes)>5 ULN (upper limit of normal) during Viramune (nevirapine) therapy and had recurrence of liver function abnormalities upon readministration of Viramune (nevirapine)"
NCT00876733:I.2007,"Herbal preparations containing St Johns wort (Hypericum perforatum) must not be used while taking Viramune (nevirapine) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine"
NCT00876733:I.2008,"The available pharmacokinetic data suggest that the concomitant use of rifampicin and Viramune (nevirapine) is not recommended."
NCT00878293:I.1001,"age 18 Years to 75 Years"
NCT00878293:I.1002,"Subjects with pain at least NRS>4 due to painful diabetic polyneuropaty."
NCT00878293:I.2001,"Contraindications to, or history of allergy or hypersensitivity to morphine, fentanyl, hydrocodone, acetaminophen, heparin, polyethylene glycol 400 USP-NF or any compound planned to be used during the anesthesia, or their excipients."
NCT00878293:I.2002,"non Caucasian or Hispanic."
NCT00878293:I.2003,"Concomitant painful disease."
NCT00878293:I.2004,"Life-long history of seizure disorder or epilepsy."
NCT00878293:I.2005,"Subjects with clinical relevant cardiac and vascular diseases."
NCT00878293:I.2006,"Renal dysfunction"
NCT00878293:I.2007,"Abnormal hepatic function"
NCT00878293:I.2008,"Female subjects who are pregnant or breastfeeding."
NCT00879658:I.1001,"age 18 Years to 55 Years"
NCT00879658:I.1002,"Diagnosis of Multiple Sclerosis (MS) as defined by revised McDonald criteria."
NCT00879658:I.1003,"A relapsing-remitting course of disease with at least 1 documented relapse during the previous year, or 2 documented relapses during the previous 2 years, or a positive gadolinium (Gd)-enhanced MRI scan at screening (in case the first MRI scan obtained at screening is negative, a second scan may be obtained 1 month later.)"
NCT00879658:I.1004,"An Expanded Disability Status Scale (EDSS) score of 0-5.0 inclusive at randomization."
NCT00879658:I.1005,"Neurologically stable with no evidence of relapse or corticosteroid treatment within 30 days prior to randomization."
NCT00879658:I.1006,"Patients who decline initiation or continuation of treatment with available disease modifying drugs for MS, for whatever reason, after having been informed about their respective benefits and possible adverse events by the investigator."
NCT00879658:I.2001,"A manifestation of another type of MS than RRMS"
NCT00879658:I.2002,"History of chronic disease of the immune system other than MS"
NCT00879658:I.2003,"Malignancies, diabetes, significant cardiovascular, pulmonary and hepatic diseases and conditions"
NCT00879658:I.2004,"Active infections"
NCT00882245:I.1001,"Age at least 18 Years"
NCT00882245:I.1003,"Subjects with a history of AD"
NCT00882245:I.1004,"Written and dated informed consent"
NCT00882245:I.1005,"Satisfactory medical assessment with no clinical relevant abnormalities."
NCT00882245:I.2001,"Subjects with current or recurrent disease (except AD) that could affect the site of application, the action, absorption or disposition of the investigational product, or clinical or laboratory assessments."
NCT00882245:I.2002,"Subjects who have medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial."
NCT00882245:I.2003,"Subjects with any skin tattoo, scar, cuts, bruises, or other skin damage, including excessive UV exposure, at the possible drug application sites which could impact the application of the test agent or confound the local assessments during this study."
NCT00882245:I.2004,"Subjects with clinically significant renal and liver parameters, as defined as>1.5 x creatinine and 3 x AST ULN (upper limit of normal) respectively."
NCT00883051:I.1001,"age 18 Years to 65 Years"
NCT00883051:I.1002,"Patients with migraine with or without aura fulfilling the IHS diagnostic criteria 1.1 and 1.2.1 (2004)"
NCT00883051:I.1003,"History of migraine of at least 1 year"
NCT00883051:I.1004,"Migraine onset before the age of 50 years"
NCT00883051:I.1005,"History of 1 - 8 migraine attacks per month"
NCT00883051:I.1007,"Female patients of child-bearing potential must be using a highly effective form of contraception (e.g., combined oral contraceptive, IUD, abstinence, vasectomized partner)"
NCT00883051:I.1008,"Able and willing to give written informed consent"
NCT00883051:I.1009,"Able and willing to complete a migraine diary card to record details of the attack treated with study medication"
NCT00883051:I.2001,"History of life threatening or intolerable adverse reaction to any triptan"
NCT00883051:I.2002,"Use of prescription migraine prophylactic drugs within 15 days (30 days for flunarizine) prior to Screening Visit and during study participation"
NCT00883051:I.2003,"Using herbal preparations (e.g., feverfew, butterbur) for migraine prophylaxis"
NCT00883051:I.2004,"Using 5-HT reuptake inhibitors"
NCT00883051:I.2005,"Using drugs known to inhibit CYP450 enzymes (see Appendix 2 for details)"
NCT00883051:I.2006,"Pregnant or breast-feeding women"
NCT00883051:I.2007,"Women of child-bearing potential not using highly effective contraception"
NCT00883051:I.2008,"History or evidence of coronary artery disease, ischemic or hemorrhagic stroke, epilepsy or any other condition placing the patient at increased risk of seizures"
NCT00883051:I.2009,"History of hypertension (controlled or uncontrolled)"
NCT00883051:I.2010,"History of orthostatic hypotension"
NCT00883051:I.2011,"Current use of hemodynamically active cardiovascular drugs"
NCT00883051:I.2012,"History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol"
NCT00883051:I.2013,"Significant renal or hepatic impairment"
NCT00883051:I.2014,"Previous participation in this clinical trial"
NCT00883051:I.2015,"Participation in any clinical trial of an experimental drug or device in the previous 30 days"
NCT00883051:I.2016,"Any medical condition or laboratory test which in the judgment of the investigator makes the patient unsuitable for the study"
NCT00883051:I.2017,"Known Hepatitis B or C or HIV infection"
NCT00883051:I.2018,"Patients who are employees of the sponsor"
NCT00883051:I.2019,"Relatives of, or staff directly reporting to, the investigator"
NCT00883051:I.2020,"Patients with known hypersensitivity to COL-144, other 5HT1F receptor agonists or to any excipient of COL-144 drug product"
NCT00883051:I.2021,"Patients who were treated with study medication in the COL MIG-201 study (Patients screened but not treated under that protocol are not excluded)"
NCT00883337:I.1001,"age at least 18 Years"
NCT00883337:I.1002,"Patients with relapsing forms of multiple sclerosis meeting McDonald's criteria for MS diagnosis at time of screening visit, and EDSS score<=5.5 at screening visit"
NCT00883337:I.1003,"Provided informed consent with signature on informed consent form"
NCT00883337:I.2001,"Patients with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia"
NCT00883337:I.2002,"Persistent significant or severe infection"
NCT00883337:I.2003,"Liver function impairment or known history of hepatitis"
NCT00883337:I.2004,"Use of adrenocorticotrophic hormone (ACTH) or systemic corticosteroids for 2 weeks prior to randomization"
NCT00883337:I.2005,"HIV Seropositivity"
NCT00883337:I.2006,"Prior use of Rebif, or prior or concomitant use of other interferons in the 3 months prior to randomization"
NCT00883337:I.2007,"Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate, mycophenolate, or natalizumab"
NCT00883337:I.2008,"Pregnant or breast-feeding women"
NCT00885937:I.1001,"age at least 18 Years"
NCT00885937:I.1002,"Skin type I, II, or III according to Fitzpatrick"
NCT00885937:I.1003,"Subjects of childbearing potential must use an acceptable method of contraception. Hormonal or oral contraceptive drugs, intra-uterine devices (IUD) and abstinence are considered acceptable methods of contraception."
NCT00885937:I.2001,"Clinical history suggestive of intolerance, allergies or idiosyncrasies to one of the products or the ingredients of the products including the patch."
NCT00885937:I.2002,"Cutaneous hypersensitivity"
NCT00885937:I.2003,"Dermatologic diseases that might interfere with the evaluation of test site reaction."
NCT00885937:I.2004,"Other(s), considered as important by the investigator (e.g. multiple birth marks in the test area, important hair growth in the test area, pigmented or extremely suntanned skin impairing visual assessment, tattoos in the test area."
NCT00885937:I.2005,"Topical use of any cosmetic preparation on the test areas within 5 days prior to Day 1 (Start of Treatment) or during the trial"
NCT00885937:I.2006,"Within 3 weeks prior to Day 1 and during the entire trial. Any systemic or topical medication likely to interfere with the trial purposes: e.g. immune-modulating therapy (e.g. corticosteroids, cytotoxics or immunosuppressants) and any dermatological medication (drug or medical device."
NCT00885937:I.2007,"Within 1 week prior to Day 1 and during the entire trial any medication with common effects on the perfusion of skin vessels (e.g. vasodilators or vasoconstrictors, beta-receptor blocking drugs, antihistamines) should not be used."
NCT00887198:I.1001,"age at least 18 Years"
NCT00887198:I.1002,"Metastatic castration-resistant prostate cancer"
NCT00887198:I.1003,"Previous anti-androgen therapy and progression after withdrawal"
NCT00887198:I.1004,"ECOG performance status of either 0 or 1"
NCT00887198:I.1005,"Medical or surgical castration with testosterone<50 ng/dL"
NCT00887198:I.1006,"Able to provide written informed consent"
NCT00887198:I.2001,"Prior cytotoxic chemotherapy or biologic therapy for CRPC"
NCT00887198:I.2002,"Prior ketoconazole for prostate cancer"
NCT00887198:I.2003,"Known brain metastasis or visceral organ metastasis"
NCT00887198:I.2004,"Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1"
NCT00889343:I.1001,"age at least 18 Years"
NCT00889343:I.1002,"ECOG Performance Status of 0 to 2"
NCT00889343:I.1003,"Life expectancy of at least 12 weeks."
NCT00889343:I.1004,"Subjects with at least one uni-dimensional (RECIST) measurable lesion of metastatic colorectal carcinoma after first-line chemotherapy with an Oxaliplatin- or Irinotecan based Fluoropyrimidine containing regimen ± bevacizumab and had a progression subsequently. Lesions must be measured by CT-scan or MRI."
NCT00889343:I.1005,"Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:"
NCT00889343:I.1006,Hemoglobin
NCT00889343:I.1007,"Absolute Neutrophil Count, ANC"
NCT00889343:I.1008,"Platelet count 100,000 microliter Total bilirubin<1.5 times the upper limit of normal"
NCT00889343:I.1009,"ALT and AST<2.5 x upper limit of normal (<5 x upper limit of normal for patients with liver involvement of their cancer)"
NCT00889343:I.1010,"Alkaline phosphatase<4 x upper limit of normal"
NCT00889343:I.1011,"PT-INR/PTT<1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.]"
NCT00889343:I.1012,"Serum creatinine<1.5 x upper limit of normal"
NCT00889343:I.1013,"Signed and dated informed consent before the start of specific protocol procedures"
NCT00889343:I.2001,"History of cardiac disease: congestive heart failure>NYHA class 2. Active CAD (MI more than 6 mo prior to study entry is allowed). Cardiac arrythmias requiring anti-arrythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension"
NCT00889343:I.2002,"History of HIV infection or chronic hepatitis B or C"
NCT00889343:I.2003,"Active clinically serious infections (>grade 2 NCI-CTC version 3.0)"
NCT00889343:I.2004,"Symptomatic metastatic brain or meningeal tumors (unless the patient is>6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry)"
NCT00889343:I.2005,"Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)"
NCT00889343:I.2006,"History of organ allograft"
NCT00889343:I.2007,"Bleeding tendency, Bleeding Disorders"
NCT00889343:I.2008,"Kidney dialysis"
NCT00889343:I.2009,"Dihydropyrimidine Dehydrogenase Deficiency"
NCT00889343:I.2010,"Contraindications for the use of atropine in patients receiving FOLFIRI"
NCT00889343:I.2011,"Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis&T1] or any cancer curatively treated>3 years prior to study entry."
NCT00889343:I.2012,"Peripheral sensory neuropathy>CTC grade 2"
NCT00889343:I.2013,"Chronic inflammatory bowel disease. Ileus. Genetic fructose intolerance"
NCT00889343:I.2014,"Pregnant or breast-feeding patients."
NCT00889343:I.2015,"Women of childbearing potential must have a negative pregnancy test performed within 7 days before the start of treatment. Fertile women and men (<2 years after last menstruation in women) must use effective means of contraception (intrauterine contraceptive device, contraceptive implants, injectables (hormonal depot), transdermal hormonal contraception (contraceptive patch), sexual abstinence or vasectomised partner) during treatment and for at least 6 months after last administration of medication."
NCT00889343:I.2016,"Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results"
NCT00889343:I.2017,"Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study"
NCT00889343:I.2018,"Patients unable to swallow oral medications."
NCT00889343:I.2019,"Any other anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry."
NCT00889343:I.2020,"Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed)."
NCT00889343:I.2021,"major surgery"
NCT00889343:I.2022,"Autologous bone marrow transplant or stem cell rescue within 4 months prior to study treatment"
NCT00889343:I.2023,"Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however, they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study]"
NCT00889343:I.2024,"Investigational drug therapy outside of this trial during or within 4 weeks of study entry"
NCT00889343:I.2025,"Prior exposure to the study drug."
NCT00889343:I.2026,"Any St. John´s wort containing remedy"
NCT00894387:I.1001,"primary diagnosis of worsening heart failure"
NCT00894387:I.1002,"age>= 18 years"
NCT00894387:I.1003,"acute heart failure symptoms (dyspnea or fatigability - NYHA Class III-IV) and signs of fluid overload (i.e., jugular venous distension, edema or positive rales auscultation or pulmonary congestion on chest x-ray) at the time of hospitalization"
NCT00894387:I.1004,"LVEF less than 40% (measured within the last 6 months)"
NCT00894387:I.1005,"Hospitalization for ADHF and remain ""stabilized"" for at least 6 hours (defined as SBP>= 110 mm Hg after acute decompensated episode) and did not receive IV vasodilators (other than nitrates) and/or IV inotropic drugs at anytime from ADHF presentation to time of randomization"
NCT00894387:I.1006,"Elevated BNP at Visit 1 or at randomization (BNP>= 400 pg/ml)"
NCT00894387:I.1007,"Patients with a history of chronic heart failure on standard therapy defined as requiring HF treatment for at least 30 days before the current hospitalization (NYHA Class II - IV)."
NCT00894387:I.2001,"Patients that required any use of IV vasodilators (except nitrates), and/or any IV inotropic therapy from the time of presentation for worsening HF to randomization."
NCT00894387:I.2002,"Concomitant use of ACEI and ARB at randomization."
NCT00894387:I.2003,"Right heart failure due to pulmonary disease."
NCT00894387:I.2004,"Diagnosis of postpartum cardiomyopathy."
NCT00894387:I.2005,"Myocardial infarction or cardiac surgery, including percutaneous transluminal coronary angioplasty (PTCA), within past 3 months."
NCT00894387:I.2006,"Patients with a history of heart transplant or who are on a transplant list."
NCT00894387:I.2007,"Unstable angina or coronary artery disease likely to require coronary artery bypass graft (CABG) or PTCA before randomization."
NCT00895037:I.1001,"Patients with hemophilia A of any severity already receiving or starting treatment with ReFacto AF"
NCT00895037:I.2001,"Patients with Hemophilia A treated with a product other than Refacto AF"
NCT00906399:I.1001,"age 18 Years to 65 Years"
NCT00906399:I.1002,"Informed Consent"
NCT00906399:I.1003,"Must have a confirmed diagnosis of relapsing MS, as defined by McDonald criteria #1-4"
NCT00906399:I.1004,"EDSS - Expanded disability status scale<= 5.0"
NCT00906399:I.1005,"Must have experienced at least 2 relapses that have been medically documented within the last 3 years with one occurring in the last 12 months"
NCT00906399:I.2001,"Other chronic disease of immune system, malignancies, urologic, pulmonary, gastrointestinal disease"
NCT00906399:I.2002,"Pregnant or nursing women"
NCT00909597:I.1001,"age 18 Years to 75 Years"
NCT00909597:I.1003,"type 2 diabetes mellitus"
NCT00909597:I.1004,"treated with stable sulfonylurea monotherapy or metformin + sulfonylurea for>=12 weeks prior to screening"
NCT00909597:I.1005,"HbA1c>=7.0% and<=10% at screening"
NCT00909597:I.1006,"stable weight +/-5% for>=12 weeks prior to screening."
NCT00909597:I.2001,"type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes"
NCT00909597:I.2002,"clinically significant diabetic complications"
NCT00909597:I.2003,"clinically symptomatic gastrointestinal disease"
NCT00909597:I.2004,">3 episodes of severe hypoglycemia within 6 months before screening."
NCT00915252:I.1001,"age at least 61 Years"
NCT00915252:I.1002,"Patients with newly diagnosed AML (except APL) according to the FAB or WHO classification, including AML evolving from MDS or other hematological diseases and AML after previous cytotoxic therapy or radiation (secondary AML)."
NCT00915252:I.1003,"Bone marrow aspirate or biopsy must contain>= 20% blasts of all nucleated cells or differential blood count must contain>= 20% blasts. In AML FAB M6>= 30% of non-erythroid cells in the bone marrow must be leukemic blasts. In AML defined by cytogenetic aberrations the proportion of blasts may be<20%."
NCT00915252:I.1004,"Informed consent, personally signed and dated to participate in the study"
NCT00915252:I.1005,"Male patients enrolled in this trial must use adequate barrier birth control measures during the course of the 5-azacytidine treatment and for at least 3 months after the last administration of 5-azacytidine."
NCT00915252:I.2001,"Patients who are not eligible for standard chemotherapy as described in chapter 5.2 and 5.3"
NCT00915252:I.2002,"Hyperleukocytosis (leukocytes>20,000/microliter) at study entry. These patients should be treated with hydroxyurea or receive leukocytapheresis treatment (if leukocytes>100,000/microliter) according to routine practice and entered into the study when leukocyte counts below 20,000/microliter are reached. This applies only for the controlled part of the study."
NCT00915252:I.2003,"Patients with initial hyperleukocytosis above 20,000/microliter can only be enrolled into the controlled part of the study, but not in the run-in dose finding part."
NCT00915252:I.2004,"Known central nervous system manifestation of AML"
NCT00915252:I.2005,"Cardiac Disease: Heart failure NYHA class 3 or 4. Unstable coronary artery disease (MI more than 6 months prior to study entry is permitted). Serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)"
NCT00915252:I.2006,"Chronically impaired renal function (creatinin clearance<30 ml / min)"
NCT00915252:I.2007,"Inadequate liver function (ALT and AST>= 2.5 x ULN) if not caused by leukemic infiltration"
NCT00915252:I.2008,"Total bilirubin>= 1.5 x ULN if not caused by leukemic infiltration"
NCT00915252:I.2009,"Known HIV and/or hepatitis C infection"
NCT00915252:I.2010,"Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy"
NCT00915252:I.2011,"Evidence or recent history of CNS disease, including primary or metastatic brain tumors, seizure disorders"
NCT00915252:I.2012,"Uncontrolled active infection"
NCT00915252:I.2013,"Concurrent malignancies other than AML with an estimated life expectancy of<2 years"
NCT00915252:I.2014,"History of organ allograft"
NCT00915252:I.2015,"Hypersensitivity to cytarabine (not including drug fever or exanthema), daunorubicin, azacytidine or mannitol"
NCT00915252:I.2016,"Previous treatment of AML except hydroxyurea and up to 2 days of<=100 mg/m2/d cytarabine"
NCT00915252:I.2017,"Previous therapy with 5-azacytidine (i.e. for an antecedent myelodysplastic syndrome)"
NCT00915252:I.2018,"Patients with investigational drug therapy outside of this trial during or within 4 weeks of study entry should be discussed with the study office whether study participation is possible"
NCT00915252:I.2019,"Any severe concomitant condition, which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol"
NCT00919373:I.1001,"age 18 Years to 80 Years"
NCT00919373:I.1002,"Coronary artery disease For the purpose of this study, coronary artery disease will be defined as the presence of a 50 % or more diameter stenosis of the left main coronary artery, or 75 % or more diameter stenosis of the left anterior descending, circumflex or right coronary arteries"
NCT00919373:I.1003,"coronary artery disease will be defined as the history of a surgical or percutaneous revascularization procedure, or history of successful thrombolysis, or a history of prior myocardial infarction (e.g.: documented by Q-wave, R-reduction, aneurysm)"
NCT00919373:I.1004,"Left ventricular ejection fraction<= 50 % as estimated by echocardiography or contrast ventriculography within the previous 30 days and evidence for old myocardial infarction (ECG, echocardiographic or venticulographic)."
NCT00919373:I.1005,"One episode of documented stable clinical VT without any reversible causes"
NCT00919373:I.1006,"Written informed consent"
NCT00919373:I.2001,"Age<18 years or>80 years"
NCT00919373:I.2002,"Protruding LV thrombus on pre-ablation echocardiogram"
NCT00919373:I.2003,"Acute myocardial infarction"
NCT00919373:I.2004,"Class IV NYHA heart failure"
NCT00919373:I.2005,"Valvular heart disease or mechanical heart valve precluding access to the left ventricle"
NCT00919373:I.2006,"Crescendo angina"
NCT00919373:I.2007,"Cardiac surgery involving cardiotomy (not CABG) within the past 2 months"
NCT00919373:I.2008,"Serum Creatinine Measurement"
NCT00919373:I.2009,"Thrombocytopenia or coagulopathy"
NCT00919373:I.2010,"Contraindication to heparin"
NCT00919373:I.2011,"Pregnancy, Gestation"
NCT00919373:I.2012,"Acute illness or active systemic infection"
NCT00919373:I.2013,"Other disease process likely to limit survival to<12 months"
NCT00919373:I.2014,"Significant medical problem that in the opinion of the principal investigator would preclude enrollment in the study"
NCT00919373:I.2015,"Participation in another investigational study"
NCT00919373:I.2016,"Unwillingness to participate or lack of availability for follow-up"
NCT00919373:I.2017,"Incessant VT or electrical storm"
NCT00919373:I.2018,"Bundle branch reentry tachycardia as the presenting VT"
NCT00919373:I.2019,"Preexisting ICD"
NCT00923754:I.1001,"age at least 18 Years"
NCT00923754:I.1002,"Descending thoracic aortic aneurysm with diameter>= 5.0 cm, or"
NCT00923754:I.1003,"Descending thoracic aortic aneurysm with a history of growth>= 0.5 cm within the previous 12 months, or"
NCT00923754:I.1004,"Descending thoracic aortic degenerative or atherosclerotic ulcers>= 10 mm in depth and 20 mm in diameter"
NCT00923754:I.2001,"Age<18 years"
NCT00923754:I.2002,"Other medical condition that may cause the patient to be non-compliant with the protocol, confound the results, or is associated with limited life expectancy (i.e.,<2 years)"
NCT00923754:I.2003,"Pregnant, breast-feeding, or planning on becoming pregnant within 24 months"
NCT00923754:I.2004,"Unwilling or unable to comply with the follow-up schedule"
NCT00923754:I.2005,"Inability or refusal to give informed consent"
NCT00923754:I.2006,"<30 days beyond primary endpoint in another investigative device or drug study"
NCT00925002:I.1001,"age 18 Years to 75 Years"
NCT00925002:I.1002,ATTR-PN
NCT00925002:I.1003,"Patient has successfully completed either Protocol Fx-006 or Fx1A-201."
NCT00925002:I.1004,"If female, patient is post-menopausal, surgically sterilized, or willing to use two acceptable methods of birth control (i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study and for 3 months from the end of the study. (A condom alone is not considered an acceptable method of birth control.)"
NCT00925002:I.1005,"Patient is, in the opinion of the investigator, willing and able to comply with the investigational product regimen and all other study requirements."
NCT00925002:I.2001,"Patient has not successfully completed either Protocol Fx-006 or Fx1A-201."
NCT00925002:I.2002,"Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs), defined as>3 to 4 times/month. The following NSAIDs are allowed: acetylsalicylic acid, etodolac, ibuprofen, indomethicin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam, and sulindac."
NCT00925002:I.2003,"If female, patient is pregnant or breast feeding."
NCT00925002:I.2004,"Clinically significant medical condition that, in the opinion of the investigator, would place the patient at an increased risk to participate in the study."
NCT00925002:I.2005,"The patient has received a liver or heart transplant."
NCT00927667:I.1001,"age 12 Years to 35 Years"
NCT00927667:I.1002,"male, male gender"
NCT00927667:I.1003,"Severe hemophilia A (<1 % FVIII:C)"
NCT00927667:I.1004,"No history of Factor VIII inhibitory antibody"
NCT00927667:I.1005,"For prophylaxis groups, having received at least two prophylactic infusions per week for 45 weeks per year for the prevention of bleeding without relevant interruption and continuing until the present."
NCT00927667:I.1006,"Complete documentation of joints bleeds and their locations prior to start of prophylaxis,"
NCT00927667:I.1007,"Bleeding history and/or treatments received during the last 5 years documented in the subjects medical records."
NCT00927667:I.1008,"For the on-demand subjects>12 bleeds/year in the last 5 years."
NCT00927667:I.1009,"Written informed consent by subject and parent/legal representative, if<18 years"
NCT00927667:I.2001,"Individuals with other coagulopathies (e.g., von Willebrand disease)"
NCT00927667:I.2002,"HIV Seropositivity"
NCT00927667:I.2003,"Individuals for whom the most clinically severe joint is not one of the 4 index joints (ankle, knee)"
NCT00927667:I.2004,"HCV seropositive individuals who underwent interferon therapy during the last 12 months"
NCT00927667:I.2005,"Arthroplasty, Replacement"
NCT00927667:I.2006,"For the on-demand treatment group, any period>8 consecutive months having received>/= 50 IU per kg per week Factor VIII for the prevention of bleeding"
NCT00927836:I.1001,"age 18 Years to 85 Years"
NCT00927836:I.1002,"diagnosis of acute ischemic stroke with an onset within 9 hours prior to start of study agent administration"
NCT00927836:I.1003,"ischemic stroke in the MCA territory confirmed by MRI (diffusion)"
NCT00927836:I.1004,"lesion size on DWI>=15 ccm"
NCT00927836:I.1005,"written informed consent"
NCT00927836:I.2001,"prior to current stroke: inability to walk or to lead an independent life"
NCT00927836:I.2002,"life expectancy<= 6 months"
NCT00927836:I.2003,"stupor or coma"
NCT00927836:I.2004,"Lacunar infarction"
NCT00927836:I.2005,"Intracerebral hemorrhage (ICH)"
NCT00927836:I.2006,"Malignant Hypertension"
NCT00927836:I.2007,"presence of history of active malignancies"
NCT00927836:I.2008,"platelet count<100/nl at randomization"
NCT00927836:I.2009,"leukocyte count>20/nl at randomization"
NCT00927836:I.2010,"Congenital neutropenia"
NCT00927836:I.2011,"pregnant or lactating women"
NCT00930319:I.1001,"age at least 18 Years"
NCT00930319:I.1002,"Advanced Hormone-dependent Prostate Carcinoma"
NCT00930319:I.1003,"therapeutic need according to SPC"
NCT00930319:I.1004,"written informed consent"
NCT00930319:I.2001,"contraindications according to SPC"
NCT00932724:I.1001,"age at least 18 Years"
NCT00932724:I.1002,"Patients are eligible with diagnosis of measurable metastatic colorectal carcinoma and radiologic documentation of disease progression during or with 3 months after termination of standard chemotherapy (fluoropyrimidine-based therapy with oxaliplatin and irinotecan). Patients who had to interrupt the 1st or 1nd line therapy due to intolerance or who were refractory or intolerant to the standard treatment regimens are eligible, too. Bevacizumab can, but does not need to be administered at discretion of treating physician. Patients with K-RAS wild-type can be treated with cetuximab or panitumumab before they enter the study."
NCT00932724:I.1003,"No chemotherapy within 4 weeks before treatment start"
NCT00932724:I.1004,"No residual significant toxicity (>NCI grade 1), in case of peripheral neuropathy: no symptoms of peripheral neuropathy of NCI CTC grade 4 within 4 weeks before treatment start."
NCT00932724:I.1005,"No previous treatment with experimental therapies after standard therapies is allowed."
NCT00932724:I.1006,"Patients must use effective contraception if of reproductive potential. Females must not be pregnant or lactating"
NCT00932724:I.1007,"Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 2"
NCT00932724:I.1008,"WBC>= 3,000/mm3, absolute neutrophil count (ANC)>= 1,500/mm3, platelet count>=100,000/mm3"
NCT00932724:I.1009,"Bilirubin<= 2.0 mg/dL (40 micromol/L) (unless due to Gilbert's syndrome in which case the bilirubin should be<=3.5 mg/dL (59.86 micromol/L)), aspartate transaminase (AST)/alanine transaminase (ALT)<= 5 x upper limit of normal (ULN). Hepatic alkaline phosphatase<= 3.0 x ULN (in case of liver metastases higher levels do not hinder inclusion of patients)"
NCT00932724:I.1010,"Serum creatinine<= 2.0 mg/dL (180 micromol/L)or creatinine clearance>= 50 ml/min. , proteinuria<2.0 g/24 hr urine collection in patients with a positive urine dipstick for protein"
NCT00932724:I.1011,"Written informed consent according to ICH-GCP and national laws and regulations prior to receipt of any trial medication or beginning trial procedures"
NCT00932724:I.2001,"Evidence of any other malignant disease (with the exception of tumors operatively cured>= 5 years prior to the trial)"
NCT00932724:I.2002,"Brain metastases"
NCT00932724:I.2003,"Uncontrolled pleural effusions"
NCT00932724:I.2004,"Interstitial pneumonitis or pulmonary fibrosis"
NCT00932724:I.2005,"Severe/ unstable systemic disease or infection and circumstances not permitting trial participation (e.g., alcoholism or substance abuse)"
NCT00932724:I.2006,"Unstable cardiac disease in the last 6 months"
NCT00932724:I.2007,"Use of conventional mistletoe preparations, any immunostimulating substances and/or monoclonal antibodies within four weeks prior to and during the trial - ongoing therapy with steroids is permitted if the dose is not>20 mg of prednisone-equivalent at the time of inclusion and during this clinical trial"
NCT00932724:I.2008,"Any evidence or history (elicited by the investigator) of symptomatic cerebrovascular events (i.e., stroke or transient ischemic attack) within 6 months prior to randomization"
NCT00932724:I.2009,"Any history or evidence of pulmonary embolism or thrombophlebitis (including deep vein thrombosis) requiring anticoagulant therapy (e.g., marcumar or heparin)"
NCT00932724:I.2010,"History of hypersensitivity to mistletoe"
NCT00932724:I.2011,"History of primary immunodeficiency"
NCT00932724:I.2012,"Known human immunodeficiency virus (HIV) or known active viral hepatic infections"
NCT00932724:I.2013,"Prior treatment with CY-503"
NCT00932724:I.2014,"A general medical or psychological condition or behaviour, including substance dependence or abuse that, in the opinion of the investigator, might not permit the patient to complete the trial or sign the informed consent"
NCT00944034:I.1001,"age 12 Months to 24 Months"
NCT00944034:I.1002,"Meningococcal Disease"
NCT00944034:I.1003,"Follow-on participants of V72P12:"
NCT00944034:I.1004,"Healthy toddlers who completed Study V72P12, aged:"
NCT00944034:I.1005,"12 months or older - Groups 1a, 2a, 3a, 4"
NCT00944034:I.1006,"18 months (0/ +29 days window) - Groups 1b, 2b, 3b"
NCT00944034:I.1007,"24 months (0/ +29 days window) - Groups 1c, 2c, 3c"
NCT00944034:I.1008,"Naive subjects newly enrolled:"
NCT00944034:I.1009,"Group 5: healthy 18-month-old toddlers (0/ +29 days window)"
NCT00944034:I.1010,"Group 6: healthy 24-month-old toddlers (0/ +29 days window)"
NCT00944034:I.2001,"History of any meningococcal B vaccine administration (only for groups 5 and 6)"
NCT00944034:I.2002,"Previous ascertained or suspected disease caused by N. meningitidis"
NCT00944034:I.2003,"History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component"
NCT00944034:I.2004,"Significant acute or chronic infection within the previous 7 days or axillary temperature>=38 degrees within the previous day"
NCT00944034:I.2005,"Antibiotics within 6 days prior to enrollment"
NCT00944034:I.2006,"Any serious chronic or progressive disease"
NCT00944034:I.2007,"Known or suspected impairment or alteration of the immune system"
NCT00944034:I.2008,"Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation."
NCT00949650:I.1001,"age at least 18 Years"
NCT00949650:I.1002,"Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology."
NCT00949650:I.1003,"Epidermal Growth Factor Receptor mutation detected by central laboratory analysis of tumour biopsy material."
NCT00949650:I.1004,"Measurable disease according to RECIST 1.1."
NCT00949650:I.1005,"Eastern Cooperative Oncology Group score of 0 or 1."
NCT00949650:I.1006,"Life expectancy of at least three months."
NCT00949650:I.1007,"Written informed consent that is consistent with ICH-GCP guidelines."
NCT00949650:I.2001,"Prior chemotherapy for relapsed and/or metastatic NSCLC. Neoadjuvant/adjuvant chemotherapy is permitted if at least 12 months has elapsed between the end of chemotherapy and randomisation."
NCT00949650:I.2002,"Prior treatment with Epidermal Growth Factor Receptor targeting small molecules or antibodies."
NCT00949650:I.2003,"Radiotherapy or surgery (other than biopsy) within 4 weeks prior to randomisation."
NCT00949650:I.2004,"Active brain metastases"
NCT00949650:I.2005,"Any other current malignancy or malignancy diagnosed within the past five years"
NCT00949650:I.2006,"Known pre-existing interstitial lung disease."
NCT00949650:I.2007,"Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom."
NCT00949650:I.2008,"History or presence of clinically relevant cardiovascular abnormalities."
NCT00949650:I.2009,"Any other concomitant serious illness or organ system dysfunction."
NCT00949650:I.2010,"Adequate absolute neutrophil count and platelet count"
NCT00949650:I.2011,"Adequate liver and kidney function"
NCT00949650:I.2012,"Active hepatitis B infection, active hepatitis C infection or known HIV carrier."
NCT00952588:I.1001,"Provision of written informed consent"
NCT00952588:I.1002,"Newly diagnosed male or female patients aged 60 and over"
NCT00952588:I.1003,"De Novo or Secondary AML"
NCT00952588:I.1004,"Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age ?75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia"
NCT00952588:I.2001,"Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product"
NCT00952588:I.2002,"Administration of LDAC is clinically contraindicated"
NCT00952588:I.2003,"Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)"
NCT00952588:I.2004,"Patients with blast crisis of chronic myeloid leukaemia"
NCT00952588:I.3001,"Informed Consent"
NCT00952588:I.3002,Age
NCT00952588:I.3003,Diagnosis
NCT00952588:I.3004,"Acute myeloic leukemia"
NCT00952588:I.3005,"WHO performance status finding"
NCT00952588:I.3006,Enrollment
NCT00952588:I.3007,"Contraindication to medical treatment"
NCT00952588:I.3008,"Acute Promyelocytic Leukemia"
NCT00952588:I.3009,"Chronic myeloid leukemia"
NCT00952588:I.3010,"Blast phase"
NCT00955565:I.1001,"age at least 18 Years"
NCT00955565:I.1002,"Radiologically confirmed sacroiliac dislocation or sacroiliac fracture"
NCT00955565:I.1003,"ARTHRITIS, SACROILIAC"
NCT00955565:I.1004,"Written informed consent by patient or his/her legal representative"
NCT00955565:I.2001,"Poor life expectancy (<3 months)"
NCT00955565:I.2002,"Fracture of pathologic origin"
NCT00955565:I.2003,"History of substance abuse (recreational drugs, alcohol)within 12 months prior to screening"
NCT00955565:I.2004,"Prisoners, correctional institution resident"
NCT00955565:I.2005,"Currently involved in another study that precludes or complicates participation"
NCT00955565:I.2006,"Disease or condition that would preclude accurate evaluation (e.g., significant psychiatric disease)"
NCT00960661:I.1001,"age at least 18 Years"
NCT00960661:I.1002,"Type 2 Diabetes Mellitus"
NCT00960661:I.1003,"Have been taking a basal insulin Glargine, at dose of>= 20 units/day, for at least 3 months prior to study start."
NCT00960661:I.1004,"Have been taking basal insulin Glargine at dose of>= 20 units/day, in combination with 1 of the following oral antidiabetic medication (OAM) regimens, for at least 3 months prior to study start:"
NCT00960661:I.1005,
NCT00960661:I.1006,"Metformin or immediate-release metformin or extended-release metformin at a  maximum tolerated and stable dose with no<500 mg/day for at least 6  weeks prior to study start and sulfonylurea at a stable dose for 6 weeks prior  to study start."
NCT00960661:I.1007,"Hemoglobin A1c (HbA1c)"
NCT00960661:I.1008,"Body mass index"
NCT00960661:I.2001,"Are currently taking OAM that is not described above and not allowed with concurrent use of insulin per local product label."
NCT00960661:I.2002,"Have taken more than 1 week within 1 month prior to the study start any glucose-lowering medications not included above either alone or in combination formulations, or have used a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phenylpropanolamine, rimonabant or similar over-the-counter medications)."
NCT00960661:I.2003,"Have taken any insulin other than Glargine within the 3 months prior to study start for more than 1 week."
NCT00960661:I.2004,"Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical, intraocular, and inhaled preparations) within 4 weeks prior to the study start."
NCT00960661:I.2005,"Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study."
NCT00960661:I.2006,"Have previously completed or been withdrawn from this study after enrollment."
NCT00964977:I.1001,"age at least 18 Years"
NCT00964977:I.1002,"histological diagnosis of a primary squamous cell carcinoma of the oral cavity or the oropharynx"
NCT00964977:I.1003,"maximum tumor diameter<4 cm in the pathohistological specimen irrespective of histological grading (pT1 or pT2)"
NCT00964977:I.1004,"concomitant histological verification of a singular ipsilateral lymph node metastasis<3cm in diameter (pN1) without penetration of the lymph node´s capsule and without presence of invasion of lymphatic vessels (lymphangiosis carcinomatosa)"
NCT00964977:I.1005,"radical resection of the tumor within adequate resection margins (R0)"
NCT00964977:I.1006,"written informed consent from the patient"
NCT00964977:I.1007,"adequate performance status ECOG Index<= 2"
NCT00964977:I.2001,"age<18 years"
NCT00964977:I.2002,"pregnant women"
NCT00964977:I.2003,"reported drug addiction"
NCT00964977:I.2004,"intake of remedies with potential influence on compliance or impaired judgment"
NCT00964977:I.2005,"patients with mental disorders or conceivable physical, familial or job related embarrassments which may preclude the patient to realize the study schedule"
NCT00964977:I.2006,"inadequate performance status ECOG Index>2"
NCT00967330:I.1001,"age 18 Years to 70 Years"
NCT00967330:I.1002,"Adult (person)"
NCT00967330:I.1003,"glioblastoma, confirmed histologically"
NCT00967330:I.1004,"no previous chemotherapy or radiotherapy for glioblastoma"
NCT00967330:I.1005,"non-methylated MGMT promoter in the tumor."
NCT00967330:I.2001,"prior systemic treatment for glioblastoma multiforme"
NCT00967330:I.2002,"prior treatment with Avastin"
NCT00967330:I.2003,"significant cardiovascular disease"
NCT00967330:I.2004,"other active malignant disease."
NCT00968708:I.1001,"age at least 18 Years"
NCT00968708:I.1002,"Diagnosis of type 2 diabetes mellitus"
NCT00968708:I.1003,"Subject is receiving monotherapy or combination antidiabetic therapy with a glycosylated hemoglobin level between 6.5% and 11.0%, inclusive, at Screening (between 7.0 and 11.0%, inclusive, if the subject's antidiabetic regimen includes insulin)"
NCT00968708:I.1004,"Diagnosis of acute coronary syndrome within 15 to 90 days prior to randomization"
NCT00968708:I.2001,"Signs of type 1 diabetes mellitus"
NCT00968708:I.2002,"Currently receiving a glucagon-like peptide-1 analogue for glycemic control of type 2 diabetes mellitus at Screening"
NCT00968708:I.2003,"Received a dipeptidyl peptidase-4 inhibitor for either more than 14 days total or within the 3 months prior to Screening"
NCT00974311:I.1001,"age at least 18 Years"
NCT00974311:I.1002,"Progressive prostate cancer"
NCT00974311:I.1003,"Medical or surgical castration with testosterone<50 ng/dl"
NCT00974311:I.1004,"One or two prior chemotherapy regimens. At least one chemotherapy regimen must have contained docetaxel"
NCT00974311:I.1005,"ECOG performance status 0-2"
NCT00974311:I.1006,"Adequate bone marrow, hepatic, and renal function"
NCT00974311:I.1007,"Able to swallow the study drug and comply with study requirements"
NCT00974311:I.1008,"Informed Consent"
NCT00974311:I.2001,"Metastases in the brain or active epidural disease"
NCT00974311:I.2002,"Another malignancy within the previous 5 years"
NCT00974311:I.2003,"Clinically significant cardiovascular disease"
NCT00974311:I.2004,"GI disorder affecting absorption"
NCT00974740:I.1001,"age 18 Years to 39 Years"
NCT00974740:I.1002,"Insulin treated patients with a newly diagnosed type 1 diabetes mellitus as defined by the ADA criteria at least two weeks but not later than 3 months after start of insulin treatment"
NCT00974740:I.1003,"Male patient or female patient using adequate contraceptive methods"
NCT00974740:I.1004,"Tested positive for at least one of the three islet autoantibodies GAD65, IA2 or ICA"
NCT00974740:I.2001,"History of neoplastic disease"
NCT00974740:I.2002,"Presence of a clinically significant hepatic or renal disease, as indicated, but not limited to a serum creatinine elevated>ten percent above the upper limit of normal, elevation of AST or ALT>3 times the upper limit of normal"
NCT00974740:I.2003,"Any other acute or chronic condition that may affect the patient's response to treatment or might be associated with an increased risk for the patient to participate, as judged by the investigator"
NCT00974740:I.2004,"Current use of anti-inflammatory or immunomodulatory drugs, antihypertensive, lipid-lowering, or antidiabetic drugs other than insulin"
NCT00974740:I.2005,"Pregnant or nursing women or women intending to become pregnant"
NCT00974740:I.2006,"Known or suspected allergy to atorvastatin or any component of the trial product"
NCT00974740:I.2007,"Known myopathy, myalgia or myositis with a serum-CPK>3 times the upper limit of normal"
NCT00974740:I.2008,"Patients who had a severe blood loss (>= 400 mL, e.g. blood donation) within 2 months prior to visit 2"
NCT00974740:I.2009,"Any significant laboratory abnormality"
NCT00974740:I.2010,"A serum LDL-cholesterol>150 mg/dL at time of screening"
NCT00974740:I.2011,"Unwillingness to comply with study procedures"
NCT00979420:I.1001,"age at least 18 Years"
NCT00979420:I.1002,"HIV Infections"
NCT00979420:I.1003,"The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843)."
NCT00979420:I.2001,"The exclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843)."
NCT00980135:I.1001,"age 18 Years to 65 Years"
NCT00980135:I.1002,"Male or female Caucasians aged between 18 and 65 years"
NCT00980135:I.1003,"Patients with mild AD presenting a scoring AD (SCORAD) rating between 3-25"
NCT00980135:I.1004,"Skin type I - IV according to Fitzpatrick"
NCT00980135:I.1005,"Acute AD symptoms on each assessment areas (local SCORAD>/=3 and<= 12)"
NCT00980135:I.1006,"Acute symptom of pruritus at Baseline"
NCT00980135:I.2001,"Any other skin disease at the test area that would interfere the clinical assessment in the opinion of the investigator"
NCT00980135:I.2002,"Moles, tattoos, strong pigmentation, or scars at the test area that would interfere the clinical assessment"
NCT00980135:I.2003,"Regular intake of antiphlogistic drugs (for example, NSAIDs)"
NCT00980135:I.2004,"Any condition or treatment which might influence the trial (e.g. any treatment with topical antibiotics, antifungals, or corticoids) within 14 days prior to screening as well as during the trial (exception: topical treatment of AD lesions other than the test areas (for example, face) with low potency steroids restricted to small areas)"
NCT00980135:I.2005,"UV-therapy or the use of solarium within 30 days before screening as well as during the trial"
NCT00980135:I.2006,"Any alternative treatment of AD (e.g. acupuncture, kinesiology, and homoeopathy) within 30 days before screening as well as during the trial"
NCT00980629:I.1001,"age 18 Years to 65 Years"
NCT00980629:I.1002,"Male or female patients (aged 18-65 years) with a diagnosis of AD."
NCT00980629:I.1003,"Female patients of child bearing potential must be using a medically acceptable form of contraception."
NCT00980629:I.1004,"Patients who are able and willing to give signed informed consent."
NCT00980629:I.1005,"Patients who have pruritus exceed the reference range."
NCT00980629:I.2001,"Patients who have a history of allergy to hydrocortisone."
NCT00980629:I.2002,"Patients who have a history of relevant drug hypersensitivity."
NCT00980629:I.2003,"Patients who have a history of contact dermatitis induced by a topical steroid."
NCT00980629:I.2004,"Patients who are taking, and who are unwilling not to take, any medications or therapy prohibited by the protocol for the complete duration of the study."
NCT00980629:I.2005,"Malignant Neoplasms"
NCT00980629:I.2006,"Patients who have any renal or liver insufficiency, or clinically significant cardiac, renal or hepatic disease."
NCT00980629:I.2007,"Patients who, in the opinion of the investigator, are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests."
NCT00980629:I.2008,"Patients who have pruritus associated with conditions other than AD."
NCT00980629:I.2009,"Patients who have pruritus only on the face and head."
NCT00980629:I.2010,"Patients who, in the opinion of the investigator, have clinically relevant history or presence of any disease, or surgical history other than AD which is likely to affect the conduct of the study."
NCT00980629:I.2011,"Patients who have used M5161(active ingredient of M516102)."
NCT00980629:I.2012,"Patients who cannot communicate reliably with the investigator."
NCT00980629:I.2013,"Patients who are pregnant or lactating."
NCT00980629:I.2014,"Patients who have used any IMP and/or participated in any clinical trial within 3 months."
NCT00981058:I.1001,"age at least 18 Years"
NCT00981058:I.1002,"Has histologically or cytologically confirmed squamous NSCLC."
NCT00981058:I.1003,"Has Stage IV disease at the time of study entry."
NCT00981058:I.1004,"Measurable or nonmeasurable disease at the time of study entry as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) (patients with only truly nonmeasurable disease are not eligible)."
NCT00981058:I.1005,"Has resolution to Grade<= 1 of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia)."
NCT00981058:I.1006,"Has adequate hepatic function"
NCT00981058:I.1007,"Has adequate renal function"
NCT00981058:I.1008,"Has adequate hematologic function"
NCT00981058:I.1009,"If female, is surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method (failure rate<1%) during and for 6 months after the treatment period (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method)."
NCT00981058:I.1010,"If male, the patient is surgically sterile or compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period."
NCT00981058:I.1011,"Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization."
NCT00981058:I.1012,"Has archived tumor tissue available for analysis of EGFR and KRAS mutation status (by PCR) and EGFR gene copy number (by FISH). Minimum of four slides, paraffin-embedded tissue, required."
NCT00981058:I.2001,"Has nonsquamous NSCLC (adenocarcinoma/large cell or other)."
NCT00981058:I.2002,"Has received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor."
NCT00981058:I.2003,"Has received previous chemotherapy for advanced NSCLC (patients who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 1 year prior to randomization)."
NCT00981058:I.2004,"Has undergone major surgery or received any investigational therapy in the 4 weeks prior to randomization."
NCT00981058:I.2005,"Has undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed)."
NCT00981058:I.2006,"Has brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants. Patients who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible."
NCT00981058:I.2007,"Has superior vena cava syndrome contraindicating hydration."
NCT00981058:I.2008,"Has current clinically-relevant coronary artery disease or uncontrolled congestive heart failure."
NCT00981058:I.2009,"Has experienced myocardial infarction within 6 months prior to randomization."
NCT00981058:I.2010,"Has an ongoing or active infection (requiring antibiotics), including active tuberculosis or known infection with the human immunodeficiency virus."
NCT00981058:I.2011,"Has a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder."
NCT00981058:I.2012,"Has any NCI-CTCAE Version 3.0 Grade>= 2 peripheral neuropathy."
NCT00981058:I.2013,"Has significant third space fluid retention, requiring repeated drainage."
NCT00981058:I.2014,"Has any other serious uncontrolled medical disorders or psychological conditions that would, in the opinion of the investigator, limit the patient's ability to complete the study or sign an informed consent document."
NCT00981058:I.2015,"Has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab (IMC-11F8), or any other contraindication to one of the administered treatments."
NCT00981058:I.2016,"Is pregnant or breastfeeding."
NCT00981058:I.2017,"History of substance abuse"
NCT00981058:I.2018,"Has a concurrent active malignancy other than adequately-treated basal cell carcinoma of the skin or preinvasive carcinoma of the cervix. A patient with previous history of malignancy other than NSCLC is eligible, provided that he/she has been free of disease for>= 3 years."
NCT00982111:I.1001,"age at least 18 Years"
NCT00982111:I.1002,"Has histologically or cytologically confirmed nonsquamous (adenocarcinoma/large cell or other) non small cell lung cancer."
NCT00982111:I.1003,"Has Stage IV disease at the time of study entry."
NCT00982111:I.1004,"Measurable or nonmeasurable disease (as defined by the Response Evaluation Criteria in Solid Tumors RECIST 1.0) at the time of study entry (patients with only truly nonmeasurable disease are not eligible)."
NCT00982111:I.1005,"Has resolution to Grade<= 1 of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia)."
NCT00982111:I.1006,"Has an Eastern Cooperative Oncology Group performance status score of 0-2."
NCT00982111:I.1007,"Has adequate hepatic function"
NCT00982111:I.1008,"Has adequate renal function"
NCT00982111:I.1009,"Has adequate hematologic function"
NCT00982111:I.1010,"If female, is surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method during and for 6 months after the treatment period (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method). If male, the patients surgically sterile or compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period."
NCT00982111:I.1011,"Female patients of childbearing potential must have a negative serum"
NCT00982111:I.2001,"Has squamous non small cell lung cancer."
NCT00982111:I.2002,"Has received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor."
NCT00982111:I.2003,"Received previous chemotherapy for advanced NSCLC (patients who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 1 year prior to randomization)."
NCT00982111:I.2004,"Undergone major surgery or received any investigational therapy in the 4 weeks prior to randomization."
NCT00982111:I.2005,"Undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed)."
NCT00982111:I.2006,"Has brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants. Patients who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible."
NCT00982111:I.2007,"Has superior vena cava syndrome contraindicating hydration."
NCT00982111:I.2008,"Has current clinically-relevant coronary artery disease or uncontrolled congestive heart failure"
NCT00982111:I.2009,"Has experienced myocardial infarction within 6 months prior to randomization."
NCT00982111:I.2010,"Has an ongoing or active infection (requiring antibiotics), including active tuberculosis or known infection with the human immunodeficiency virus."
NCT00982111:I.2011,"Has a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder, potentially precluding protocol compliance."
NCT00982111:I.2012,"Has Grade>= 2 peripheral neuropathy."
NCT00982111:I.2013,"Has significant third space fluid retention, requiring repeated drainage."
NCT00982111:I.2014,"Has any other serious uncontrolled medical disorders or psychological conditions that would, in the opinion of the investigator, limit the patient's ability to complete the study or sign an informed consent document."
NCT00982111:I.2015,"The patient has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of IMC-11F8, or any other contraindication to one of the administered treatments."
NCT00982111:I.2016,"Is pregnant or breastfeeding."
NCT00982111:I.2017,"History of substance abuse"
NCT00982111:I.2018,"Has a concurrent active malignancy other than adequately-treated basal cell carcinoma of the skin or preinvasive carcinoma of the cervix. A patient with previous history of malignancy other than NSCLC is eligible, provided that he/she has been free of disease for>= 3 years."
NCT00983138:I.1001,"age up to 364 Days"
NCT00983138:I.1002,"Previously untreated T-lineage or precursor B-lineage ALL or biphenotypic leukaemia according to EGIL criteria."
NCT00983138:I.1003,"Morphological verification of the diagnosis, confirmed with cyto-chemistry and immunophenotyping."
NCT00983138:I.1004,"Written informed consent of the parents or other legally authorised guardian of the patient."
NCT00983138:I.1005,"Treatment according to protocol INTERFANT 06"
NCT00983138:I.2001,"Mature B-lineage ALL, defined by the immunophenotypical presence of surface immunoglobulins or t(8;14) and breakpoint as in B-ALL."
NCT00983138:I.2002,"The presence of the t(9;22)(q34;q11) or bcr-abl fusion in the leukaemic cells."
NCT00983138:I.2003,"Systemic use of corticosteroids<4 weeks before diagnosis. Patients who received corticosteroids by aerosol are eligible."
NCT00983138:I.2004,"Known allergy to any ASNase preparation."
NCT00983138:I.2005,"Pre-existing known coagulopathy (e.g. haemophilia)."
NCT00983138:I.2006,"Pre-existing pancreatitis."
NCT00983138:I.2007,"Liver insufficiency (bilirubin>50 micromol/L, SGOT/SGPT>10 x the upper limit of normal)."
NCT00984867:I.1001,"age at least 18 Years"
NCT00984867:I.1002,"Patients with type 2 diabetes"
NCT00984867:I.1003,"Patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these"
NCT00984867:I.1004,"Patients will be screened by a blood test and only those who need additional therapy can be enrolled"
NCT00984867:I.2001,"Diabetes Mellitus, Insulin-Dependent"
NCT00984867:I.2002,"Diabetes mellitus poor control"
NCT00984867:I.2003,"Any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study"
NCT00985712:I.1001,"age at least 8 Years"
NCT00985712:I.1002,"Type 1 diabetes mellitus"
NCT00985712:I.1003,"receiving at least 3 prandial injections per day with short-acting or analogue insulin"
NCT00985712:I.2001,"Insulin pump therapy"
NCT00985712:I.2002,"receiving pre-mixed insulin preparations"
NCT00987636:I.1001,"age 48 Months to 50 Years"
NCT00987636:I.1002,"Diagnosis: Histologically confirmed Ewing sarcoma of bone or soft tissue."
NCT00987636:I.1003,"Age and sex: Either sex, age>48 months (for GPOH patients) and<50 years at the date of diagnostic biopsy. Younger or elderly patients may be reported to the appropriate office (see section 1.4) but are not included in this study."
NCT00987636:I.1004,"Registration:<= 45 days after diagnostic biopsy/surgery."
NCT00987636:I.1005,"Start of chemotherapy:<= 45 days after diagnostic biopsy/surgery."
NCT00987636:I.1006,"Informed consent: Must be signed prior to study entry."
NCT00987636:I.1007,"Performance status: Lansky or Karnofsky score>50%, may be modified for handicapped patients."
NCT00987636:I.1008,"Haematological parameters:"
NCT00987636:I.1009,"Haemoglobin>8 g/dl (transfusion allowed),"
NCT00987636:I.1010,"Platelets>80.000/nicrol (transfusion allowed),"
NCT00987636:I.1011,"Leukocyte, WBC - White blood cell"
NCT00987636:I.1012,"Cardiac values: LVEF>40%, SF>28%."
NCT00987636:I.2001,">one cycle of other chemotherapy prior to registration"
NCT00987636:I.2002,"Neoplasms, Second Primary"
NCT00987636:I.2003,"Pregnancy and lactation"
NCT00987636:I.2004,"Concurrent treatment within any other clinical trial, except trials with different endpoints that due to the nature of their endpoints must run parallel to EWING 2008 e.g. trials on antiemetics, antimycotics, antibiotics, strategies for psychosocial support, etc..."
NCT00987636:I.2005,"Any other medical, psychiatric, or social condition incompatible with protocol treatment"
NCT00989261:I.1001,"age 18 Years to 85 Years"
NCT00989261:I.1002,"Males and females age ?18 years in second relapse or refractory."
NCT00989261:I.1003,"Males and females age ?60 years in first relapse or refractory."
NCT00989261:I.1004,"Must have baseline bone marrow sample taken."
NCT00989261:I.1005,"Morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS with ?20% bone marrow or peripheral blasts), as defined by the World Health Organization (WHO) criteria, confirmed by pathology review at treating institution."
NCT00989261:I.1006,"Able to swallow the liquid study drug."
NCT00989261:I.1007,"ECOG performance status of 0 to 2"
NCT00989261:I.1008,"In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. The use of chemotherapeutic or antileukemic agents other than hydroxyurea is not permitted during the study with the possible exception of intrathecal (IT) therapy at the discretion of the Investigator and with the agreement of the Sponsor."
NCT00989261:I.1009,"Persistent chronic clinically significant non-hematological toxicities from prior treatment must be<= Grade 1."
NCT00989261:I.1010,"Prior therapy with FLT3 inhibitors is permitted, except previous treatment with AC220."
NCT00989261:I.1011,"Serum creatinine ?1.5 × ULN and glomerular filtration rate (GFR)>30 mL/min"
NCT00989261:I.1012,"Serum potassium, magnesium, and calcium levels should be at least within institutional normal limits."
NCT00989261:I.1013,"Total serum bilirubin ?1.5 × ULN"
NCT00989261:I.1014,"Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ?2.5 × ULN"
NCT00989261:I.1015,"Females of childbearing potential must have a negative pregnancy test (urine ?-hCG)."
NCT00989261:I.1016,"Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study."
NCT00989261:I.1017,"Procurement of patient informed consent, investigational study"
NCT00989261:I.2001,"Patients over the age of 85 years except at the discretion of the Investigator and with agreement of the Sponsor."
NCT00989261:I.2002,"Diagnosis of acute promyelocytic leukemia"
NCT00989261:I.2003,"Diagnosis of chronic myelogenous leukemia (CML) in blast crisis"
NCT00989261:I.2004,"AML in relapse or refractory after 3 or more previous lines of chemotherapy (and/or HSCT) treatment"
NCT00989261:I.2005,"AML or antecedent MDS secondary to prior chemotherapy"
NCT00989261:I.2006,"Persistent clinically significant non-hematological toxicity that is Grade>1 by NCI CTCAE v4 from prior chemotherapy"
NCT00989261:I.2007,"Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have>Grade 1 persistent non hematological toxicity related to the transplant"
NCT00989261:I.2008,"Clinically active central nervous system (CNS) leukemia. Patients with CNS leukemia, which is controlled, but who are still receiving IT therapy at study entry may be considered eligible and continue receive IT therapy at the discretion of the Investigator and with agreement of the Sponsor."
NCT00989261:I.2009,"Patients who have previously received AC220"
NCT00989261:I.2010,"Disseminated intravascular coagulation (DIC) (diagnosis by laboratory or clinical assessment)"
NCT00989261:I.2011,"Major surgery within 4 weeks prior to enrollment in the study"
NCT00989261:I.2012,"Radiation therapy within 4 weeks prior to, or concurrent with study"
NCT00989261:I.2013,"Use of concomitant drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors are prohibited with the exception of antibiotics, antifungals, and other antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient."
NCT00989261:I.2014,"Uncontrolled or significant cardiovascular disease"
NCT00989261:I.2015,"Women who are pregnant, lactating, or unwilling to use contraception if of childbearing potential"
NCT00989261:I.2016,"Men who are unwilling to use contraception if their partners are of childbearing potential"
NCT00989261:I.2017,"Active, uncontrolled infection"
NCT00989261:I.2018,"HIV Seropositivity"
NCT00989261:I.2019,"Active hepatitis B or C or other active liver disease"
NCT00989261:I.2020,"History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the possible exception of patients in complete remission"
NCT00993473:I.1001,"age 1 Year to 6 Years"
NCT00993473:I.1002,"Pediatric patients with type 1 diabetes mellitus aged>= one year to<6 years at screening, for whom signed written informed consent has been obtained from parent or legal guardian to participate in the study"
NCT00993473:I.2001,"Diagnosis of type 1 diabetes for<one year"
NCT00993473:I.2002,"HbA1c at screening>12% or<6%"
NCT00993473:I.2003,"Diabetes other than type 1 diabetes"
NCT00993473:I.2004,"Parents and patients not willing to undergo all study assessments and treatments, including home blood glucose monitoring, Continuous Glucose Monitoring System (CGMS) sensor placement and maintenance both at the site and at home, multiple daily insulin injections, and visits, as dictated by the protocol (if a telephone is not available patients may undergo all visits in person)"
NCT00993473:I.2005,"Patients and families for whom 6 days in total (not necessarily continuous) of useable CGMS data cannot be obtained (either by home sensor replacement, or by sensor replacement at the site at additional screening visits if needed) during the screening CGMS evaluations between Visit 2 and the randomization visit"
NCT00993473:I.2006,"Patients treated with insulin pump therapy during the two months prior to screening"
NCT00993473:I.2007,"History of primary seizure disorder"
NCT00993473:I.2008,"History of severe hypoglycemic episode accompanied by seizure and/or coma, or diabetic ketoacidosis leading to hospitalization or to care in the emergency ward, in the 2 months prior to the screening visit"
NCT00993473:I.2009,"Need for chronic treatment with acetaminophen (paracetamol)-containing medications"
NCT00993473:I.2010,"Serum creatinine>2.0mg/dL at screening"
NCT00993473:I.2011,"Serum ALT or AST>3x upper limit of normal for the patient's age and gender, at screening"
NCT00993473:I.2012,"Hemoglobin<10g/dL, or platelet count<100,000/cu mm, at screening"
NCT00993473:I.2013,"Treatment with any pharmacologic anti-hyperglycemic oral agent for>3 months at any time"
NCT00993473:I.2014,"Treatment with any non-insulin antihyperglycemic medication (eg, Symlin) for the 3 months prior to screening"
NCT00993473:I.2015,"Treatment with systemic glucocorticoids within the month prior to screening"
NCT00997230:I.1001,"age at least 18 Years"
NCT00997230:I.1002,"Histologically confirmed locally advanced or metastatic NSCLC (stage IIIB/IV). Mixed histology of small cell and non-small cell lung cancer"
NCT01011205:I.1001,"age at least 18 Years"
NCT01011205:I.1002,"Undergoing orthotopic liver or split liver allograft transplantation"
NCT01011205:I.1003,"Female subject of childbearing potential must have a negative serum or urine pregnancy test at enrollment and must agree to maintain effective birth control during the study"
NCT01011205:I.2001,"Receiving a multi-organ transplant or having previous received an organ transplant (including liver re-transplantation)"
NCT01011205:I.2002,"Receiving an auxiliary graft or in whom a bio-artificial liver (cell system) has been used"
NCT01011205:I.2003,"Receiving ABO incompatible graft or a graft from a non heart beating donor"
NCT01011205:I.2004,"Ongoing dosing with systemic corticosteroids"
NCT01011205:I.2005,"Subjects with systemic infection requiring treatment except viral hepatitis"
NCT01011205:I.2006,"Diagnosis of new-onset malignancy prior to transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully. However, subjects with primary liver carcinoma can be included if they meet the following criteria:"
NCT01011205:I.2007,"<3 nodes"
NCT01011205:I.2008,"no node larger than 5 cm"
NCT01011205:I.2009,"No metastases (tumor staging)"
NCT01011205:I.2010,"Vascular invasion by tumor absent"
NCT01011205:I.2011,"Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer"
NCT01011205:I.2012,"Subject or donor known to be HIV positive"
NCT01011205:I.2013,"Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, basiliximab or mycophenolate mofetil or any of the product excipients"
NCT01011205:I.2014,"Pregnant woman or breast-feeding mother"
NCT01011205:I.2015,"Currently participating in another clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment"
NCT01011205:I.2016,"Unlikely to comply with the Visits scheduled in the protocol"
NCT01011205:I.2017,"Any unstable medical condition that could interfere with the study objectives in the opinion of the Investigator"
NCT01011205:I.2018,"Receiving prohibited concomitant therapy, or received prohibited concomitant therapy within 28 days prior to enrollment"
NCT01011205:I.2019,"Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the Investigator, may complicate communication with the Investigator"
NCT01011738:I.1001,"age at least 18 Years"
NCT01011738:I.1002,"Adult (person)"
NCT01011738:I.1003,"chronic hepatitis B"
NCT01011738:I.1004,"treatment with peginterferon alfa-2A"
NCT01011738:I.2001,"coinfection with HAV, HCV and HIV"
NCT01012973:I.1001,"age at least 18 Years"
NCT01012973:I.1002,"Center-involved macular edema secondary to central retinal vein occlusion (CRVO) for no longer than 9 months with mean central subfield thickness>= 250 microm on optical coherence tomography (OCT)"
NCT01012973:I.1003,"Adult (person)"
NCT01012973:I.1004,"Early treatment diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 to 24 letters) in the study eye"
NCT01012973:I.2001,"Any prior treatment with anti-VEGF agents in the study eye (Pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc.) or previous administration of systemic anti-angiogenic medications"
NCT01012973:I.2002,"Prior panretinal laser photocoagulation or macular laser photocoagulation in the study eye"
NCT01012973:I.2003,"CRVO disease duration>9 months from date of diagnosis"
NCT01012973:I.2004,"Previous use of intraocular corticosteroids in the study eye or use of periocular corticosteroids in the study eye within the 3 months prior to Day 1"
NCT01012973:I.2005,"Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in either the study eye or fellow eye"
NCT01016275:I.1001,"age at least 18 Years"
NCT01016275:I.1002,"Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable for stenting (on indication for primary stenting, based on the discretion of the investigator)"
NCT01016275:I.1003,"Patient presenting a score from 2 to 5 following Rutherford classification"
NCT01016275:I.1004,"Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study"
NCT01016275:I.1005,"Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study"
NCT01016275:I.1006,"Patient is eligible for treatment with the Misago (Terumo)"
NCT01016275:I.1007,"The target lesion is either a modified TASC-II class A or B lesion with one of the listed specifications:"
NCT01016275:I.1008,"Type A lesions"
NCT01016275:I.1009,"Unilateral or bilateral stenoses of the Common Iliac Artery"
NCT01016275:I.1010,"Unilateral or bilateral single short (<=3 cm) stenosis of the External Iliac  Artery"
NCT01016275:I.1011,"Type B lesions"
NCT01016275:I.1012,"Unilateral Common Iliac Artery occlusion"
NCT01016275:I.1013,"Single or multiple stenosis totaling 3-10 cm involving the External Iliac  Artery not extending into the Common Femoral Artery"
NCT01016275:I.1014,"Unilateral External Iliac Artery occlusion not involving the origins of  Internal Iliac Artery or Common Iliac Artery"
NCT01016275:I.1015,"The target lesion has angiographic evidence of stenosis or restenosis>50% or occlusion which can be passed with standard guidewire manipulation"
NCT01016275:I.1016,"There is angiographic evidence of a patent Common an Deep Femoral Artery"
NCT01016275:I.2001,"The target lesion is either a modified TASC-II class B lesion with aortic lesion involvement:"
NCT01016275:I.2002,"Short (<=3 cm) stenosis of infrarenal aorta"
NCT01016275:I.2003,"The target lesion is either a modified TASC-II class C or D lesion with aortic lesion involvement:"
NCT01016275:I.2004,"Presence of aneurysm at the level of the iliac arteries"
NCT01016275:I.2005,"Previously implanted stent(s) at the same lesion site"
NCT01016275:I.2006,"Reference segment diameter is not suitable for available stent design"
NCT01016275:I.2007,"Untreatable lesion located at the distal outflow arteries"
NCT01016275:I.2008,"Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure"
NCT01016275:I.2009,"Refusal of treatment by patient"
NCT01016275:I.2010,"Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated"
NCT01016275:I.2011,"Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site"
NCT01016275:I.2012,"Perforation at the angioplasty site evidenced by extravasation of contrast medium"
NCT01016275:I.2013,"Patients with a history of prior life-threatening contrast medium reaction"
NCT01016275:I.2014,"Patients with known hypersensitivity to nickel-titanium"
NCT01016275:I.2015,"Patients with uncorrected bleeding disorders"
NCT01016275:I.2016,"Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding"
NCT01016275:I.2017,"Life expectancy of<twelve months"
NCT01016275:I.2018,"Any planned surgical intervention/procedure within 30 days of the study procedure"
NCT01016275:I.2019,"Any patient considered to be hemodynamically unstable at onset of procedure"
NCT01016275:I.2020,"Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period."
NCT01018069:I.1001,"age at least 18 Years"
NCT01018069:I.1002,"Patients with AML, except those with APL (acute promyelocytic leukemia), failing a single standard dose cytarabine based frontline induction regimen. The diagnosis of refractory AML is based on the presence of either>10% blasts in marrow or blood or 5-10% blasts in either site together with cytopenia (Hb<10 g/dL, or platelets<100 x 109/L, or neutrophil count<1.0 x 109/L)."
NCT01018069:I.1003,"ECOG performance status finding<=2"
NCT01018069:I.1004,"Male, or female patients who are post-menopausal (amenorrheic for at least 12 months), or surgically or biologically sterile."
NCT01018069:I.1005,"Patients must have adequate organ and immune function as indicated by the following laboratory values:"
NCT01018069:I.1006,"Parameter Laboratory Values Serum creatinine; ?2.0 mg/dL (? 177 ?mol/L Total Bilirubin ?2.0 mg/dL (? 34 ?mol/L) AST (SGOT) and ALT (SGPT) ?3 X ULN"
NCT01018069:I.1007,"The patient must understand, be able and willing and likely to fully comply with study procedures, including scheduled follow-up, and restrictions."
NCT01018069:I.2001,"Clinical evidence of ongoing grade 3 or 4 non-hematological toxicities from the initial standard dose cytarabine-based induction chemotherapy"
NCT01018069:I.2002,"Patients with a prior history of peripheral neuropathy of grade>= 2."
NCT01018069:I.2003,"Clinical evidence of active CNS leukemic involvement."
NCT01018069:I.2004,"Active and uncontrolled infection. Patients with an infection who are under active treatment with antibiotics and whose infections are controlled may be entered to the study."
NCT01018069:I.2005,"Current evidence of invasive fungal infection (blood or tissue culture)."
NCT01018069:I.2006,"Current evidence of an active second malignancy except for non-melanoma skin cancer."
NCT01018069:I.2007,"Uncontrolled medical problems, unrelated to the malignancy, or of sufficient severity that in the opinion of the investigator, impair a patient's ability to give informed consent or unacceptably reduce the safety of the proposed treatment."
NCT01018069:I.2008,"Neurological or psychiatric disorders that would interfere with consent or study follow-up."
NCT01018069:I.2009,"Known or suspected intolerance or hypersensitivity to the study drugs [or closely related compounds] or any of their stated ingredients. Study drugs being the antisense, cytarabine and idarubicin."
NCT01018069:I.2010,"History of alcohol or other substance abuse within the last year."
NCT01018069:I.2011,"Use of another investigational agent within the last 14 days prior to enrolment. Patients who have received a previous antisense agent in the last 90 days will be excluded."
NCT01018069:I.2012,"Female patients who are pregnant, lactating, or with a positive pregnancy test at screening must be excluded."
NCT01019174:I.1001,"age at least 18 Years"
NCT01019174:I.1002,"Understand and voluntarily sign an informed consent form."
NCT01019174:I.1003,"Able to adhere to the study visit schedule and other protocol requirements."
NCT01019174:I.1004,"Previously diagnosed with multiple myeloma based on standard criteria and requires therapy for primary refractory disease or 1st - 3rd relapse because of progressive disease (PD), defined as a 25% increase in M-protein, development of new or worsening of existing lytic bone lesions or soft tissue plasmacytoma, or hypercalcemia (serum calcium>11.3 mg/dL), or clinical relapse from CR."
NCT01019174:I.1005,"At least one measurable disease manifestation defined as follows:"
NCT01019174:I.1006,"For secretory multiple myeloma, measurable disease is defined as any  quantifiable serum monoclonal protein value (generally, but not exclusively,>1g/dL IgG M-protein or>0.5 g/dL IgA) and, where applicable, urine light-chain  excretion of>= 200 mg/24 h."
NCT01019174:I.1007,"For oligo- or non-secretory multiple myeloma, measurable disease is defined by the presence of soft tissue (not bone) plasmacytomas as determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan) or a quantifiable plasma cell infiltration of the bone marrow as determined by bone marrow biopsy."
NCT01019174:I.1008,"ECOG performance status<= 2 at time of randomization/registration (see Appendix I)."
NCT01019174:I.1009,"Laboratory test results within these ranges within 1 week prior to randomization/registration:"
NCT01019174:I.1010,"Absolute neutrophil count>= 1.5 x 109/L without the use of colony stimulating  factors within 14 days before the laboratory test."
NCT01019174:I.1011,"Platelet count>= 75 x 109/L without transfusion support within 14 days before  the laboratory test."
NCT01019174:I.1012,"Hemoglobin>= 7.5 g/dL (regardless of transfusion support or prior medication  with erythropoietin)."
NCT01019174:I.1013,"Calculated creatinine clearance>= 50 mL/minute."
NCT01019174:I.1014,"Total Bilirubin Measurement"
NCT01019174:I.1015,"AST (SGOT) and ALT (SGPT)<= 2,5 x ULN."
NCT01019174:I.1016,"Corrected Serum Calcium Measurement"
NCT01019174:I.1017,"Female subjects of childbearing potential must:"
NCT01019174:I.1018,"Understand that the study medication could have a potential teratogenic risk"
NCT01019174:I.1019,"Agree to use, and be able to comply with, effective contraception without  interruption, 4 weeks before starting study drug, throughout study drug therapy  (including dose interruptions) and for 4 weeks after the end of study drug  therapy, even if she has amenorrhoea. This applies unless the subject commits to  absolute and continued abstinence confirmed on a monthly basis. The following  are effective methods of contraception:"
NCT01019174:I.1020,"Contraceptive Implant"
NCT01019174:I.1021,"INSERTION OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM"
NCT01019174:I.1022,"Medroxyprogesterone acetate depot"
NCT01019174:I.1023,"Tubal sterilization"
NCT01019174:I.1024,"Sexual intercourse with a vasectomised male partner only. Vasectomy must be  confirmed by two negative semen analyses"
NCT01019174:I.1025,"Ovulation inhibitory progesterone-only pills (i.e., desogestrel)."
NCT01019174:I.1026,"Combined oral contraceptive pills are not recommended. If a subject was using combined oral contraception, she must switch to one of the methods above. The increased risk of VTE continues for 4 to 6 weeks after stopping combined oral contraception"
NCT01019174:I.1027,"Prophylactic antibiotics should be considered at the time of insertion particularly in patients with neutropenia due to risk of infection"
NCT01019174:I.1028,"Agree to have a medically supervised pregnancy test with a minimum sensitivity  of 25 mIU/ml not more than 3 days from the start of study medication once the  subject has been on effective contraception for at least 4 weeks. This  requirement also applies to women of childbearing potential who practice  complete and continued abstinence."
NCT01019174:I.1029,"Agree to have a medically supervised pregnancy test every 4 weeks including 4  weeks after the end of study treatment, except in the case of confirmed tubal  sterilization. These tests should be performed not more than 3 days before the  start of next treatment. This requirement also applies to women of childbearing  potential who practice complete and continued abstinence"
NCT01019174:I.1030,"Male subjects must"
NCT01019174:I.1031,"Agree to use condoms throughout study drug therapy, during any dose interruption  and for one week after cessation of study therapy if their partner is of  childbearing potential and has no contraception."
NCT01019174:I.1032,"Agree not to donate semen during study drug therapy and for one week after end  of study drug therapy."
NCT01019174:I.1033,"All subjects must"
NCT01019174:I.1034,"Agree to abstain from donating blood while taking study drug therapy and for one  week following discontinuation of study drug therapy."
NCT01019174:I.1035,"Agree not to share study medication with another person and to return all unused  study drug to the investigator."
NCT01019174:I.1036,"Disease free of prior malignancies for ? 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma""in situ""of the cervix or breast"
NCT01019174:I.1037,"Able and willing to take heparin (usually low-molecular weight - LMWH) or low acetylsalicylic acid (100 mg) daily as prophylactic anticoagulation."
NCT01019174:I.1038,"Life-expectancy>3 months."
NCT01019174:I.2001,"Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form."
NCT01019174:I.2002,"Females, who are pregnant, calculate to get pregnant or are breast feeding (Lactating females must agree not to breast feed while taking lenalidomide)."
NCT01019174:I.2003,"Any condition, including the presence of laboratory abnormalities, which places the subject at an unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study."
NCT01019174:I.2004,"Patient currently is enrolled in another clinical research study or has been enrolled in such a study within 4 weeks before randomization/registration and/or is receiving an investigational agent for any reason or has received such an agent within 4 weeks before randomization/registration."
NCT01019174:I.2005,"Known hypersensitivity to thalidomide, dexamethasone, or cyclophosphamide or similar drugs."
NCT01019174:I.2006,"Any prior use of lenalidomide."
NCT01019174:I.2007,"Concurrent use of other anti-cancer agents or treatments."
NCT01019174:I.2008,"Known positive for HIV or infectious hepatitis, type A, B or C."
NCT01019174:I.2009,"Any other chemotherapy or high-dose dexamethasone within 4 weeks before randomization/registration."
NCT01019174:I.2010,"Immunotherapy or antibody therapy within 8 weeks before randomization/registration."
NCT01019174:I.2011,"major surgery"
NCT01019174:I.2012,"Myocardial infarction within 6 months before randomization/registration, New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities."
NCT01019174:I.2013,"Senile cardiac amyloidosis, Cardiac amyloidosis, AS transthyretin amyloidosis"
NCT01019174:I.2014,"Poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol."
NCT01019174:I.2015,"Any systemic infection requiring treatment."
NCT01019174:I.2016,Cystitis
NCT01019174:I.2017,"Disturbance of urinary flow."
NCT01019174:I.2018,"Unable or unwilling to take heparin (usually low-molecular weight - LMWH) or low acetylsalicylic acid (100 mg) daily as prophylactic anticoagulation."
NCT01019473:I.1001,"age 30 Years to 85 Years"
NCT01019473:I.1002,"Huntington's disease (based on DNA testing polyQ>36) with a UHDRS maximal chorea score of>10"
NCT01019473:I.1003,"patient with concomitant Huntington's medication (anti-depressants, neuroleptics, benzodiazepines) are allowed but the total daily dose and dosing regimen has to be stable for at least one months prior to randomization"
NCT01019473:I.1004,"female patients without childbearing potential (post-menopausal or surgically sterilized), all patients must using a double-barrier local contraception"
NCT01019473:I.2001,"patients with marked cognitive impairment (MMSE<18), with presence of psychosis and/or confusional states"
NCT01019473:I.2002,"patients with a history or presence of renal impairment and/or liver disease"
NCT01021670:I.1001,"age 18 Years to 64 Years"
NCT01021670:I.1002,"In accordance with the therapeutic indication stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be candidates for enrollment if they have an intravaginal ejaculatory latency time of<two minutes"
NCT01021670:I.1003,"Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes"
NCT01021670:I.1004,"Marked personal distress or interpersonal difficulty as a consequence of premature ejaculation"
NCT01021670:I.1005,"Poor control over ejaculation"
NCT01021670:I.2001,"In accordance with the contraindications, special warnings and precautions for use as stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be excluded from treatment if they have hypersensitivity to dapoxetine hydrochloride or to any of the excipients"
NCT01021670:I.2002,"Significant pathological cardiac conditions such as: heart failure (New York Heart Association [NYHA] class II-IV), conduction abnormalities (second or third degree atrioventicular (AV) block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease, or significant valvular disease"
NCT01021670:I.2003,"Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with an MAOI"
NCT01021670:I.2004,"Concomitant treatment with thioridazine, concomitant treatment with serotonin reuptake inhibitors (selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants [TCAs)] or other medicinal/herbal products with serotonergic effects (for example, L-tryptophan, triptans, tramadol, linezolid, lithium, St. John's Wort (Hypericum perforatum)"
NCT01021670:I.2005,"Concomitant treatment of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazadone, nelfinavir, atazanavir, etc."
NCT01021670:I.2006,"Moderate and severe hepatic impairment"
NCT01026142:I.1001,"age at least 18 Years"
NCT01026142:I.1002,"Adult (person)"
NCT01026142:I.1003,"Metastatic HER2 positive breast cancer"
NCT01026142:I.1004,"ECOG performance status 0 or 1"
NCT01026142:I.1005,"Disease progression during or following trastuzumab-based therapy for 1st line metastatic breast cancer (trastuzumab must have been part of the last prior treatment regimen)"
NCT01026142:I.1006,"Prior treatment with taxane-containing regimen"
NCT01026142:I.1007,"LVEF - Left ventricular ejection fraction"
NCT01026142:I.1008,"For women of childbearing potential agreement to use highly effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by patient and/or partner. Contraception must continue for duration of study treatment and for at least 6 months after last dose of study drug treatment"
NCT01026142:I.2001,"Prior treatment with pertuzumab or capecitabine"
NCT01026142:I.2002,"Concurrent treatment with other experimental drug"
NCT01026142:I.2003,"Concurrent immunotherapy or anticancer hormonal therapy"
NCT01026142:I.2004,"Serious concurrent disease (e.g. active infection, uncontrolled hypertension, cardiovascular disease)"
NCT01026142:I.2005,"CNS metastases, which are not well controlled"
NCT01026142:I.2006,"History of exposure to anthracycline cumulative dose equivalent to 360mg/m2 doxorubicin"
NCT01026142:I.2007,"History of congestive heart failure of any New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment"
NCT01026142:I.2008,"Past history of myocardial infarction"
NCT01026142:I.2009,"History of LVEF decline to below 50% during or after prior trastuzumab therapy or other cardiac toxicity during previous trastuzumab treatment that necessitated discontinuation of trastuzumab"
NCT01031680:I.1001,"age at least 45 Years"
NCT01031680:I.1002,"Type 2 diabetes mellitus."
NCT01031680:I.1003,"Disease affecting entire cardiovascular system"
NCT01031680:I.1004,"Hypertensive disease, High Blood Pressure"
NCT01031680:I.2001,"Patients with type 1 diabetes or diabetes insipidus"
NCT01031680:I.2002,"Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes"
NCT01031680:I.2003,"Any clinically significant illness, which would compromise the patient's safety and their participation in the study"
NCT01033097:I.1001,"age 18 Years to 45 Years"
NCT01033097:I.1002,"Male and female atopic dermatitis patients,18 to 45 years of age inclusive, who fulfill the following criteria:"
NCT01033097:I.1003,"Requirement of systemic therapy"
NCT01033097:I.1004,"Itch VAS score>50 mm"
NCT01033097:I.1005,"EASI score>8"
NCT01033097:I.2001,"Pregnant or breastfeeding women. Women of child-bearing potential or men who are not willing to follow the restrictions in inclusion criteria 3 and 4, respectively, are not allowed in the study."
NCT01033097:I.2002,"Any systemic immunosuppressive treatment and/or phototherapy within 4 weeks prior to the first dosing."
NCT01033097:I.2003,"Any topical or oral treatment for atopic dermatitis within 2 weeks prior to the first dosing. Use of any topical or systemic treatment for atopic dermatitis (with the exception of emollients prescribed by the Investigator) will not be allowed during the study period."
NCT01035502:I.1001,"age at least 18 Years"
NCT01035502:I.1002,"Patients with a confirmed diagnosis of AML according to WHO classification (excluding acute promyelocytic leukaemia)"
NCT01035502:I.1003,"Patients who have received one previous standard dose ara-C-containing regimen aiming at induction of complete remission (CR) and who have>5 % remaining blast cells in bone marrow following the first course of remission-induction or by other means documented residual disease (i.e. circulating blasts, persistent chloromas, other evident disease from day 12 on)."
NCT01035502:I.1004,"Patients from whom samples for determination of hENT1 status on leukemic blast cells can be taken and prepared at diagnosis and/or at baseline"
NCT01035502:I.1005,"Patients must have ECOG performance status (PS) of 0 - 2"
NCT01035502:I.1006,"Left ventricular ejection fraction (LVEF) must be>= 45 % as measured by MUGA scan or 2D ECHO within 14 days prior to start of therapy."
NCT01035502:I.1007,"Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this study"
NCT01035502:I.1008,"Male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last elacytarabine dose"
NCT01035502:I.1009,"Patients must be capable of understanding and complying with parameters as outlined in the protocol, and able and willing to sign a written informed consent form"
NCT01035502:I.1010,"Patients must have the following clinical laboratory values:"
NCT01035502:I.1011,"Serum creatinine<= 1.5 x the institutional upper limit of normal (ULN)"
NCT01035502:I.1012,"Total bilirubin<= 1.5 x the ULN according to national prescribing information  unless considered due to Gilbert's syndrome"
NCT01035502:I.1013,"Alanine aminotransferase (ALT) (SGPT), or aspartate aminotransferase (AST)  (SGOT)<= 2.5 x the ULN unless considered due to organ leukemic involvement"
NCT01035502:I.1014,"Patients must be eligible for administration of idarubicin according to current national prescribing information for idarubicin"
NCT01035502:I.2001,"A history of allergic reactions to egg, idarubicin and/or other anthracyclines or other components of the products. A history of allergic reactions to ara-C of CTCAE grade 3 or 4"
NCT01035502:I.2002,"Persistent clinically significant and relevant toxicities from the previous course of chemotherapy"
NCT01035502:I.2003,"A cancer history, that according to the investigator might confound the assessment of the study endpoints"
NCT01035502:I.2004,"Patients with prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 300 mg/m2 according to the following calculation index: X/300 + Y/160<1 where X is the doxorubicin or equivalent dose in mg/m2 and Y is the mitoxantrone dose in mg/m2. These calculations are to be used as guidance as there is no maximum cumulative dose defined in the summary of product characteristics (SPC) for idarubicin. The patient should tolerate minimum one course of combination therapy"
NCT01035502:I.2005,"Active heart disease including myocardial infarction within the previous 3 months, symptomatic coronary disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure. Any NYHA grade 3 or 4"
NCT01035502:I.2006,"HIV Seropositivity"
NCT01035502:I.2007,"Pregnant and nursing patients are excluded because the effects of elacytarabine on a fetus or a nursing child are unknown"
NCT01035502:I.2008,"Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, or psychiatric illness/social situations that may reduce compliance with study requirements"
NCT01035502:I.2009,"Patients receiving hydroxyurea within the last 12 hours prior to treatment on this protocol or any other investigational or standard cytotoxic treatment within the last 14 days, except the first remission-induction course"
NCT01035502:I.2010,"Any medical condition, which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities"
NCT01036763:I.1001,"age at least 18 Years"
NCT01036763:I.1002,"COPD patients requiring long-acting bronchodilators according to approved Summary of Product Characteristics (SPC) and guidelines"
NCT01036763:I.2001,"Patients cannot be recruited if any of the general or specific contraindications listed in the Patient information leaflet or the Summary of Product Characteristics applies."
NCT01042769:I.1001,"age at least 18 Years"
NCT01042769:I.1002,"Adult (person)"
NCT01042769:I.1003,"Type 2 diabetes mellitus"
NCT01042769:I.1004,"Hospitalization for ACS event and randomization 2-6 weeks after day of hospitalization"
NCT01042769:I.2001,"Estimated glomerular filtration rate<45mL/min/1.73m2"
NCT01042769:I.2002,"Concomitant treatment with a thiazolidinedione and/or fibrate"
NCT01042769:I.2003,Triglyceride
NCT01042769:I.2004,Anaemia
NCT01042769:I.2005,"Symptomatic congestive heart failure classified as NYHA class II-IV"
NCT01042977:I.1001,"age at least 45 Years"
NCT01042977:I.1002,"Type 2 diabetes mellitus."
NCT01042977:I.1003,"Disease affecting entire cardiovascular system"
NCT01042977:I.1004,"Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment"
NCT01042977:I.2001,"Patients with type 1 diabetes or diabetes insipidus"
NCT01042977:I.2002,"Patients with>= 3 oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes"
NCT01042977:I.2003,"Any clinically significant illness, which would compromise the patient's safety and their participation in the study"
NCT01043029:I.1001,"age at least 18 Years"
NCT01043029:I.1002,"Adult (person)"
NCT01043029:I.1003,"Diabetes mellitus, Type 2"
NCT01043029:I.1004,"Moderately impaired kidney function"
NCT01043029:I.1005,"Drug naive or up to 2 antihyperglycemic medications at stable dose for over 1 month at screening"
NCT01043029:I.1006,"Body mass index"
NCT01043029:I.2001,"Current or previous treatment with a thiazolidinedione"
NCT01043029:I.2002,"Current or previous treatment with insulin"
NCT01043029:I.2003,"Treatment with fibrates<3 months prior to screening"
NCT01043029:I.2004,"History of renal disease other than diabetic nephropathy"
NCT01046448:I.1001,"age 6 Years to 17 Years"
NCT01046448:I.1002,
NCT01046448:I.2001,"Active systemic vasculitis"
NCT01046448:I.2002,"Diabetes mellitus"
NCT01046448:I.2003,"Renal vascular anomalies"
NCT01046448:I.2004,"Anomalies of the limbs preventing standardized diagnostic procedures"
NCT01064401:I.1001,"age 18 Years to 55 Years"
NCT01064401:I.1002,"Informed Consent"
NCT01064401:I.1003,"Must have a confirmed diagnosis of RRMS, and a cranial MRI demonstrating lesion(s) consistent with MS"
NCT01064401:I.1004,"Must have a baseline EDSS between 0.0 and 5.0, inclusive"
NCT01064401:I.1005,"Male subjects and female subjects of childbearing potential must be willing to practice effective contraception during the study and be willing and able to continue contraception for 4 months after their last dose of study treatment"
NCT01064401:I.2001,"Known intolerance, contraindication to, or history of non compliance with Avonex 30 mcg"
NCT01064401:I.2002,"History of treatment with Dac HYP"
NCT01064401:I.2003,"History of neoplastic disease"
NCT01064401:I.2004,"History of severe allergic or anaphylactic reactions"
NCT01064401:I.2005,"Known hypersensitivity to study drugs or their excipients"
NCT01064401:I.2006,"History of abnormal laboratory results indicative of any significant disease"
NCT01064401:I.2007,"History of human immunodeficiency virus (HIV) or other immunodeficient conditions"
NCT01064401:I.2008,"History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization"
NCT01064401:I.2009,"History of seizure disorder or unexplained blackouts OR history of a seizure within 6 months prior to Baseline"
NCT01064401:I.2010,"History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 3 months prior to Day 1"
NCT01064401:I.2011,"An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization"
NCT01064401:I.2012,"Known history of, or positive screening test result for hepatitis C virus or hepatitis B virus"
NCT01064401:I.2013,"Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before screening"
NCT01064401:I.2014,"Exposure to varicella zoster virus within 21 days before screening"
NCT01066208:I.1001,"age at least 18 Years"
NCT01066208:I.1002,"Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin."
NCT01066208:I.1003,"Inclusion Criteria for Classification criteria:"
NCT01066208:I.1004,"Presumed diagnosis of a primary systemic vasculitis."
NCT01066208:I.1005,"diagnostic criteria"
NCT01066208:I.1006,"Suspected diagnosis of a primary systemic vasculitis"
NCT01066208:I.1007,"Inclusion criteria for controls group for diagnostic criteria:"
NCT01066208:I.1008,"Patients presenting to secondary care with one of the following clinical presentations:"
NCT01066208:I.1009,"Multi-system disease. Presentation of disease with at least 2 organs involved."
NCT01066208:I.1010,"Pulmonary-renal syndrome. Defined as haemoptysis / pulmonary haemorrhage with acute renal impairment."
NCT01066208:I.1011,"Kidney Failure, Acute"
NCT01066208:I.1012,"Acute respiratory distress"
NCT01066208:I.1013,"Chronic upper airways symptoms and signs."
NCT01066208:I.1014,"Inflammatory polyarthritis"
NCT01066208:I.1015,"Fever of unknown origin"
NCT01066208:I.1016,"Acute or chronic abdominal pain"
NCT01066208:I.1017,"Hypertensive disease, High Blood Pressure"
NCT01066208:I.1018,"Referred to secondary care with suspicion of vasculitis but confirmed not to have vasculitis."
NCT01066208:I.1019,"New onset headache"
NCT01066208:I.1020,"Jaw or tongue pain"
NCT01066208:I.1021,"Sudden visual loss"
NCT01066208:I.1022,"Limb claudication"
NCT01066208:I.1023,"Aneurysm of aorta"
NCT01066208:I.2001,"age<18 Years"
NCT01066208:I.2002,"Exclusion criteria for classification criteria:"
NCT01066208:I.2003,"Inability to provide informed consent."
NCT01066208:I.2004,"Hepatitis B or C"
NCT01066208:I.2005,"Co-morbidities that explain the clinical symptoms and signs on which the diagnosis of vasculitis is made. E.g. infection, tumour, other inflammatory condition, etc."
NCT01066208:I.2006,"diagnostic criteria"
NCT01066208:I.2007,"Patient or next of kin unable or unwilling to provide informed consent or assent."
NCT01069419:I.1001,"age at least 18 Years"
NCT01069419:I.1002,"Rheumatoid Arthritis"
NCT01069419:I.1003,"Patients eligible for treatment with Cimzia as defined in EU approved SmPC"
NCT01069419:I.2001,"Patient previously treated with Cimzia."
NCT01069419:I.2002,"Patient with known hypersensitivity to any component of Cimzia."
NCT01079182:I.1001,"age at least 18 Years"
NCT01079182:I.1002,"Active, ankylosing spondylitis in adults with insufficient response to conventional therapy."
NCT01079182:I.2001,"Hypersensitivity against the drug or one of the other ingredients"
NCT01079182:I.2002,"Active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections)"
NCT01079182:I.2003,"Moderate to severe cardiac insufficiency."
NCT01081782:I.1001,"age 18 Years to 55 Years"
NCT01081782:I.1002,"Adult male or female aged 18-55 years inclusive at screening"
NCT01081782:I.1003,"Patients who have a definite diagnosis of relapsing-remitting Multiple Sclerosis"
NCT01081782:I.2001,"Multiple Sclerosis course other than relapsing-remitting multiple sclerosis"
NCT01081782:I.2002,"History of neoplastic disease"
NCT01081782:I.2003,"History of clinically significant chronic disease of the immune system (other than Multiple Sclerosis)"
NCT01081782:I.2004,"Inability to undergo Gd-enhanced MRI scans"
NCT01081782:I.2005,"Diagnosis of diabetes mellitus (type I or type II)"
NCT01085136:I.1001,"age at least 18 Years"
NCT01085136:I.1002,"Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV who have failed treatment with erlotinib (Tarceva) or gefitinib (Iressa)."
NCT01085136:I.1003,"Patients should have received and failed at least one line of cytotoxic chemotherapy including a platinum-based regimen in patients eligible for platinum-based therapy and pemetrexed in pemetrexed eligible patients (unless pemetrexed is not considered a regulatory or clinical standard of care e.g. no label indication, no availability or no coverage by 3rd party payer(s)) for advanced or metastatic disease and have progressive disease following at least 12 weeks of treatment with erlotinib or gefitinib"
NCT01085136:I.1004,"Patients pretreated with taxane-based chemotherapy for advanced or metastatic disease must have experienced stable disease, partial or complete response as best response"
NCT01085136:I.1005,"Eastern Cooperative Oncology Group performance Score 0 or 1."
NCT01085136:I.1006,"Patients with at least one tumor lesion that can accurately be measured by magnetic resonance imaging (MRI), or computed tomography (CT) in at least one dimension with longest diameter to be recorded as 20 mm or greater using conventional techniques or10 mm or greater with spiral CT scan according to RESIST 1.1."
NCT01085136:I.1008,"Life expectancy of>= three (3) months."
NCT01085136:I.1009,"Written informed consent that is consistent with ICH-GCP guidelines. Part B 1) Clinical benefit (disease stabilization or antitumor response) of 12 weeks duration in Part A of the trial determined on the second tumour assessment."
NCT01085136:I.2001,"Chemo-, hormone- (other than megestrol acetate, steroids required for maintenance non-cancer therapy or as premedication before chemotherapy) or immunotherapy within the past 4 weeks; except for TKI pretreatment (2 weeks only)"
NCT01085136:I.2002,"Active brain metastases (stable<4 weeks, symptomatic, requiring treatment with anticonvulsants, or leptomeningeal disease). Dexamethasone therapy will be allowed if administered as a stable dose for at least one month before randomization."
NCT01085136:I.2003,"Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease, mal-absorption, or CTCAE Grade>2 diarrhea of any etiology at baseline"
NCT01085136:I.2004,"Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug"
NCT01085136:I.2005,"Other malignancies diagnosed within the past five (5) years (other than non-melanomatous skin cancer and in situ cervical cancer)"
NCT01085136:I.2006,"Radiotherapy within the past 2 weeks prior to treatment with the trial drug"
NCT01085136:I.2007,"History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of 3"
NCT01085136:I.2008,"Cardiac left ventricular function with resting ejection fraction of<50% measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram"
NCT01085136:I.2009,"QTC interval"
NCT01085136:I.2010,"Prior treatment with anthracyclines with a cumulative dose of doxorubicin (or equivalent) at or>400 mg/m2"
NCT01085136:I.2011,"Absolute Neutrophil Count"
NCT01085136:I.2012,"Platelet count - finding"
NCT01085136:I.2013,"Bilirubin at or>1.5 mg / dL (>26 mol / L, SI unit equivalent)"
NCT01085136:I.2014,"Aspartate amino transferase (AST) or alanine amino transferase (ALT) at or>three times the upper limit of normal (if related to liver metastases at or>five times the upper limit of normal)"
NCT01085136:I.2015,"Serum creatinine at or>1.5 times the upper normal limit or calculated/measured creatinine clearance at or<60 mL/min"
NCT01085136:I.2016,"Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial"
NCT01085136:I.2017,"Pregnancy or breast feeding"
NCT01085136:I.2018,"Patients unable to comply with the protocol"
NCT01085136:I.2019,"Patients with any serious active infection including known human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C"
NCT01085136:I.2020,"Known or suspected active drug or alcohol abuse"
NCT01085136:I.2021,"Interstitial lung disease (SMQ)"
NCT01085136:I.2022,"Peripheral polyneuropathy Grade>= 2"
NCT01090089:I.1001,"age 60 Years to 75 Years"
NCT01090089:I.1002,"Understand and voluntarily sign an informed consent form."
NCT01090089:I.1003,"Able to adhere to the study visit schedule and other protocol requirements."
NCT01090089:I.1004,"Symptomatic MM requiring therapy."
NCT01090089:I.1005,"Measurable monoclonal protein in serum and/or urine"
NCT01090089:I.1006,"Monoclonal plasma cells in the bone marrow>/= 10% and/or biopsy-proven plasmacytoma"
NCT01090089:I.1007,"Myeloma-related organ dysfunction, at least one of"
NCT01090089:I.1008,"Calcium Serum Increased"
NCT01090089:I.1009,"[R] Renal insufficiency (creatinine>173 ?mol/l or>2 mg/dL)"
NCT01090089:I.1010,"[A] Anemia (Hb<10 g/dL or 2 g/dL<normal)"
NCT01090089:I.1011,"[B] Bone lesions or general osteoporosis"
NCT01090089:I.1012,"ECOG performance status finding<=2"
NCT01090089:I.1013,"Laboratory test results within these ranges within 1 week prior to randomization:"
NCT01090089:I.1014,"Absolute Neutrophil Count"
NCT01090089:I.1015,"Platelet count>/= 75 x 109/L or in case of bone marrow infiltration with myeloma cells>/= 30 x 109/L."
NCT01090089:I.1016,"Total Bilirubin Measurement"
NCT01090089:I.1017,"AST (SGOT) and ALT (SGPT)</= 3 x ULN."
NCT01090089:I.1018,"Female subjects of childbearing potential must:"
NCT01090089:I.1019,"o Understand the study drug is expected to have a teratogenic risk"
NCT01090089:I.1020,"o Agree to use, ..., effective contraception without interruption,..."
NCT01090089:I.1021,"o Understand that even if she has amenorrhea, she must follow all the advice on effective contraception."
NCT01090089:I.1022,"o She understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy"
NCT01090089:I.1023,"o Agree to have a medically supervised pregnancy test ..."
NCT01090089:I.1024,"Male subjects must"
NCT01090089:I.1025,"o Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study drug therapy ..."
NCT01090089:I.1026,"Agree not to donate semen during study drug therapy and for one week after end  of study drug therapy."
NCT01090089:I.1027,"All subjects must"
NCT01090089:I.1028,"Agree to abstain from donating blood while taking study drug therapy and for one  week following discontinuation of study drug therapy."
NCT01090089:I.1029,"Agree not to share study drug with another person and to return all unused study  drug to the investigator."
NCT01090089:I.1030,"Disease free of prior malignancies for>/= 5 years with exception of  currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma  in situ of the cervix or breast."
NCT01090089:I.1031,"Able to receive antithrombotic prophylaxis (...)."
NCT01090089:I.1032,"Life-expectancy>3  months."
NCT01090089:I.2001,"Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the ICF."
NCT01090089:I.2002,"Pregnant or lactating females"
NCT01090089:I.2003,"Any condition, incl. the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study."
NCT01090089:I.2004,"Patient currently is enrolled in another clinical research study or has been enrolled ...within 4 weeks before randomization and/or is receiving an investigational agent for any reason ..."
NCT01090089:I.2005,"Known hypersensitivity to thalidomide, dexamethasone, or melphalan."
NCT01090089:I.2006,"The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs."
NCT01090089:I.2007,"Any prior use of lenalidomide."
NCT01090089:I.2008,"Concurrent use of other anti-cancer agents or treatments."
NCT01090089:I.2009,"Known positive for HIV or active infectious hepatitis, type A, B or C or treponema pallidum"
NCT01090089:I.2010,"Prior treatment with dexamethasone discontinued because of ? grade 3 dexamethasone-related toxicity."
NCT01090089:I.2011,"Any prior chemotherapy with the exception of a short course of dexamethasone>4 weeks before randomization."
NCT01090089:I.2012,"Immunotherapy or antibody therapy within 8 weeks before randomization."
NCT01090089:I.2013,"major surgery"
NCT01090089:I.2014,"Renal failure requiring dialysis."
NCT01090089:I.2015,"Myocardial infarction within 6 months before randomization, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities."
NCT01090089:I.2016,"Severe pulmonary disease (diffusion capacity<60% of normal)."
NCT01090089:I.2017,"Treatment for cancer other than MM within 5 years before randomization, with the exception of basal cell carcinoma or cervical cancer in situ."
NCT01090089:I.2018,"Senile cardiac amyloidosis, Cardiac amyloidosis, AS transthyretin amyloidosis"
NCT01090089:I.2019,"Poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol."
NCT01090089:I.2020,"Any systemic infection requiring treatment."
NCT01090089:I.2021,"Unability or unwillingness of the patient to receive antithrombotic prophylaxis."
NCT01092533:I.1001,"age 18 Years to 80 Years"
NCT01092533:I.1002,"Subjects with a documented at least 6 months history of unilateral or bilateral intermediate uveitis either idiopathic or due to non-infectious systemic disease (e.g. sarcoidosis, multiple sclerosis)"
NCT01092533:I.1003,"Uveitis has to be considered to be active at the timepoint of enrolment according to at least one of the following criteria:"
NCT01092533:I.1004,"Grade 2+ or higher for vitreous haze"
NCT01092533:I.1005,"Grade 2+ or higher for anterior chamber cells"
NCT01092533:I.1006,"Presence of cystoid macular edema in OCT"
NCT01092533:I.1007,"Presence of retinal vessel leakage in FA"
NCT01092533:I.1008,"Considered by the investigator to require systemic treatment."
NCT01092533:I.1009,"Not planning to undergo elective ocular surgery during the study"
NCT01092533:I.1010,"Capable of understanding the purposes and risks of the study, able to give informed consent and to comply with the study requirements"
NCT01092533:I.1011,"Subjects of both gender with reproductive potential who are sexually active agree to use contraception throughout the course of the study and for at least 3 months after completion of their study participation."
NCT01092533:I.1012,"Women of childbearing potential have to use a highly effective method of birth control defined as one which results in a low failure rate (i.e.<1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, hormonal IUDs combined with barrier methods (e.g. condom, diaphragm or spermicide), sexual abstinence or vasectomised partner."
NCT01092533:I.1013,"Women of childbearing age must have a negative urine pregnancy test (UPT) within 48 hours prior to starting study drug and must not be lactating."
NCT01092533:I.1014,"Female subjects of non-childbearing potential must meet at least one of the following criteria:"
NCT01092533:I.1015,"Postmenopausal females, defined as:"
NCT01092533:I.1016,"Females over the age of 60 years."
NCT01092533:I.1017,"Females who are 45 to 60 years of age must be amenorrheic for at least 2 years."
NCT01092533:I.1018,"Females who had a hysterectomy and/or bilateral oophorectomy."
NCT01092533:I.2001,"Uveitis of infectious etiology"
NCT01092533:I.2002,"Signs of tuberculosis in chest x-ray during the past 12 months before study entry"
NCT01092533:I.2003,"Clinically suspected or confirmed central nervous system or ocular lymphoma"
NCT01092533:I.2004,"Primary diagnosis of anterior or posterior uveitis"
NCT01092533:I.2005,"Uncontrolled glaucoma or known steroid response"
NCT01092533:I.2006,"Subjects who received treatment with a systemic immunosuppressive drug, a monoclonal antibody or any other biologic therapy within 90 days prior study entry"
NCT01092533:I.2007,"Treatment with mycophenolate mofetil or mycophenolate sodium in the past"
NCT01092533:I.2008,"Treatment with a periocular steroid injection within 6 weeks prior to study entry"
NCT01092533:I.2009,"Presence of absolute contraindications for Decortin H and/or Myfortic as mentioned in the product informations (Appendix 1 and 2)"
NCT01092533:I.2010,"Presence of relative contraindications for Decortin H and/or Myfortic as mentioned in the product information (Appendix 1 and 2) if the disorder leading to the relative contraindication can not sufficiently managed by concomitant medication."
NCT01092533:I.2011,"Recipients of a solid organ transplant"
NCT01092533:I.2012,"Subjects with lens opacities or obscured ocular media upon enrolment making unable evaluation of the posterior eye segment"
NCT01092533:I.2013,"Subjects with a history of herpes zoster or varicella infection within 3 months before enrollment"
NCT01092533:I.2014,"Active, extraocular infection requiring the prolonged or chronic use of antimicrobial agents or the history/presence of active hepatitis A, B or C"
NCT01092533:I.2015,"HIV Seropositivity"
NCT01092533:I.2016,"Alanine transaminase (ALT), aspartate transaminase (AST), or gamma-glutamyl transferase (GGT)>= 2x upper limit of normal (ULN)"
NCT01092533:I.2017,"Severe anemia (hemoglobin<8 g/dL), leukopenia (white blood cell count [WBC]<2500 mm3), thrombocytopenia (platelet count<80,000 mm3)"
NCT01092533:I.2018,"Malignant Neoplasms"
NCT01092533:I.2019,"Pregnant or lactating women"
NCT01092533:I.2020,"Known allergy for fluorescein natrium"
NCT01092533:I.2021,"Currently participating in another clinical trial with an investigational agent in the 30 days prior to study participation and/or has not recovered from any reversible effects or side effects of prior investigational agent"
NCT01092533:I.2022,"Subjects with non-ocular, medically significant co-morbid conditions that impair normal activities, require systemic corticosteroids or immunosuppressives, or any medical condition that would likely have an impact on the participant´s ability to comply with the study visit schedule"
NCT01092533:I.2023,"Any current or history of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication"
NCT01094678:I.1001,"age at least 18 Years"
NCT01094678:I.1002,"stenosis of the above-the-knee femoropopliteal artery"
NCT01094678:I.1003,"appropriate size and location of the lesion"
NCT01094678:I.2001,"pregnant or breast feeding"
NCT01094678:I.2002,"failure or inability to give informed consent"
NCT01094678:I.2003,"simultaneously participating in another drug or device study"
NCT01095926:I.1001,"age up to 17 Years"
NCT01095926:I.1002,"plan to receive at least two cycles of doxorubicin"
NCT01095926:I.1003,"must be enrolled in a national or European protocol for treatment of Wilms Tumours, Neuroblastoma, Soft tissue sarcoma, Ewing Sarcoma or Acute lymphoblastic leukaemia and must be treated with doxorubicin according to that protocol Or Patients<3 years enrolled or listed in any national or European study protocol for any paediatric malignancy. Treatment with doxorubicin has to be according to that protocol."
NCT01095926:I.1004,"Parents or legal representative(s) must provide written informed consent to participate in the trial according to national regulations. Patients that are able to understand should provide assent to participate in the trial."
NCT01095926:I.1005,"Life expectancy of at least 3 month"
NCT01095926:I.1006,"Karnofsky performance status (assessment scale)"
NCT01095926:I.1007,"Additional blood withdrawal is acceptable for the patient. The decision is left to the investigator"
NCT01095926:I.2001,"prior cardiac problems"
NCT01103284:I.1001,"age 20 Years to 45 Years"
NCT01103284:I.1002,"clinical diagnosis of type 1 diabetes within last 6 months"
NCT01103284:I.1003,"fasting basal C-peptide>= 0.22nmol/L,<0.8nmol/L"
NCT01103284:I.1004,"BMI between 17 and 30 at screening"
NCT01103284:I.2001,"Significant disease or condition other than type 1 diabetes"
NCT01103284:I.2002,"Complications of Diabetes Mellitus"
NCT01103284:I.2003,"Ongoing treatment with immunosuppressive or immunomodulating agents including chronic corticosteroids"
NCT01104584:I.1001,"age at least 18 Years"
NCT01104584:I.1002,"Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology [ACR] and performed no longer than 6 weeks prior to enrollment into the study) and has been referred for a contrast-enhanced Magnetic Resonance Mammography (MRM) prior to surgery of the breast."
NCT01104584:I.1003,"if female, a digital XRM is required if any of the following criteria is met:"
NCT01104584:I.1004,"age<50 Years"
NCT01104584:I.1005,"b. patient has heterogeneously or extremely dense breasts"
NCT01104584:I.1006,"c. is not post-menopausal (post-menopause defined as at least 12 months prior to  inclusion without menstruation)."
NCT01104584:I.1007,"if female of childbearing potential, MRM should be performed on the 7-14th day of the menstrual cycle."
NCT01104584:I.1008,"has an estimated glomerular filtration rate (eGFR) value>/= 60 mL/min/1.73m2 derived from a serum creatinine result within 2 weeks prior to study enrollment."
NCT01104584:I.2001,"is a female patient who is pregnant or lactating"
NCT01104584:I.2002,"has any contraindication to the MRM examination (e.g. metal implants, phobia) or the use of gadolinium-containing contrast agents."
NCT01104584:I.2003,"has received any contrast agent within 24 hours prior to the study MRM, or is scheduled to receive any contrast agent within 24 hours after the study MRM."
NCT01104584:I.2004,"has severe cardiovascular disease (e.g., known long QT syndrome, acute myocardial infarction [<14 days], unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (<48 hours))."
NCT01104584:I.2005,"has acute renal insufficiency of any severity due to hepato-renal syndrome or in the peri-operative liver transplantation period or who has acute or chronic moderate or severe renal insufficiency (glomerular filtration rate<60 mL/min/1.73m2)."
NCT01104584:I.2006,"has received chemotherapy or hormonal therapy for breast cancer within 6 months."
NCT01104584:I.2007,"has received hormone replacement therapy within 4 weeks prior to study drug administration."
NCT01104584:I.2008,"is scheduled or likely to require a surgery and/or biopsy in the time period up to 24 hours following study drug application"
NCT01104584:I.2009,"has prior excisional biopsy or breast surgery<6 months before enrollment and between XRM and study MRM"
NCT01107886:I.1001,"age at least 40 Years"
NCT01107886:I.1002,"Patients with type 2 diabetes mellitus"
NCT01107886:I.1003,"HbA1c>=6.5%. (based on the last measured and documented laboratory measurement within 6 months)"
NCT01107886:I.1004,"High risk for CV events -Established cardiovascular disease and/or multiple risk factors"
NCT01107886:I.2001,"Current or previous (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics"
NCT01107886:I.2002,"Acute vascular event<2months prior to randomisation"
NCT01113710:I.1001,"age at least 18 Years"
NCT01113710:I.1002,"The patient's treatment must be in accordance with the local marketing authorization (MA) for Neupro"
NCT01113710:I.1003,"The patient must have a diagnosis of moderate to severe idiopathic RLS"
NCT01113710:I.1004,"The patient is considered reliable and capable of adhering to the visit schedule or medication administration according to the judgment of the investigator"
NCT01113710:I.1005,"The decision to prescribe the drug has been made by the physician independently of his/her decision to include the patient in the study"
NCT01113710:I.1006,"Subject is informed and given ample time and opportunity to think about his/her participation in the study and has given written informed data consent"
NCT01113710:I.2001,"Hypersensitivity to the active substance or to any of the excipients"
NCT01113710:I.2002,"Magnetic resonance imaging or cardioversion (see SmPC)"
NCT01117441:I.1001,"age 1 Year to 18 Years"
NCT01117441:I.1002,"newly diagnosed acute lymphoblastic leukemia"
NCT01117441:I.1003,"no Ph+ (BCR/ABL or t(9;22)-positive) ALL"
NCT01117441:I.1004,"no evidence of pregnancy or lactation period"
NCT01117441:I.1005,"no participation in another clinical study"
NCT01117441:I.1006,"patient enrolled in a participating center"
NCT01117441:I.1007,"written informed consent"
NCT01117441:I.2001,"pre-treatment with cytostatic drugs"
NCT01117441:I.2002,"steroid pre-treatment with>= 1 mg/kg/d for>two weeks during the last month before diagnosis"
NCT01117441:I.2003,"treatment started according to another protocol"
NCT01117441:I.2004,"underlying diseases that prohibit treatment according to the protocol"
NCT01117441:I.2005,"ALL diagnosed as second malignancy steroid pre-treatment with>= 1 mg/kg/d for more than two weeks during the last month before diagnosis"
NCT01120301:I.1001,"age 40 Years to 80 Years"
NCT01120301:I.1002,"Clinical diagnosis of acute ischemic stroke"
NCT01120301:I.1003,"Subject is not a candidate for treatment with neurothrombectomy"
NCT01120301:I.1004,"Initiation of the TLT procedure begins between 4.5 and 24 hours"
NCT01120301:I.1005,"Baseline NIHSS score range: 7-17"
NCT01120301:I.1006,"Full functional independence just prior to the present stroke episode"
NCT01120301:I.1007,"Negative pregnancy test in females of childbearing potential"
NCT01120301:I.1008,"Subject Informed Consent obtained prior to enrollment into this study"
NCT01120301:I.2001,"Evidence of an intracranial, subdural, or subarachnoid hemorrhage"
NCT01120301:I.2002,"Acute ischemic strokes located exclusively in the brainstem, or cerebellum, or small deep infarctions, or massive hemispheric strokes"
NCT01120301:I.2003,"Seizure at stroke onset or within the 7 days prior to stroke onset"
NCT01120301:I.2004,"Sustained blood glucose>300 or<60 mg/dl"
NCT01120301:I.2005,"Sustained hypertension (SBP>220 mmHg or DBP>140 mmHg)"
NCT01120301:I.2006,"Sustained hypotension (SBP<80 mmHg or DBP<50 mmHg)"
NCT01120301:I.2007,"A presumed and/or confirmed septic embolus"
NCT01120301:I.2008,"History of CNS vascular disease (e.g. aneurysm, AVM) or history of CNS disease or damage (e.g. neoplasm or dementia) which may influence the subject's outcome assessment."
NCT01120301:I.2009,"Head implant of any kind"
NCT01120301:I.2010,"Significant skin condition of the scalp (eg. psoriasis)"
NCT01120301:I.2011,"Use of any intravenous or intra-arterial thrombolytic medication"
NCT01120301:I.2012,"Use of any diagnostic or therapeutic interventional neurovascular procedure"
NCT01120301:I.2013,"Female who is pregnant or lactating or who is of childbearing potential and not using a medically acceptable method of birth control."
NCT01122277:I.1001,"age at least 18 Years"
NCT01122277:I.1002,"ICU patients with an indication for fluid/volume therapy"
NCT01122277:I.2001,"Patients hospitalized by order of a court of law or a government agency"
NCT01126580:I.1001,"age at least 18 Years"
NCT01126580:I.1002,"Have type 2 diabetes for>= 3 months and<= 5 years based on the disease diagnostic criteria (refer to the World Health Organization's [WHO]Classification of Diabetes)."
NCT01126580:I.1003,"Are treatment-naive, not optimally controlled with diet and exercise alone, or are taking 1 oral antihyperglycemic medication (OAM) as monotherapy (excluding thiazolidinediones)."
NCT01126580:I.1004,"Are able and willing to tolerate a minimum dose of 1500 mg/day or up to 2000 mg/day of metformin."
NCT01126580:I.1005,"Hemoglobin A1c (HbA1c)"
NCT01126580:I.1006,
NCT01126580:I.1007,"a)test negative for pregnancy at screening based on a serum pregnancy test, and"
NCT01126580:I.1008,"b)agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug, or"
NCT01126580:I.1009,"Not Lactating"
NCT01126580:I.1010,"Have a stable weight (plus or minus 5%)>=  3 months prior to screening."
NCT01126580:I.1011,"Body mass index"
NCT01126580:I.1012,"Are well-motivated, capable, and willing to:"
NCT01126580:I.1013,"a)perform SMBG testing"
NCT01126580:I.1014,"b)learn how to self-inject treatment (LY2189265 or placebo)and"
NCT01126580:I.1015,"c)maintain a study diary."
NCT01126580:I.2001,"Diabetes Mellitus, Insulin-Dependent"
NCT01126580:I.2002,"You are being or have been treated with any of the following medications:"
NCT01126580:I.2003,"a)chronically treated with insulin for the treatment of diabetes in the past,  however, a short-term use of>3 months prior to screening is allowable,"
NCT01126580:I.2004,"b)GLP-1 analogs within 3 months prior to this screening,"
NCT01126580:I.2005,"c)drugs to cause weight loss within 3 months prior to screening,"
NCT01126580:I.2006,"d)thiazolidinediones (TZDs)within 3 months prior to screening,"
NCT01126580:I.2007,"e)chronically treated(>= 14 days) an oral glucocorticoid or have received this type of therapy within 4 weeks prior to screening,or"
NCT01126580:I.2008,"Illicit Drugs"
NCT01126580:I.2009,"You have had 1 or more cases of uncontrolled diabetes which required hospitalization in the 6 months prior to screening,"
NCT01126580:I.2010,"You have a problem with your stomach or have chronically taken medication to increase movement in your digestive tract or slow down the emptying of your digestive tract or you have had gastric bypass (bariatric) surgery."
NCT01126580:I.2011,"You have had problems with your heart or brain in the past 2 months prior to screening, such as a heart attack, chest pain, heart failure, heart bypass operation, angioplasty or stent insertion,a heart rhythm problem, or a stroke."
NCT01126580:I.2012,"You have a serum creatinine result which shows a>= 1.5 mg/dL for men or>= 1.4 mg/dL for women."
NCT01126580:I.2013,"You have a problem with your liver or pancreas."
NCT01126580:I.2014,"You have creatinine clearance result which shows<60 mL/minute, evidence of a significant active, uncontrolled endocrine (hormone) or active autoimmune abnormality."
NCT01126580:I.2015,"You have a serum calcitonin test and it shows a>= 20 pcg/mL at the time of screening."
NCT01126580:I.2016,"You have or have a family history of medullary C-cell hyperplasia or endocrine neoplasia type 2A or type 2B."
NCT01126580:I.2017,"You have cancer (except for skin cancer) or have been in remission from cancer for<5 years."
NCT01126580:I.2018,"You have had an organ transplant except for corneal transplant."
NCT01126580:I.2019,"You have received treatment within the last 30 days with a drug which has not been regulatory approved."
NCT01126580:I.2020,"You have participated in a medical, surgical, or pharmaceutical study where these types of procedures were performed on you within 30 days prior to screening."
NCT01126580:I.2021,"You have any condition that is a contraindication to or would interfere with medications provided for this study to treat your diabetes."
NCT01126580:I.2022,"You have a blood disorder that would interfere with us drawing blood glucose measurement or lab samples."
NCT01126580:I.2023,"You have previously participated or signed an informed consent document for this same type of study and study drug."
NCT01131585:I.1001,"age at least 18 Years"
NCT01131585:I.1002,"Reduced visual acuity"
NCT01131585:I.1003,"Macular Edema in at least one eye"
NCT01131585:I.1004,"Type 1 or Type 2 Diabetes Mellitus"
NCT01131585:I.1005,"Stable medication of diabetes in past 3 month"
NCT01131585:I.2001,"Patients with uncontrolled systemic or ocular diseases"
NCT01131585:I.2002,"Laser photocoagulation in the study eye for the last 3 months"
NCT01131585:I.2003,"Any history of any intraocular surgery in the study eye within the past 3 months"
NCT01131585:I.2004,"Blood pressure (BP)"
NCT01134107:I.1001,"age at least 13 Years"
NCT01134107:I.1002,"Diagnosed with type 1 diabetes (World Health Organization criteria) for at least 24 months"
NCT01134107:I.1003,"Treated with continuous subcutaneous insulin infusion (CSII) therapy for the previous 6 months"
NCT01134107:I.1004,"Mean total daily insulin dose for 3 days prior to screening<= 46 units/day if using a 300-Unit reservoir or<= 26 units/day if using a 180 unit reservoir"
NCT01134107:I.1005,"Baseline body mass index (BMI)<= 35.0 kg/m2"
NCT01134107:I.1006,"Baseline HbA1c 5% to 9%"
NCT01134107:I.2001,"Currently using continuous glucose monitoring (CGM), unless patients agree to not use their personal CGM during the study"
NCT01134107:I.2002,"Impaired renal function (serum creatinine>= 2.0 mg/dl)"
NCT01134107:I.2003,"Legal Blindness"
NCT01134107:I.2004,"Have had any episode in the 12 months prior to screening of hypoglycemic coma, seizures, or disorientation"
NCT01134107:I.2005,"Have had hypoglycemia unawareness (routinely asymptomatic at BG<45 mg/dl) in the 12 months prior to screening."
NCT01134107:I.2006,"Have had any emergency room visits or hospitalizations due to poor glucose control in the 12 months prior to screening."
NCT01134107:I.2007,"Have had a pump-related infusion site abscess in the 12 months prior to screening."
NCT01134107:I.2008,"Have had multiple, clinically significant occlusions as judged by the investigator."
NCT01134107:I.2009,"Infection due to Staphylococcus aureus"
NCT01134107:I.2010,"Have one of the following concomitant diseases: presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, or any other serious disease considered by the investigator to be exclusionary."
NCT01134107:I.2011,"Patients with malignancy other than basal cell or squamous cell skin cancer who have not yet been treated, are currently being treated, or who were diagnosed less than 5 years ago."
NCT01134107:I.2012,"Have had a blood transfusion or severe blood loss within the 3 months prior to screening or have known hemoglobinopathy, hemolytic or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with HbA1c methodology."
NCT01134107:I.2013,"Are receiving chronic systemic glucocorticoid therapy, or have received such therapy within the 4 weeks preceding screening."
NCT01134107:I.2014,"Abnormal sleep-wake cycles"
NCT01134107:I.2015,"Have a known hypersensitivity or allergy to any of the study insulins or their excipients"
NCT01134107:I.2016,"Are breastfeeding or pregnant, or intend to become pregnant during the course of the study, or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable."
NCT01134107:I.2017,"Are currently enrolled in, or discontinued within the last 30 days from a clinical trial involving off-label use of an investigational drug or device, or currently enrolled in any other type of medical research not to be scientifically or medically compatible with this study."
NCT01134107:I.2018,"Are unwilling or unable to comply with the use of a data collection device to directly record data from the patient."
NCT01207388:I.1001,"age at least 18 Years"
NCT01207388:I.1002,"Patients with B-precursor ALL in complete hematological remission after at least 3 intense chemotherapy blocks"
NCT01207388:I.1003,"Presence of minimal residual disease at a level of>=10-3"
NCT01207388:I.1004,"Availability of bone marrow specimen from primary diagnosis for clone-specific MRD assessment"
NCT01207388:I.1005,"Negative HIV test, negative hepatitis B (HbsAg) test and hepatitis C virus (anti-HCV) test"
NCT01207388:I.1006,"Negative pregnancy test in women of childbearing potential"
NCT01207388:I.1007,"ECOG performance status 0 or 1"
NCT01207388:I.2001,"Presence of circulating blasts or current extra-medullary involvement by ALL"
NCT01207388:I.2002,"History of relevant CNS pathology or current CNS pathology"
NCT01207388:I.2003,"Prior allogeneic HSCT"
NCT01207388:I.2004,"Eligibility for treatment with TKIs"
NCT01207388:I.2005,"Systemic cancer chemotherapy within 2 weeks prior to study treatment"
NCT01207388:I.2006,"Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to study treatment"
NCT01207388:I.2007,"Previous treatment with blinatumomab"
NCT01144338:I.1001,"age at least 18 Years"
NCT01144338:I.1002,"Patient has type 2 diabetes mellitus"
NCT01144338:I.1003,"Patient has an HbA1c of>= 7.0 % and<= 10.0% on stable doses of up to three oral antihyperglycemic agents for at least 3 months (i.e. no oral antihyperglycemic agent adjustments in the past 3 months)"
NCT01144338:I.1004,"Female patients must not be breast feeding and agree to use an effective method of contraception or must not otherwise be at risk of becoming pregnant."
NCT01144338:I.2001,"Patient has a diagnosis of type 1 diabetes mellitus, or a history of ketoacidosis."
NCT01144338:I.2002,"Patient has taken insulin within 2 weeks of screening visit or for>1 week within 3 months of screening visit."
NCT01144338:I.2003,"Patient has ever been treated with an approved or investigational GLP-1 receptor agonist e.g. BYETTA (exenatide), Exenatide Once Weekly, VICTOZA (liraglutide), or taspoglutide."
NCT01144338:I.2004,"Patient is enrolled in another experimental protocol which involves the use of an investigational drug or device, or an intervention that would interfere with the conduct of the trial."
NCT01144338:I.2005,"Patient has a planned or anticipated revascularization procedure."
NCT01144338:I.2006,"Pregnancy or planned pregnancy during the trial period."
NCT01144338:I.2007,"Patient has previously been enrolled in EXenatide Study of Cardiovascular Event Lowering (EXSCEL)."
NCT01146444:I.1001,"age 18 Years to 85 Years"
NCT01146444:I.1002,"Patients with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE), or lupus erythematosus tumidus (LET) according to the Düsseldorf Classification 2004 (Kuhn and Ruzicka 2004) confirmed by histological analysis."
NCT01146444:I.1003,"Women of childbearing potential with a negative pregnancy test at screening (urine test) and using a medically accepted contraceptive regimen (intra-uterine device, partner's vasectomy,>3 months previous hormonal contraception (oestrogen plus gestagen pill, depot injections, or subcutaneous depot) combined with a barrier method (preservative, vaginal diaphragm, cervical cap, spermicide) during the study and for 8 weeks after the last UV exposure."
NCT01146444:I.1004,"Women clinically sterile (post-menopausal, undergone hysterectomy or tubal ligation)."
NCT01146444:I.1005,"Actively cooperating to participate in the study, to follow the instructions of the investigator and to attend the centre at the agreed times."
NCT01146444:I.1006,"Development of skin lesions any time under current systemic treatment if patient is receiving systemic medication for the treatment of CLE."
NCT01146444:I.1007,"Signed informed consent form after the nature of the study has been fully explained."
NCT01146444:I.2001,"Pregnancy or lactation and women with positive pregnancy test."
NCT01146444:I.2002,"Known hypersensitivity or allergic contact reactions to components of the study agents."
NCT01146444:I.2003,"Treatment with photosensitizing drugs."
NCT01146444:I.2004,"Exposure to direct natural (sunlight) or artificial UV radiation on the back within 4 weeks prior to entering the study."
NCT01146444:I.2005,"History of another photodermatosis, except polymorph light eruption (PLE)."
NCT01146444:I.2006,"Any current known skin malignancy or any history of skin malignancy within the previous 5 years or Xeroderma pigmentosum."
NCT01146444:I.2007,"Initiation or change in the dose of any current systemic medication for the treatment of CLE within 8 weeks prior to standardized photoprovocation."
NCT01146444:I.2008,"Local therapy for the treatment of CLE within two weeks prior to standardized photoprovocation at the back of the patient"
NCT01146444:I.2009,"Acute exacerbation of CLE skin disease within 2 weeks prior to entering the study."
NCT01146444:I.2010,"Acute illness within 7 days prior to phototesting or major illness including infection or hospitalization within 1 month of study entry."
NCT01146444:I.2011,"Anti-dsDNA (RIA)>7 U/ml and/or at least one of the following criteria:"
NCT01146444:I.2012,"Serositis: pleuritis or pericarditis documented by electrocardiogram or rub or evidence of pericardial effusion"
NCT01146444:I.2013,"Renal disorder: proteinuria>0.5 g/d or>3+, or cellular casts"
NCT01146444:I.2014,"Neurologic disorder: seizures or psychosis without other cause."
NCT01146444:I.2015,"Patients with a documented HIV and/or hepatitis B or C infection."
NCT01146444:I.2016,"Any medical condition, which would place the subject at undue risk of, or make it unlikely that follow-up-measurements could be obtained"
NCT01147939:I.1001,"age at least 18 Years"
NCT01147939:I.1002,"confirmed diagnosis of AML according to WHO classification (excluding acute promyelocytic leukaemia) who have received two or three previous induction/re-induction regimens or patients of age>= 65 with adverse cytogenetics who have received 1-3 previous induction/re-induction regimens. One of the (re-)induction regimens could be stem cell transplantation (SCT) for achievement of remission. Maintenance and consolidation (including SCT) may have been given, but are not counted as previous regimens."
NCT01147939:I.1003,"bone marrow aspirates and/or biopsies must contain>5 % leukaemic blast cells or patient must have biopsy-proven extramedullary AML, or patient's peripheral blood shows occurrence of leukaemic blast cells"
NCT01147939:I.1004,"Needed (qualifier value), Needs"
NCT01147939:I.1005,"have never attained CR or CRi (primary refractory), or"
NCT01147939:I.1006,"have failed initial induction therapy, and have attained CR or CRi after salvage  therapy(ies), and then relapsed within<6 months, or"
NCT01147939:I.1007,"have attained CR or CRi after initial induction therapy and relapsed within<12  months, and failed to respond to salvage therapy(ies), or"
NCT01147939:I.1008,"have relapsed after the latest CR or CRi within<6 months"
NCT01147939:I.1009,"Patients younger than 65 years should have received previous treatment with cytarabine"
NCT01147939:I.1010,"Patients must have recovered from previous bone marrow and/or stem cell transplantation to a stage that the patient can tolerate the study treatment. There is no restriction on number of regimens or type of treatment administered for maintenance or consolidation during previous stages of the disease"
NCT01147939:I.1011,"ECOG performance status (PS) of 0 - 2"
NCT01147939:I.1012,"Women of child-bearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to treatment start"
NCT01147939:I.1013,"Male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last elacytarabine dose"
NCT01147939:I.1014,"capable of understanding and complying with protocol requirements, and must be able and willing to sign a written informed consent form"
NCT01147939:I.2001,"A history of allergic reactions to egg. A history of allergic reactions of CTCAE grade 3 or 4 to cytarabine"
NCT01147939:I.2002,"Persistent clinically significant toxicities from previous chemotherapy"
NCT01147939:I.2003,"A cancer history that, according to the investigator, might confound the assessment of the study endpoints"
NCT01147939:I.2004,"HIV Seropositivity"
NCT01147939:I.2005,"Pregnant and nursing patients"
NCT01147939:I.2006,"Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that would limit compliance with study requirements"
NCT01147939:I.2007,"Impairment of hepatic or renal function to such an extent that the patient, in the opinion of the investigator, will be exposed to an excessive risk if entered into this clinical study"
NCT01147939:I.2008,"Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure. Any New York Heart Association (NYHA) functional classification grade 3 or 4"
NCT01147939:I.2009,"Applicable only for patients for whom an anthracycline is part of the selected control treatment: Left ventricular ejection fraction (LVEF) must be>= 45 % as measured by MUGA scan or 2D ECHO within 14 days prior to start of therapy. Either method is acceptable for measuring LVEF"
NCT01147939:I.2010,"Applicable only for patients for whom an anthracycline is part of the selected control treatment: The patient should tolerate minimum one course of combination therapy"
NCT01147939:I.2011,"any anti-leukaemic agents within the last 3 weeks. Hydroxyurea,however, is allowed for up to 12 hours prior to study treatment"
NCT01147939:I.2012,"any investigational treatment within the last 14 days"
NCT01147939:I.2013,"Any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities"
NCT01152606:I.1001,"age at least 18 Years"
NCT01152606:I.1002,"HER2 Positive Early Breast Cancer"
NCT01152606:I.1003,"All patients who are considered candidates to receive Herceptin for this indication"
NCT01152606:I.2001,"Patients for whom Herceptin is contraindicated"
NCT01154751:I.1001,"age at least 18 Years"
NCT01154751:I.1002,"Patient or legal guardian understands registry procedures and has voluntarily signed an informed consent in accordance with institutional and local regulatory policies. (Note: Retrospective data may be collected and entered into the EDC system after a fully executed informed consent has been provided)."
NCT01154751:I.1003,"Rutherford-Becker classification 2 through 5 only"
NCT01154751:I.1004,"Patient is at least 18 years of age and of legal age of consent."
NCT01154751:I.1005,"Patient must be willing to participate in the registry for at least 5 years."
NCT01154751:I.1006,"Target lesion is a single de novo or restenotic (outside a stent) SFA or Popliteal artery lesion>= 1 cm from origin of another stent.  Additional lesions may be present, but there is only one target lesion."
NCT01154751:I.1007,"All SFA target lesions are to be located with the proximal point at least 2 cm below the origin of the profunda femoris artery."
NCT01154751:I.1008,"All Popliteal Artery target lesions are to be located with the most distal point at least 1 cm proximal to the bifurcation of the anterior tibial artery and the tibioperoneal trunk."
NCT01154751:I.1009,"Target lesion length 1-20 cm (visual estimate)"
NCT01154751:I.1010,"Target lesion stenosis>=50% (visual estimate)"
NCT01154751:I.1011,"Popliteal artery patent if the lesion is in the SFA"
NCT01154751:I.1012,"SFA patent if the lesion is in the popliteal artery"
NCT01154751:I.1013,"At least one widely patent (<50% stenosis) infrapopliteal artery (for distal run-off)"
NCT01154751:I.2001,"Evidence of heparin induced thrombocytopenia (HIT), or intravenous tPA, Plavix, Ticlid, or aspirin therapy sensitivities"
NCT01154751:I.2002,"Patient is participating in a clinical study that could confound results"
NCT01154751:I.2003,"Patient is pregnant/breastfeeding at time enrollment or plans to become pregnant during the course of participation in the registry."
NCT01154751:I.2004,"Target lesion length>20 cm"
NCT01154751:I.2005,"Instent restenotic / reoccluded target lesion"
NCT01154751:I.2006,"Acute (<= 4 weeks) thrombotic occlusion"
NCT01154751:I.2007,"Untreated ipsilateral pelvic stenosis"
NCT01157871:I.1001,"age at least 40 Years"
NCT01157871:I.1002,"History of typical intermittent claudication lasting for at least 3 months, showing no improvement and consistent with treadmill test findings"
NCT01157871:I.1003,"Objective evidence of Peripheral Arterial Occlusive Disease. After 10 minutes of rest, either by Ankle brachial index measure (ABI)<0.8 or Systolic ankle pressure (AP)<50 mmHg or Systolic toe pressure<50 mmHg"
NCT01157871:I.1004,"Patent femoral inflow above the level of injections recently (<2 weeks) documented either with Doppler ultrasonography or Magnetic Resonance Angiography or Angiography"
NCT01157871:I.2001,"Evidence of other causes for leg pain other than intermittent claudication."
NCT01157871:I.2002,"Illnesses limiting subject exercise capacity (angina pectoris, heart failure, respiratory disease, orthopaedic disease, neurological disorders)"
NCT01157871:I.2003,"Pain at rest"
NCT01157871:I.2004,"Thromboangiitis Obliterans"
NCT01157871:I.2005,"Positive serology for HIV 1 or 2, positive serology hepatitis B or C."
NCT01157871:I.2006,"Subjects with serum creatinine>2 mg/dl (176 micromol/l) and subjects on dialysis."
NCT01157871:I.2007,"Active proliferative retinopathy defined by the presence of new vessel formation and scarring."
NCT01157871:I.2008,"Subjects who had a stroke or neurologic deficit presumed to be due to stroke within 3 months prior to the first administration of study treatment"
NCT01157871:I.2009,"Previous treatment with any angiogenic growth factor"
NCT01157871:I.2010,"Pregnant or breast feeding women or who disagree to practice a medically accepted method of birth control. Men and women who do not agree to use condoms as the only accepted protection barrier, for the entire study period"
NCT01157871:I.2011,"Serious concomitant medical conditions not adequately controlled."
NCT01157871:I.2012,"Current alcohol or drug abuse"
NCT01159691:I.1001,"age at least 18 Years"
NCT01159691:I.1002,"The decision to prescribe Neupro must have been made by the physician before and independently of his/her decision to include the patient in the study."
NCT01159691:I.1003,"The patient's treatment must be in accordance with the terms of the local marketing authorization (MA) for Neupro"
NCT01159691:I.1004,"The patients must have a diagnosis of Idiopathic Parkinson's disease."
NCT01159691:I.1005,"Only patients having signed the Consent form regarding study information, data transfer and use"
NCT01159691:I.1006,"Patients suffering from gastrointestinal symptoms whilst on a label compliant dose of anti-Parkinson's medication"
NCT01159691:I.2001,"Patients not fulfilling the inclusion criteria"
NCT01159691:I.2002,"And according to SmPC:"
NCT01159691:I.2003,"Hypersensitivity to the active substance or to any of the excipients"
NCT01159691:I.2004,"Magnetic resonance tomography (MRT) or cardioversion"
NCT01164592:I.1001,"age at least 22 Years"
NCT01164592:I.1002,"Severe Chronic Heart Failure (CHF) with NYHA class III-IV or NYHA class II with at least one hospitalisation for HF within the last 24 months"
NCT01164592:I.1003,"Left ventricular ejection fraction (LVEF)<= 45% by means of echocardiography, radionucleotide angiography, left ventriculography or cardiac MRI documented<12 weeks before randomisation"
NCT01164592:I.1004,"Diagnosis of sleep disordered breathing (SDB) with an apnoea-hypopnoea-index (AHI) of>15/hr with at least 50% central events and a central AHI of at least 10/hr"
NCT01164592:I.1005,"Clinically stable with no change in medication and no unplanned hospitalisation for heart failure in preceding month"
NCT01164592:I.1006,"Optimised medical treatment according to the applicable guidelines"
NCT01164592:I.1007,"Able to provide informed consent"
NCT01164592:I.1008,"Predominant central sleep apnoea (apnoea hypopnoea index>15/hour with ? 50% central events and a central AHI ?10/hour, derived from full polysomnography (based on total sleep time), documented<4 weeks before randomization. Flow measurements have to be performed with nasal cannula"
NCT01164592:I.2001,"Significant chronic obstructive pulmonary disease (COPD) with Forced Expiratory Volume within one second (FEV1)<50% predicted"
NCT01164592:I.2002,"Oxygen saturation at rest during the day 90% at the time of inclusion"
NCT01164592:I.2003,"Current use of Positive Airway Pressure (PAP) therapy"
NCT01164592:I.2004,"Life expectancy<1 year for diseases unrelated to chronic heart failure"
NCT01164592:I.2005,"Cardiac surgery, Percutaneous coronary intervention (PCI), Myocardial Infarction (MI) or unstable angina within 6 months prior to randomisation"
NCT01164592:I.2006,"Implantation of ICD (implanted cardiodefibrillator) or CRT (cardiac resynchronisation therapy) scheduled or within 6 months prior to randomisation"
NCT01164592:I.2007,"Transient ischemic attack (TIA) or Stroke within 3 months prior to randomisation"
NCT01164592:I.2008,"Primary hemodynamically significant uncorrected valvular heart disease, obstructive or regurgitant, or any valvular disease expected to lead to surgery during the trial"
NCT01164592:I.2009,"Acute myocarditis/pericarditis within 6 months prior to randomisation"
NCT01164592:I.2010,"Untreated or therapy refractory Restless legs Syndrome (RLS)"
NCT01164592:I.2011,"Pregnancy, Gestation"
NCT01164592:I.2012,"Amyloidosis, hypertrophic obstructive cardiomyopathy or arteriovenous fistulas"
NCT01164592:I.2013,"Dosage changes of diuretics more than doubled within the last 4 weeks prior to randomisation"
NCT01171417:I.1001,"age at least 18 Years"
NCT01171417:I.1002,"Signed written informed consent"
NCT01171417:I.1003,"Female postmenopausal patient (or patient post-ovarectomy) and age>=18 years Postmenopause ist defined as"
NCT01171417:I.1004,"Age>= 60 years and natural menopause with menses>1year ago or"
NCT01171417:I.1005,"FSH and E2 levels in the postmenopausal range or"
NCT01171417:I.1006,"Patients who had bilateral ovariectomy (NCCN V.I. 2009)"
NCT01171417:I.1007,"Histologically confirmed ER+ locally advanced or metastatic breast cancer"
NCT01171417:I.1008,"Not eligible for curative therapy"
NCT01171417:I.1009,"Prior treatment with tamoxifen"
NCT01171417:I.1010,"Suitable to undergo endocrine treatment for ER+ ABC with SERD / sAI"
NCT01171417:I.1011,"Patient is able to read and understand German"
NCT01171417:I.2001,"Known hypersensitivity to Faslodex or Exemestan or any compounds of the drugs"
NCT01171417:I.2002,"Prior treatment with Faslodex 500 mg or Faslodex 250 mg, for patients who receive treatment with Faslodex 500 mg within this observational study. Patients who are included in the exemestane arm may have received prior Faslodex treatment."
NCT01171417:I.2003,"Prior treatment with Exemestan for patients who receive treatment with Exemestan within this observational study"
NCT01171417:I.2004,"Acutely life threatening disease"
NCT01171417:I.2005,"Treatment with Faslodex 250 mg/month (previously approved dose)"
NCT01171417:I.2006,"Prior palliative chemotherapy"
NCT01174446:I.1001,"age 12 Years to 65 Years"
NCT01174446:I.1002,"Subject is 12 to 65 years old at the time of screening"
NCT01174446:I.1003,"Subject and/or legal representative has/have provided signed informed consent"
NCT01174446:I.1004,"Subject has severe (factor IX (FIX) level<1%) or moderately severe (FIX level<= 2%) hemophilia B (based on the one stage activated partial thromboplastin time [aPTT] assay), as tested at screening at the central laboratory"
NCT01174446:I.1005,"Subject is previously treated with plasma-derived or recombinant FIX concentrate(s) for a minimum of 150 exposure days (EDs)(based on the subject's medical records)"
NCT01174446:I.1006,"Subject has no evidence of a history of FIX inhibitors (based on the subject's medical records). If a verifiable, documented history is unavailable, the subject can be enrolled if s/he has participated in Study 050901 for at least 50 EDs to Immunine prior to enrollment."
NCT01174446:I.2001,"The subject has a history of FIX inhibitors with a titer>= 0.6 Bethesda Units (BU) (as determined by the Nijmegen modification of the Bethesda assay or the assay employed in the respective local laboratory) at any time prior to screening"
NCT01174446:I.2002,"The subject has a detectable FIX inhibitor at screening, with a titer>= 0.6 BU as determined by the Nijmegen modification of the Bethesda assay in the central laboratory"
NCT01174446:I.2003,"Abnormal weight (finding)"
NCT01174446:I.2004,"The subject has a history of allergic reaction, eg, anaphylaxis, following exposure to FIX concentrate(s)"
NCT01174446:I.2005,"The subject has a known hypersensitivity to hamster proteins or rFurin"
NCT01174446:I.2006,"The subject has ongoing or recent evidence of a thrombotic disease, fibrinolysis or DIC"
NCT01177033:I.1001,"age 50 Years to 85 Years"
NCT01177033:I.1002,"Patient is able to verbally acknowledge and understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of this trial. The patients, by providing informed consent, agree to these risks and benefits as stated in the patient informed consent document."
NCT01177033:I.1003,"Patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in following the study protocol."
NCT01177033:I.1004,"Intermittent claudication (IC) class 2 or 3 (Rutherford) assessed by treadmill testing or 6-Minute Walk Test."
NCT01177033:I.1005,"Lasting>3 months."
NCT01177033:I.1006,"Failed conservative therapy and the patient's desire for further treatment."
NCT01177033:I.1007,"Atherosclerotic single or multiple stenoses (>50%) or an occlusion of the Superficial Femoral Artery (SFA) with a target lesion length of 10-20 cm without involvement of the common/deep femoral artery and/or the popliteal artery confirmed by duplex ultrasound and angiography."
NCT01177033:I.1008,"At least one patent tibioperoneal artery with no stenosis>50% in diameter. Technical and morphological accessibility for both catheter intervention and bypass surgery."
NCT01177033:I.1009,"Absence of other disease that would limit exercise (e.g. angina or chronic respiratory disease)."
NCT01177033:I.2001,">50% stenosis or occlusion of the iliac, the common, the deep femoral or the popliteal artery."
NCT01177033:I.2002,"Surgical reconstruction or catheter intervention on the index leg within the last six months."
NCT01177033:I.2003,"Unsuitability of treadmill testing / Six-Minute Walk Test. Chronic limb ischemia (intermittent claudication class 2 to 6) on the contralateral leg."
NCT01177033:I.2004,"Known allergy to contrast agents containing iodine."
NCT01177033:I.2005,"Contraindication for antiplatelet agents or anticoagulants."
NCT01177033:I.2006,"Clinically manifested heart insufficiency (NYHA III, IV) and/or uncorrected hyperthyreosis."
NCT01177033:I.2007,"Serious general disease state with an estimated life expectancy<2 years (ASA IV, V)."
NCT01177033:I.2008,"Pregnancy, Gestation"
NCT01179620:I.1001,"age at least 18 Years"
NCT01179620:I.1002,"Patients requiring hemodialysis"
NCT01179620:I.1003,"Patients requiring anticoagulation therapy during hemodialysis"
NCT01179620:I.1004,"Written informed consent"
NCT01179620:I.2001,"Hypersensitivity to study medication"
NCT01179620:I.2002,"Genetic abnormality or disease of clotting system"
NCT01179620:I.2003,"Prior major surgery or bleeding"
NCT01179620:I.2004,"Other protocol-defined inclusion/exclusion criteria may apply"
NCT01179984:I.1001,"age at least 21 Years"
NCT01179984:I.1002,"The subject or legal representative has been informed of the nature of the evaluation, agrees to its provisions, and has signed the informed consent form (ICF)."
NCT01179984:I.1003,"Subject agrees to comply with the protocol-mandated follow-up procedures and visits."
NCT01179984:I.1004,"Female subjects of childbearing potential must have a negative urine or serum pregnancy test within seven days prior to index procedure. Female subjects who are surgically sterile or post-menopausal are exempt from having a pregnancy test."
NCT01179984:I.1005,"The subject has lifestyle-limiting claudication or ischemic rest pain defined as: Rutherford Category1 2-4 (moderate claudication to ischemic rest pain)."
NCT01179984:I.1006,"The target lesion(s) has angiographic evidence of stenosis or restenosis ?50% or occlusion (by visual estimate) and is amenable to PTA and stenting."
NCT01179984:I.1007,"The total treated segment(s) must be ? 240 mm."
NCT01179984:I.1008,"The target vessel reference diameter is ?4.0 mm and ?6.5 mm (by visual estimate) and therefore appropriate for treatment with available stent diameters of 6.0 mm and 7.0 mm."
NCT01179984:I.1009,"There is angiographic evidence of at least one vessel runoff to the foot (at the level of the malleolus)."
NCT01179984:I.2001,"The subject is unable or unwilling to provide informed consent or is unable or unwilling to comply with the study follow-up procedure and visits."
NCT01179984:I.2002,"The subject has claudication or critical limb ischemia described as Rutherford Category1 1 (mild claudication), 5 (minor tissue loss) or 6 (major tissue loss)."
NCT01179984:I.2003,"The subject has a known contraindication (including allergic reaction) or sensitivity to antiplatelet/anticoagulant medications, nickel, titanium or tantalum."
NCT01179984:I.2004,"The subject has a known sensitivity to contrast media that is not amenable to pretreatment with steroids or/and antihistamines."
NCT01179984:I.2005,"The subject has a history of bleeding diatheses or coagulopathy."
NCT01179984:I.2006,"The subject has concomitant renal failure with a creatinine of>2.5 mg/dL."
NCT01179984:I.2007,"The subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus (SLE), or deep vein thrombosis (DVT) at the time of the study procedure."
NCT01179984:I.2008,"The subject is receiving dialysis or immunosuppressive therapy."
NCT01179984:I.2009,"The subject is participating in an investigational drug or another investigational device study."
NCT01179984:I.2010,"The subject has another medical condition, which, in the opinion of the investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with limited life expectancy of<two years."
NCT01179984:I.2011,"The subject has extensive peripheral vascular disease, which, in the opinion of the investigator, precludes safe insertion of an introducer sheath."
NCT01179984:I.2012,"The target lesion(s) is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion(s)."
NCT01179984:I.2013,"The subject has angiographic evidence of poor inflow, which would be deemed inadequate to support a vascular bypass graft."
NCT01179984:I.2014,"The subject is diagnosed with septicemia at the time of the study procedure."
NCT01179984:I.2015,"Patients with a stent previously implanted into the target vessel."
NCT01179984:I.2016,"Bilateral disease in the native SFA and/or proximal popliteal artery where both limbs meet the inclusion/exclusion criteria and it is planned to treat both limbs within 30 days. Note: One limb may be enrolled in the study, but only if the second limb is planned to be treated after the 30-day follow-up visit has taken place. The limb that may be enrolled has to be the limb with the more severe lesion and the reasons for treating this specific limb will need to be stated in the CRF."
NCT01185223:I.1001,"age at least 18 Years"
NCT01185223:I.1002,"Patient following allogeneic SCT"
NCT01185223:I.1003,"Patient with a first episode of positive CMV-PCR (DNAemia) or pp65 antigenemia assay (antigenemia) up to 100 days after SCT"
NCT01185223:I.1004,"Absolute neutrophil count (ANC)>=1000 cells/microL on 2 consecutive follow-ups within 10 days before randomization"
NCT01185223:I.1005,"Patient has a creatinine clearance of>=25 mL/min (calculated by the Cockcroft-Gault formula, see Part I Section 6.1.2) with evidence of improving renal function,"
NCT01185223:I.1006,"None or gastrointestinal graft-versus-host disease (GVHD) up to grade 2"
NCT01185223:I.2001,"Patient has a suspected or diagnosed CMV disease"
NCT01185223:I.2002,"Patient has received syngeneic SCT"
NCT01185223:I.2003,"Patient who received an investigational medicinal product (IMP) within the last 30 days prior to screening or who is simultaneously participating in another clinical study with an IMP"
NCT01185223:I.2004,"Body weight (observable entity)"
NCT01185223:I.2005,"Patient has received anti-CMV therapy within the past 30 days prior to screening (the use of acyclovir, valacyclovir, or famciclovir is permitted)"
NCT01185223:I.2006,"Patient who has participated in this study before,"
NCT01185223:I.2007,"Patient who shows a neutropenia, thrombocytopenia, or anemia within 10 days before or at the time point of randomization as following:"
NCT01185223:I.2008,"The ANC is<1000 cells/microL on 2 consecutive follow-ups, or"
NCT01185223:I.2009,"A platelet count of>=25000/microL can not be achieved/maintained with platelet  transfusions"
NCT01185223:I.2010,"A hemoglobin level of>=8g/dL can not be achieved/maintained by red blood cell  transfusions"
NCT01185821:I.1001,"age 18 Years to 56 Years"
NCT01185821:I.1002,"Relapsing Remitting Multiple Sclerosis"
NCT01185821:I.1003,"Patients completed the core study BAF312A2201"
NCT01185821:I.1004,"Written informed consent provided before any assessment of the extension study"
NCT01185821:I.1005,"Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception"
NCT01185821:I.2001,"Newly diagnosed systemic disease other than MS (which may require immunosuppressive treatment)"
NCT01185821:I.2002,"Malignancies, diabetes, significant cardiovascular and pulmonary diseases and conditions"
NCT01185821:I.2003,"Active infections"
NCT01190839:I.1001,"age at least 18 Years"
NCT01190839:I.1002,"Have a documented diagnosis of CD confirmed by endoscopic, histologic and/or radiologic studies prior to resection or by tissue obtained at resection"
NCT01190839:I.1003,"Have undergone an ileocolonic surgical resection"
NCT01190839:I.1004,"Patients must also be at an increased risk of recurrence of active CD"
NCT01190839:I.1005,"Patients must not have previously discontinued infliximab as a result of tolerability issues or they must be naive to treatment with infliximab. Provided patients meet the above criteria pertaining to infliximab, they are eligible to enroll if they received prior treatment with adalimumab and/or certolizumab"
NCT01190839:I.1006,"Patients must undergo screening for HBV"
NCT01190839:I.1007,"Baseline CDAI<200"
NCT01190839:I.1008,"Have adequate blood and liver test values"
NCT01190839:I.2001,"Have a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening"
NCT01190839:I.2002,"Have a chest radiograph within 3 months prior to the first infusion of study agent that shows a clinically significant abnormality, such as a malignancy or infection, or any abnormalities suggestive of TB"
NCT01190839:I.2003,"Have macroscopically active CD which was not resected at the time of surgery"
NCT01190839:I.2004,"Do not meet the criteria for being at an increased risk of postoperative recurrence of active CD as outlined in the inclusion criteria"
NCT01190839:I.2005,"Have evidence of an active infection at the time of randomization or have had a serious infection not related to CD (e.g., hepatitis, pneumonia, or pyelonephritis), within 6 months prior to screening"
NCT01190839:I.2006,"Have or have had an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening"
NCT01190839:I.2007,"Have any known malignancy or history of malignancy within the 5-year period prior to screening (with the exception of squamous or basal cell carcinoma of the skin that has been completely excised without evidence of recurrence)"
NCT01190839:I.2008,"Have any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements."
NCT01194154:I.1001,"age at least 18 Years"
NCT01194154:I.1002,"Adult (person)"
NCT01194154:I.1003,"For diabetic patients: Type 2 diabetes mellitus with HbA1c>7% or anti-diabetic treatment"
NCT01194154:I.1004,"For renal allograft recipients: Status between 6 months and 10 years post transplantation"
NCT01194154:I.1005,"Chronic kidney disease stage III"
NCT01194154:I.1006,"Urinary albumine-to-creatinine ratio between>100 and<1000 mg/g creatinine"
NCT01194154:I.2001,"Hemoglobin Measurement"
NCT01194154:I.2002,"Initiation of angiotensin converting enzyme inhibitor, angiotensin 2 receptor blocker or aliskiren treatment less than 3 months before enrolment"
NCT01194154:I.2003,"Iron deficiency"
NCT01194154:I.2004,"Hemoglobin A1c (HbA1c)"
NCT01194219:I.1001,"age at least 18 Years"
NCT01194219:I.1002,"Males or females, ? 18 years of age at the time of signing the informed consent document"
NCT01194219:I.1003,"Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening"
NCT01194219:I.1004,"Have moderate to severe plaque psoriasis at Screening and Baseline"
NCT01194219:I.1005,"Must meet all laboratory criteria"
NCT01194219:I.1006,"Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use 2 forms of contraception as described by the Study Doctor while on study medication and for at least 28 days after taking the last dose of study medication"
NCT01194219:I.1007,"Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex condom or any nonlatex condom NOT made out of natural [animal] membrane [eg, polyurethane]) while on study medication and for a least 28 days after the last dose of study medication."
NCT01194219:I.2001,"Other than psoriasis, history of any clinically significant (as determined by the Investigator) or other major uncontrolled disease."
NCT01194219:I.2002,"Pregnant or breast feeding"
NCT01194219:I.2003,"History of allergy to any component of the study drug"
NCT01194219:I.2004,"Hepatitis B surface antigen positive at Screening"
NCT01194219:I.2005,"Anti-hepatitis C antibody positive at Screening"
NCT01194219:I.2006,"Active tuberculosis (TB) or a history of incompletely treated TB"
NCT01194219:I.2007,"Clinically significant abnormality on 12-Lead ECG at Screening"
NCT01194219:I.2008,"Clinically significant abnormal chest x-ray"
NCT01194219:I.2009,"History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency"
NCT01194219:I.2010,"Active substance abuse or a history of substance abuse within 6 months prior to Screening"
NCT01194219:I.2011,"Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening"
NCT01194219:I.2012,"Malignancy or history of malignancy (except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured]cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years)"
NCT01194219:I.2013,"Psoriasis flare or rebound within 4 weeks prior to Screening"
NCT01194219:I.2014,"Evidence of skin conditions that would interfere with clinical assessments"
NCT01194219:I.2015,"Topical therapy within 2 weeks of randomization"
NCT01194219:I.2016,"Systemic therapy for psoriasis within 4 weeks prior to randomization"
NCT01194219:I.2017,"Use of phototherapy within 4 weeks prior to randomization (ie, UVB, PUVA)"
NCT01194219:I.2018,"Adalimumab, etanercept, infliximab, or certolizumab pegol within 12 weeks prior to randomization"
NCT01194219:I.2019,"Alefacept, briakinumab, or ustekinumab within 24 weeks prior to randomization"
NCT01194219:I.2020,"Use of any investigational drug within 4 weeks prior to randomization"
NCT01194219:I.2021,"Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources"
NCT01194219:I.2022,"Prior treatment with apremilast"
NCT01194570:I.1001,"age 18 Years to 55 Years"
NCT01194570:I.1002,"Adult (person)"
NCT01194570:I.1003,"Primary Progressive Multiple Sclerosis (according to revised McDonald criteria)"
NCT01194570:I.1004,"EDSS - Expanded disability status scale 3-6.5"
NCT01194570:I.1005,"Disease duration from onset of MS symptoms<15 years if EDSS>5.0,<10 years if EDSS>/= 5.0"
NCT01194570:I.1006,"Sexually active male and female patients of reproductive potential must use two methods of contraception throughout the study treatment phase and for 48 weeks after the last dose"
NCT01194570:I.2001,"History of relapsing remitting multiple sclerosis, secondary progressive, or progressive relapsing multiple sclerosis at screening"
NCT01194570:I.2002,"Contraindications for Magnetic Resonance Imaging (MRI)"
NCT01194570:I.2003,"Known presence of other neurologic disorders"
NCT01194570:I.2004,"Known active infection or history of or presence of recurrent or chronic infection"
NCT01194570:I.2005,"History of cancer, including solid tumors and hematological malignancies (except for basal cell, in situ squamous cell carcinomas of the skin and in situ carcinoma of the cervix that have been excised and resolved)"
NCT01194570:I.2006,"Previous treatment with B-cell targeted therapies (e.g. rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)"
NCT01194570:I.2007,"Any previous treatment with lymphocyte trafficking blockers, with alemtuzumab, anti-CD4, cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation"
NCT01194570:I.2008,"Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study"
NCT01195480:I.1001,"age up to 18 Years"
NCT01195480:I.1002,"Pre-emptive arm"
NCT01195480:I.1003,"Children (18 years or younger) with CD19+ precursor B cell ALL fulfilling one of the following criteria who are undergoing an allogeneic stem cell transplant from an EBV-seropositive donor:"
NCT01195480:I.1004,"In first remission, if at least one of the following criteria are met:"
NCT01195480:I.1005,"t(9;22) and prednisone poor response or not in molecular remission (BCR-ABL/ABL ratio>0.02%) pre-HSCT or"
NCT01195480:I.1006,"Infant ALL age<6 months at diagnosis with MLL gene rearrangement and either presenting wcc>300 x 109/L or poor steroid early response (i.e circulating blast count>1x109/L following 7 day steroid pre-phase of Interfant 06) or"
NCT01195480:I.1007,"Resistant disease (>30% blasts at end of induction treatment day 28-33) in subsequent morphological CR or"
NCT01195480:I.1008,"High level bone marrow MRD (>1 in 1000) at week 12 ALL-BFM 2000/AIEOP BFM ALL 2009/EORTC 58951 protocols, week 12-15 of FRALLE A or at week 14 of UKALL2010"
NCT01195480:I.1009,"Relapsed patients if at least one of the following criteria are met:"
NCT01195480:I.1010,"Very early (<18 months from diagnosis) bone marrow or extramedullary relapse in second CR or"
NCT01195480:I.1011,"Early (within 6 months of finishing therapy) isolated bone marrow relapse with bone marrow MRD>1 in 100 at day 35 of reinduction in second CR or"
NCT01195480:I.1012,"Early (within 6 months of finishing therapy) bone marrow or combined relapse with high level bone marrow MRD (>1 in 1000) at the end of consolidation therapy (week 12-13 UKALL R3/INTREALL and COOPRALL protocols, prior to protocol M in BFM relapse protocol (ALL-REZ BFM 2002) and after Protocol II-IDA in AIEOP LLA Rec 2003) These patients have a high (>50%) risk of relapse and will be monitored for evidence of MRD in bone marrow aspirates (monthly for months 1-6, 6 weekly months 7.5-12 post HSCT) for the first year post-transplant. Patients who become MRD +ve in the marrow at a level minimum 5 x 10-4 but are in morphological remission (<5% blasts in BM) will be eligible to be treated pre-emptively with CD19zeta transduced CTL"
NCT01195480:I.1013,"Prophylaxis arm"
NCT01195480:I.1014,"Additionally, any patient (? 18 years) with ALL relapsing in the bone marrow (isolated or combined) after myeloablative allogeneic HSCT who achieves morphological remission after re-induction and who is a candidate for second HSCT at one of the participating centres is eligible to receive CD19zeta transduced CTL prophylactically"
NCT01195480:I.1015,"Stem cell donors must be EBV sero-positive and HLA-matched (10/10) or a single antigenic/allelic (9/10) mismatch with the recipient"
NCT01195480:I.1016,"A life expectancy of at least 8 weeks"
NCT01195480:I.1017,"Karnofsky score of>60% if>10 years old or Lansky performance score of>60 if<= 10 years old"
NCT01195480:I.1018,"Patients must have transduced donor-derived EBV-specific CTLs with 15% or higher expression of CD19zeta determined by flow-cytometry which meet the specified release criteria"
NCT01195480:I.1019,"Informed written consent indicating that patients are aware this is a research study and have been told of its possible benefits and toxic side effects"
NCT01195480:I.2001,"EBV seronegative or>single antigenic/allelic HLA-mismatched donor"
NCT01195480:I.2002,"Active acute GVHD overall Grade 2 or higher or significant chronic GVHD requiring systemic steroids at the time of scheduled infusion of transduced CTL will be excluded until the patient is GVHD-free and off steroids"
NCT01195480:I.2003,"Pre-existing severe lung disease (FEV1 or FVC<50% predicted) pre-HSCT or an oxygen requirement of>28% O2 supplementation or active pulmonary infiltrates on chest X-ray at the time scheduled for transduced CTL infusion"
NCT01195480:I.2004,"Serum bilirubin>3 times the upper limit of normal or an AST or ALT>5 times the upper limit of normal"
NCT01195480:I.2005,"Serum creatinine>3 times upper limit of normal"
NCT01195480:I.2006,"Active severe intercurrent infection at the time of transduced CTL infusion (if present consult with Chief investigator)."
NCT01195480:I.2007,"Patients in whom transduced donor-derived EBV-specific CTLs don't meet release criteria"
NCT01195480:I.2008,"Serologically positive for Hepatitis B, C or HIV pre-HSCT"
NCT01195480:I.2009,"Females of childbearing age with a positive pregnancy test"
NCT01196091:I.1001,"age at least 18 Years"
NCT01196091:I.1002,"Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria"
NCT01196091:I.1003,"Positive Antinuclear Antibody Test"
NCT01196091:I.1004,"Agree not to become pregnant throughout the course of the trial"
NCT01196091:I.1005,"Have the appropriate Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)score at screening"
NCT01196091:I.2001,"Have active severe Lupus kidney disease"
NCT01196091:I.2002,"Have active Central Nervous System or peripheral neurologic disease"
NCT01196091:I.2003,"Have received intravenous immunoglobulin (IVIg) within 180 days of randomization"
NCT01196091:I.2004,"Have active or recent infection within 30 days of screening"
NCT01196091:I.2005,"Have had a serious infection within 90 days of randomization"
NCT01196091:I.2006,"Have evidence or test positive for Hepatitis B"
NCT01196091:I.2007,"Viral hepatitis C, Hepatitis C Infection"
NCT01196091:I.2008,"HIV Seropositivity"
NCT01196091:I.2009,"Have evidence of active or latent tuberculosis (TB)"
NCT01196091:I.2010,"Presence of significant laboratory abnormalities at screening"
NCT01196091:I.2011,"Have had a malignancy in the past 5 years, except for cervical carcinoma in-situ or basal cell or squamous epithelial skin cell that were completely resected with no reoccurrence in the 3 yrs prior to randomization"
NCT01196091:I.2012,"Have received>40 mgs of prednisone or equivalent in the past 30 days"
NCT01196091:I.2013,"Have changed your dose of antimalarial drug in the past 30 days"
NCT01196091:I.2014,"Have changed your dose of immunosuppressive drug in the past 90 days"
NCT01196091:I.2015,"Have previously received rituximab"
NCT01197729:I.1001,"Age up to 1 Day"
NCT01197729:I.1002,"all patients admitted to hospital with an acute ST-Elevation myocardial infarction or with an acute Non-ST-Elevation myocardial infarction, both not older than 24 h"
NCT01197729:I.2001,"missing informed consent"
NCT01200758:I.1001,"age at least 18 Years"
NCT01200758:I.1002,"Adult (person)"
NCT01200758:I.1003,"CD20-positive, follicular Non-Hodgkin's lymphoma grade 1, 2, 3a. A tumor biopsy must have been performed within 6 months before study entry with material available for central review."
NCT01200758:I.1004,"No prior treatment"
NCT01200758:I.1005,"ECOG performance status 0-2"
NCT01200758:I.2001,"Follicular lymphoma grade IIIb"
NCT01200758:I.2002,"Transformation to high-grade lymphoma secondary to follicular lymphoma"
NCT01200758:I.2003,"Types of Non-Hodgkin's lymphoma other than follicular lymphoma"
NCT01200758:I.2004,"CNS disorder, Central Nervous System Disease"
NCT01200758:I.2005,"Corticoid therapy during the last 4 weeks, except prednisone treatment<20 mg per day"
NCT01204710:I.1001,"age at least 18 Years"
NCT01204710:I.1002,"histologically-confirmed adenocarcinoma of the prostate"
NCT01204710:I.1003,"radiographic evidence of metastatic prostate cancer (stage M1 or D2)"
NCT01204710:I.1004,"has prostate cancer unresponsive or refractory to medical or surgical castration with a serum testosterone level of<50 ng/mL"
NCT01204710:I.1005,"has had disease progression or intolerance on docetaxel-based therapy"
NCT01204710:I.1006,"Prostate-Specific Antigen"
NCT01204710:I.1007,"all clinically significant toxic effects of prior surgery, radiotherapy, chemotherapy or hormonal therapy have resolved to<= Grade 1, based on NCI CTCAE v 4.02"
NCT01204710:I.1008,"patient has an ECOG Performance Status 0-2"
NCT01204710:I.1009,"adequate hematologic function"
NCT01204710:I.1010,"adequate hepatic function"
NCT01204710:I.1011,"adequate renal function"
NCT01204710:I.1012,"urinary protein is<= 1 on dipstick or routine analysis"
NCT01204710:I.1013,"life expectancy of>3 months"
NCT01204710:I.1014,"fertile man with partners that are women of childbearing potential must use an adequate method of contraception during the study"
NCT01204710:I.1015,"signed Informed Consent document"
NCT01204710:I.2001,"concurrent active malignancy other than adequately treated nonmelanomatous skin cancer or other noninvasive or in situ neoplasms"
NCT01204710:I.2002,"The patient has received more than 1 prior cytotoxic chemotherapy regimen for metastatic disease"
NCT01204710:I.2003,"prior therapy with mitoxantrone for advanced prostate cancer"
NCT01204710:I.2004,"The patient has a history of symptomatic congestive heart failure or has a pre study echocardiogram or multigated acquisition scan with left ventricular ejection fraction that is>= 10% below the lower limit of normal institutional range"
NCT01204710:I.2005,"history of prior treatment with other agents that directly inhibit PDGF or platelet-derived growth factor receptors"
NCT01204710:I.2006,"known allergy to any of the treatment components: IMC 3G3, mitoxantrone, and/or prednisone"
NCT01204710:I.2007,"radiotherapy within 21 days prior to first dose of IMC-3G3"
NCT01204710:I.2008,"any investigational therapy within 30 days of randomization"
NCT01204710:I.2009,"is receiving corticosteroids at a dose>5 mg prednisone orally (PO) 2 times per day (BID) or equivalent"
NCT01204710:I.2010,"received prior strontium-89, rhenium-186, rhenium-188, or samarium-153 radionucleotide therapy and has either ongoing evidence of bone marrow dysfunction or poorly controlled bone pain"
NCT01204710:I.2011,"has any ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, psychiatric illness, active bleeding or pathological condition that carries a high risk of bleeding, or any other serious uncontrolled medical disorders"
NCT01204710:I.2012,"known or suspected brain or leptomeningeal metastases"
NCT01204710:I.2013,"known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness"
NCT01206647:I.1001,"age 18 Years to 80 Years"
NCT01206647:I.1002,"Diabetes Mellitus, Type 2"
NCT01206647:I.1003,"Combination of OAD and basal insulin treatment (BOT) or intensified conventional therapy (ICT,>2 injections of basal and prandial) or conventional insulin therapy (CIT, 1 or 2 injections of basal or biphasic)"
NCT01206647:I.1004,"Hemoglobin A1c (HbA1c)"
NCT01206647:I.1005,"History of - insulin therapy"
NCT01206647:I.1006,"Insulin dose<120 IU/day"
NCT01206647:I.1007,"Fasting C-peptide>0.6 ng/l"
NCT01206647:I.1008,"Elevated fasting glucose"
NCT01206647:I.1009,"Full legal, mental and physical ability to give informed consent"
NCT01206647:I.1010,"Patient consent that the general physician will be informed of trail participation"
NCT01206647:I.1011,"Experience in self measurement of blood glucose>1 year"
NCT01206647:I.2001,"Diabetes Mellitus, Insulin-Dependent"
NCT01206647:I.2002,"History of drug or alcohol abuse within the last five years prior to screening"
NCT01206647:I.2003,"History of severe or multiple allergies"
NCT01206647:I.2004,"Progressive fatal disease"
NCT01206647:I.2005,"History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT>3 times the normal reference range), neurological, psychiatric and/or haematological disease as judged by the investigator"
NCT01206647:I.2006,"Renal insufficiency or history of significant renal diseases (creatinine clearance<60 ml/min determined using the Cockroft-Goult equation)."
NCT01206647:I.2007,"Contra-indications for study drugs including contraindications for the rescue drugs"
NCT01206647:I.2008,"Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures"
NCT01206647:I.2009,"Pregnancy or breast feeding"
NCT01206647:I.2010,"Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner"
NCT01206647:I.2011,"Treatment with any other investigational drug within 3 months prior to screening"
NCT01206647:I.2012,"Lack of compliance or other similar reason, that according to investigator, precludes satisfactory participation in the study"
NCT01206803:I.1001,"age 18 Years to 45 Years"
NCT01206803:I.1002,"Infertility, Subfertility"
NCT01206803:I.1003,"Female patients for who the treating physician decides that treatment with long acting FSH 150microg in a GnRH-antagonist protocol is indicated."
NCT01206803:I.2001,"Contraindications for the use of gonadotropins (e.g., tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts) Use of hormonal preparations within one month prior to inclusion"
NCT01209286:I.1001,"age at least 18 Years"
NCT01209286:I.1002,"Patients with B-precursor ALL relapsed after at least induction and consolidation or having refractory disease"
NCT01209286:I.1003,"More than 5% blasts in bone marrow"
NCT01209286:I.1004,"ECOG performance status finding<= 2"
NCT01209286:I.1005,"Life expectancy of>= 12 weeks"
NCT01209286:I.2001,"History or presence of clinically relevant CNS pathology"
NCT01209286:I.2002,"Infiltration of cerebrospinal fluid (CSF) by ALL"
NCT01209286:I.2003,"Autologous/allogeneic HSCT within six weeks/three months prior to start of blinatumomab treatment"
NCT01209286:I.2004,"Active Graft-versus-Host Disease (GvHD)"
NCT01209286:I.2005,"Patients with Ph+ ALL eligible for treatment with dasatinib or imatinib"
NCT01209286:I.2006,"Cancer chemotherapy within two weeks prior to start of blinatumomab treatment"
NCT01209286:I.2007,"Immunotherapy (e.g. rituximab) within four weeks prior to start of blinatumomab treatment"
NCT01209286:I.2008,"Infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive)"
NCT01209286:I.2009,"Pregnant or nursing women"
NCT01209286:I.2010,"Previous treatment with blinatumomab"
NCT01212991:I.1001,"age at least 18 Years"
NCT01212991:I.1002,"Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features"
NCT01212991:I.1003,"Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy"
NCT01212991:I.1004,"Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bony disease"
NCT01212991:I.1005,"No prior treatment with cytotoxic chemotherapy"
NCT01212991:I.1006,"Asymptomatic or mildly symptomatic from prostate cancer"
NCT01212991:I.2001,"Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment"
NCT01212991:I.2002,"Known or suspected brain metastasis or active leptomeningeal disease"
NCT01212991:I.2003,"History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer"
NCT01217528:I.1001,"age at least 18 Years"
NCT01217528:I.1002,"Approved indication for new ICD implantation for primary prevention of sudden cardiac death"
NCT01217528:I.1003,"Written informed consent"
NCT01217528:I.2001,"ICD indication for secondary prevention reasons"
NCT01217528:I.2002,"ICD indication for electrical disorders (i.e. long/short QT syndrome, Brugada syndrome etc...)"
NCT01217528:I.2003,"ICD change or upgrade"
NCT01217528:I.2004,"Pregnancy, Gestation"
NCT01217528:I.2005,Nonage
NCT01217528:I.2006,"Patient is already participating to another study with active therapy arm"
NCT01217528:I.2007,"Patient will most likely not be able to participate to the routine follow ups in the study center."
NCT01229215:I.1001,"age 60 Years to 89 Years"
NCT01229215:I.1002,"Willingness and ability to provide signed Informed Consent. In addition, at U.S. sites, Health Insurance Portability and Accountability Act (HIPAA) authorization, in other countries, as applicable according to national laws"
NCT01229215:I.1003,"Well-demarcated area of GA secondary to age-related macular degeneration (AMD) in the absence of choroidal neovascularization (CNV)"
NCT01229215:I.2001,"History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye"
NCT01229215:I.2002,"Previous subfoveal focal laser photocoagulation in the study eye"
NCT01229215:I.2003,"Laser photocoagulation in the study eye"
NCT01229215:I.2004,"Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy in the study eye"
NCT01229215:I.2005,"GA in either eye due to causes other than AMD"
NCT01229215:I.2006,"Diabetic retinopathy in either eye"
NCT01229215:I.2007,"Active or history of wet AMD in either eye"
NCT01229215:I.2008,"History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug or that might affect interpretation of the results of the study or that renders the patient at high risk for treatment complications"
NCT01229215:I.2009,"Active malignancy or history of malignancy within the past 5 years"
NCT01229215:I.2010,"Previous participation in any studies of investigational drugs within 3 months preceding Day 0"
NCT01232452:I.1001,"age at least 18 Years"
NCT01232452:I.1002,"The patient has histologically or cytologically confirmed, nonsquamous (adenocarcinoma/large cell or other) NSCLC."
NCT01232452:I.1003,"The patient has Stage IV disease at the time of study entry."
NCT01232452:I.1004,"Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 2 weeks prior to randomization, or after surgical resection performed at least 28 days prior to randomization. The patient may have no evidence of Grade 1 (or greater) Central Nervous System (CNS) hemorrhage based on pretreatment scans(performed within 21 days before randomization)."
NCT01232452:I.1005,"The patient has measurable or nonmeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 guidelines."
NCT01232452:I.1006,"The patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1."
NCT01232452:I.1007,"If prior adjuvant chemotherapy, the last dose of adjuvant treatment was administered at least 6 months prior to randomization."
NCT01232452:I.1008,"The patient has adequate bone marrow reserve, and renal and hepatic function"
NCT01232452:I.1009,"The patient has fasting serum glucose<= 100 mg/dL, and hemoglobin A1C<= 6%."
NCT01232452:I.1010,"Females with reproductive potential: Must have a negative serum or urine pregnancy test within 7 days prior to the first dose of any study drug."
NCT01232452:I.1011,"Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for 6 months following the last dose of any study drug."
NCT01232452:I.1012,"The patient has the ability to understand and the willingness to sign a written informed consent form."
NCT01232452:I.1013,"Previous radiation therapy is allowed to<25% of the bone marrow, but should have been limited and must not have included whole pelvis radiation."
NCT01232452:I.1014,"The patient has archived tumor tissue available for analysis (can be either primary tumor or metastases)."
NCT01232452:I.1015,"The patient has an estimated life expectancy of at least 12 weeks."
NCT01232452:I.2001,"Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study."
NCT01232452:I.2002,"Patients who have squamous histology."
NCT01232452:I.2003,"The patient's tumor fully or partially contains Small Cell Lung Cancer (SCLC)."
NCT01232452:I.2004,"Leptomeningeal disease"
NCT01232452:I.2005,"The patient is currently or has previously received chemotherapy for advanced (Stage IV) NSCLC. Patients who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization"
NCT01232452:I.2006,"The patient has a history of treatment with other agents targeting the Insulin-like or Epidermal Growth factor receptors."
NCT01232452:I.2007,"Patients who have received prior Pemetrexed treatment."
NCT01232452:I.2008,"The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components."
NCT01232452:I.2009,"Diabetes mellitus"
NCT01232452:I.2010,"The patient has an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, uncontrolled hypertension, clinically significant cardiac arrhythmia,or psychiatric/social situations that would limit compliance with study requirements."
NCT01232452:I.2011,"The patient has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy."
NCT01232452:I.2012,"The patient has undergone major surgery within 28 days prior to randomization."
NCT01232452:I.2013,"The patient has received a prior autologous or allogeneic organ or tissue transplantation."
NCT01232452:I.2014,"The patient is pregnant or lactating."
NCT01232452:I.2015,"The patient has a history of another primary cancer, with the exception of the following: curatively resected nonmelanomatous skin cancer, curatively treated carcinoma in situ, or other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 5 years."
NCT01232452:I.2016,"The patient has superior vena cava syndrome contraindicating hydration."
NCT01232452:I.2017,"The patient has current clinically-relevant coronary artery disease (New York Heart Association III or IV) or uncontrolled congestive heart failure."
NCT01232452:I.2018,"The patient has any Grade 2 (or greater) peripheral neuropathy."
NCT01232452:I.2019,"The patient has clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry."
NCT01232452:I.2020,"The patient is unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose<= 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)."
NCT01232452:I.2021,"The patient is unwilling or unable to take premedications (folic acid, vitamin B12, or corticosteroids) required by the pemetrexed label."
NCT01232452:I.2022,"The patient has received a recent (within 30 days of enrollment) or is receiving concurrent yellow fever vaccination."
NCT01233440:I.1001,"age 12 Years to 65 Years"
NCT01233440:I.1002,"Male, 12 - 65 years, with body weight>= 30 kg and<= 120 kg"
NCT01233440:I.1003,"Documented severe Hemophilia B (FIX activity of<= 2%) or tested by the central laboratory at screening"
NCT01233440:I.1004,"Subjects who have received FIX products for>150 exposure days (EDs) (estimated)"
NCT01233440:I.1005,"No confirmed prior history of FIX inhibitor (history of positive FIX inhibitor defined as two consecutive positive tests - a confirmatory test on a second, separately drawn sample shortly after the previous positive test) and confirmed no detectable FIX inhibitors (negative FIX inhibitor defined as<0.6 Bethesda Units [BU] by the central laboratory at screening"
NCT01233440:I.1006,"Subjects can be treated on-demand or under prophylactic therapy"
NCT01233440:I.1007,"Signed Informed Consent/Assent"
NCT01233440:I.2001,"Known hypersensitivity (allergic reaction or anaphylaxis) to any FIX product or hamster protein"
NCT01233440:I.2002,"Any known congenital or acquired coagulation disorder other than congenital FIX deficiency"
NCT01233440:I.2003,"Platelet count - finding"
NCT01233440:I.2004,"Immunocompromised (CD4 count<200/mm3), (HIV positive subjects may participate in the study and protease inhibitors and antiviral therapy are permitted, at the discretion of the Investigator)"
NCT01233440:I.2005,"Currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment"
NCT01233440:I.2006,"Serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) concentration>5 times (x) the upper limit of normal (ULN)"
NCT01233440:I.2007,"Serum creatinine>2 x ULN"
NCT01233440:I.2008,"Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months prior to enrollment"
NCT01233440:I.2009,"Use of an Investigational Medicinal Product (IMP) within 30 days prior to the first rIX-FP administration"
NCT01233440:I.2010,"Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months prior to study entry"
NCT01233440:I.2011,"Subject currently on a dose and/or regimen of FIX that would preclude participation in the study due to possible increased risk of bleeding because of the requirement to withhold treatment during the PK sampling period"
NCT01233440:I.2012,"Suspected inability (e.g., language problem or mental condition) or unwillingness to comply with study procedures or history of noncompliance"
NCT01234311:I.1001,"age at least 18 Years"
NCT01234311:I.1002,"Age at least 18 years at the time of signing the informed consent form. For patients in Taiwan the minimum age is 20 years."
NCT01234311:I.1003,"Histologically confirmed diagnosis of adenocarcinoma of the prostate."
NCT01234311:I.1004,"Evidence of bone metastatic disease on radiographic examination, whether from bone scan or other imaging modality."
NCT01234311:I.1005,"Castrate levels of serum testosterone (?50 ng/dL or 1.7 nmol/L)."
NCT01234311:I.1006,"Evidence of progressive disease."
NCT01234311:I.1007,"Karnofsky performance status (assessment scale)"
NCT01234311:I.1008,"Meet screening laboratory values as specified in the protocol."
NCT01234311:I.1009,"If sexually active with partner of childbearing potential, patient will agree to use adequate contraceptive methods (barrier contraceptive with spermicide or vasectomy) while on study drug. The adequate contraceptive method should be continued for 14 days after the patient stops taking study drug."
NCT01234311:I.1010,"No evidence (within 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin)."
NCT01234311:I.1011,"Able to swallow and retain oral medication."
NCT01234311:I.1012,"Able to adhere to the study visit schedule and other protocol requirements."
NCT01234311:I.1013,"Ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to cooperate with the investigator and to comply with the requirements of the entire study."
NCT01234311:I.1014,"Able (or patient's legal guardian, if applicable) to sign and date the written informed consent after being informed of the full nature and purpose of the study, including possible risks and side effects, and given ample time and opportunity to read and understand this information."
NCT01234311:I.2001,"Prior cytotoxic chemotherapy for the treatment of prostate ca within 2 years or within 4 weeks for Estracyt (estramustine) prior to study treatment."
NCT01234311:I.2002,"Previous anticancer therapy using radiation, biologics or vaccines, including abiraterone, TAK-700 (Orteronel), or MDV3100 within 4 weeks prior or sipuleucel-T (Provenge) within 2 weeks prior to the start of study treatment. If radiation therapy is applied after baseline scan, a new baseline scan needs to be done at least 4 weeks after the radiation therapy."
NCT01234311:I.2003,"Previous therapy with antiandrogens within 4 weeks (within 6 weeks for bicalutamide eg, Casodex) prior to study treatment."
NCT01234311:I.2004,"Concurrent use of other anticancer agents or treatments, with the following exceptions:"
NCT01234311:I.2005,"Ongoing treatment with luteinizing hormone-releasing hormone agonists or antagonists, denosumab (Prolia) or bisphosphonate (eg, zoledronic acid) is allowed. Ongoing treatment should be kept at a stable schedule; however, if medically required, a change of dose, compound, or both is allowed."
NCT01234311:I.2006,"Any treatment modalities involving major surgery within 4 weeks prior to the start of study treatment."
NCT01234311:I.2007,"Prostate ca pain that requires ongoing treatment with narcotic analgesics or warrants the initiation of radio- or chemotherapy."
NCT01234311:I.2008,"Ongoing treatment with warfarin unless the international normalized ratio (INR) is well controlled and below 4 (Section 4.6.8.1)."
NCT01234311:I.2009,"Maintenance treatment with corticosteroids corresponding to a prednisolone or prednisone dose above 10 mg/day. The dose must have been stable for at least 5 days."
NCT01234311:I.2010,"Systemic exposure to ketoconazole or other strong cytochrome P450 (CYP) 3A4 isozyme inhibitors or inducers within 14 days prior to the start of study treatment. Systemic exposure to amiodarone is not allowed within 1 year prior to the start of study treatment."
NCT01234311:I.2011,"Ongoing treatment with sensitive CYP1A2 substrate or CYP1A2 substrate with narrow therapeutic range at the start of study treatment."
NCT01234311:I.2012,"Ongoing treatment with CYP3A4 substrate with narrow therapeutic range at the start of study treatment."
NCT01234311:I.2013,"Simultaneous participation in any other study involving treatment with investigational drugs or having received treatment with investigational drugs<4 weeks prior to the start of study treatment."
NCT01234311:I.2014,"Myocardial infarction, percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass graft, class III/IV congestive heart failure, cerebrovascular accident, transient ischemic attack, or limb claudication at rest, within 6 months prior to start of study treatment and ongoing symptomatic dysrhythmias, unstable angina, uncontrolled hypertension, and uncontrolled atrial or ventricular arrhythmias."
NCT01234311:I.2015,"History of pancreatitis."
NCT01234311:I.2016,"Known brain or epidural metastases."
NCT01234311:I.2017,"Known positive serology for HIV (patients with known history of HIV will be excluded because of potential for unforeseen toxicity and morbidity in an immunocompromised host)."
NCT01234311:I.2018,"Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of a chronic viral hepatitis or known viral hepatitis carrier (patients who have recovered from hepatitis will be allowed to enter the study)."
NCT01234311:I.2019,"Patients with active tuberculosis (TB), or with known, untreated latent TB. (Country-specific TB therapy should have been given for at least 30 days prior to the start of study treatment and the patient should intend to complete the entire course of that therapy.)"
NCT01234311:I.2020,"Any condition, including other active or latent infections, medical or psychiatric conditions, or the presence of laboratory abnormalities, which could confound the ability to interpret data from the study or places the patient at unacceptable risk if he participates in the study."
NCT01234311:I.2021,"Any patient who in the opinion of the investigator should not participate"
NCT01234727:I.1001,"age 18 Years to 75 Years"
NCT01234727:I.1002,"Subjects diagnosed with type 1 or type 2 diabetes mellitus"
NCT01234727:I.1003,"Patients with stable blood glucose in judgment of the investigator."
NCT01234727:I.1004,"Subjects receive intensive insulin therapy (Multiple Daily Injection defined as at least two insulin injections per day)"
NCT01234727:I.1005,"Patients perform blood glucose self measurements on a routine basis"
NCT01234727:I.1006,"Patients must have experience in self measurement blood glucose for at least 6 months."
NCT01234727:I.2001,"Patients with unstable blood glucose in judgment of the investigator."
NCT01234727:I.2002,"Patient has been diagnosed with progressive / serious diseases that in judgment of the investigator preclude successful completion of the observational period."
NCT01234727:I.2003,"Lack of compliance or other justifications that, in the discretion of the investigator, precludes satisfactory participation in the study."
NCT01234727:I.2004,"Subject without legal capacity."
NCT01234727:I.2005,"Blood donation within the last 30 days."
NCT01234727:I.2006,"Pregnancy, Gestation"
NCT01234727:I.2007,"Subject has already participated in the study."
NCT01238029:I.1001,"age at least 18 Years"
NCT01238029:I.1002,"Written informed consent"
NCT01238029:I.1003,"Able to comply with the protocol"
NCT01238029:I.1004,"ECOG performance status 0-1"
NCT01238029:I.1005,"Adequate contraception"
NCT01238029:I.1006,"Confirmed Her2/neu-positive, adenocarcinoma of the breast"
NCT01238029:I.1007,"At least one measurable lesion according to RECIST 1.1 criteria"
NCT01238029:I.1008,"First or second chemotherapy after diagnosis of metastasis"
NCT01238029:I.1009,"Lapatinib treatment indicated (adjuvant trastuzumab treatment<12 months ago or progressive disease with trastuzumab treatment)"
NCT01238029:I.1010,"No signs and symptoms of CHF (chronic heart failure), LVEF (left ventricular ejection fraction) at study start at least 55%"
NCT01238029:I.1011,"Adequate hepatic and renal function value"
NCT01238029:I.1012,"Adequate hematologic function values"
NCT01238029:I.2001,"Pregnant or lactating women"
NCT01238029:I.2002,"Concurrent participation in another clinical trial. Prior participation is allowed if the last study medication was administered more than 4 weeks prior to randomization"
NCT01238029:I.2003,"Asymptomatic with regards to tumor illness"
NCT01238029:I.2004,"Previous treatment with lapatinib, capecitabine or vinorelbine"
NCT01238029:I.2005,"Necessity of planned treatment with other chemotherapeutics oder anti-hormone therapy"
NCT01238029:I.2006,"Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of the study"
NCT01238029:I.2007,"Evidence of cardiovascular disease, e.g. myocardial infection, unstable angina pectoris or arrhythmia"
NCT01238029:I.2008,"History of vascular or cardiovascular disease within the past 6 months"
NCT01238029:I.2009,"All illnesses that result in malabsorption of oral medication or inability to take oral medication"
NCT01238029:I.2010,"Concurrent treatment with anti-viral drugs based on sorivudine or with aminoglycosides"
NCT01238029:I.2011,"Concurrent treatment with any drug interfering with study medication, especially, those that induce CYP3A"
NCT01238029:I.2012,"Concurrent treatment with allopurinol"
NCT01238029:I.2013,"Other malignancies (except for basal cell carcinoma of the skin and cervical carcinoma in situ). Patient can be included in the study if no recurrent disease has been observed for at least 5 years"
NCT01238029:I.2014,"Concurrent illnesses or other circumstances that could interfere with trial participation, efficacy or safety of the patient"
NCT01239797:I.1001,"age at least 18 Years"
NCT01239797:I.1002,"Multiple Myeloma"
NCT01239797:I.1003,"Documented progression from most recent line of therapy"
NCT01239797:I.1004,"1 - 3 prior lines of therapy"
NCT01239797:I.1005,"Measurable Disease"
NCT01239797:I.1006,"Life expectancy>=3 months"
NCT01239797:I.1007,"Prior treatment with Lenalidomide permitted if:"
NCT01239797:I.1008,"Best response achieved was ? Partial Response (PR)"
NCT01239797:I.1009,"Patient was not refractory"
NCT01239797:I.1010,"Patient did not discontinue due to a Grade ? 3 related adverse event"
NCT01239797:I.1011,"Subject did not receive>9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progression"
NCT01239797:I.2001,"Subjects with non-secretory or oligo-secretory or free light-chain only myeloma"
NCT01239797:I.2002,"Active plasma cell leukemia"
NCT01239797:I.2003,"Positive for Hepatitis B, C or Human Immunodeficiency Virus (HIV)"
NCT01241396:I.1001,"age at least 18 Years"
NCT01241396:I.1002,"Requires commencement of a new line of treatment for MMY at any stage, regardless of type of therapy selected."
NCT01241396:I.2001,"Patients currently participating in another investigational study or clinical trial."
NCT01241448:I.1001,"age 18 Years to 70 Years"
NCT01241448:I.1002,"Have a diagnosis of Type 2 diabetes mellitus according to the World Health Organization (WHO) diagnostic criteria"
NCT01241448:I.1003,"Are women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause."
NCT01241448:I.1004,"Are male patients using a reliable method of birth control during the study and until 3 months after the last dose of study medication."
NCT01241448:I.1005,"Are being treated with either diet and exercise alone, or with diet and exercise in combination with metformin. Metformin therapy must have been stable and unchanged for at least 3 months prior to screening and at a dose of at least 1000 mg/day."
NCT01241448:I.1006,"Have an HbA1c value of 7.0% to 10.5% , inclusive."
NCT01241448:I.1007,"Body mass index"
NCT01241448:I.1008,"In the opinion of the investigator, are capable and willing to:"
NCT01241448:I.1009,"Perform self-monitoring of blood glucose"
NCT01241448:I.1010,"Complete a study diary as required for this protocol"
NCT01241448:I.1011,"Maintain consistent dietary, physical activity, and sleeping patterns throughout the duration of the study"
NCT01241448:I.1012,"Comply with treatment regimens"
NCT01241448:I.1013,"Have given written informed consent to participate in this study in accordance with local regulations and the Ethical Review Board (ERB) governing the study site."
NCT01241448:I.2001,"Have>1 episode of severe hypoglycemia (defined as an event during which the patient requires the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) within 6 months prior to screening, or have a current diagnosis of hypoglycemia unawareness."
NCT01241448:I.2002,"Have had two or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening."
NCT01241448:I.2003,"Have gastrointestinal disease that may significantly impact gastric emptying or motility or have undergone gastric bypass or gastric banding surgery."
NCT01241448:I.2004,"Have had a previous diagnosis of pancreatitis."
NCT01241448:I.2005,"Have New York Heart Association (NYHA) class II, III, or IV symptoms of heart failure"
NCT01241448:I.2006,"Have a history of myocardial infarction, unstable angina, or a coronary revascularization procedure within 6 months of screening."
NCT01241448:I.2007,"Have a history of supraventricular tachycardia, ventricular tachycardia, or other cardiac arrhythmia."
NCT01241448:I.2008,"Have a history of transient ischemic attack (TIA) or stroke within 6 months of screening."
NCT01241448:I.2009,"Have poorly controlled hypertension (systolic blood pressure>= 150 mm Hg or diastolic blood pressure>= 90 mm Hg) as determined by the mean of three separate measurements."
NCT01241448:I.2010,"Show evidence of labile blood pressure, including symptomatic postural hypotension."
NCT01241448:I.2011,"Have any abnormality of the ECG that would impact patient safety or data interpretation."
NCT01241448:I.2012,"Show clinical signs or symptoms of liver disease, or liver function tests (LFTs, aspartate aminotransferase [AST] or alanine aminotransferase [ALT])>2.5 times upper limit of normal (ULN) as determined by the central laboratory at screening."
NCT01241448:I.2013,"Have a current or previous diagnosis of Gilbert's disease."
NCT01241448:I.2014,"Have previous or current diagnosis of Hepatitis B or C"
NCT01241448:I.2015,"Have a serum creatinine>2 mg/dL or, in patients being treated with metformin, a serum creatinine above (or creatinine clearance below) what is approved in the metformin product labeling in the respective country."
NCT01241448:I.2016,"Show evidence of uncorrected hypothyroidism or hyperthyroidism based on clinical evaluation and/or an abnormal thyroid stimulating hormone result as determined by the central laboratory at screening. Patients receiving dose-stable thyroid replacement therapy for at least 3 months prior to screening will be allowed to participate in the study."
NCT01241448:I.2017,"Have any other abnormal laboratory value that, in the opinion of the investigator, precludes the patient from participation in the study. Laboratory abnormalities consistent with type 2 diabetes mellitus and all other eligibility criteria are acceptable: for example, abnormalities of blood glucose, hemoglobin A1C (HbA1c), urinary glucose, and urinary protein (with a range of trace to 1+ on dipstick)."
NCT01241448:I.2018,"Have a currently suspected or treated malignancy, or are in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years."
NCT01241448:I.2019,"Have a personal or family history of pancreatic neoplasia."
NCT01241448:I.2020,"Have non-fasting triglycerides>600 mg/dL."
NCT01241448:I.2021,"Use or have used insulin or GLP-1 agonists (for more than 1 week within the 3-month period prior to screening), or any oral antihyperglycemic medication (OAM) other than metformin within the 3-month period prior to screening."
NCT01241448:I.2022,"Currently use or intend to use prescription or over-the-counter medications, including herbal supplements, to promote weight loss or to regulate blood glucose."
NCT01241448:I.2023,"Have current chronic (>2 weeks) systemic glucocorticoid therapy (excluding ocular topical, other topical, inhaled preparations)or have received such therapy within 8 weeks prior to screening."
NCT01241448:I.2024,"Currently use hyperglycemia-causing agents, hypoglycemia-causing agents (other than metformin), class II and III antiarrythmic agents, agents that reduce gastrointestinal motility,central nervous system stimulants (with the exception of caffeinated beverages), fibrates, and niacin>= 1 gm/day."
NCT01241448:I.2025,"Have an average weekly alcohol intake that exceeds 2 units per day for males and 1 unit per day for females (1 unit = 12 oz or 360 mL of beer, 5 oz or 150 mL of wine, 1.5 oz or 45 mL of distilled spirits)."
NCT01241448:I.2026,"Currently use drugs that are known to prolong the QT interval."
NCT01241448:I.2027,"Currently use or intend to use potent inhibitors of CYP3A, which include but are not limited to atazanavir, indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, and telithromycin."
NCT01241448:I.2028,"Have previously completed or withdrawn from this study or any other study investigating LY2409021."
NCT01241448:I.2029,"Have known allergies to LY2409021 or related compounds."
NCT01241448:I.2030,"Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or unapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study"
NCT01241448:I.2031,"Have any other condition such as alcohol abuse, drug abuse, or psychiatric disorder that may affect the ability to participate in the trial."
NCT01243177:I.1001,"age at least 16 Years"
NCT01243177:I.1002,"Subject able to comply with study requirements"
NCT01243177:I.1003,"Subject is 16 years and older (female, male). Minors will be included in countries only if legally permitted"
NCT01243177:I.1004,"Subject has newly or recently diagnosed epilepsy experiencing partial onset seizures (POS) or generalized tonic-clonic seizures with at least 2 unprovoked seizures separated by 48 hours in the year before enrollment with 1 seizures 3 months before enrollment"
NCT01243177:I.1005,"Subject has normal electroencephalogram (EEG) which must be normal or consistent with partial onset seizures (POS) and a Computerized Axial Tomography (CT) scan or Magnetic Resonance Imaging (MRI) with diagnosis of POS or generalized tonic clonic seizures (without clear focal origin) within year before enrollment"
NCT01243177:I.2001,"Subject has a history or presence of seizures of other types than partial-onset (IA, IB, IC with clear focal origin) and generalized tonic-clonic (without clear focal origin) seizures (eg, myoclonic, absence)"
NCT01243177:I.2002,"Subject has a history or presence of seizures occurring only in clustered patterns, defined as repeated seizures occurring over a short period of time (ie,<20 minutes) with or without function regained between 2 ictal events"
NCT01243177:I.2003,"Subject has a history, clinical, or Electroencephalogram (EEG) finding suggestive of idiopathic generalized epilepsy (IGE) at randomization"
NCT01243177:I.2004,"Subject has current or previous diagnosis of pseudoseizures, conversion disorders, or other nonepileptic ictal events which could be confused with seizures"
NCT01243177:I.2005,"Subject has any medical or psychiatric condition"
NCT01243177:I.2006,"Subject has a history of suicide attempt, has received professional counselling for suicidal ideation, or is currently experiencing active suicidal ideation"
NCT01243177:I.2007,"Prior use of felbamate or vigabatrin is not allowed"
NCT01243177:I.2008,"Subject has received treatment with phenobarbital or primidone within 28 days prior to Visit 1"
NCT01243177:I.2009,"Subject is taking benzodiazepines for a nonepilepsy indication"
NCT01243177:I.2010,"Benzodiazepines as rescue therapy for epilepsy may have been used as needed in this time period, but not more frequently than once per week)"
NCT01243177:I.2011,"Subject has been treated for epilepsy with any antiepileptic drug (AED) (including benzodiazepines) in the last 6 months before Visit 1 (however, acute and subacute seizure treatment is accepted with a maximum of 2 weeks duration and if treatment was stopped at least 1 week before Visit 1"
NCT01243177:I.2012,"Subject has a medical condition that could reasonably be expected to interfere with drug absorption, distribution, metabolism, or excretion, has a history of alcohol or drug abuse within the previous 2 years"
NCT01243177:I.2013,"Asian ancestry and tests positive for HLA-B*1502 allele"
NCT01243424:I.1001,"age 40 Years to 85 Years"
NCT01243424:I.1002,"Type 2 diabetes"
NCT01243424:I.1003,"Elevated glycosylated heamoglobin (HbA1c): 6.5 - 8.5%, inclusive, if treatment naïve or mono-/dual therapy with metformin and/or an alpha-glucosidase inhibitor; 6.5 - 7.5%, inclusive, if treatment with sulphonylurea/glinide in mono- or dual (with metformin OR an alpha-glucosidase inhibitor) therapy)"
NCT01243424:I.1004,"Pre-existing cardiovascular disease OR specified diabetes end-organ damage OR age =>70 years OR two or more specified cardiovascular risk factor"
NCT01243424:I.2001,"Diabetes Mellitus, Insulin-Dependent"
NCT01243424:I.2002,"Treatment with other antidiabetic drugs (e.g. rosiglitazone, pioglitazone, Glucagon-like peptide 1 (GLP-1) analogue/agonists, Dipeptidyl-peptidase IV (DPP-IV) inhibitors or any insulin) prior to informed consent (previous short term use of insulin (up to two weeks) is allowed if taken at least 8 weeks prior informed consent)"
NCT01243424:I.2003,"Inappropriateness of glimepiride treatment for renal safety issues according to local prescribing information"
NCT01246752:I.1001,"age 18 Years to 60 Years"
NCT01246752:I.1002,"AML in first remission"
NCT01246752:I.1003,"cytological standard risk, i.e. karyotype not listed under exclusion criteria"
NCT01246752:I.1004,"Identification of HLA-identical sibling or HLA-compatible related or unrelated donor (9/10 HLA-alleles matched, high resolution typing for HLA-A, B, Cw, DRB1 and DQB1)"
NCT01246752:I.1005,"medically fit for allogeneic stem cell transplantation"
NCT01246752:I.1006,"CR / CRi after induction therapy"
NCT01246752:I.2001,"core-binding factor leukemia (t(8;21), inv16)"
NCT01246752:I.2002,"Acute Promyelocytic Leukemia"
NCT01246752:I.2003,"Complex Karyotype"
NCT01246752:I.2004,"karyotypes: -7, -5, del5q, t(3;3), t(6;11), t(6;9), 11q aberrations, trisomy 8 ± one single additional aberration"
NCT01246752:I.2005,"pregnancy / nursing"
NCT01246752:I.2006,Non-compliant
NCT01246986:I.1001,"age at least 18 Years"
NCT01246986:I.1002,"Have histological evidence of a diagnosis of HCC not amenable to curative surgery"
NCT01246986:I.1003,"Serum alpha fetoprotein>= 1.5 Upper Limits of Normal"
NCT01246986:I.1004,"Child-Pugh Stage A"
NCT01246986:I.1005,"Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). A lesion that has been previously treated by local therapy will qualify as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapy"
NCT01246986:I.1006,"Have given written informed consent prior to any study-specific procedures"
NCT01246986:I.1007,"Have adequate hematologic, hepatic and renal function"
NCT01246986:I.1008,"ECOG performance status finding<= 1"
NCT01246986:I.1009,"Have received sorafenib and have progressed or were intolerant to sorafenib or are ineligible for sorafenib treatment"
NCT01246986:I.1010,"Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures"
NCT01246986:I.1011,"Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug"
NCT01246986:I.1012,"Females with childbearing potential must have had a negative serum pregnancy test<= 7 days prior to the first dose of study drug"
NCT01246986:I.1013,"Are able to swallow capsules or tablets"
NCT01246986:I.2001,"Are currently enrolled in, or discontinued within the last 28 days from a clinical trial involving an investigational drug or device or not approved use of a drug or device (other than the study drug used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study"
NCT01246986:I.2002,"Known HCC with fibro-lamellar or mixed histology"
NCT01246986:I.2003,"Presence of clinically relevant ascitis"
NCT01246986:I.2004,"History of liver transplant"
NCT01246986:I.2005,"Have received>1 line of systemic treatment"
NCT01246986:I.2006,"Have moderate or severe cardiac disease:"
NCT01246986:I.2007,"Have the presence of cardiac disease, including a myocardial infarction within 6  months prior to study entry, unstable angina pectoris, New York Heart  Association (NYHA) Class III/IV congestive heart failure, or uncontrolled  hypertension"
NCT01246986:I.2008,"Have documented major electrocardiogram (ECG) abnormalities at the  investigator's discretion"
NCT01246986:I.2009,"Have major abnormalities documented by echocardiography with Doppler. For  additional details"
NCT01246986:I.2010,"Have predisposing conditions that are consistent with development of aneurysms  of the ascending aorta or aortic stress"
NCT01246986:I.2011,"Have serious preexisting medical conditions that, in the opinion of the investigator, that cannot be adequately controlled with appropriate therapy or would preclude participation in this study"
NCT01246986:I.2012,"Females who are pregnant or lactating"
NCT01246986:I.2013,"Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) unless in complete remission and off all therapy for that disease for a minimum of 3 years"
NCT01246986:I.2014,"Have active infection that would interfere with the study objectives or influence study compliance"
NCT01250379:I.1001,"age at least 18 Years"
NCT01250379:I.1002,"female, female gender"
NCT01250379:I.1003,"Histologically confirmed HER2-negative breast cancer"
NCT01250379:I.1004,"Disease progression during or following first-line treatment with Avastin and chemotherapy for locally recurrent or metastatic breast cancer"
NCT01250379:I.1005,"Avastin treatment in first-line setting must have been a minimum of 4 cycles (15 mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy"
NCT01250379:I.1006,"ECOG performance status 0-2"
NCT01250379:I.1007,"At least 28 days since prior radiation therapy or surgery and recovery from treatment"
NCT01250379:I.2001,"Anti-angiogenic therapy or anti-vascular endothelial growth factors other than Avastin for first-line treatment"
NCT01250379:I.2002,"Active malignancy other than superficial basal cell and superficial squamous cell carcinoma of the skin, or in situ carcinoma of the cervix or breast within the last 5 years"
NCT01250379:I.2003,"Inadequate renal function"
NCT01250379:I.2004,"Clinically relevant cardio-vascular disease"
NCT01250379:I.2005,"Known CNS disease except for treated brain metastases"
NCT01250379:I.2006,"Chronic daily treatment with high-dose aspirin (>325 mg/day) or clopidogrel (>75 mg/day)"
NCT01250379:I.2007,"Pregnant or lactating women"
NCT01261793:I.1001,"age at least 18 Years"
NCT01261793:I.1002,"Positive antinuclear antibodies (ANA) at Screening (Visit 1)"
NCT01261793:I.1003,"Current clinical diagnosis of Systemic Lupus Erythematosus (SLE) by American College of Rheumatology (ACR) criteria such that at least 4 of the 11 criteria are met"
NCT01261793:I.1004,"Active moderate to severe SLE activity as demonstrated by the British Isles Lupus Assessment Group Index (BILAG)"
NCT01261793:I.1005,"Active moderate to severe SLE disease as demonstrated by SLE disease activity index (SLEDAI) total score"
NCT01261793:I.1006,"On stable SLE treatment regimen, including mandatory corticosteroids and immunosuppressants or antimalarials"
NCT01261793:I.2001,"Subjects who are breastfeeding, pregnant, or plan to become pregnant"
NCT01261793:I.2002,"Subjects with active, severe SLE disease activity which involves the renal system"
NCT01261793:I.2003,"Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring BILAG level A disease."
NCT01261793:I.2004,"Subjects with the evidence of an immunosuppressive state"
NCT01261793:I.2005,"Subjects who, in the opinion of the investigator, are at a particularly high risk of significant infection"
NCT01261793:I.2006,"History of malignant cancer, except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma."
NCT01261793:I.2007,"Subjects receiving any live vaccination within the 8 weeks prior to screening (Visit 1)."
NCT01261793:I.2008,"Subjects with history of infections, including but not limited to concurrent acute or chronic viral hepatitis B or C"
NCT01261793:I.2009,"Subjects with substance abuse or dependence or other relevant concurrent medical condition"
NCT01261793:I.2010,"Subjects with history of thromboembolic events within 1 year of screening Visit."
NCT01261793:I.2011,"Subjects with significant hematologic abnormalities"
NCT01261793:I.2012,"Subject has received treatment with other anti-B cell antibodies within 12 months prior to screening (visit 1)"
NCT01261793:I.2013,"Subject use of oral anticoagulant (not including) nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 weeks prior to screening (Visit 1)"
NCT01261793:I.2014,"Subject has previously participated in this study or has previously received epratuzumab treatment."
NCT01271699:I.1001,"age 18 Years to 50 Years"
NCT01271699:I.1002,"Patients at age 18-50 years old with a confirmed or probably diagnosis of Multiple Sclerosis according to the McDonald diagnostic criteria for MS"
NCT01271699:I.1003,"Patients with confirmed diagnosis of Multiple Sclerosis according to the McDonald diagnostic criteria but without confirmation of oligoclonal IgG in the CSF"
NCT01271699:I.1004,"Patients with present oligoclonal IgG in the CSF but without proof of dissemination of spinal inflammatory processes in the MRI"
NCT01271699:I.1005,"Signed informed consent"
NCT01271699:I.2001,"Patients being younger than 18 years or older than 50 years"
NCT01271699:I.2002,"Patients without performed MRI of the brain and spinoaxis"
NCT01271699:I.2003,"Patients with a structural change in the brain that is not caused by a chronic inflammatory disease of the CNS"
NCT01271699:I.2004,"Missing signed informed consent"
NCT01272232:I.1001,"age at least 18 Years"
NCT01272232:I.1002,"Procurement of patient informed consent, investigational study"
NCT01272232:I.1003,"Subjects diagnosed with type 2 diabetes and treated with either diet and exercise alone, metformin, SU, glitazone as single agent therapy or any combination of the previously mentioned compounds (metformin+SU, metformin+glitazone, SU+glitazone, metformin+SU+glitazone)"
NCT01272232:I.1004,"Hemoglobin A1c (HbA1c)"
NCT01272232:I.1005,"Body mass index"
NCT01272232:I.1006,"Stable body weight"
NCT01272232:I.1007,"Preceding failed dietary effort"
NCT01272232:I.2001,"Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or insulin within the last 3 months"
NCT01272232:I.2002,"Known proliferative retinopathy or maculopathy"
NCT01272232:I.2003,"History of acute or chronic pancreatitis"
NCT01272232:I.2004,"Obesity induced by drug treatment"
NCT01272232:I.2005,"Use of approved weight lowering pharmacotherapy"
NCT01272232:I.2006,"Previous surgical treatment of obesity"
NCT01272232:I.2007,"History of major depressive disorder or suicide attempt"
NCT01272232:I.2008,"Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or diastolic blood pressure of 100 mmHg or above)"
NCT01272232:I.2009,"Screening calcitonin of 50 ng/L or above"
NCT01272232:I.2010,"Familial or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)"
NCT01272232:I.2011,"Personal history of non-familial medullary thyroid carcinoma"
NCT01282294:I.1001,"age at least 18 Years"
NCT01282294:I.1002,"Adult (person)"
NCT01282294:I.1003,"Open or closed tibia fracture according to the surgical technique"
NCT01282294:I.2001,"Women who are pregnant or breast-feeding or are planning to become pregnant during the study"
NCT01282294:I.2002,"Patients with consumptive/ malignant primary disease and a life expectancy of<3 months"
NCT01282294:I.2003,"Patients with a known allergy to aminoglycosides"
NCT01282294:I.2004,"Physical or mental incapacity, which makes it impossible to obtain informed consent"
NCT01282294:I.2005,"History of drug and alcohol abuse"
NCT01282294:I.2006,"Patient unlikely to cooperate"
NCT01282294:I.2007,"Legal incompetence"
NCT01282645:I.1001,"age at least 18 Years"
NCT01282645:I.1002,"Cranial Defects"
NCT01282645:I.1004,"Received a Synthes PSI made of PEEK intended for replacement of bony voids in the cranial/craniofacial skeleton at least 24 months before inclusion in the study"
NCT01282645:I.1005,"Ability to obtain written informed consent from the recipient or the recipient's legal guardian"
NCT01282645:I.1006,"Ability to comply with the procedures described in the protocol, including responding to simple questionnaires either by the recipient in person or by a next relative (spouse, parent) who lives with the recipient"
NCT01282645:I.2001,"Patient was contraindicated to receive a PSI made of PEEK at the time of implantation"
NCT01283724:I.1001,"age 12 Years to 17 Years"
NCT01283724:I.1002,"Female adolescents after menarche (12 -<18 years of age) at screening. For Finland: Adolescents aged 12 - 14 years old who present with clinical features of endometriosis will only be enrolled into the study if their diagnosis of endometriosis has been confirmed by laparoscopy."
NCT01283724:I.1003,"Dysmenorrhea of at least moderate intensity, with or without chronic pelvic pain, for at least 2 cycles in the previous 4 months and one of the following conditions:"
NCT01283724:I.1004,"Clinically suspected endometriosis based on the presence of pelvic pain  incompletely relieved by non steroidal anti-inflammatory drugs and/or oral  contraceptives"
NCT01283724:I.1005,"Any abdominal pain associated with ultrasound findings suggestive of  endometriosis (abdominal, vaginal or rectal - only after additional specific  consent and assent)"
NCT01283724:I.1006,"Failure of surgical treatment for endometriosis (with cyclic or chronic pelvic  pain of at least 4 months duration postsurgery)"
NCT01283724:I.1007,"Threshold for endometriosis-associated pelvic pain (EAPP) score: at least 30 on  a 100 units visual analog scale retrospectively evaluated at screening for the  last 4 weeks"
NCT01283724:I.2001,"Absence of endometriosis at laparoscopy"
NCT01283724:I.2002,"Previous application of hormonal agents including oral contraceptives within 2 months, progestins, danazol within 3 months, and Gonadotropin Releasing Hormone (GnRH) agonists within 6 months prior to start of treatment"
NCT01283724:I.2003,"Chronic pelvic pain that might be related to genitourinary disease or to chronic or recurrent gastrointestinal disease, including irritable bowel syndrome (defined as a disease characterized by pain relieved by defecation and irregular defecation patterns lasting at least 3 months)"
NCT01283724:I.2004,"Clinically established need for primary surgical treatment of endometriosis"
NCT01285167:I.1001,"age at least 18 Years"
NCT01285167:I.1002,"severe COPD"
NCT01285167:I.2001,"Child pugh (classified B and C)"
NCT01285180:I.1001,"age at least 18 Years"
NCT01285180:I.1002,"severe COPD"
NCT01285180:I.2001,"Child pugh (classified B and C)"
NCT01285401:I.1001,"age 18 Years to 50 Years"
NCT01285401:I.1002,"Diagnosis of a relapsing-remitting form of MS"
NCT01285401:I.1003,"Brain and/or spinal MRI with findings typical of MS"
NCT01285401:I.1004,"A first clinical event prior to Screening."
NCT01285401:I.1005,"Active disease diagnosis"
NCT01285401:I.1006,"EDSS score of<= 4.0 at Screening."
NCT01285401:I.1007,"Currently treated with interferon-beta-1a (tiw) sc"
NCT01285401:I.1008,"Willingness and ability to comply with the protocol"
NCT01285401:I.1009,"Written informed consent"
NCT01285401:I.2001,"Pregnancy and lactation period"
NCT01285401:I.2002,"Any disease other than MS that could better explain signs and symptoms."
NCT01285401:I.2003,"Complete transverse myelitis or bilateral optic neuritis."
NCT01285401:I.2004,"Currently receiving or use at any time of monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy (excluding systemic steroids and adrenocorticotrophic hormone [ACTH]), B cell modulating therapies (e.g. RituxiMab or BelimuMab), total lymphoid irradiation or bone marrow transplantation."
NCT01285401:I.2005,"Use of any cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, or any investigational drug or experimental procedure"
NCT01285401:I.2006,"Use of oral or systemic corticosteroids or ACTH"
NCT01285401:I.2007,"Have abnormalities of Vitamin D related hormonal system other than low dietary intake or decreased sun exposure, i.e. primary hyperparathyroidism or granulomatous disorders."
NCT01285401:I.2008,"Have an urine calcium/creatinine (mmol/mmol) ratio>1.0 or hypercalcaemia"
NCT01285401:I.2009,"Are taking medications that influence Vitamin D metabolism other than corticosteroids, e.g., phenytoin, barbiturates, thiazide diuretics and cardiac glycosides."
NCT01285401:I.2010,"Are taking>400 IU (10 microg) of Vitamin D supplement daily."
NCT01285401:I.2011,"Have conditions with increased susceptibility to hypercalcaemia, e.g., known arrhythmia or heart disease, treatment with Digitalis, or Hydrochlorothiazide and those who suffer from nephrolithiasis."
NCT01285401:I.2012,"Have inadequate liver function"
NCT01285401:I.2013,"Moderate to severe renal impairment"
NCT01285401:I.2014,"Inadequate bone marrow reserve"
NCT01285401:I.2015,"History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (NYHA class 3 or 4)."
NCT01285401:I.2016,"History or presence of severe depression, history of suicide attempt, or current suicidal ideation."
NCT01285401:I.2017,"Epilepsy or seizures not adequately controlled by treatment."
NCT01285401:I.2018,"Current or past alcohol or drug abuse."
NCT01285401:I.2019,"Any major medical or psychiatric illness (such as psychosis, bipolar disorder) that in the opinion of the Investigator could create undue risk to the subject or could affect adherence with the trial protocol."
NCT01285401:I.2020,"Known contra-indication to treatment with vitamin D"
NCT01285401:I.2021,"Known hypersensitivity to interferon or its excipient(s)"
NCT01285401:I.2022,"Known hypersensitivity to gadolinium."
NCT01285401:I.2023,"Any other condition that would prevent the subject from undergoing an MRI scan."
NCT01285401:I.2024,"Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such."
NCT01285401:I.2025,"Positive HIV, hepatitis C, or hepatitis B (HBsAg and HBc antibody) serology (test performed at screening)."
NCT01285401:I.2026,"Legal incapacity or limited legal capacity."
NCT01285401:I.2027,"Another current autoimmune disease, except diabetes."
NCT01286779:I.1001,"age 12 Years to 65 Years"
NCT01286779:I.1002,"Subject and/or legal representative has/have voluntarily provided signed informed consent"
NCT01286779:I.1003,"Subject has completed Baxter clinical study 250901"
NCT01286779:I.1004,"Subject has severe (FIX level<1%) or moderately severe (FIX level<= 2%) hemophilia B (based on the one stage activated partial thromboplastin time (aPTT) assay), as tested at screening at the central laboratory"
NCT01286779:I.1005,"Subject has not developed an inhibitory FIX antibody during Baxter clinical study 250901"
NCT01286779:I.2001,"Subject received factor IX product(s) other than BAX 326 upon completion of Baxter protocol 250901"
NCT01286779:I.2002,"Subject has been diagnosed with an acquired hemostatic defect other than hemophilia B"
NCT01286779:I.2003,"Body weight (observable entity)"
NCT01286779:I.2004,"Subject is planned to take part in any other clinical study, with the exception of BAX 326 Surgery study as described in this protocol, during the course of the continuation study"
NCT01290679:I.1001,"age at least 18 Years"
NCT01290679:I.1002,"Genotype 1 hepatitis C infection (confirmed at screening)"
NCT01290679:I.1003,"patient has not received any prior treatment for hepatitis C"
NCT01290679:I.1004,"patient must have had a liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection"
NCT01290679:I.1005,"must agree to use 2 forms of effective contraception throughout study (both males and females)."
NCT01290679:I.2001,"Infection with HIV or non genotype 1 hepatitis C"
NCT01290679:I.2002,"liver disease not related to hepatitic C infection"
NCT01290679:I.2003,"Hepatic failure, Liver decompensation"
NCT01290679:I.2004,"significant laboratory abnormalities or other active diseases"
NCT01290679:I.2005,"pregnant or planning to become pregnant"
NCT01291810:I.1001,"age 18 Years to 65 Years"
NCT01291810:I.1003,"Have had a diagnosis of Crohn's disease for at least 6 months."
NCT01291810:I.1004,"Moderate to severe active Crohn's disease defined as a Crohn's Disease Activity Index (CDAI) score ? 220 and ? 450, and presence of colonic mucosal ulcerations in at least 2 segments, or ulcerations on ? 10% of the mucosal surface if only one segment is involved."
NCT01291810:I.1005,"Have developed secondary resistance to anti-TNF? therapy."
NCT01291810:I.2001,"Primary non-response to a previously received treatment directed against TNF? Or Intolerance related to the primary pharmacological effect of anti-TNF? such as for instance, but not limited to, severe or opportunistic infections and demyelinating or autoimmune diseases."
NCT01291810:I.2002,"History of severe systemic bacterial, fungal, viral, or parasitic infections within the 3 months prior to screening; or the occurrence of any acute infection within 2 weeks of the first administration of study drug."
NCT01291810:I.2003,"Treatment with immunosuppressive or immunomodulatory drugs"
NCT01294774:I.1001,"age 18 Years to 65 Years"
NCT01294774:I.1002,"Male and female patients,18 to 65 years of age inclusive, who have been defined as having SCLE based on the typical clinical picture and the characteristic histopathological features as described by Sontheimer et al. at least three months before study entry (screening)"
NCT01294774:I.2001,"Patients with preexisting nephritis, central nervous or pulmonary involvement or any major internal organ damage, either related or unrelated to lupus, which are deemed by the Investigator to be clinically significant. Patients having signs or symptoms of other autoimmune diseases such as systemic lupus erythematosus or Sjogren`s syndrome are allowed to enter the study at the Investigator`s discretion."
NCT01294774:I.2002,"Treated by"
NCT01294774:I.2003,"immunoglobulins and/or monoclonal antibodies within 6 months prior to  randomization."
NCT01294774:I.2004,"rituximab, cyclophosphamide, or other immunosuppressive treatments with effects  potentially lasting over 6 months, within 12 months prior to randomization."
NCT01294774:I.2005,"a medium or high dose (>= 1 mg prednisone or equivalent per body weight kg)  corticosteroid therapy in the last 8 weeks prior to randomization."
NCT01294774:I.2006,"antimalarial agents (hydroxychloroquine, chloroquine or quinacrine) in the last  6 weeks prior to randomization."
NCT01294774:I.2007,"biologic therapies, such as etanercept, within the last 4 weeks prior to  randomization."
NCT01294774:I.2008,"any other immunosuppressive or immunomodulatory therapy such as methotrexate,  azathioprine, cyclosporin A or mycophenolate, thalidomide, retinoids or dapsone  in the last 4 weeks prior to randomization."
NCT01294774:I.2009,"total lymphoid irradiation or bone marrow transplantation."
NCT01294774:I.2010,"Pregnant, planning to get pregnant, and/or lactating females or males planning to father a child within time period of the study or subsequent exclusionary period."
NCT01295307:I.1001,"age at least 40 Years"
NCT01295307:I.1002,"Diagnosis of AML according to WHO criteria."
NCT01295307:I.1003,"Untreated relapse or refractory disease after a minimum of one standard induction therapy. Treatment of relapse with leukocyte-apheresis or up to 5 days with low dose cytarabine or hydroxyurea is allowed."
NCT01295307:I.1004,"Refractory disease is defined as>=5% blasts after the second cycle of induction  therapy or no reduction in marrow blasts at early treatment assessment (day +15)  after the first cycle of induction therapy."
NCT01295307:I.1005,"Relapse is defined as an increase in bone marrow blast count>=5%, re-appearance  of blasts in the peripheral blood or extramedullary disease."
NCT01295307:I.1006,"Have adequate renal and hepatic functions as indicated by the following laboratory values:"
NCT01295307:I.1007,"Serum creatinine<=1.0 mg/dL. If serum creatinine>1.0 mg/dL, then the estimated  glomerular filtration rate (GFR) must be>60 mL/min/1.73 m2 (see reference  below*)"
NCT01295307:I.1008,"Serum bilirubin<=1.5 x upper limit of normal (ULN)"
NCT01295307:I.1009,"Aspartate transaminase (AST)/alanine transaminase (ALT)<=2.5 x ULN"
NCT01295307:I.1010,"Alkaline phosphatase<=2.5 x ULN"
NCT01295307:I.1011,"Eligibility for intensive chemotherapy"
NCT01295307:I.1012,"Patient needs to be capable to understand the clinical trial as an investigational approach to bridge the time to potential allogeneic HCT, potential risks and benefits of the study."
NCT01295307:I.1013,"Signed written informed consent."
NCT01295307:I.1014,"Female patients of childbearing potential must have a negative serum"
NCT01295307:I.1015,"Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment."
NCT01295307:I.2001,"For refractory disease, more than two prior induction chemotherapies or more than one prior salvage chemotherapy containing high-dose cytarabine (cumulative dose of cytarabine>= 5 g/m2)."
NCT01295307:I.2002,"Second or higher relapse. Patients who received hypomethylating agents like azacytidine or decitabine as a treatment of first relapse, respond and relapse later on may be included."
NCT01295307:I.2003,"Acute promyelocytic leukemia with t(15;17)(q22;q12) molecular detection or (PML/RARalpha)."
NCT01295307:I.2004,"Central nervous system involvement (i.e. WBC>= 5/microL in cerebrospinal fluid with blasts present on cytospin)."
NCT01295307:I.2005,"Prior allogeneic HCT"
NCT01295307:I.2006,"Autologous transplantation within 100 days prior to start of study treatment"
NCT01295307:I.2007,"Use of investigational agents or anticancer therapy within 10 days before study entry with the exception of hydroxyurea or low-dose cytarabine."
NCT01295307:I.2008,"Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo transplantation."
NCT01295307:I.2009,"Patients with known refractoriness to platelet support."
NCT01295307:I.2010,"Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)."
NCT01295307:I.2011,"Pregnant or lactating patients."
NCT01295307:I.2012,"Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results."
NCT01303302:I.1001,"age 18 Years to 70 Years"
NCT01303302:I.1003,"Body mass index"
NCT01303302:I.1004,"Type 2 diabetes duration more than 6 month"
NCT01303302:I.1005,"Type 2 diabetic sublecys treated with oral anti-diabetic agents"
NCT01303302:I.1006,"Stable anti-diabetic medication for at least 3 month prior to enrollment"
NCT01303302:I.1007,"HbA1c>=7.5% and<=9.5% on visit 1. Subjects with T2DM duration .10 years should have<=9.0% at visit 1"
NCT01303302:I.1008,"Stable HbA1c, defined as no significant change (variation<=0.5%)between a historical value recorded in the subject's medical record with in 3 month prior to enrollment and the HbA1c gathered at visit 1"
NCT01303302:I.1009,"Fasting blood glucose>120 and<240 mg/dl on visit 1. Subjects with T2DM duration>10 yaers should have .120 ans<=180 mg/dl at visit 1"
NCT01303302:I.1010,"Women with child bearing potential (i.e, not post menopausal or surgically sterilized) must agree to use adequate birth control methods"
NCT01303302:I.1011,"Stable weight, defined as no significant weight change (variation<5%)within three months prior to enrollment"
NCT01303302:I.1012,"If taking these medication, stable anti-hepertensive and lipid-lowering medication for at least one month prior to enrollment"
NCT01303302:I.1013,"If subject is under anti-depressant medication the treatment needs to be stable for at least six month prior to enrollment"
NCT01303302:I.1014,"Willingness to refrain from using prescription, over the counter or herbal weight loss product for the duration of the trial"
NCT01303302:I.1015,"Ability and willingliness to perform required study and data collection procedures and adhere to operating requirements of the TANTALUS II System"
NCT01303302:I.1016,"Alert, mentally competant, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial"
NCT01303302:I.1017,"Able to provide voluntary informed consent"
NCT01303302:I.2001,"Insulin therapy"
NCT01303302:I.2002,"Taking GLP-1 analogue, such as exenatide (Byette) in the last 3 month before enrollment Taking medication known to affect gastric mobility such as narcotics (chronic use) and anticholinergics/antispasmodics"
NCT01303302:I.2003,"Use of prescription, over the counter or herbal weight loss product or obesity drugs during the past two month"
NCT01303302:I.2004,"Experiencing severe and progressing diabetic complications (i.e retinopathy not stabilized, nephropathy with macroalbuminuria)"
NCT01303302:I.2005,"Prior wound healing problems"
NCT01303302:I.2006,"Diagnosed with past or present psychiatric condition that may impair his or her ability to comply with the study procedure"
NCT01303302:I.2007,"Use of anti-psychotic medication"
NCT01303302:I.2008,"Diagnosed with an eating disorder such as bulimia or binge eating"
NCT01303302:I.2009,"Obesity due to endocrinopathy (e.g.Cushing disease, Hypothyroidism)"
NCT01303302:I.2010,"Hiatal hernia requiring surgical repair or paraesophageal hernia"
NCT01303302:I.2011,"Pregnant or lactating"
NCT01303302:I.2012,"Diagnosed with impaired liver function (liver enzymes 3 times graeted than normal)"
NCT01303302:I.2013,"Any prior bariatric surgery"
NCT01303302:I.2014,"Any history of pancreatitis"
NCT01303302:I.2015,"Personal history of peptic ulcer disease"
NCT01303302:I.2016,"Diagnosed with gastroparesis or GI motility disorder"
NCT01303302:I.2017,"Use of active medical device (either implantable or external) such as ICD, pacemaker, drug infusion device, or neurostimulator (either implantable or worn)"
NCT01303302:I.2018,"Subjects using an external active device who are able and willing to avoid use of the device during the study may be enrolled."
NCT01303302:I.2019,"Cardiac history that physician feels should exclude the subject from the study."
NCT01303302:I.2020,"Use of another investigational device agent in the 30 days prior to enrollment"
NCT01303302:I.2021,"A history of life threatening disease within 5 years of enrollment"
NCT01303302:I.2022,"Change in diabetic medication from between visit 1 and visit 3"
NCT01303302:I.2023,"Any additional condition(S) that in the investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study"
NCT01303315:I.1001,"age 21 Years to 70 Years"
NCT01303315:I.1003,"Type 2 diabetes duration>6 months and<10 years"
NCT01303315:I.1004,"7.8%<HbA1c<10.5% if T2DM duration<= 5 years"
NCT01303315:I.1005,"7.8%<HbA1c<10.0% if T2DM duration>5 years"
NCT01303315:I.1006,"Body mass index"
NCT01303315:I.1007,"Taking at least one oral anti-diabetic medication"
NCT01303315:I.1008,"Patients treated with GLP-1 receptor agonist with at least one oral anti-diabetic medication may be included under the following conditions:"
NCT01303315:I.1009,"a. The HbA1c, before GLP-1 receptor agonist therapy was administered, was: i. 7.8%<HbA1c<10.5% if T2DM duration<5 years ii. 7.8%<HbA1c<10.0% if T2DM duration>5 years"
NCT01303315:I.1010,"b. The patient was on GLP-1 receptor agonist therapy for no more than 12 weeks"
NCT01303315:I.1011,"Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods"
NCT01303315:I.1012,"If subject is taking lipid-lowering medication, the treatment must be stable for at least one month prior to enrollment"
NCT01303315:I.1013,"If subject is taking anti-hypertensive medication, the treatment must be stable for at least one month prior to enrollment"
NCT01303315:I.1014,"If subject is taking anti-depressant medication, the treatment must be stable for at least one month prior to enrollment"
NCT01303315:I.1015,"Willingness to refrain from using prescription, over the counter, or herbal weight loss products for the duration of the trial"
NCT01303315:I.1016,"Ability and willingness to perform required study and data collection procedures and adhere to operating requirements of the TANTALUS® System"
NCT01303315:I.1017,"Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial"
NCT01303315:I.1018,"Able to provide voluntary informed consent"
NCT01303315:I.2001,"Insulin therapy within the last 3 months"
NCT01303315:I.2002,"GLP-1 receptor agonist therapy longer than 3 months"
NCT01303315:I.2003,"Diagnosed with renal dysfunction or history of renal dysfunction"
NCT01303315:I.2004,"Taking medications known to affect gastric motility"
NCT01303315:I.2005,"Use of prescription, over the counter or herbal weight loss products or obesity drugs during the past two months"
NCT01303315:I.2006,"Experiencing severe and progressing diabetic complications"
NCT01303315:I.2007,"Prior wound healing problems"
NCT01303315:I.2008,"Diagnosed with past or current psychiatric condition that may impair his or her ability to comply with the study procedures"
NCT01303315:I.2009,"Use of anti-psychotic medications"
NCT01303315:I.2010,"Diagnosed with eating disorder such as bulimia or binge eating"
NCT01303315:I.2011,"Obesity due to an endocrinopathy"
NCT01303315:I.2012,"Hiatal hernia requiring surgical repair or a paraesophageal hernia"
NCT01303315:I.2013,"Pregnant or lactating"
NCT01303315:I.2014,"Diagnosed with impaired liver function"
NCT01303315:I.2015,"Any prior bariatric surgery"
NCT01303315:I.2016,"Any history of pancreatitis"
NCT01303315:I.2017,"Personal history of peptic ulcer disease"
NCT01303315:I.2018,"Diagnosed with Gastroparesis or other GI motility disorder"
NCT01303315:I.2019,"Use of active medical devices (either implantable or external) such as ICD, drug infusion device, or neurostimulator (either implanted or worn)."
NCT01303315:I.2020,"Subjects using an external active device who are able and willing to avoid use of the device during the study may be enrolled."
NCT01303315:I.2021,"Cardiac history that physician feels should exclude the subject from the study."
NCT01303315:I.2022,"Use of another investigational device or agent in the 30 days prior to enrollment"
NCT01303315:I.2023,"A history of life-threatening disease within 5 years of enrollment"
NCT01303315:I.2024,"Any additional condition(s) that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study"
NCT01307397:I.1001,"age at least 18 Years"
NCT01307397:I.1002,"Adult (person)"
NCT01307397:I.1003,"Histologically confirmed metastatic melanoma with BRAF V600 mutation determined by Cobas 4800 BRAF Mutation Test"
NCT01307397:I.1004,"Disease Progression after at least one prior systemic treatment for metastatic melanoma"
NCT01307397:I.1005,"Eastern Cooperative Oncology Group (ECOG) performance status 0-2"
NCT01307397:I.1006,"Adequate hematologic, renal and liver function"
NCT01307397:I.2001,"Evidence of symptomatic CNS lesions"
NCT01307397:I.2002,"Previous malignancy (other than melanoma) within the past 2 years, except for treated and controlled basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix"
NCT01307397:I.2003,"Concurrent administration of any anti-cancer therapies other than those administered in the study"
NCT01307397:I.2004,"Clinically significant cardiovascular disease or event within the 6 months prior to first administration of study drug"
NCT01307397:I.2005,"Refractory nausea or vomiting, external biliary shunt, or significant bowel resection that would preclude adequate absorption"
NCT01311687:I.1001,"age at least 18 Years"
NCT01311687:I.1002,"Subjects must have documented diagnosis of multiple myeloma and have measurable disease"
NCT01311687:I.1003,"Subjects must have undergone prior treatment with>= 2 treatment lines of anti-myeloma therapy"
NCT01311687:I.1004,"Subjects must have either refractory or relapsed and refractory disease defined as documented disease progression during or within 60 days of completing their last myeloma therapy"
NCT01311687:I.1005,"All subjects must have received at least 2 consecutive cycles of prior treatment that included lenalidomide and bortezomib"
NCT01311687:I.1006,"All subjects must have failed treatment with both lenalidomide and bortezomib in one of the following ways:"
NCT01311687:I.1007,"1) Documented progressive disease on or within 60 days of completing treatment with lenalidomide and/or bortezomib, or"
NCT01311687:I.1008,"2) In case of prior response [>= partial response (PR)] to lenalidomide or bortezomib, subjects must have relapsed within 6 months after stopping treatment with lenalidomide and/or bortezomib-containing regimens, or"
NCT01311687:I.1009,"3) Subjects who have not had a>= minimal response (MR) and have developed intolerance/toxicity after a minimum of two cycles of lenalidomide"
NCT01311687:I.1010,"Patients must have received adequate prior alkylator therapy"
NCT01311687:I.1011,"Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2"
NCT01311687:I.1012,"Females of childbearing potential (FCBP) must not become pregnant for 28 days prior to initiation of study drug, during the study, and for 28 days after discontinuation"
NCT01311687:I.1013,"Females must agree to abstain from breastfeeding during study participation and 28 days after study drug discontinuation"
NCT01311687:I.1014,"Males must agree to use a latex condom during any sexual during the study and for 28 days following discontinuation from this study"
NCT01311687:I.1015,"Males must also agree to refrain from donating semen or sperm while on pomalidomide and for 28 days after discontinuation from this study"
NCT01311687:I.2001,"Any of the following laboratory abnormalities:"
NCT01311687:I.2002,"Absolute Neutrophil Count"
NCT01311687:I.2003,"Platelet count<75,000/microL for subjects in whom<50% of bone marrow nucleated  cells are plasma cells"
NCT01311687:I.2004,"Creatinine clearance (CrCl)  measurement"
NCT01311687:I.2005,"Corrected Serum Calcium Measurement"
NCT01311687:I.2006,Hemoglobin
NCT01311687:I.2007,"Serum glutamic oxaloacetic transaminase (SGOT)/ aspartate aminotransferase (AST)  or Transaminase, serum glutamic pyruvic (SGPT)/ alanine aminotransferase (ALT)>3.0 x upper limit of normal (ULN)"
NCT01311687:I.2008,"Serum Total Bilirubin Measurement"
NCT01311687:I.2009,"Previous therapy with Pomalidomide"
NCT01311687:I.2010,"Hypersensitivity to thalidomide, lenalidomide, or dexamethasone"
NCT01311687:I.2011,"Resistance to high-dose dexamethasone used in the last line of therapy"
NCT01311687:I.2012,"Peripheral neuropathy>= Grade 2"
NCT01311687:I.2013,"Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant"
NCT01311687:I.2014,"Subjects who are planning for or who are eligible for stem cell transplant"
NCT01311687:I.2015,"Subjects with any one of the following: 1) Congestive heart failure, 2) Myocardial infarction within 12 months prior to starting study treatment, 3) Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris"
NCT01311687:I.2016,"Subjects who received any of the following within the last 14 days of initiation of study treatment: 1) Plasmapheresis, 2) Major surgery, 3) Radiation therapy, 4) Use of any anti-myeloma drug therapy"
NCT01311687:I.2017,"Use of any investigational agents within 28 days or 5 half-lives (whichever is longer) of treatment"
NCT01311687:I.2018,"Subjects with conditions requiring chronic steroid or immunosuppressive treatment"
NCT01311687:I.2019,"Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study"
NCT01311687:I.2020,"Incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide"
NCT01311687:I.2021,"Subjects unable or unwilling to undergo antithrombotic prophylactic treatment"
NCT01311687:I.2022,"Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subjects from signing the informed consent form"
NCT01311687:I.2023,"Pregnant or breastfeeding females"
NCT01311687:I.2024,"Known Human Immunodeficiency Virus (HIV) positivity or active infectious hepatitis A, B or C"
NCT01319487:I.1001,"age at least 18 Years"
NCT01319487:I.1003,"Diagnosis of diabetes mellitus"
NCT01319487:I.1004,"Patient must be able to self administer study drug."
NCT01319487:I.1005,"Clinically significant diabetic macular edema in at least one eye (""study eye"") involving the center of the macula:"
NCT01319487:I.1006,"Mild to severe non proliferative diabetic retinopathy (Early Treatment Diabetic Retinopathy Study [ETDRS] grade between 20 and 53)."
NCT01319487:I.1007,"BCVA score ? 34 letters and<80 letters in the study eye."
NCT01319487:I.1008,"Women of childbearing potential must have a negative urine pregnancy test at Screening and be using two highly effective methods of contraception throughout the study."
NCT01319487:I.1009,"Male patients with partners of childbearing potential must agree to use at least one highly effective method of contraception throughout the study."
NCT01319487:I.2001,"Any ocular condition in the study eye that in the opinion of the investigator would prevent improvement in visual acuity."
NCT01319487:I.2002,"Proliferative diabetic retinopathy in the study eye."
NCT01319487:I.2003,"History of panretinal scatter photocoagulation(PRP)in the study eye within 4 months prior to screening, and/or anticipated need for PRP in the 3 months following randomization."
NCT01319487:I.2004,"Active optic disc or retinal neovascularization, rubeosis iridis, active or history of choroidal neovascularization in the study eye."
NCT01319487:I.2005,"History of pars plana vitrectomy at any time, intraocular surgery in the study eye within 90 days prior to screening."
NCT01319487:I.2006,"History of use of intravitreal injectable or periocular depots corticosteroids (other than triamcinolone acetonide)within 3 months prior to the screening visit in the study eye."
NCT01319487:I.2007,"Patients who have previously received triamcinolone acetonide in the study eye:"
NCT01319487:I.2008,"The intended dose for each triamcinolone acetonide injection was>4 mg."
NCT01319487:I.2009,"The most recent dose was<3 months prior to the screening visit."
NCT01319487:I.2010,"Any treatment-related adverse event that was seen, and in the opinion of the investigator, has the potential to worsen or reoccur with study treatment."
NCT01319487:I.2011,"Patients who have previously received anti-VEGF therapy within 3 months prior to the screening visit in the study eye."
NCT01319487:I.2012,"Uncontrolled glaucoma or glaucoma treated by 2 or more medications."
NCT01319487:I.2013,"Aphakia or intraocular lens placement in the anterior chamber of the study eye."
NCT01319487:I.2014,"Any active ocular infection; any history of recurrent or chronic infection or inflammation in the study eye."
NCT01319487:I.2015,"History of herpetic infection in either eye."
NCT01319487:I.2016,"History of corneal pathology/surgery"
NCT01319487:I.2017,"Contact lens use at any time during the study."
NCT01319487:I.2018,"Uncontrolled systemic disease."
NCT01319487:I.2019,"Diabetes mellitus poor control"
NCT01319487:I.2020,"Impaired renal function"
NCT01319487:I.2021,"Poorly controlled arterial hypertension"
NCT01324947:I.1001,"age at least 18 Years"
NCT01324947:I.1002,"Subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in Study CC-4047-MM-003 and discontinued study therapy with dexamethasone alone after disease progression."
NCT01324947:I.1003,"Subjects must have documented diagnosis of multiple myeloma and have measurable disease"
NCT01324947:I.1004,"Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2."
NCT01324947:I.1005,"Females of childbearing potential (FCBP) must not become pregnant for 28 days prior to initiation of study drug, during the study, and for 28 days after discontinuation"
NCT01324947:I.1006,"Females must agree to abstain from breastfeeding during study participation and 28 days after study discontinuation."
NCT01324947:I.1007,"Males must agree to use a latex condom during any sexual contact during the study and for 28 days following discontinuation from this study"
NCT01324947:I.1008,"Males must also agree to refrain from donating semen or sperm while on pomalidomide and for 28 days after discontinuation from this study."
NCT01324947:I.2001,"Subjects with multiple myeloma who were not treated as a part of Study CC-4047-MM-003 (high dose dexamethasone)."
NCT01324947:I.2002,"Subjects who received any treatments (steroids, anti-myeloma, or anti-cancer therapy) within the last 14 days before initiation of study treatment."
NCT01324947:I.2003,"Subjects who discontinued CC-4047-MM-003 study ?120 days."
NCT01324947:I.2004,"Subjects who initiate another anti-myeloma therapy from the time of disease progression on study CC-4047-MM-003 to the time of treatment initiation in the companion study."
NCT01324947:I.2005,"Abnormal Laboratory Test Result"
NCT01324947:I.2006,"Absolute Neutrophil Count"
NCT01324947:I.2007,"Platelet count<75,000/?L for subjects in whom<50% of bone marrow nucleated cells are plasma cells, or a platelet count<30,000/uL for subjects in whom>= 50% of bone marrow nucleated cells are plasma cells"
NCT01324947:I.2008,"Creatinine clearance (CrCl)  measurement"
NCT01324947:I.2009,"Corrected serum calcium>14 mg/dL Hemoglobin ? 8 g/dL"
NCT01324947:I.2010,"SGOT/AST or SGPT/ALT>3.0 x upper limit of normal (ULN)"
NCT01324947:I.2011,"Prior history of malignancies, other than MM, unless the subject has been free of the disease for ? 3 years."
NCT01324947:I.2012,"Hypersensitivity to thalidomide or lenalidomide"
NCT01324947:I.2013,"Peripheral neuropathy ? Grade 2."
NCT01324947:I.2014,"Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant."
NCT01324947:I.2015,"Subjects who are planning for or who are eligible for stem cell transplant."
NCT01324947:I.2016,"Subjects with any one of the following: 1) Congestive heart failure, 2) Myocardial infarction within 12 months prior to starting study treatment, 3) Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris"
NCT01324947:I.2017,"Subjects who received any of the following within the last 14 days of initiation of study treatment:1) Plasmapheresis, 2) Major surgery, 3) Radiation therapy"
NCT01324947:I.2018,"Use of any investigational agents within 28 days or 5 half-lives (whichever is longer) of treatment."
NCT01324947:I.2019,"Subjects with chronic conditions such as rheumatoid arthritis, multiple sclerosis and lupus."
NCT01324947:I.2020,"Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study."
NCT01324947:I.2021,"Incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide."
NCT01324947:I.2022,"Subjects unable or unwilling to undergo antithrombotic prophylactic treatment."
NCT01324947:I.2023,"Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form."
NCT01324947:I.2024,"Pregnant or breastfeeding females."
NCT01324947:I.2025,"Known Human Immunodeficiency Virus (HIV) positivity or active infectious hepatitis A, B or C."
NCT01332019:I.1001,"age 18 Years to 70 Years"
NCT01332019:I.1002,"Relapsing Multiple Sclerosis"
NCT01332019:I.1003,"Must have completed the study treatment and visit schedule through Week 96 in Study 105MS301."
NCT01332019:I.2001,"Subjects exceeding more than 6 weeks since completion of the Week 96 visit of Study 105MS301."
NCT01332019:I.2002,"Subjects with any clinically significant lab abnormalities, malignancies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease"
NCT01332019:I.2003,"Pregnant or nursing women."
NCT01332968:I.1001,"age at least 18 Years"
NCT01332968:I.1002,"Adult (person)"
NCT01332968:I.1003,"CD20-positive indolent B-cell non-Hodgkin's lymphoma (follicular lymphoma or splenic, nodal or extranodal marginal zone lymphoma)"
NCT01332968:I.1004,"Stage III or IV disease, or Stage II bulky disease, requiring treatment"
NCT01332968:I.1005,"At least one bi-dimensionally measurable lesion (>2 cm in its largest dimension by CT scan or MRI)"
NCT01332968:I.1006,"Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2"
NCT01332968:I.1007,"Adequate hematologic function"
NCT01332968:I.2001,"Central nervous system lymphoma, leptomeningeal lymphoma, or histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma"
NCT01332968:I.2002,"Grade 3b follicular lymphoma, small lymphocytic lymphoma or Waldenström's macroglobulinaemia"
NCT01332968:I.2003,"Ann Arbor Stage I disease"
NCT01332968:I.2004,"History of severe allergic or anaphylactic reactions to monoclonal antibody therapy, known hypersensitivity to any of the study drugs or sensitivity to murine products, or history of sensitivity to mannitol"
NCT01332968:I.2005,"For patients with follicular lymphoma: prior treatment for non-Hodgkin's lymphoma with chemotherapy, immunotherapy, or radiotherapy"
NCT01332968:I.2006,"For patients with non-follicular lymphoma: prior treatment with chemotherapy or immunotherapy"
NCT01332968:I.2007,"History of prior malignancy with the exception of curatively treated basal or squamous cell carcinoma of the skin and low-grade in situ carcinoma of the cervix"
NCT01332968:I.2008,"Known active infection, or major episode of infection within 4 week prior to the start of Cycle 1"
NCT01332968:I.2009,"Positive for HIV, HTLV1, hepatitis C or chronic hepatitis B"
NCT01335399:I.1001,"age at least 18 Years"
NCT01335399:I.1002,"Subjects who are newly diagnosed with symptomatic Multiple Myeloma (MM) and who:"
NCT01335399:I.1003,"have not received any prior systemic anti-myeloma therapy AND"
NCT01335399:I.1004,"Measurable Disease"
NCT01335399:I.1005,"are not candidates for high-dose therapy plus stem-cell transplantation because  of age (>= 65 years) or coexisting conditions"
NCT01335399:I.2001,"Subjects with non-secretory or oligo-secretory or free light-chain only myeloma"
NCT01335399:I.2002,"Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions"
NCT01335399:I.2003,"Monoclonal gammopathy of undetermined significance (MGUS)"
NCT01335399:I.2004,"Active plasma cell leukemia"
NCT01335399:I.2005,"Positive for Hepatitis B, C or Human Immunodeficiency Virus (HIV)"
NCT01335477:I.1001,"age at least 40 Years"
NCT01335477:I.1002,"IPF diagnosed, according to most recent American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management, within 5 years"
NCT01335477:I.1003,"Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of IPF"
NCT01335477:I.1004,"Dlco (corrected for Hb): 30%-79% predicted of normal"
NCT01335477:I.1005,"Forced vital capacity"
NCT01335477:I.2001,"Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT)>1.5 x Upper Limit of Normal (ULN)"
NCT01335477:I.2002,"Bilirubin>1.5 x ULN"
NCT01335477:I.2003,"Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC<0.7)"
NCT01335477:I.2004,"Patient likely to have lung transplantation during study (being on transplantation list is acceptable for participation)"
NCT01335477:I.2005,"Myocardial infarction within 6 months"
NCT01335477:I.2006,"Unstable angina within 1 month"
NCT01335477:I.2007,"Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or ulcers or major injury or surgery within 3 months);"
NCT01335477:I.2008,"Thrombotic risk (inherited predisposition; history of thrombotic event (including stroke and transient ischemic attacks) within 12 months;"
NCT01335477:I.2009,"International normalised ratio (INR)>2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by>50% of institutional ULN)"
NCT01335477:I.2010,"N-ACetyl Cystein, prednisone>15mg/day or equivalent received within 2 weeks of visit 1"
NCT01335477:I.2011,"Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of visit 1"
NCT01347671:I.1001,"age 18 Years to 75 Years"
NCT01347671:I.1003,"Type 1 or type 2 diabetes."
NCT01347671:I.1004,"Painful DPN symptoms and signs for at least 3 months."
NCT01347671:I.1005,"Blood glucose controlled with medication."
NCT01347671:I.1006,"Glycosylated hemoglobin<= 9.5 or 11%, country dependent."
NCT01347671:I.1007,"Prior analgesic medication."
NCT01347671:I.1008,"Average score of>= 4 on the 11 point NRS during the last 3 days prior to randomization."
NCT01347671:I.2001,"Impaired liver, cardiac or renal function."
NCT01347671:I.2002,"Breastfeeding and pregnancy."
NCT01347671:I.2003,"History of substance abuse, alcohol or medication."
NCT01347671:I.2004,"Chronic gastrointestinal disease."
NCT01347671:I.2005,"History of seizures and or epilepsy."
NCT01347671:I.2006,"Malignant Neoplasms"
NCT01347671:I.2007,"Presence of painful medical conditions that are not due to diabetic neuropathy, e.g. rheumatoid arthritis."
NCT01347671:I.2008,"Allergies to opioids, acetaminophen or excipients of the medications."
NCT01355120:I.1001,"age at least 18 Years"
NCT01355120:I.1002,"Histologically proven ocular melanoma"
NCT01355120:I.1003,"Measurable disease according to RECIST in unresectable stage III-IV"
NCT01355120:I.1004,"Able and willing to give valid written inform consent"
NCT01355120:I.1005,"Patients with or without prior systemic treatment for advanced malignant melanoma are eligible ."
NCT01355120:I.1006,"In case of systemic pre-treatment, an interval of at least 28 days since treatment with chemotherapy, biochemotherapy, surgery, radiation, or immunotherapy is mandatory as well as recovery from any clinically significant toxicity experienced during treatment is recommended. Prior treatment must be completed by the time of ipilimumab administration. Palliative radiation therapy outside of the brain or therapeutic radiation to the brain after the patient's condition is stabilized and systemic steroids required for the management of symptoms due to brain metastases is decreased to the lowest fixed dose possible and does not require the 28-day waiting period. Patient must have recovered from any acute toxicity associated with prior therapy."
NCT01355120:I.1007,"Expected survival of at least six months"
NCT01355120:I.1008,"ECOG Performance Status 0, 1 or 2."
NCT01355120:I.1009,"Within the last 2 weeks prior to study day 1 the following laboratory parameters, which should be within the ranges specified:"
NCT01355120:I.1010,"Lab Parameter Range White blood cells (WBC)>= 2500/mm3 (? 1 2.5 x 109/L) Absolute neutrophil count (ANC)>= 1000/mm3 (? 1.0 x 109/L) Platelets ?75.000/mm3 (? 75 x 109/L) Hemoglobin ? 9 g/dL (? 90 g/L; may be transfused) Creatinine<= 2.0 x ULN Bilirubin total<= 2.0 x ULN (excepted patients with Gilbert's Syndrome, who must have a total bilirubin<3.0 mg/dL)<= 5 x ULN for patients with liver metastases"
NCT01355120:I.1011,"No childbearing potential or negative pregnancy test of women of childbearing potential performed within 7 days prior to the start of treatment."
NCT01355120:I.1012,"Women of childbearing potential (WOCP) must be using an effective method of contraception (Pearl-Index<1, e.g. oral contraceptives, other hormonal contraceptives [vaginal products, skin patches, or implanted or injectable products], or mechanical products such as an intrauterine device or barrier methods [diaphragm, spermicides]) throughout the study and for up to 26 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized."
NCT01355120:I.1013,"No men of fathering potential or men of fathering potential must be using an effective method of contraception to avoid conception throughout the study and for up to 26 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized."
NCT01355120:I.1014,"WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not post-menopausal."
NCT01355120:I.1015,"Post-menopause is defined as:"
NCT01355120:I.1016,"Amenorrhea>= 12 consecutive months without another cause, or"
NCT01355120:I.1017,"For women with irregular menstrual periods and taking hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level>=35 mIU/mL."
NCT01355120:I.1018,"Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (eg, vasectomy) should be considered to be of childbearing potential."
NCT01355120:I.1019,"WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) at Baseline within 7 days before the start of ipilimumab and at week 12."
NCT01355120:I.2001,"The patient requires concomitant therapy with any of the following: IL 2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; any other systemic therapy for cancer including any other experimental treatment."
NCT01355120:I.2002,"The patient requires chronic use of systemic corticosteroids. Systemic steroids for management of symptoms due to brain mets should be avoided if possible or subject should be stable on the lowest clinically effective dose. Topical or inhalational steroids are permitted."
NCT01355120:I.2003,"Use of any investigational or non-registered product (drug or vaccine) other than the study treatment."
NCT01355120:I.2004,"Active autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (eg, rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [eg, Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis)."
NCT01355120:I.2005,"Symptomatic CNS metastases (Remark: Asymptomatic stable, untreated or pretreated central nervous system (CNS) metastasis are allowed)"
NCT01355120:I.2006,"Family history of congenital or hereditary immunodeficiency."
NCT01355120:I.2007,"The patient is known to be positive for Human Immunodeficiency Virus (HIV) or other chronic infections (HBV, HCV) or has another confirmed or suspected immunosuppressive or immunodeficient condition."
NCT01355120:I.2008,"The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the trial procedures."
NCT01355120:I.2009,"Lack of availability for clinical follow-up assessments."
NCT01355120:I.2010,"The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk."
NCT01355120:I.2011,"Other serious illnesses, e.g., serious infections requiring antibiotics or bleeding disorders."
NCT01355120:I.2012,"Patients with serious intercurrent illness, requiring hospitalization."
NCT01355120:I.2013,"For female patients: the patient is pregnant or lactating. Women of childbearing potential: Refusal or inability to use effective means of contraception"
NCT01355120:I.2014,"Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of ipilimumab hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea."
NCT01355120:I.2015,"Subjects with melanoma who have another active, concurrent, malignant disease are not eligible for this trial, with the exception of adequately treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix."
NCT01355120:I.2016,"Previous treatment with ipilimumab"
NCT01357681:I.1001,"age at least 18 Years"
NCT01357681:I.1002,"Chorea Huntington (CAG repeats>39)"
NCT01357681:I.1003,"UHDRS TFC>5"
NCT01357681:I.1004,"Normal liver function laboratory test"
NCT01357681:I.1005,"Stable concomitant medication regimen>4 weeks prior to Baseline"
NCT01357681:I.1006,"Motivation for women with childbearing potential to use highly efficient contraception"
NCT01357681:I.2001,"Clinically relevant abnormal findings in the ECG, vital signs, physical examination or laboratory values at Screening,"
NCT01357681:I.2002,"Long-term treatment with potentially hepatoxic medication"
NCT01357681:I.2003,"Any unstable medical condition"
NCT01357681:I.2004,"Depression (BDI Depression score>9)"
NCT01357681:I.2005,"Cognitive dysfunction defined as a score<23 in the Mini-Mental State Examination (MMSE) at Screening"
NCT01357681:I.2006,"Liver or renal disease"
NCT01357681:I.2007,"Consumption of>two cups of black tea per day, consumption of green tea, consumption of>500 ml /day of grapefruit juice"
NCT01358877:I.1001,"age at least 18 Years"
NCT01358877:I.1002,"Adult (person)"
NCT01358877:I.1003,"Non-metastatic primary invasive HER2-positive carcinoma of the breast that is adequately excised, and that is either node-positive (except T0) or node-negative but with presence of at least one risk factor as defined by the protocol"
NCT01358877:I.1004,"ECOG performance status finding<= 1"
NCT01358877:I.1005,"The interval between definitive surgery for breast cancer and randomization must be at least 3 weeks but no more than 7 weeks and the patient must be willing and able to start treatment within 1 week of randomization"
NCT01358877:I.1006,"Known hormone receptor status (estrogen receptor and progesterone receptor)"
NCT01358877:I.1007,"Baseline LVEF>/= 55%"
NCT01358877:I.1008,"Women of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception (as defined by the protocol) by the patient and/or partner for the duration of the study treatment and for at least 6 months after the last dose of study drug"
NCT01358877:I.2001,"History of any prior (ipsi- and/or contralateral) invasive breast cancer"
NCT01358877:I.2002,"History of non-breast malignancies within the 5 years prior to study entry, except for carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin"
NCT01358877:I.2003,"Any clinical T4 tumor as defined by TNM, including inflammatory breast cancer"
NCT01358877:I.2004,"Any previous systemic chemotherapy for cancer or radiotherapy for cancer"
NCT01358877:I.2005,"Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for cancer"
NCT01358877:I.2006,"Concurrent anti-cancer treatment in another investigational trial"
NCT01358877:I.2007,"Serious cardiac or cardiovascular disease or condition"
NCT01358877:I.2008,"Pregnant or lactating women"
NCT01360008:I.1001,"age at least 18 Years"
NCT01360008:I.1002,"Documented paroxysmal AF (2 episodes of PAF within the last 3 months) or Persistent AF (lasting<1 year)"
NCT01360008:I.1003,"First ablation of AF"
NCT01360008:I.1004,"Documented inefficacy of at least 1 AAD not including beta-blockers"
NCT01360008:I.1005,"Written informed consent"
NCT01360008:I.2001,"Longstanding persistent AF lasting>1 year"
NCT01360008:I.2002,"ACS - Acute coronary syndrome"
NCT01360008:I.2003,"Heart failure NYHA IV"
NCT01360008:I.2004,"Thrombocytosis, thrombocytopenia"
NCT01360008:I.2005,"Any condition contraindicating chronic anticoagulation"
NCT01360008:I.2006,"Stroke or TIA within 6 months prior to ablation"
NCT01360008:I.2007,"Uncontrolled hyperthyroidism"
NCT01360008:I.2008,"Pregnancy, Gestation"
NCT01360008:I.2009,"Life expectancy<1 year"
NCT01361334:I.1001,"age at least 18 Years"
NCT01361334:I.1002,"Subjects must provide written informed consent prior to performance of study-specific procedures or assessments which are not routinely performed for diagnosis or monitoring of acute myeloid leukemia (AML), and the subjects must be willing to comply with treatment and to follow up assessments and procedures"
NCT01361334:I.1003,"Histologically or cytologically confirmed diagnosis of AML relapsed after or refractory to at least one induction regimen, or patients with AML at initial diagnosis who are not eligible for allogeneic transplant or intensive induction chemotherapy, except for AML M3 (acute promyelocytic leukemia)"
NCT01361334:I.1004,"ECOG performance status finding<= 3"
NCT01361334:I.1005,"Measurable disease burden (blasts in BM and/or PB, extramedullary blasts [chloroma])"
NCT01361334:I.1006,"Able to swallow and retain oral medication"
NCT01361334:I.1007,"A life expectancy of at least 4 weeks"
NCT01361334:I.1008,"Adequate contraception methods"
NCT01361334:I.1009,"Adequate organ function as defined in the study protocol"
NCT01361334:I.2001,"Patients with a valid option for intensive chemotherapy and/or stem cell transplantation (Patients after allogeneic stem cell transplant must be off immunosuppressive agents for at least 2 weeks prior to study entry and Graft-versus host disease must have resolved to Grade ?2)"
NCT01361334:I.2002,"History of cancer that according to the Investigator might confound the assessment of the endpoints of the study"
NCT01361334:I.2003,"Uncontrolled peptic ulcer disease or clinically significant gastrointestinal abnormalities which interfere with oral dosing or any unstable or serious concurrent condition (e.g., active uncontrolled infection)"
NCT01361334:I.2004,"Poorly controlled hypertension [defined as systolic blood pressure (SBP) of>=140 mmHg or diastolic blood pressure (DBP) of>90 mmHg]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour. on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be<140/90 mmHg in order for a subject to be eligible for the study"
NCT01361334:I.2005,"Prolonged QTc interval"
NCT01361334:I.2006,"History of any one of more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, symptomatic peripheral vascular disease, class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)"
NCT01361334:I.2007,"History of cerebrovascular infarction or bleeding, pulmonary embolism, or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulant agents for at least 6 weeks are eligible"
NCT01361334:I.2008,"Evidence of serious active bleeding or bleeding diathesis (except for bleeding or petechiae due to AML-related thrombocytopenia which will be treated using platelet transfusions). Also, patients with known endobronchial lesions and/or lesions infiltrating major pulmonary vessels will be excluded from the study due to excess risk of bleeding."
NCT01361334:I.2009,"Prior major surgery or trauma within 28 days prior to first dose of study drug"
NCT01361334:I.2010,"Treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer prior to the first dose of study drug (for bevacizumab 60 days)."
NCT01361334:I.2011,"Concurrent cytoreductive chemotherapy (hydroxyurea must be discontinued at least one day before start of study medication)"
NCT01361334:I.2012,"Known immediate or delayed hypersensitivity reaction or idiosyncrasy to pazopanib"
NCT01361334:I.2013,"Patients with psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol"
NCT01361334:I.2014,"Pregnant or lactating and actively breastfeeding patients"
NCT01361334:I.2015,"Patients taking any of the following prohibited medication:"
NCT01361334:I.2016,"clarithromycin, telithromycin, troleandomycin (antibiotics)"
NCT01361334:I.2017,"ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir (HIV  protease inhibitors)"
NCT01361334:I.2018,"itraconazole, ketoconazole, voriconazole, fluconazole (antifungals)"
NCT01361334:I.2019,"nefazodone (antidepressant)"
NCT01363427:I.1001,"age at least 18 Years"
NCT01363427:I.1002,"Crohn's Disease"
NCT01363427:I.1003,"therapeutic need according to SPC"
NCT01363427:I.1004,"written informed consent"
NCT01363453:I.1001,"age at least 18 Years"
NCT01363453:I.1002,"Ulcerative Colitis"
NCT01363453:I.1003,"therapeutic need according to SPC"
NCT01363453:I.1004,"written informed consent"
NCT01363453:I.2001,"contraindications according to SPC"
NCT01363752:I.1001,"age at least 18 Years"
NCT01363752:I.1002,"End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation (unless the graft was lost from rejection within 6 months)"
NCT01363752:I.1003,"Receiving a kidney transplant from a deceased or living (non Human Leukocyte Antigen [HLA] identical) donor with compatible ABO blood type"
NCT01363752:I.1004,"Female subject of childbearing potential has a negative serum or urine pregnancy test at enrollment"
NCT01363752:I.1005,"Female and male subjects agree to maintain highly effective birth control during the study and for 90 days after discontinuation of dosing with study drugs. A highly effective method of birth control is defined as those which result in a low failure rate (CPMP/ ICH/ 286/ 95 modified) of<1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some Intrauterine Devises (IUDs), sexual abstinence or vasectomized partner"
NCT01363752:I.2001,"Receiving or having previously received an organ transplant other than a kidney"
NCT01363752:I.2002,"Cold ischemia time of the donor kidney>30 hours"
NCT01363752:I.2003,"Panel-reactive antibody"
NCT01363752:I.2004,"Receiving a graft from a non-heart-beating donor other than of Maastricht category 3 (withdrawal of support awaiting cardiac arrest)"
NCT01363752:I.2005,"Significant liver disease, defined as having continuously elevated SGPT/ ALT and/ or SGOT/ AST and/ or total bilirubin levels>= 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor"
NCT01363752:I.2006,"Requiring initial sequential or parallel therapy with immunosuppressive antibody preparation(s)"
NCT01363752:I.2007,"Requiring ongoing dosing with a systemic immunosuppressive drug prior to transplantation (other than minimal levels of immunosuppression following failure of previous transplantation without nephrectomy)"
NCT01363752:I.2008,"Significant, uncontrolled concomitant infections and/ or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer"
NCT01363752:I.2009,"Pregnant woman or breast-feeding mother"
NCT01363752:I.2010,"Subject or donor known to be HIV positive"
NCT01363752:I.2011,"Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, sirolimus, MMF or any of the product excipients or iodine"
NCT01363752:I.2012,"Evidence of malignant disease within the last 5 years, not including non-malignant skin cancers"
NCT01363752:I.2013,"Currently participating in another clinical trial, and/ or has taken an investigational drug within 28 days prior to enrollment"
NCT01363752:I.2014,"Unlikely to comply with the visits scheduled in the protocol"
NCT01365351:I.1001,"Children With Growth Hormone Deficiency"
NCT01365351:I.1002,"therapeutic need according to SPC"
NCT01365351:I.1003,"written informed consent"
NCT01365351:I.2001,"contraindications according to SPC"
NCT01369342:I.1001,"age at least 18 Years"
NCT01369342:I.1002,"Have Crohn's disease of at least 3 months'duration with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, or endoscopy"
NCT01369342:I.1003,"Have active Crohn's disease, defined as a baseline Crohn Disease Activity Index (CDAI) score of>= 220 and<= 450, with confirmation of active inflammation"
NCT01369342:I.1004,"Has failed conventional therapy as demonstrated by having received corticosteroids and/or immunomodulators(ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Have a history of failure to respond to or tolerate an adequate course of corticosteroids and/or immunomodulators (ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Is corticosteroid dependent or has had a history of corticosteroid dependency AND Has not previously demonstrated failure of or intolerance to 1 or more TNF-antagonist therapies (ie, infliximab, adalimumab, or certolizumab pegol) per study criteria"
NCT01369342:I.1005,"Have screening laboratory test results within protocol-specified parameters"
NCT01369342:I.2001,"Patients who have had any kind of bowel resection within 6 months"
NCT01369342:I.2002,"Are pregnant or planning pregnancy (both men and women) while enrolled in the study or for 20 weeks after receiving study agent"
NCT01369342:I.2003,"Patients who have received infliximab, adalimumab or certolizumab pegol<= 8 weeks before the first administration of study drug"
NCT01369342:I.2004,"Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug"
NCT01369342:I.2005,"Patients with a history of or ongoing chronic or recurrent infectious disease"
NCT01369342:I.2006,"Patients who have previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)"
NCT01374789:I.1001,"age at least 18 Years"
NCT01374789:I.1002,"Histologically or cytologically confirmed, unresectable urothelial carcinoma of the bladder or the upper urinary tract"
NCT01374789:I.1003,"Wild-type HRAS"
NCT01374789:I.1005,"General condition ECOG 0-1"
NCT01374789:I.1006,"Life expectancy at least 12 weeks"
NCT01374789:I.1007,"Women of child-bearing potential: negative pregnancy test and use of effective contraception(oral contraceptive, coil). Men: use of adequate male contraception (condom) for up to 3 months after discontinuation of panitumumab therapy"
NCT01374789:I.1008,"Locally advanced or metastatic disease (T3b,T4 and/or N+ and/or M+)"
NCT01374789:I.1009,"At least one unidimensionally measurable lesion detectable in CT or MRI corresponding to the RECIST criteria"
NCT01374789:I.1010,"Adequate haematological, hepatic, renal and metabolic function parameters:"
NCT01374789:I.1011,"Leukocytes>3000/mm³, ANC>= 1500/mm³, platelets>= 100,000/mm³, hemoglobin>9 g/dl Creatinine clearance>= 50 ml/min and serum creatinine<= 1.5 x upper limit of normal Bilirubin<= 1.5 x upper limit of normal, GOT-GPT<= 2.5 x upper limit of normal in absence of liver metastases, or<= 5 x upper limit of normal in presence of liver metastases, AP<= 5 x upper limit of normal Magnesium>= lower limit of normal. Calcium>= lower limit of normal INR and PTT<1.5 x the upper limit of the normal reference range"
NCT01374789:I.2001,"HRAS mutation"
NCT01374789:I.2002,"Absence of any of the above-listed inclusion criteria"
NCT01374789:I.2003,"Dialysis-dependence following nephrectomy"
NCT01374789:I.2004,"Patients with cerebral tumours and/or cerebral metastases"
NCT01374789:I.2005,"Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia)<= 1 year before enrolment."
NCT01374789:I.2006,"Patients with uncontrolled hypertension. Systolic blood pressure>150 mmHg or diastolic blood pressure>90 mmHg despite optimal medical treatment"
NCT01374789:I.2007,"History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan."
NCT01374789:I.2008,"Patients with thrombotic or embolic events, such as stroke or pulmonary embolism"
NCT01374789:I.2009,"Patients with recent or known history of haemorrhagic diathesis"
NCT01374789:I.2010,"Known significant neurological or psychiatric disorders, including dementia and epileptic seizures"
NCT01374789:I.2011,"Serious inflammatory eye conditions, hearing impairment"
NCT01374789:I.2012,"Pulmonary (pO2<60 mmHg), haemopoietic (e.g. serious bone marrow aplasia), hepatic or renal disorders"
NCT01374789:I.2013,"Diabetes mellitus poor control"
NCT01374789:I.2014,"Serious bacterial or fungal infections (>grade 2 NCI CTC Version 3)"
NCT01374789:I.2015,"Chronic hepatitis B or C. HIV infection"
NCT01374789:I.2016,"Autoimmune Disease"
NCT01374789:I.2017,"Allergic reaction to one of the medications to be used"
NCT01374789:I.2018,"Status post organ transplantation"
NCT01374789:I.2019,"Status post autologous bone marrow transplantation or stem cell transplantation in the 4 months prior to study commencement"
NCT01374789:I.2020,"Manifest secondary malignancy or other form of cancer in the previous 5 years (excluding basalioma, in situ cervical cancer, incidental prostatic cancer)"
NCT01374789:I.2021,"Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment"
NCT01374789:I.2022,"Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 3 months (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidal jelly)."
NCT01374789:I.2023,"Active participation in other clinical studies in the previous 4 weeks"
NCT01374789:I.2024,"Prior systemic therapy with cytostatics or immunotherapeutic agents"
NCT01374789:I.2025,"Concurrent use of other anticancer treatments after study commencement"
NCT01374789:I.2026,"intravesical chemotherapy"
NCT01374789:I.2027,"radiation therapy, RT"
NCT01374789:I.2028,"Previous radiotherapy in which all lesions to be used for the evaluation of tumour response were irradiated"
NCT01374789:I.2029,"Patients in a closed institution according to an authority or court decision"
NCT01376700:I.1001,"age up to 1 Year"
NCT01376700:I.1002,"Subjects with severe and moderately severe hemophilia A (FVIII<= 2%). Certain FVIII mutation types (e.g., large multi-domain deletions, nonsense mutations, insertions/deletions/inversions that result in a premature stop codon, intron 22 inversions) can be used to corroborate a severe hemophilia A phenotype when laboratory assays show FVIII levels>= 1% because of rounding errors or carryover effect from a previous FVIII administration. A central laboratory FVIII assay is required to confirm subject eligibility."
NCT01376700:I.1003,"Subjects must have<= 3 exposure days (EDs) to any FVIII concentrate or FVIII-containing product used for treatment of minor bleeds (bleeds requiring no more than 2 infusions per event), or for preventative or precautionary infusions following possible injury"
NCT01376700:I.1004,"Subjects with prior circumcision are allowed to enroll only if bleeding issues related to circumcision were the cause for the original diagnosis of hemophilia A and no more than 2 EDs of FVIII treatment were required"
NCT01376700:I.1005,"Adequate venous access (without need for CVAD-placement) as determined by the physician"
NCT01376700:I.1006,"Written informed consent from legally authorized representative(s)"
NCT01376700:I.2001,"Life-threatening conditions (intracranial hemorrhage, severe trauma) or requirement for surgery at the time of enrollment"
NCT01376700:I.2002,"Evidence of inhibitor>= 0.6 BU in Nijmegen-modified Bethesda Assay at study start (samples may be retested using lupus-insensitive inhibitor tests to reduce the number of false positive inhibitor test results)"
NCT01376700:I.2003,"Inherited or acquired hemostatic defect other than hemophilia A"
NCT01376700:I.2004,"Any clinically significant, chronic disease other than hemophilia A"
NCT01376700:I.2005,"Known hypersensitivity to ADVATE or any of its constituents"
NCT01376700:I.2006,"Any planned elective surgery that cannot be postponed until after the first 20 EDs"
NCT01376908:I.1001,"age up to 4 Years"
NCT01376908:I.1002,"Male or female PKU infants and young children<4 years of age at the scheduled Day 1 visit of the 26-week Study Period (taking into consideration the maximum of 21 days in the Screening Period)."
NCT01376908:I.1003,"Confirmed clinical and biochemical PKU, including at least two previous blood Phe levels ? 400 micromol/L obtained on 2 separate occasions."
NCT01376908:I.1004,"Previously responded, as assessed by the Investigator, to a BH4 test, if all 3 of the following criteria are satisfied:"
NCT01376908:I.1005,"The BH4 dose was 20 mg/kg/day."
NCT01376908:I.1006,"The duration of the test was at least for 24 hours."
NCT01376908:I.1007,"A 30% decrease in blood Phe levels."
NCT01376908:I.1008,"Defined level of dietary Phe tolerance consistent with the diagnosis of PKU;"
NCT01376908:I.1009,"Good adherence to dietary treatment, including prescribed dietary Phe restriction and prescribed amounts of Phe-free protein supplements and low-Phe foods."
NCT01376908:I.1010,"Maintenance of blood Phe levels within the therapeutic target range of 120-360 micromol/L (defined as ?120 to<360 micromol/L) over a 1-month period prior to Screening, as assessed by the Investigator."
NCT01376908:I.1011,"Parent(s) and/or guardian(s) willing to comply with all study procedures, maintain strict adherence to the diet, and willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to any study procedures."
NCT01376908:I.2001,"Use of Kuvan, Biopten, or any unregistered preparation of tetrahydrobiopterin within the previous 30 days, unless for the purposes of a BH4 responsiveness test."
NCT01376908:I.2002,"Previous exposure to Kuvan, Biopten, or any unregistered preparation of tetrahydrobiopterin for>30 days."
NCT01376908:I.2003,"Known hypersensitivity to Kuvan or its excipients."
NCT01376908:I.2004,"Known hypersensitivity to other approved or non-approved formulations of tetrahydrobiopterin."
NCT01376908:I.2005,"Previous diagnosis of BH4 deficiency."
NCT01376908:I.2006,"Current use of methotrexate, trimethoprim, or other dihydrofolate reductase inhibitors."
NCT01376908:I.2007,"Current use of medications that are known to affect nitric oxide synthesis, metabolism or action."
NCT01376908:I.2008,"Current use of levodopa."
NCT01376908:I.2009,"Current use of experimental/other investigational or unregistered drugs that may affect the study outcomes."
NCT01376908:I.2010,"Inability to comply with study procedures."
NCT01376908:I.2011,"Inability to tolerate oral intake."
NCT01376908:I.2012,"History of organ transplantation."
NCT01376908:I.2013,"Concurrent disease or condition that would interfere with study participation or increase the risk for adverse events, including seizure disorders, corticosteroid administration, active malignancy, diabetes mellitus, severe congenital heart disease, renal or hepatic failure."
NCT01376908:I.2014,"Other significant disease that in the Investigator's opinion would exclude the subject from the trial."
NCT01376908:I.2015,"Any condition that, in the view of the Principal Investigator renders the subject at high risk for failure to comply with treatment or to complete the study."
NCT01377090:I.1001,"age at least 18 Years"
NCT01377090:I.1003,"Signed informed consent prior to enrollment"
NCT01377090:I.1005,"Diagnosis of systemic sclerosis (SSc) according to the American College of Rheumatology and/or limited cutaneous SSc or diffuse cutaneous SSc according to LeRoy criteria"
NCT01377090:I.1006,"For patients with no history of digital ulcers (DU) and no DU at enrollment only:"
NCT01377090:I.1007,"Enrollment must be within 2 years of the first physician-documented non-Raynaud clinical feature"
NCT01377090:I.2001,"Systemic sclerosis without skin thickening"
NCT01377090:I.2002,"Patients who underwent stem cell transplantation"
NCT01377090:I.2003,"Participation in interventional clinical trials within 3 months prior to enrollment and/or during the study"
NCT01377090:I.2004,"Inability to undergo Nailfold Videocapillaroscopy (NVC) assessment (e.g., inability to extend fingers sufficiently)"
NCT01385657:I.1001,"age at least 18 Years"
NCT01385657:I.1003,"Chronic AD diagnosed by the Eichenfield revised criteria of Hannifin and Rajka that has been present for at least 3 years before the screening visit"
NCT01385657:I.1004,"Eczema Area and Severity Index (EASI) score>/= 12 at the screening and baseline visits"
NCT01385657:I.1005,"Investigator's Global Assessment (IGA) score>/= 3 at the screening and baseline visits"
NCT01385657:I.1006,">/= 10% body surface area (BSA) of AD involvement at the screening and baseline visits"
NCT01385657:I.1007,"History of inadequate response to a stable (>/= 1 month) regimen of topical corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before the screening visit"
NCT01385657:I.2001,"Positive Hepatitis B surface antigen, and/or positive Hepatitis C antibody at the screening visit"
NCT01385657:I.2002,"Treatment with an investigational drug within 8 weeks or within 5 half-lives, if known, whichever is longer, before the baseline visit"
NCT01385657:I.2003,"Treatment with leukotriene inhibitors within 4 weeks before the baseline visit"
NCT01385657:I.2004,"Treatment with systemic corticosteroids within 4 weeks before the baseline visit"
NCT01385657:I.2005,"Treatment with topical corticosteroids, tacrolimus, and/or pimecrolimus within 1 week before the baseline visit"
NCT01385657:I.2006,"Systemic treatment for AD with an immunosuppressive/immunomodulating substance within 4 weeks before the baseline visit"
NCT01385657:I.2007,"Chronic or acute infection requiring treatment with oral or IV antibiotics, antivirals, or antifungals within 4 weeks before the screening visit or superficial skin infections within 1 week before the screening visit"
NCT01385657:I.2008,"Known history of human immunodeficiency virus (HIV) infection"
NCT01385657:I.2009,"History of clinical parasite infection, other than treated trichomoniasis"
NCT01385657:I.2010,"History of malignancy within 5 years before the baseline visit, with the following exceptions: patients with a history of completely treated carcinoma in situ of cervix, and non-metastatic squamous or basal cell carcinoma of the skin are allowed"
NCT01385657:I.2011,"Any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results"
NCT01385657:I.2012,"Pregnant or breast-feeding women"
NCT01385657:I.2013,"Unwilling to use adequate birth control, if of reproductive potential and sexually active"
NCT01386944:I.1001,"age at least 18 Years"
NCT01386944:I.1002,"The adult patient has a diagnosis of moderate to severe idiopathic Restless Leg Syndrome (RLS)"
NCT01386944:I.1003,"The patient must be experiencing augmentation due to a prior dopaminergic treatment"
NCT01386944:I.1004,"The decision to prescribe Neupro has been made by the physician independently of his/her decision to enroll the patient in the study"
NCT01386944:I.1005,"Patient is informed and given ample time and opportunity to think about his/her participation in the study and has given written informed data consent"
NCT01386944:I.2001,"Patients diagnosed with secondary Restless Leg Syndrome (RLS) should not be enrolled in this observational study"
NCT01396057:I.1001,"age at least 18 Years"
NCT01396057:I.1002,"Patients diagnosed with visual impairment due to macular edema following BRVO"
NCT01396057:I.1003,"Diagnosis of BRVO at maximum 6 months prior to Screening"
NCT01396057:I.1004,"BCVA using ETDRS charts of 20/40 to 20/400 in the study eye"
NCT01396057:I.2001,"Media clarity, pupillary dilation and patient cooperation not sufficient for adequate fundus photographs"
NCT01396057:I.2002,"Central retinal thickness (CRT)<250 microm in the study eye"
NCT01396057:I.2003,"Prior episode of RVO in the study eye"
NCT01396057:I.2004,"Active formation of new vessels in the study eye"
NCT01396057:I.2005,"Anti-VEGF-treatment in the study or the fellow eye 3 months prior to Baseline"
NCT01396057:I.2006,"IOP>= 30mmHg or uncontrolled glaucoma. Patients may be re-screened after 1 month if they have undergone glaucoma treatment"
NCT01396057:I.2007,"Improvement of>10 letters on BCVA between Screening and Baseline"
NCT01396083:I.1001,"age at least 18 Years"
NCT01396083:I.1002,"Patients diagnosed with visual impairment due to macular edema following CRVO"
NCT01396083:I.1003,"Diagnosis of CRVO at maximum 6 months prior to Screening"
NCT01396083:I.1004,"BCVA using ETDRS charts of 20/40 to 20/400 in the study eye"
NCT01396083:I.2001,"Media clarity, pupillary dilation and patient cooperation not sufficient for adequate fundus photographs"
NCT01396083:I.2002,"Central retinal thickness (CRT)<250 microm in the study eye"
NCT01396083:I.2003,"Prior episode of RVO in the study eye"
NCT01396083:I.2004,"Active formation of new vessels in the study eye"
NCT01396083:I.2005,"Anti-VEGF-treatment in the study or the fellow eye 3 months prior to Baseline"
NCT01396083:I.2006,"IOP>= 30mmHg or uncontrolled glaucoma. Patients may be re-screened after 1 month if they have undergone glaucoma treatment"
NCT01396083:I.2007,"Improvement of>10 letters on BCVA between Screening and Baseline"
NCT01403376:I.1001,"age 18 Years to 59 Years"
NCT01403376:I.1002,"Male or female patients<60 years old with relapsing multiple sclerosis"
NCT01403376:I.1003,"treated for at least 6 months with 7 or 14 mg teriflunomide in one of the  studies LTS6048 or LTS6050 or"
NCT01403376:I.1004,"treated with a stable dose of IFN-beta-1 for at least 6 months"
NCT01403376:I.1005,"Patient's Signature on Informed Consent Form"
NCT01403376:I.2001,"Having concomitant infectious pathology at the time of vaccination"
NCT01403376:I.2002,"MS relapse within 1 month before vaccination"
NCT01403376:I.2003,"Systemic corticosteroids within 1 month before the vaccination"
NCT01403376:I.2004,"Any contraindication to influenza vaccine"
NCT01403376:I.2005,"Any vaccination within the last 6 months."
NCT01403376:I.2006,"Prior use of any investigational drug or participation to a clinical trial within 1 year (only for patients under interferon Beta-1)"
NCT01403376:I.2007,"Prior or concomitant use (for a minimum of 1 year before study entry) of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate, mycophenolate, natalizumab (Tysabri), leflunomide or fingolimod or other immunomodulator/immunosuppressant in development"
NCT01403376:I.2008,"Prior or concomitant use of Glatiramer acetate within 1 year before study entry"
NCT01403376:I.2009,"Prior or concomitant use of intravenous immunoglobulins within 3 months before study entry"
NCT01403376:I.2010,"Pregnant or breast feeding women"
NCT01403376:I.2011,"Women of childbearing potential without adequate contraception."
NCT01404741:I.1001,"age 55 Years to 70 Years"
NCT01404741:I.1002,"Patients with proven de novo or therapy-related MDS / CMML (WBC<13 GPT/l)according to FAB and risk profile according to IPSS: intermediate II- risk or high-risk or intermediate I with high-risk cytogenetic (according to IPSS, taking into account that IPSS, however, was not validated for t- MDS), patients with secondary AML (according to WHO) and blasts<= 30 % (= RAEB-t according to FAB)"
NCT01404741:I.1003,"Previously untreated or maximal 1 cycle of 5-azacytidine (Vidaza)"
NCT01404741:I.1005,"Understand and voluntarily sign an informed consent form"
NCT01404741:I.1006,"ECOG performance status finding<= 2"
NCT01404741:I.1007,"Adequate renal and liver function: creatinine and bilirubin<3 x the upper limit of normal"
NCT01404741:I.1008,"Sufficient cardiac function (ejection fraction>30 %)"
NCT01404741:I.2001,"Blasts>30 % in bone marrow at time of diagnosis"
NCT01404741:I.2002,"Central nervous system (CNS) involvement status"
NCT01404741:I.2003,"Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as"
NCT01404741:I.2004,"Total bilirubin, SGPT or SGOT>= 3 times upper the normal level"
NCT01404741:I.2005,"LVEF - Left ventricular ejection fraction"
NCT01404741:I.2006,"Creatinine clearance (CrCl)  measurement"
NCT01404741:I.2007,"DLCO<35 % and/or receiving supplementary continuous oxygen"
NCT01404741:I.2008,"Pregnant or breastfeeding female subject"
NCT01404741:I.2009,"Patients with a life-expectancy of<six months because of another debilitating disease"
NCT01404741:I.2010,"Serious psychiatric or psychological disorders"
NCT01404741:I.2011,"Uncontrolled invasive fungal infection at time of registration"
NCT01404741:I.2012,"Known positive for HIV or acute infectious hepatitis, type A, B or C"
NCT01404741:I.2013,"Participation in another study with ongoing use of unlicensed investigational product from 28 days before study enrollment until the end of the study"
NCT01408095:I.1001,"age 18 Years to 70 Years"
NCT01408095:I.1002,"Clinical diagnosis of type 2 diabetes mellitus prior to entering the trial"
NCT01408095:I.1003,"May be treated with:"
NCT01408095:I.1004,"1. Diet and exercise alone or"
NCT01408095:I.1005,"2. Diet and exercise in combination with a stable dose of metformin for at least 3  months before Screening or"
NCT01408095:I.1006,"3. Diet and exercise in combination with a stable dose of sulfonylurea or  meglitinide (repaglinide, nateglinide) for at least 3 months before Screening or"
NCT01408095:I.1007,"4. Diet and exercise in combination with stable doses of metformin and sulfonylurea  or metformin and meglitinides for at least 3 months before Screening and have  had diabetes for at least 6 years"
NCT01408095:I.1008,"Must have an Hemoglobin A1c value between 7% and 10%"
NCT01408095:I.1009,"Body mass index"
NCT01408095:I.1010,"Must have stable weight during the 3 months prior to Screening (weight change not to exceed 5 kg (11 lb))"
NCT01408095:I.1011,"If female, you must not be able to get pregnant"
NCT01408095:I.1012,"Must be well motivated, capable, and willing to complete study required glucose monitoring and instruction"
NCT01408095:I.2001,"Use of insulin or any antidiabetic agent other than metformin or sulfonylurea or meglitinide during the 3 months prior to Screening"
NCT01408095:I.2002,"Have a gastrointestinal disease that significantly impacts gastric emptying or motility or have undergone gastric bypass or gastric banding surgery"
NCT01408095:I.2003,"Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study, or are currently diagnosed as having hypoglycemia unawareness or have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months"
NCT01408095:I.2004,"Are currently taking or have taken within the last 2 months, prescription or over-the counter medications which affect body weight"
NCT01408095:I.2005,"Have cardiac disease with functional status that is New York Heart Association [NYHA] Class II, III, or IV or a history of myocardial infarction, unstable angina, or decompensated congestive heart failure in the past 6 months."
NCT01408095:I.2006,"Have poorly controlled hypertension, history of malignant hypertension, evidence of renal artery stenosis and/or evidence of labile blood pressure including symptomatic postural hypotension. Doses of antihypertensive medications must be stable for 30 days before randomization"
NCT01408095:I.2007,"Have a QTcB (Bazett's-corrected QT interval) interval>450 msec for men or>470 for women at Screening or any personal history of ventricular tachycardia or unexplained syncope"
NCT01408095:I.2008,"Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or significantly elevated liver blood tests"
NCT01408095:I.2009,"Are currently receiving renal dialysis, have a serum creatinine>2.0 mg/dL (177 micromol/L) or a calculated creatinine clearance of<60 ml/min or in patients being treated with metformin, have other known contradictions to metformin use including, but not limited to, a serum creatinine above (or creatinine clearance below) what is approved in the metformin product label"
NCT01408095:I.2010,"Have fasting state hypertriglyceridemia (defined as>5.65 mmol/L, 500 mg/dl) at Screening. If taking lipid-lowering agents, doses of these medications must be stable for 30 days prior to randomization."
NCT01408095:I.2011,"Are receiving chronic (for>2 weeks) systemic glucocorticoid therapy (excluding topical or inhaled preparations) or have received such therapy within 4 weeks immediately prior to Randomization"
NCT01408095:I.2012,"Have an active or untreated malignancy or have been in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for<5 years"
NCT01408095:I.2013,"Have a history of seizure disorder"
NCT01408095:I.2014,"Are currently using or intend to use inhibitors of Cytochrome P450 family 3A (CYP3A4)"
NCT01408095:I.2015,"Currently taking a medication that is a sensitive substrate of the CYP3A4 pathway with a narrow therapeutic index"
NCT01410916:I.1001,"age at least 2 Months"
NCT01410916:I.1002,"Patient must be willing and able to give written informed consent/Assent."
NCT01410916:I.1003,"Adults, adolescents, or pediatric (>=2 months and>=5kg) patients"
NCT01410916:I.1004,"Patient has been diagnosed with Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)"
NCT01410916:I.2001,"Known complement regulatory mutation or family history of complement regulatory mutation"
NCT01410916:I.2002,"Unresolved systemic meningococcal disease"
NCT01410916:I.2003,"Hypersensitivity to eculizumab, to murine proteins or to one of the excipients"
NCT01413139:I.1001,"age at least 18 Years"
NCT01413139:I.1002,"De novo, restenotic or reoccluded lesion located in the femoropopliteal arteries suitable for endovascular treatment"
NCT01413139:I.1003,"Patient presenting with a score from 2 to 4 according to the Rutherford classification"
NCT01413139:I.1004,"Patient is willing to comply with specified follow-up evaluations at the predefined time intervals times"
NCT01413139:I.1005,"Patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study"
NCT01413139:I.1006,"Prior to enrollment, the target lesion was crossed with standard guidewire manipulation"
NCT01413139:I.1007,"Patient is eligible for treatment with 4F compatible devices"
NCT01413139:I.1008,"The target lesions are located within the native superficial femoral artery: Distal point 3 cm above knee joint and 1 cm below the origin of the profunda femoralis."
NCT01413139:I.1009,"The target lesion has angiographic evidence of stenosis or restenosis>50% or occlusion"
NCT01413139:I.1010,"Length of the target lesion is =20 cm by visual estimation and can be covered with one stent"
NCT01413139:I.1011,"Target vessel diameter visually estimated is =4 mm and =6.5 mm"
NCT01413139:I.1012,"There is angiographic evidence of at least one-vessel-runoff to the foot"
NCT01413139:I.2001,"Presence of another stent in the target vessel that was placed during a previous procedure"
NCT01413139:I.2002,"Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis"
NCT01413139:I.2003,"Previous bypass surgery in the same limb"
NCT01413139:I.2004,"Patients contraindicated for antiplatelet therapy, anticoagulants or thrombolytics"
NCT01413139:I.2005,"Patients who exhibit persistent acute intraluminal thrombus at the target lesion site"
NCT01413139:I.2006,"Perforation at the angioplasty site evidenced by extravasation of contrast medium"
NCT01413139:I.2007,"Patients with known hypersensitivity to nickel-titanium"
NCT01413139:I.2008,"Patients with uncorrected bleeding disorders"
NCT01413139:I.2009,"Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding"
NCT01413139:I.2010,"Life expectancy of<12 months"
NCT01413139:I.2011,"Ipsilateral iliac artery treatment before target lesion treatment with a residual stenosis>30%"
NCT01413139:I.2012,"Use of thrombectomy, atherectomy or laser devices during procedure"
NCT01413139:I.2013,"Any planned surgical intervention/procedure 30 days after the study procedure"
NCT01413139:I.2014,"Any patient considered to be hemodynamically unstable at onset of procedure"
NCT01413139:I.2015,"Patient is currently participating in another investigational drug or device study that has not reached the primary endpoint"
NCT01423747:I.1001,"age 3 Months to 18 Years"
NCT01423747:I.1002,"Lymphoblastic Leukemia, Acute, Childhood"
NCT01423747:I.1003,"age at time of initial diagnosis or relapse diagnosis, respectively under or equal 18 years"
NCT01423747:I.1004,"indication for allogeneic HSCT"
NCT01423747:I.1005,"complete remission before HSCT"
NCT01423747:I.1006,"written consent of the parents (legal guardian) and, if necessary, the minor patient via Informed Consent Form"
NCT01423747:I.1007,"Not Pregnant, Non-pregnant state"
NCT01423747:I.1008,"no secondary malignancy"
NCT01423747:I.1009,"no previous HSCT"
NCT01423747:I.1010,"HSCT is performed in a study participating centre."
NCT01423747:I.2001,"age at time of initial diagnosis or relapse diagnosis, respectively above 18 years"
NCT01423747:I.2002,"no indication for allogeneic HSCT"
NCT01423747:I.2003,"no complete remission before SCT"
NCT01423747:I.2004,"no written consent of the parents (legal guardian) and, if necessary, the minor patient via Informed Consent Form"
NCT01423747:I.2005,"Pregnancy, Gestation"
NCT01423747:I.2006,"Secondary malignant neoplastic disease"
NCT01423747:I.2007,"previous HSCT"
NCT01423747:I.2008,"HSCT is not performed in a study participating centre."
NCT01428297:I.1001,"Healthy male and female subjects of non childbearing potential, 18 to 65 years of age inclusive and in good health"
NCT01428297:I.2001,"Male and female subjects, 18 to 65 years of age inclusive and having passed screening examinations"
NCT01428297:I.2002,"Presence of atopic dermatitis confirmed by Itchy skin condition in the past 12 months (must have) Plus three or more of the following:
1. History of involvement of the skin creases2. Personal history of asthma or hay fever
3. History of generally dry skin in the past year4. Onset before age of 2 years
5. Visible flexural dermatitis"
NCT01428297:I.2003,"Diagnosis of at least moderate atopic dermatitis by the IGA and a minimum target area (right or left) situated on the forearm including the antecubital fossa with a corresponding baseline total lesional sign score (TLSS)"
NCT01428297:I.3001,"Patients with Netherton syndrome, male and female subjects, 18 to 65 years of age inclusive and having passed screening examinations"
NCT01428297:I.3002,"Confirmed diagnosis of Netherton syndrome (SPINK5 mutation or LEKTI deficiency in the skin)"
NCT01428297:I.3003,"Minimum total lesional sign score NS (TLSS-NS) of 5-9 for two selected target areas at baseline. The TLSS-NS values need to be similar between the two areas at baseline"
NCT01428297:I.4001,"History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction."
NCT01428297:I.4002,"Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing"
NCT01428297:I.5001,"History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction."
NCT01428297:I.5002,"History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (screening), including tanning and sun beds"
NCT01428297:I.5003,"Pregnant or nursing (lactating) women"
NCT01428297:I.5004,"Women of child-bearing potential must use highly effective contraception (as further defined in study protocol)"
NCT01428297:I.5005,"Use of topical prescription treatment for eczema within 1 week prior to initial dosing of topical corticosteroids (TCS)."
NCT01428297:I.5006,"Recent previous treatment with systemic treatment including phototherapy. A washout period will be required for such patients to be eligible to participate in the trial."
NCT01428297:I.6001,"History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction"
NCT01428297:I.6002,"History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (screening), including tanning and sun beds"
NCT01428297:I.6003,"Pregnant or nursing (lactating) women"
NCT01428297:I.6004,"Women of child-bearing potential must use highly effective contraception (as further defined in study protocol)"
NCT01428297:I.6005,"Use of topical prescription treatment within 2 week prior to initial dosing of study drug"
NCT01428297:I.6006,"Recent previous treatment with systemic treatment. A washout period will be required for such patients to be eligible to participate in the trial."
NCT01428297:I.7001,Age
NCT01428297:I.7002,"Healthy Subject"
NCT01428297:I.7003,Diagnosis
NCT01428297:I.7004,"Dermatitis, Atopic"
NCT01428297:I.7005,Pruritus
NCT01428297:I.7006,"Skin crease"
NCT01428297:I.7007,Asthma
NCT01428297:I.7008,"Hay fever (Seasonal Allergy)"
NCT01428297:I.7009,"Dry skin"
NCT01428297:I.7010,Onset
NCT01428297:I.7011,"Flexural eczema"
NCT01428297:I.7012,"Allergic reaction, due to correct medicinal substance properly administered"
NCT01428297:I.7013,Medication
NCT01428297:I.7014,"Dietary Supplements"
NCT01428297:I.7015,"Ultraviolet Rays"
NCT01428297:I.7016,pregnant
NCT01428297:I.7017,"Breast feeding, Nursing"
NCT01428297:I.7018,Contraception
NCT01428297:I.7019,"Topical Corticosteroid"
NCT01428297:I.7020,Phototherapy
NCT01428726:I.1001,"Age 18 Years to 55 Years"
NCT01428726:I.1002,"Patients who meet the diagnosis criteria for RRMS"
NCT01428726:I.1003,"clinical disability measured by EDSS score between 0 and 5.0"
NCT01428726:I.2001,"Patients with medical conditions such as diabetes, hypotension, insulinoma, hyperuricemia, or other conditions (drug abuse, inability to consent or to perform all the procedures of the clinical trial)"
NCT01428726:I.2002,"Patients who had received or are candidates for liver transplantation"
NCT01428726:I.2003,"Relapse in the 30 days period before baseline visit"
NCT01428726:I.2004,"Patients with corticosteroid therapy in the last month, interferon-beta or glatiramer acetate in the last 3 months, or natalizumab in the last 6 months"
NCT01428726:I.2005,"Patients treated with chemotherapy"
NCT01428726:I.2006,"Positive pregnancy test, breast feeding women or childbearing potential"
NCT01428726:I.3001,Age
NCT01428726:I.3002,Diagnosis
NCT01428726:I.3003,"Multiple Sclerosis, Relapsing-Remitting"
NCT01428726:I.3004,"Kurtzke multiple sclerosis rating scale, Expanded Disability Status Scale"
NCT01428726:I.3005,"Diabetes mellitus"
NCT01428726:I.3006,Hypotension
NCT01428726:I.3007,insulinoma
NCT01428726:I.3008,Hyperuricemia
NCT01428726:I.3009,"Drug abuse"
NCT01428726:I.3010,Compliance
NCT01428726:I.3011,"Transplantation of liver"
NCT01428726:I.3012,"Recurrent Disease"
NCT01428726:I.3013,"Corticosteroid therapy"
NCT01428726:I.3014,Chemotherapy
NCT01428726:I.3015,"Pregnancy Tests"
NCT01428726:I.3016,"Breast feeding, Nursing"
NCT01435616:I.1001,"Age 18 Years and older"
NCT01435616:I.1002,"Have type 2 diabetes mellitus, not treated with insulin, for at least one year prior to the study"
NCT01435616:I.1003,"Have been receiving at least 2 oral antihyperglycemic medication for at least 3 months before entering the study"
NCT01435616:I.1004,"Have hemoglobin A1c value between 7.0% and 11.0%, inclusive, at screening"
NCT01435616:I.1005,"Are capable of, and willing to inject insulin with a vial and syringe and perform self blood glucose monitoring"
NCT01435616:I.1006,"Woman of Childbearing potential only: are not breastfeeding, have a negative pregnancy test at the time of screening and randomization and intend to not become pregnant during the trial. Have practiced a reliable method of birth control for at least 6 weeks prior to screening and agree to use a reliable method of birth control during the study and until 2 weeks following the last dose of study drug"
NCT01435616:I.2001,"Have used insulin therapy (outside of pregnancy) anytime in the past 2 years, except for short-term treatment of acute conditions, and up to a maximum of 4 continuous weeks"
NCT01435616:I.2002,"Use of rosiglitazone, pramlintide, glucagon-like peptide 1 (GLP-1) receptor agonist (for example, exenatide, exenatide once weekly, or liraglutide) concurrently or within 3 months prior to screening"
NCT01435616:I.2003,"Are currently taking, or have taken within the 3 months preceding screening, medications to promote weight loss"
NCT01435616:I.2004,"Have had any episodes of severe hypoglycemia within 6 months prior to screening"
NCT01435616:I.2005,"Have had 1 or more episodes of ketoacidosis or hyperosmolar state/coma in the 6 months prior to the study"
NCT01435616:I.2006,"Have cardiac disease with functional status that is New York Heart Association Class III or IV (per New York Heart Association [NYHA] Cardiac Disease Classification)"
NCT01435616:I.2007,"Have a history of renal transplantation, or are currently receiving renal dialysis or have serum creatinine greater or equal than 2 mg/dL"
NCT01435616:I.2008,"Have obvious clinical signs or symptoms of liver disease (excluding non- alcoholic fatty liver disease [NAFLD]), acute or chronic hepatitis, non-alcoholic steatohepatitis (NASH), or elevated liver enzyme measurements at screening"
NCT01435616:I.2009,"Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of hemoglobin A1c"
NCT01435616:I.2010,"Have active or untreated malignancy, have been in remission from clinically significant malignancy for less than 5 years"
NCT01435616:I.2011,"Have fasting or nonfasting triglycerides greater than 400 mg/dL (greater than 4.5 mmol/L) at screening"
NCT01435616:I.2012,"Are using lipid lowering medication at a dose that has not been stable for 90 days prior to screening"
NCT01435616:I.2013,"Are using niacin preparations as a lipid lowering medication and bile acid sequestrants within 90 days prior to screening"
NCT01435616:I.3001,Age
NCT01435616:I.3002,Diagnosis
NCT01435616:I.3003,"Diabetes Mellitus, Non-Insulin-Dependent"
NCT01435616:I.3004,Anti-hyperglycemics
NCT01435616:I.3005,"Hemoglobin A1c (HbA1c)"
NCT01435616:I.3006,"Self-monitoring of blood glucose"
NCT01435616:I.3007,"Serum pregnancy test (B-HCG)"
NCT01435616:I.3008,Contraception
NCT01435616:I.3009,"Breast feeding, Nursing"
NCT01435616:I.3010,"Therapeutic insulin"
NCT01435616:I.3011,Medication
NCT01435616:I.3012,rosiglitazone
NCT01435616:I.3013,Pramlintide
NCT01435616:I.3014,"GLP-1 Receptor Agonist"
NCT01435616:I.3015,"Weight-Loss Drugs"
NCT01435616:I.3016,Hypoglycemia
NCT01435616:I.3017,Ketoacidosis
NCT01435616:I.3018,"Hyperosmolar coma associated with diabetes mellitus"
NCT01435616:I.3019,"Cardiac disease"
NCT01435616:I.3020,"New York Heart Association Classification"
NCT01435616:I.3021,"Renal transplant"
NCT01435616:I.3022,"Renal dialysis"
NCT01435616:I.3023,"Liver diseases"
NCT01435616:I.3024,"Blood transfusion"
NCT01435616:I.3025,"Malignant Neoplasms"
NCT01435616:I.3026,Triglycerides
NCT01435616:I.3027,"Lipid lowering drug"
NCT01440426:I.1001,"Age 18 Years to 70 Years"
NCT01440426:I.1002,"2-4 adjacent gingival recession (one at least 3 mm deep)"
NCT01440426:I.2001,"Interdental attachment loss greater than 1 mm at recession sites"
NCT01440426:I.3001,Age
NCT01440426:I.3002,Diagnosis
NCT01440426:I.3003,"Gingival Recession"
NCT01440426:I.3004,Interdental
NCT01440426:I.3005,"Periodontal operation"
NCT01440426:I.3006,"Mucogingival graft"
NCT01442636:I.1001,"Age>18 Years"
NCT01442636:I.1002,"Patient presenting with rest pain or minor tissue loss (Rutherford class 4 or 5)"
NCT01442636:I.1003,"Patient is willing to comply with specified follow-up evaluations at the specified times"
NCT01442636:I.1004,"Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study"
NCT01442636:I.1005,"Life-expectancy of at least 12 months"
NCT01442636:I.1006,"Eligibility for treatment with XIENCE PRIME stent (Abbott Vascular)"
NCT01442636:I.1007,"Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure"
NCT01442636:I.2001,"De novo lesion or restenotic lesion after PTA in the infrapopliteal arteries, suitable for endovascular therapy"
NCT01442636:I.2002,"Target lesion length minimally 30mm and maximally 100mm"
NCT01442636:I.2003,"Target vessel diameter>2.0mm and<3.5mm"
NCT01442636:I.2004,"Guidewire and delivery system successfully traversed lesion"
NCT01442636:I.3001,"Patient refusing treatment"
NCT01442636:I.3002,"Reference segment diameter not suitable for stent design"
NCT01442636:I.3003,"Untreated flow-limiting inflow lesions"
NCT01442636:I.3004,"Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment"
NCT01442636:I.3005,"Any previous surgery in the target vessel (including prior ipsilateral crural bypass)"
NCT01442636:I.3006,"Aneurysm in the target vessel"
NCT01442636:I.3007,"Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)"
NCT01442636:I.3008,"Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 1-year life expectancy"
NCT01442636:I.3009,"Major distal amputation (above the transmetatarsal) in the study limb or non-study limb"
NCT01442636:I.3010,"Septicemia or bacteremia"
NCT01442636:I.3011,"Any previously known coagulation disorder, including hypercoagulability"
NCT01442636:I.3012,"Contraindication to anticoagulation or antiplatelet therapy"
NCT01442636:I.3013,"Known allergies to stent or stent components; Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure"
NCT01442636:I.3014,"Hypersensitivity to heparin, including patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II"
NCT01442636:I.3015,"Currently participating in another clinical research trial"
NCT01442636:I.3016,"Angiographic evidence of intra-arterial thrombus or atheroembolism from inflow treatment"
NCT01442636:I.3017,"Target lesion access not performed by transfemoral approach"
NCT01442636:I.4001,Age
NCT01442636:I.4002,Diagnosis
NCT01442636:I.4003,"Pain at rest"
NCT01442636:I.4004,Compliance
NCT01442636:I.4005,"Informed Consent"
NCT01442636:I.4006,"Life expectancy"
NCT01442636:I.4007,"Eligibility Determination"
NCT01442636:I.4009,Contraception
NCT01442636:I.4010,"Serum pregnancy test (B-HCG)"
NCT01442636:I.4011,"Percutaneous transluminal angioplasty of vessel"
NCT01442636:I.4012,"Vessel lumen diameter"
NCT01442636:I.4013,"Stent, device"
NCT01442636:I.4014,"Therapeutic procedure"
NCT01442636:I.4015,Aneurysm
NCT01442636:I.4016,Embolism
NCT01442636:I.4017,"Thromboangiitis Obliterans"
NCT01442636:I.4018,Vasculitis
NCT01442636:I.4019,"Coronary Artery Disease"
NCT01442636:I.4020,"Congestive heart failure"
NCT01442636:I.4021,"Chronic Obstructive Pulmonary Disease"
NCT01442636:I.4022,"Malignant Neoplasms"
NCT01442636:I.4023,Dementia
NCT01442636:I.4024,Amputation
NCT01442636:I.4025,Septicemia
NCT01442636:I.4026,Bacteremia
NCT01442636:I.4027,Hypercoagulability
NCT01442636:I.4028,"Contraindication to medical treatment"
NCT01442636:I.4029,Hypersensitivity
NCT01442636:I.4030,Heparin
NCT01442636:I.4031,Thrombocytopenia
NCT01442636:I.4032,Thrombus
NCT01442636:I.4033,Atheroembolism
NCT01442636:I.4034,Enrollment
